---
document_datetime: 2023-11-09 19:33:02
document_pages: 119
document_pathfilename: www.ema.europa.eu/en/documents/variation-report/keytruda-h-c-003820-ii-0133-epar-assessment-report-variation_en.pdf
document_name: keytruda-h-c-003820-ii-0133-epar-assessment-report-variation_en.pdf
version: success
processing_time: 357.9329033
conversion_datetime: 2025-12-21 17:26:02.635125
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

20 July 2023 EMA/359366/2023 Committee for Medicinal Products for Human Use (CHMP)

## Assessment report

## Keytruda

International non-proprietary name: pembrolizumab

Procedure No. EMEA/H/C/003820/II/0133

## Note

Variation assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure                                                                              | ..............................................6                                                                                                                         |
|-------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1.1. Type II variation ................................................................................................ | 6                                                                                                                                                                       |
| 1.2. Steps taken for the assessment of the product                                                                      | ....................................................... 6                                                                                                               |
| 2. Scientific discussion                                                                                                | ................................................................................7                                                                                       |
| 2.1. Introduction                                                                                                       | ...................................................................................................... 7                                                                |
| 2.1.1. Problem statement                                                                                                | .......................................................................................... 7                                                                            |
| 2.1.2. About the product                                                                                                | ........................................................................................... 9                                                                           |
| 2.1.3. The development programme/compliance with CHMP guidance/scientific advice                                        | ..... 10                                                                                                                                                                |
| 2.1.4. General comments on compliance with GCP                                                                          | ...................................................... 10                                                                                                               |
| 2.2. Non-clinical aspects..........................................................................................     | 10                                                                                                                                                                      |
| 2.2.1. Ecotoxicity/environmental risk assessment........................................................                | 10                                                                                                                                                                      |
| 2.3. Clinical aspects                                                                                                   | ................................................................................................ 10                                                                     |
| 2.3.1. Introduction                                                                                                     | ................................................................................................. 10                                                                    |
| 2.3.2. Pharmacokinetics                                                                                                 | .......................................................................................... 12                                                                           |
| 2.3.3. Pharmacodynamics........................................................................................         | 21                                                                                                                                                                      |
| 2.3.4. PK/PD modelling............................................................................................      | 26                                                                                                                                                                      |
| 2.3.5. Discussion on clinical pharmacology                                                                              | ................................................................. 26                                                                                                    |
| 2.3.6. Conclusions on clinical pharmacology                                                                             | ............................................................... 27                                                                                                      |
| 2.4. Clinical efficacy                                                                                                  | ................................................................................................ 27                                                                     |
| 2.4.1. Dose response study(ies)                                                                                         | ............................................................................... 28                                                                                      |
| 2.4.2. Main study                                                                                                       | ................................................................................................... 28                                                                  |
| 2.4.3. Discussion on clinical efficacy                                                                                  | .......................................................................... 79                                                                                           |
| 2.4.4. Conclusions on the clinical efficacy...................................................................          | 83                                                                                                                                                                      |
| 2.5. Clinical safety                                                                                                    | .................................................................................................. 83                                                                   |
| 2.5.1. Discussion on clinical safety                                                                                    | ...........................................................................110                                                                                          |
| 2.5.2. Conclusions on clinical safety                                                                                   | .........................................................................112                                                                                            |
| 2.5.3. PSUR cycle                                                                                                       | ..................................................................................................112                                                                   |
| 2.6. Risk management plan.....................................................................................112       |                                                                                                                                                                         |
| 2.7. Update of the Product information                                                                                  | .....................................................................114                                                                                                |
| 2.7.1. User consultation..........................................................................................114   |                                                                                                                                                                         |
| 3. Benefit-Risk Balance............................................................................115                  |                                                                                                                                                                         |
| 3.1. Therapeutic Context                                                                                                | ........................................................................................115                                                                             |
| 3.1.1. Disease or condition......................................................................................115    |                                                                                                                                                                         |
| 3.1.3. Main clinical studies                                                                                            |                                                                                                                                                                         |
|                                                                                                                         | ......................................................................................115                                                                               |
| 3.2. Favourable effects...........................................................................................115   |                                                                                                                                                                         |
| 3.3. Uncertainties and limitations about favourable effects                                                             | ..........................................115                                                                                                                           |
| 3.4. Unfavourable effects........................................................................................116    |                                                                                                                                                                         |
| 3.5. Uncertainties and limitations about unfavourable effects                                                           | .......................................116                                                                                                                              |
| 3.6. Effects Table                                                                                                      | ..................................................................................................116 ..............................................................117 |
| 3.7. Benefit-risk assessment and discussion 3.7.1. Importance of favourable and unfavourable                            | effects ...........................................117                                                                                                                  |
| 3.7.2. Balance of benefits and risks..........................................................................118       |                                                                                                                                                                         |

<div style=\"page-break-after: always\"></div>

3.7.3. Additional considerations on the benefit-risk balance .........................................  118

3.7.4. Conclusions .................................................................................................  118

4. Recommendations ...............................................................................  118

5. EPAR changes  ......................................................................................  119

<div style=\"page-break-after: always\"></div>

## List of abbreviations

| Abbreviation    | Definition                                                                                     |
|-----------------|------------------------------------------------------------------------------------------------|
| 3L+             | Third-line therapy (participants who have received 2 prior therapies)                          |
| 5-FU            | 5-fluorouracil                                                                                 |
| AE              | Adverse event                                                                                  |
| AEOSI           | Adverse event of special interest                                                              |
| APaT            | All participants as treated                                                                    |
| AST             | Aspartate aminotransferase                                                                     |
| BICR            | Blinded independent central review                                                             |
| CAPOX           | Capecitabine plus oxaliplatin                                                                  |
| CE              | Confirmatory Europe                                                                            |
| CI              | Confidence interval                                                                            |
| CPS             | Combined positive score                                                                        |
| DCO             | Data cutoff                                                                                    |
| DCR             | Disease control rate                                                                           |
| DOR             | Duration of response                                                                           |
| EC50            | Half-maximal effective concentration                                                           |
| ECOG            | Eastern Cooperative Oncology Group                                                             |
| EMA             | European Medicines Agency                                                                      |
| EORTC QLQ-C30   | European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-C30   |
| EORTC QLQ-STO22 | European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-STO22 |
| EQ-5D-5L        | EuroQoL-5 Dimension Questionnaire                                                              |
| E-R             | Exposure-response                                                                              |
| EU              | European Union                                                                                 |
| FDA             | Food and Drug Administration                                                                   |
| FP              | cisplatin plus 5-fluorouracil                                                                  |
| GCP             | Good Clinical Practice                                                                         |
| GEJ             | Gastroesophageal junction                                                                      |
| HER2            | Human epidermal growth factor receptor 2                                                       |
| HNSCC           | Head and neck squamous cell carcinoma                                                          |
| HR              | Hazard ratio                                                                                   |
| IA              | Interim analysis                                                                               |
| IFNy            | Interferon gamma                                                                               |
| IgG4            | Immunoglobulin G4                                                                              |

<div style=\"page-break-after: always\"></div>

| Abbreviation   | Definition                                   |
|----------------|----------------------------------------------|
| IHC            | Immunohistochemical                          |
| IL-2           | Interleukin 2                                |
| ITT            | Intention to treat                           |
| KM             | Kaplan-Meier                                 |
| LS             | Least square                                 |
| LVEF           | Left ventricular ejection fraction           |
| mAb            | Monoclonal antibody                          |
| NCCN           | National Comprehensive Cancer Network        |
| NK             | Natural killer                               |
| NSCLC          | Non-small cell lung cancer                   |
| ORR            | Objective response rate                      |
| OS             | Overall survival                             |
| PD-1           | Programmed cell death 1                      |
| PD-L1          | Programmed cell death ligand 1               |
| PD-L2          | Programmed cell death ligand 2               |
| PFS            | Progression-free survival                    |
| PK             | Pharmacokinetic(s)                           |
| PRO            | Patient-reported outcome                     |
| Q3W            | Every 3 weeks                                |
| Q6W            | Every 6 weeks                                |
| RECIST         | Response evaluation criteria in solid tumors |
| ROC            | Receiver operating characteristic            |
| RSD            | Reference safety dataset                     |
| SAE            | Serious adverse event                        |
| SOC            | Standard-of-care                             |
| SOX            | Oxaliplatin + S-1                            |
| sSAP           | Supplemental statistical analysis plan       |
| TNBC           | Triple-negative breast cancer                |
| TNFα           | Tumor necrosis factor alpha                  |
| ToGA           | Trastuzumab in gastric cancer                |
| TTP            | Time to progression                          |
| TTR            | Time to response                             |
| UC             | Urothelial cancer                            |
| VS             | Versus                                       |

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1. Type II variation

Pursuant to Article 16 of Commission Regulation (EC) No 1234/2008, Merck Sharp &amp; Dohme B.V. submitted to the European Medicines Agency on 8 February 2023 an application for a variation.

The following variation was requested:

| Variation requested   | Type                                                                                                                           | Type    | Annexes affected   |
|-----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a               | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I and IIIB         |

Extension of indication to include in combination with trastuzumab, fluoropyrimidine and platinumcontaining chemotherapy for treatment of locally advanced unresectable or metastatic HER2- positive gastric or gastro-oesophageal junction adenocarcinoma for Keytruda in adults whose tumours express PD-L1 with a CPS ≥ 1, based on interim results from study KEYNOTE-811, an ongoing Phase 3, doubleblind trial comparing trastuzumab plus chemotherapy and pembrolizumab with trastuzumab plus chemotherapy and placebo as first-line treatment in participants with HER2-positive advanced gastric or gastro-oesophageal junction adenocarcinoma;  As a consequence, sections 4.1, 4.8, and 5.1 of the SmPC are updated. The Package Leaflet and Labelling are updated in accordance. Version 40.1 of the RMP has also been submitted.

## Information on paediatric requirements

Pursuant to Article 8 of Regulation (EC) No 1901/2006, the application included (an) EMA Decision(s) P/0043/2018 on the agreement of a paediatric investigation plan (PIP).

At the time of submission of the application, the PIP was completed.

## Information relating to orphan market exclusivity

## Similarity

Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000, the MAH did not submit a critical report addressing the possible similarity with authorised orphan medicinal products because there is no authorised orphan medicinal product for a condition related to the proposed indication.

## Scientific advice

The MAH did not seek Scientific Advice at the CHMP.

## 1.2. Steps taken for the assessment of the product

The Rapporteur and Co-Rapporteur appointed by the CHMP were:

Rapporteur:

Armando Genazzani

Co-Rapporteur:

N/A

<div style=\"page-break-after: always\"></div>

| Timetable                                                                            | Actual dates     |
|--------------------------------------------------------------------------------------|------------------|
| Submission date                                                                      | 8 February 2023  |
| Start of procedure                                                                   | 25 February 2023 |
| CHMP Rapporteur's preliminary assessment report circulated on                        | 24 April 2023    |
| PRAC Rapporteur's preliminary assessment report circulated on                        | 26 April 2023    |
| PRAC RMP advice and assessment overview adopted by PRAC on                           | 12 May 2023      |
| CHMP Rapporteur's updated assessment report circulated on                            | 19 May 2023      |
| Request for supplementary information adopted by the CHMP on                         | 25 May 2023      |
| MAH's responses submitted to the CHMP on                                             | 30 May 2023      |
| PRAC Rapporteur's preliminary assessment report on the MAH's responses circulated on | 26 June 2023     |
| CHMP Rapporteur's preliminary assessment report on the MAH's responses circulated on | 05 July 2023     |
| PRAC RMP advice and assessment overview adopted by PRAC on                           | 6 July 2023      |
| CHMP Rapporteur's updated assessment report on the MAH's responses circulated on     | 14 July 2023     |
| CHMP opinion adopted on                                                              | 20 July 2023     |

## 2. Scientific discussion

## 2.1. Introduction

## 2.1.1. Problem statement

## Disease or condition

Locally advanced unresectable or metastatic HER2- positive gastric or gastro-oesophageal junction adenocarcinoma.

## State the claimed therapeutic indication

KEYTRUDA, in combination with trastuzumab, fluoropyrimidine and platinum-containing chemotherapy, is indicated for the first-line treatment of locally advanced unresectable or metastatic HER2-positive gastric or gastro-oesophageal junction adenocarcinoma in adults whose tumours express PD-L1 with a CPS ≥ 1.

## Epidemiology and risk factors, screening tools/prevention

The gastric and gastro-oesophageal junction cancer are two different clinical entities, representing the 4 th  and 6 th  most common cause of cancer-related mortalities according with the GLOBOCAN 2020

<div style=\"page-break-after: always\"></div>

database. While the gastric cancer incidence has been declining in Western countries thanks to economic development, preventative programs focused on dietary habits, and better food preservation practices, recent studies have reported an increase in younger age groups (&lt;50 years), and a rise in the incidence of the gastro-oesophageal junction disease has also been observed. Asia is the leading geographic area for incidence and mortality of the disease, with 48.6% of all global deaths occurring in China alone.

Genetic predisposition has been recognised in a minority of cases of gastric cancer (10%), while dietrelated factors, smoking habit, H. pylori infection, together with excess body weight, gastroesophageal reflux disease and oesophageal intestinal metaplasia are among the key risk factors. Considering the modifiable nature of the most important etiopathogenetic factors for gastric and gastro-oesophageal cancer, prevention has a relevant impact on burden of disease.

## Biologic features, Aetiology and pathogenesis

Approximately 90% of gastric cancers are adenocarcinomas (ACs). Adenocarcinoma accounts for roughly two-thirds of oesophageal cancer cases. In terms of biological features, gastric and junctional cancer are highly heterogeneous. Among molecular hallmarks, the HER-2 over-expression provides a marker for selecting patients who benefit from a targeted-therapeutic approach in addition to chemotherapy.

## Clinical presentation, diagnosis and stage/prognosis

Patients are generally asymptomatic in the early stages. In advanced disease, they can present with non-specific symptoms including dysphagia, asthenia, indigestion, vomiting, weight loss, early satiety and/or iron deficiency anaemia. Because of the silent progression, diagnosis is often delayed so that the majority of patients are at an advanced stage of disease at presentation, and this compromises the curative potential of available treatments. Endoscopic examination and biopsies are the gold standard for diagnosis. Prognosis is generally poor, with an overall mortality at 1 year.

The current 5-year survival rate for advanced gastric cancer, diagnosed at the distant/metastatic stage is 5.9% and therefore represents an area of high unmet medical need for a treatment regimen that improves upon outcomes for these patients. Cancer. 2020; 126: 4553-4562; Gut. 2020; 69: 823-829; CA Cancer J Clin. 2021; : caac.21660; World J Gastroenterol. 2018; 24: 2818-2832

## Management

In HER-2-positive advanced tumours, the use of trastuzumab in addition to chemotherapy demonstrated survival advantage over chemotherapy alone, based on the phase III ToGA study (HR 0.74; 95% CI 0.60-0.91; P =0.0046 in OS). The current recommended management of patients is illustrated below, according with current ESMO guidelines (Annals of Oncology 2022;33(10):1005).

<div style=\"page-break-after: always\"></div>

<!-- image -->

## 2.1.2. About the product

Keytruda (pembrolizumab) is a humanized mAb IgG4/kappa isotype directed against PD-1. By blocking the interaction between PD-1 and its ligands PD-L1/2, pembrolizumab enhances T cell lymphocyte activity with consequent stimulation of the immune-mediated anti-tumour activity. Pembrolizumab also modulates the level of IL2, TNFα, IFNγ, and other cytokines. The antibody pot entiates existing immune responses in the presence of antigen only; it does not non-specifically activate T cells.

Junttila et al demonstrated that combining trastuzumab-based bispecific antibody HER2-TDB with antiPD-L1 yielded a combination immunotherapy that enhanced tumor growth inhibition, increasing the rates and durability of therapeutic response (Junttila et al. Antitumor efficacy of a bispecific antibody that targets HER2 and activates T cells. Cancer Res. 2014 Oct 1;74(19):5561-7). In addition, nonclinical studies have shown that a mAb against PD-1 substantially boosts the efficacy of anti-HER2 treatment and shows improved activity (Junttila et al. Antitumor efficacy of a bispecific antibody that targets HER2 and activates T cells. Cancer Res. 2014 Oct 1;74(19):5561-7).

Pembrolizumab is already approved as monotherapy or in combination with chemotherapeutic agents across a wide range of clinical indications. Within the clinical setting of gastroesophageal disease, Keytruda has been approved, in combination with chemotherapy, for the first-line treatment of the oesophagus or HER-2 negative gastroesophageal junction adenocarcinoma with CPS ≥ 10.

Figure2.Treatmentalgorithmforfirst-linetreatmentofadvanced/metastatic unresectablegastriccancer.

Purple: general categories or stratification; red: surgery; white: other aspects of management; blue: systemic anticancer therapy.

5-FU, 5-fluorouracil; ChT, chemotherapy; CPS, combined positive score; EMA, European Medicines Agency;ESCAT, ESMO Scale for Clinical Actionability of MolecularTargets;FDA,Food and DrugAdministration;HER2,humanepidermal growth factorreceptor 2;IHC,immunohistochemistry;MCBS,ESMO-Magnitude of Clinical Benefit Scale; PD-L1, programmed death-ligand 1; S-1, tegafurgimeracil-oteracil.

Recommendedplatinumcompounds are oxaliplatin or cisplatin.Oxaliplatinis intravenous 5-FU,oralcapecitabine or oralS-1.Irinotecan-5-FUcanbe consideredanalternative optionforpatients whodonottolerateplatinum compounds.

CPD-L1 status should be reported according to the CPS.

PHER2 IHC 3+ or IHC 2+/FISH-positive.

dESMO-MCBS v1.1l12 was used to calculate scores for therapies/indications MCBS Working Group and validated by the ESMO Guidelines Committee (https://www.esmo.org/guidelines/esmo-mcbs/esmo-mcbs-evaluation-forms).

fNivolumab-ChT is recommended for advanced, untreated gastric cancer with a PD-L1 CPS score &gt;5 (FDA approved without PD-L1 CPS restriction, EMA approved for PD-L1 CPS ≥5).

eESCAT scores apply to genomic alterations only. These scores have been defined by theguideline authors andvalidatedby theESMOTranslationalResearchand Precision Medicine Working Group. 111

$Gastrectomy is not recommended in metastatic gastric cancer unless required for palliation of symptoms.

hResection of metastases cannot be recommended in general, but might be considered as an individual approach in highly selected cases with oligometastatic disease and response to ChT.

<div style=\"page-break-after: always\"></div>

The applied and approved indication is:

Gastric or gastro-oesophageal junction (GEJ) adenocarcinoma

KEYTRUDA, in combination with trastuzumab, fluoropyrimidine and platinum-containing chemotherapy, is indicated for the first-line treatment of locally advanced unresectable or metastatic HER2-positive gastric or gastro-oesophageal junction adenocarcinoma in adults whose tumours express PD-L1 with a CPS ≥ 1.

The recommended dose of KEYTRUDA in adults is either 200 mg every 3 weeks or 400 mg every 6 weeks administered as an intravenous infusion over 30 minutes.

## 2.1.3. The development programme/compliance with CHMP guidance/scientific advice

No scientific advice was sought on study KEYNOTE-811 pivotal for this application.

## 2.1.4. General comments on compliance with GCP

The Clinical trials were performed in accordance with GCP as claimed by the MAH. The MAH has provided a statement to the effect that clinical trials conducted outside the community were carried out in accordance with the ethical standards of Directive 2001/20/EC.

## 2.2. Non-clinical aspects

No new non-clinical data have been submitted in this application, which is considered acceptable.

## 2.2.1. Ecotoxicity/environmental risk assessment

Keytruda is a protein and is therefore exempt from the ERA requirements. This is compliant to the current Guideline on the Environmental Risk Assessment of Medicinal Products for Human Use (EMEA/CHMP/SWP/4447/00).

## 2.3. Clinical aspects

## 2.3.1. Introduction

## GCP

The Clinical trials were performed in accordance with GCP as claimed by the MAH.

The MAH has provided a statement to the effect that clinical trials conducted outside the community were carried out in accordance with the ethical standards of Directive 2001/20/EC.

<div style=\"page-break-after: always\"></div>

## · Tabular overview of clinical studies

Table 2.5-gastric5: 2 Overview of the Pembrolizumab Clinical Development Program in Gastric or GEJ Adenocarcinoma

| Study Number Status                  | Study Design                                       | Study Population                                                                                                                                                                 | Number of Participants by Intervention Group                                                                                                                                   | Primary Endpoint(s)   |
|--------------------------------------|----------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------|
| 2L Treatment                         | 2L Treatment                                       | 2L Treatment                                                                                                                                                                     | 2L Treatment                                                                                                                                                                   | 2L Treatment          |
| KEYNOTE-012 Final analyses completed | Phase 1B, multi-cohort, nonrandomized, multicenter | Cohort D: PD-L1 positive Gastric/GEJ adenocarcinoma                                                                                                                              | Cohort D: Pembrolizumab 10 mg/kg IV Q2W (N=39)                                                                                                                                 | ORR                   |
| KEYNOTE-059 Final analyses completed | Phase 2, multisite, nonrandomized, open- label     | Recurrent and/or metastatic gastric/GEJ adenocarcinoma; Cohort 1:3L+,HER2-negative or HER2-positive and previously treated with trastuzumab; Cohorts 2 and 3: 1L, HER2- negative | Cohort 1: Pembrolizumab 200 mgQ3W (N=259) Cohort 2: Pembrolizumab 200 mg Q3W + cisplatin and 5-FU (or capecitabine in Japan) (N=25) Cohort 3: Pembrolizumab 200 mg Q3 W (N=31) | ORR                   |
| KEYNOTE-061 Final analyses completed | Phase 3, randomized, open-label, active comparator | Advanced gastric/GEJ adenocarcinoma;HER2-negative or HER2-positive and previously treated with trastuzumab                                                                       | Pembrolizumab 200 mgQ3W (N=296) OR Paclitaxel 80 mg/m² on Days 1, 8, and 15 of every 28-day (4-week) cycle (N=296)                                                             | PFS, OS               |
| KEYNOTE-063 Study discontinueda      | Phase 3, randomized, open-label                    | Advanced gastric/GEJ adenocarcinoma in Asian participants; HER2-negative or HER2-positive and previously treatedwithtrastuzumab                                                  | Pembrolizumab 200 mgQ3W (N=47) OR Paclitaxel 80 mg/m² on Days 1, 8, and 15 of every 28-day (4-week) cycle (N=47)                                                               | PFS, OS               |

| 1L Treatment                         | 1L Treatment                                              | 1L Treatment                                                        | 1L Treatment                                                                                                                                                                                                                                                                                                                                                                                                    | 1L Treatment   |
|--------------------------------------|-----------------------------------------------------------|---------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------|
| KEYNOTE-062 Final analyses completed | Phase 3, randomized, active-controlled, partially blinded | Advanced gastric/GEJ adenocarcinoma;HER2-negative                   | Pembrolizumab 200 mg Q3 W (N=256) OR Pembrolizumab 200 mg Q3W+ cisplatin 80 mg/m² Q3 W + 5-FU 800 mg/m2/day continuous IV infusion Days 1-5 (120 hours) or capecitabine (in place of 5-FU)1000 mg/m² BID Days 1-14 Q3W (N=257) OR Placebo Q3 W + cisplatin 80 mg/m² Q3 W + 5-FU 800 mg/m2/day continuous IV infusion Days 1-5 (120 hours) or capecitabine (in place of 5-FU) 1000 mg/m²BID Days1-14 Q3W (N=250) | PFS, OS        |
| KEYNOTE-659 Final analysis completed | Phase 2b, single-arm, open-label                          | HER2-negative participants with advancedgastric/GEJ adenocarcinoma  | Cohort 1: Pembrolizumab 200 mg Q3W IV + TS-1 BID continuous oral administration for 14 days followed by a recovery period of 7 days + oxaliplatin130 mg/m²Q3W IV(N=54) Cohort 2: Pembrolizumab 200 mg Q3W IV + TS 1 BID continuous oral administration for 14 days followed by a recovery period of 7 days + cisplatin 60 mg/m² Q3W IV (N=46)                                                                   | ORR            |
| KEYNOTE-811 Ongoing                  | Phase 3,randomized, double-blind                          | Unresectable or metastaticHER2- positive gastric/GEJ adenocarcinoma | Pembrolizumab 200 mg Q3 W in combination with trastuzumab+ cisplatin+5-FU or oxaliplatin + capecitabine (N=350) OR Placeboin combination with trastuzumab+ cisplatin+5-FU or oxaliplatin+ capecitabine (N=348)                                                                                                                                                                                                  | PFS, OS        |

<div style=\"page-break-after: always\"></div>

| Study Number Status                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Study Design                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | StudyPopulation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Number of Participants by Intervention Group                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | Primary Endpoint(s)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| KEYNOTE-859 Ongoing                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Phase 3, randomized, double-blind                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Unresectable or metastatic HER2-negative gastric/GEJ adenocarcinoma                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Pembrolizumab200mgQ3Wincombinationwith cisplatin + 5-FU or oxaliplatin + capecitabine (N=790) OR Placebo in combination with cisplatin + 5-FU or oxaliplatin + capecitabine (N=789)                                                                                                                                                                                                                                                                                                                                                                                     | OS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| LEAP-015 Ongoing                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | Phase 3,randomized, open-label                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | HER2-negative participants with advanced or metastaticgastric or GEJ adenocarcinoma in the 1L setting                                                                                                                                                                                                                                                                                                                                                                                                                                                  | Pembrolizumab 400 mg Q6W × 2 + lenvatinib 8 mg QD +CAPOX (Q3W)or mFOLFOX6(Q2W) (induction), then pembrolizumab 400 mg + lenvatinib 20 mg QD (consolidation) OR CAPOX (Q3W) or mFOLFOX6 (Q2W) Approximately 880 participants to be enrolled                                                                                                                                                                                                                                                                                                                              | PFS, OS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Neoadjuvant/AdjuvantTreatment                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Neoadjuvant/AdjuvantTreatment                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Neoadjuvant/AdjuvantTreatment                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Neoadjuvant/AdjuvantTreatment                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Neoadjuvant/AdjuvantTreatment                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| KEYNOTE-585 Ongoing                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Phase 3, randomized, double-blind                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Neoadjuvant/adjuvant treatment for participants with gastric/GEJ adenocarcinoma                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Neoadjuvant Combination therapy (3 cycles): Pembrolizumab200mgQ3W+ cisplatin+5-FU or capecitabine OR Placebo + cisplatin + 5-FU or capecitabine Adjuvant Combination therapy (3 cycles): Pembrolizumab 200 mg Q3W+ cisplatin+ 5-FU or capecitabine OR Placebo+cisplatin+5-FUor capecitabine Monotherapy (11 cycles) Pembrolizumab 200 mg Q3W OR Placebo FLOTSafety CohortNeoadjuvant Combination                                                                                                                                                                        | EFS, OS, pCR                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | FLOT (docetaxel + oxaliplatin + 5-FU + leucovorin) OR Placebo Q3 W + FLOT (docetaxel + oxaliplatin + 5-FU + leucovorin [calcium folinate]) FLOT Safety Cohort Adjuvant Combination therapy (3 cycles):Pembrolizumab 200 mg Q3 W + FLOT(docetaxel+oxaliplatin+5-FU+ leucovorin) OR Placebo + FLOT (docetaxel + oxaliplatin + 5-FU + leucovorin [calcium folinate]) FLOT Safety Cohort Monotherapy (11 cycles) Pembrolizumab 200 mg Q3W OR Placebo Approximately 800 participants to be enrolled and an additional 200 participants to be enrolled to FLOT safety cohort. |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| 1L=first-line; 2L=second-line; 3L+=third line plus; 5-FU=5 fluorouracil;BID=twice daily; CAPOX=capecitabine and oxaliplatin; CR=complete response;EFS=event-free survival;FOLFOX=5-FU+oxaliplatin+leucovorin;GEJ=gastroesophagealjunction;HER2=human endothelial growth factorreceptor 2;IV=intravenous;ORR=objective response rate; OS=overall survival; pCR=pathological complete response; PD-L1=programmed cell death ligand 1; PFS=progression-free survival; Q2W=every 2 weeks; Q3W=every 3wecks;QD=once daily;TS-1=tegafur+ gimeracil+oteracil. | 1L=first-line; 2L=second-line; 3L+=third line plus; 5-FU=5 fluorouracil;BID=twice daily; CAPOX=capecitabine and oxaliplatin; CR=complete response;EFS=event-free survival;FOLFOX=5-FU+oxaliplatin+leucovorin;GEJ=gastroesophagealjunction;HER2=human endothelial growth factorreceptor 2;IV=intravenous;ORR=objective response rate; OS=overall survival; pCR=pathological complete response; PD-L1=programmed cell death ligand 1; PFS=progression-free survival; Q2W=every 2 weeks; Q3W=every 3wecks;QD=once daily;TS-1=tegafur+ gimeracil+oteracil. | 1L=first-line; 2L=second-line; 3L+=third line plus; 5-FU=5 fluorouracil;BID=twice daily; CAPOX=capecitabine and oxaliplatin; CR=complete response;EFS=event-free survival;FOLFOX=5-FU+oxaliplatin+leucovorin;GEJ=gastroesophagealjunction;HER2=human endothelial growth factorreceptor 2;IV=intravenous;ORR=objective response rate; OS=overall survival; pCR=pathological complete response; PD-L1=programmed cell death ligand 1; PFS=progression-free survival; Q2W=every 2 weeks; Q3W=every 3wecks;QD=once daily;TS-1=tegafur+ gimeracil+oteracil. | 1L=first-line; 2L=second-line; 3L+=third line plus; 5-FU=5 fluorouracil;BID=twice daily; CAPOX=capecitabine and oxaliplatin; CR=complete response;EFS=event-free survival;FOLFOX=5-FU+oxaliplatin+leucovorin;GEJ=gastroesophagealjunction;HER2=human endothelial growth factorreceptor 2;IV=intravenous;ORR=objective response rate; OS=overall survival; pCR=pathological complete response; PD-L1=programmed cell death ligand 1; PFS=progression-free survival; Q2W=every 2 weeks; Q3W=every 3wecks;QD=once daily;TS-1=tegafur+ gimeracil+oteracil.                  | 1L=first-line; 2L=second-line; 3L+=third line plus; 5-FU=5 fluorouracil;BID=twice daily; CAPOX=capecitabine and oxaliplatin; CR=complete response;EFS=event-free survival;FOLFOX=5-FU+oxaliplatin+leucovorin;GEJ=gastroesophagealjunction;HER2=human endothelial growth factorreceptor 2;IV=intravenous;ORR=objective response rate; OS=overall survival; pCR=pathological complete response; PD-L1=programmed cell death ligand 1; PFS=progression-free survival; Q2W=every 2 weeks; Q3W=every 3wecks;QD=once daily;TS-1=tegafur+ gimeracil+oteracil. |

## 2.3.2. Pharmacokinetics

Substantial characterization of the PK and immunogenicity of pembrolizumab have been provided in previous submissions. In particular, pembrolizumab PK disposition has been characterized via pooled population PK analyses using serum concentration-time data contributed from subjects across various clinical studies using a time-dependent PK (TDPK) model. The PK reference dataset for monotherapy includes all available PK data from subjects enrolled on KEYNOTE-001, KEYNOTE-002, KEYNOTE-006,

<div style=\"page-break-after: always\"></div>

KEYNOTE-010, and KEYNOTE-024, with an overall sample size of 2993. This serves as the PK reference analysis to support descriptions of pembrolizumab pharmacokinetics in the USPI and EU SmPC.

An additional dosing regimen of 400 mg Q6W has been approved in certain regions, including in the US for all adult indications in the monotherapy and combination therapy settings. In addition to the dosing regimens of 200 mg Q3W or 2 mg/kg Q3W, the 400 mg Q6W dosing regimen was also approved in the EU for all adult monotherapy indications (procedure number EMEA/H/C/003820/II/0062) and for all adult indications in combination with other anticancer agents (procedure number EMEA/H/C/003820/II/0102).

## Absorption

Pembrolizumab  is  dosed  via  the  intravenous  route  and  therefore  is  immediately  and  completely bioavailable.

## Distribution

Consistent  with  a  limited  extravascular  distribution,  the  volume  of  distribution  of  pembrolizumab  at steady  state  is  small  (6.0  L;  coefficient  of  variation  [CV]:  20%).  As  expected  for  an  antibody, pembrolizumab does not bind to plasma proteins in a specific manner.

## Elimination

Pembrolizumab  CL  is  approximately  23%  lower  (geometric  mean,  195  mL/day  [CV%:  40%])  after achieving maximal change at steady state compared with the first dose (252 mL/day [CV%: 37%]); this decrease in CL with time is not considered clinically meaningful. The geometric mean value (CV%) for the terminal half-life is 22 days (32%) at steady-state.

## Pharmacokinetic in target population

Considering that an extensive characterization of the PK and immunogenicity profile of pembrolizumab have been provided in previous submissions, in this submission the focus is on the data related to the characterization  of  the  pharmacology  for  the  combination  of  pembrolizumab  with  trastuzumab  plus chemotherapy (hereafter referred to as pembrolizumab plus SOC) from KEYNOTE-811 IA2.

The study includes a Global Cohort, in which the chemotherapy is composed by Fluoropyrimidine (FP) or Oxaliplatin and capecitabine ( CAPOX), and a Japan-specific S-1 and oxaliplatin (SOX) Cohort, in which the chemotherapy is composed by S-1 plus oxaliplatin. Clinical pharmacology results from the global cohort are presented herein. The clinical pharmacology results from Japan-specific SOX cohort are not presented. Clinical pharmacology results from global cohort specific to this submission include:

- PK and (Antidrug antibody) ADA data of pembrolizumab at 200 mg Q3W for pembrolizumab plus SOC treatment.

- PK and ADA data of trastuzumab at 8 mg/kg loading dose followed by 6 mg/kg Q3W maintenance doses for pembrolizumab plus SOC and SOC treatments.

## PK Data Keynote-811

<div style=\"page-break-after: always\"></div>

Keynote-811 is a phase III, Randomized, Double-blind Trial Comparing Trastuzumab Plus Chemotherapy and  Pembrolizumab  With  Trastuzumab  Plus  Chemotherapy  and  Placebo  as  First-line  Treatment  in Participants with HER2 Positive Advanced Gastric or Gastroesophageal Junction Adenocarcinoma'.

Figure 2.7.3-gastric5: 1 KEYNOTE-811 Study Design (Global Cohort)

<!-- image -->

Abbreviations: 5-FU=5 fluorouracil; CAPOX=capecitabine + oxaliplatin; FP=cisplatin + 5-FU; HER2=human epidermal growth factor receptor 2; N=number;PD-L1=programmed cell death-ligand 1; R=randomized.

## PK Analysis Pembrolizumab

Table 1 Overview of Cohorts IncludedinKEYNOTE-811 Pembrolizumab PK Analysis

| Study/Cohort              | Cancer Type                                                | Treatment                             | Analyte       |   Number of subjects providing PKb |
|---------------------------|------------------------------------------------------------|---------------------------------------|---------------|------------------------------------|
| KEYNOTE-811 Global Cohort | (HER2) posilive with advanced gastric or GEJadenocarcinoma | Pembrolizumab (200 mg Q3 W) plus SOCa | Pembrolizumab |                                350 |

SOC=Standardofcare treatment:Trastuzumabplus eithercisplatinplus5-FU(FP)or oxaliplatinpluscapecitabine (CAPOX)

- AtCycle 1,Trastuzumab8mg/kgloadingdosewas administeredandthen6mg/kg maintenancethereafter(Q3W).
- b Unique subjects providing an evaluable pk sample; PK samples from patients dosed with placebo were not analyzed. HER2=Human epidermalgrowth factorreceptor 2

Q3W=Every3weeks

Source:[082S3M: adpcpem]

PK  sampling  schedule  in  KEYNOTE-811  for  pembrolizumab:  pre  infusion  pembrolizumab  serum concentrations (Ctrough) were obtained within 24 hours prior to dosing at Cycle 1, 2, 4 and 8 and every 4 cycles thereafter. Post-dose samples (Cmax) were drawn at Cycle 1 and 8, approximately 30 minutes after the end of pembrolizumab infusion.

Phoenix™ WinNonlin® (Version 8.1.1.279) software was used for pharmacokinetic analysis.

<div style=\"page-break-after: always\"></div>

## Summary descriptive statistics of the predose concentrations by cycle are presented in the following table:

Table 2 Summary Statistics of Pembrolizumab Predose (Ctrough) and Postdose (Cmax) Serum Concentration Values for Pembrolizumab plus SOC Group FollowingAdministrationof MultipleI.V.dosesof 200mgQ3W PembrolizumabinKEYNOTE-811, Global Cohort

<!-- image -->

Source:[082S3M: adpcpem]

Observed pembrolizumab concentration data in KEYNOTE-811 Global Cohort for pembrolizumab plus SOC group are overlaid on the simulated profile using the reference PK model as shown in Figure 3

<div style=\"page-break-after: always\"></div>

Figure 3 ObservedPembrolizumabConcentrationDatainKEYNOTE-811for PembrolizumabplusSOCGroup,GlobalCohortSubjectsReceiving200 mgQ3WwithReference Model-PredictedPharmacokineticProfile for 200 mg Q3W Dose Regimen at Cycle 1 and Steady State (at and after Cycle 8)

## KEYNOTE-811IA-2Cycle 1

<!-- image -->

## KEYNOTE-811IA-2SteadyState

<!-- image -->

Note:Pembrolizumabmodel predictions andobservedconcentration dataforKEYNOTE-811subjectsoftheGlobal Cohort. a) Afer 1st dose; b) at and after cycle 8 (21 weeks), with a 28 day time since last dose sample cut off. Symbols are individual observed data(nominal time);black dashed line ismedianpredicted concentrations from the model fora regimen of200 mg Q3W and the grey shaded area represents the 90% prediction interval; plots are displayed on log scale.

Source: [082S3M: adpepem]

Tabular summaries of descriptive statistics and boxplots from early drug treatment at Cycle 1 end of infusion  (post-dose)  and  at  pre-dose  Cycle  2  and  Cycle  8,  comparing  observed  pembrolizumab concentrations of 200 mg (Q3W) from participants with advanced gastric or GEJ adenocarcinoma in KEYNOTE-811 and monotherapy trials in non-small cell lung cancer (NSCLC, KEYNOTE-024), urothelial cancer (UC, KEYNOTE-045 and KEYNOTE- 052), head and neck squamous cell cancer (HNSCC, KEYNOTE048 and KEYNOTE-055), classical Hodgkin Lymphoma  (HL,  KEYNOTE-087),  microsatellite instability-high cancer (MSIH, KEYNOTE-158)  and  MSIH  colorectal  cancer  (MSIH-CRC,  KEYNOTE-164  and  KEYNOTE-177),  are presented in Table 3 and Figure 4 reported below.

<div style=\"page-break-after: always\"></div>

Table 3 SummaryStatisticsofObservedPembrolizumabConcentrationsatCycle 1 Postdose,Cycle 2 and Cycle 8 Predose inVarious Monotherapy Trials (KEYNOTE-024,-045,-048,-052,-055,-087,158MSIHn0n CRC,-164,177)andKEYNOTE-811AdvancedGastricorGEJAdenocarcinoma

| Time point       |   Dose (mg) | Study/Indication   |   N | GM(C V%) (g/mL)   | AM(SD) (g/mL)   |   Min (g/mL) |   Median (μg/mL) |   Max (ng/mL) |
|------------------|-------------|--------------------|-----|-------------------|-----------------|--------------|------------------|---------------|
| Postdose Cycle 1 |         200 | KN024 NSCLC        | 147 | 67.5 (23.1)       | 69.3 (16.2)     |       36.6   |             66.8 |         132   |
|                  |         200 | KN045UC            | 247 | 65.7 (26.2)       | 67.9 (18.2)     |       33.9   |             65.9 |         144   |
|                  |         200 | KN048 ILHNSCC      | 495 | 61.8 (28.7)       | 64.2 (17.6)     |        9.48  |             61.7 |         165   |
|                  |         200 | KN052UC            | 298 | 58.0 (27.9)       | 60.2 (17.3)     |       22.8   |             57.4 |         148   |
|                  |         200 | KN055HNSCC         |  43 | 56.5 (27.8)       | 58.9 (20.7)     |       33.1   |             54.9 |         162   |
|                  |         200 | KN087 HL           | 195 | 60.7 (28)         | 63.1 (18.3)     |       31.2   |            613   |         183   |
|                  |         200 | KN158 MSIH- NonCRC |  90 | 64.4 (27)         | 66.7 (18.3)     |       31.2   |             65.2 |         133   |
|                  |         200 | KNI64 MSIH-CRC     |  56 | 62.2 (27.8)       | 64.6 (19.1)     |       34.9   |             61.2 |         150   |
|                  |         200 | KNI77MSIH-CRC      | 115 | 65.0 (25.7)       | 67.1 (17.1)     |       36.4   |             65.7 |         113   |
|                  |         200 | KN811-GEJ          | 323 | 56.6 (27.3)       | 58.8 (18)       |       14.7   |             56.2 |         201   |
| Cycle 2 Predose  |         200 | KN024 NSCLC        | 132 | 11.1 (54.1)       | 12.3 (4.7)      |        0.535 |             12.2 |          28.5 |
|                  |         200 | KN045UC            | 233 | 13.1 (47.2)       | 14.2 (4.9)      |        0.475 |             13.9 |          29.3 |
|                  |         200 | KN0481LHNSCC       | 458 |                   | 13.4 (4.6)      |        0     |             13.2 |          29.6 |
|                  |         200 | KN052UC            | 286 | 11.1 (42.3)       | 11.9 (4.4)      |        2.07  |             11.5 |          26.2 |
|                  |         200 | KN055 HNSCC        |  40 | 10.7 (47.2)       | 11.8 (5.2)      |        3.45  |             11.6 |          33.1 |
|                  |         200 | KN087 HL           | 200 | 14.4 (39.5)       | 15.4 (5.1)      |        3.06  |             15.3 |          30   |
|                  |         200 | KNI64 MSIH-CRC     |  56 | 12.5 (35.3)       | 13.2 (4.6)      |        5.44  |             12.4 |          25.6 |
|                  |         200 | KNI77 MSIH-CRC     |  96 | 13.2 (45.7)       | 14.4 (5.9)      |        3.64  |             13.9 |          35.5 |
|                  |         200 | KN811-GEJ          | 328 | 11.0 (36.2)       | 11.7 (3.8)      |        3.58  |             11.5 |          27.6 |
| Cycle 8 Predose  |         200 | KN024 NSCLC        |  82 | 30.6 (49.6)       | 33.6 (13.3)     |        5.26  |             32.7 |          64.1 |
|                  |         200 | KN045UC            | 104 | 33.4 (63.7)       | 37.8 (16.5)     |        1.13  |             37.5 |          95.6 |
|                  |         200 | KN048ILHNSCC       | 235 | 34.2 (50.3)       | 37.5 (15.1)     |        1.77  |             34.8 |         127   |
|                  |         200 | KN052UC            |  59 | 28.0 (38.4)       | 29.9 (10.4)     |        8.15  |             27.9 |          59.8 |
|                  |         200 | KN055HNSCC         |   7 | 27.8 (41)         | 29.6 (11.4)     |       16.8   |             24.5 |          43.3 |
|                  |         200 | KN087 HL           |  68 | 43.9 (43.5)       | 47.4 (17)       |       13.9   |             47.5 |          92.4 |
|                  |         200 | KNI64 MSIH-CRC     |  34 | 33.6 (43.1)       | 36.2 (13.8)     |        8.4   |             33.7 |          78.8 |
|                  |         200 | KNI77 MSIH-CRC     |  53 | 32.9 (49.2)       | 36.2 (15.1)     |        9.76  |             34.7 |          68.5 |
|                  |         200 | KN811-GEJ          | 223 | 26.7 (43.4)       | 28.9 (11)       |        4.27  |             27.8 |          63.7 |

GM=GeometricMean;%CV=Geometric Coefficient ofVariation;AM=ArithmeticMean;SD=Standard Deviation;NSCLC=non-small celllung cancer;UC=urothelial cancer;HNSCC=headand neck squamous cell carcinoma; HL =Hodgkin lymphoma; MSIH CRC= micro satellite instability high cancer colorectal cancer; GEJ = Gastroesophageal Jumction.

<div style=\"page-break-after: always\"></div>

Figure4 PembrolizumabObservedPembrolizumabConcentrationsatCycle1 Postdose,Cycle 2 and Cycle 8PredoseinVarious Monotherapy Trials (KEYNOTE-024,-045,-048,-052,-055,-087,158MSIHn0nCRC,-164,177)andKEYNOTE-811

Cycle 1Postdose

<!-- image -->

Cycle 2Predose

<!-- image -->

Cycle 8Predose

<!-- image -->

NonCRC

CRC

CRC

<div style=\"page-break-after: always\"></div>

## PK Analysis Trastuzumab

Table 5 OverviewofCohortsIncludedinKEYNOTE-8i1Trastuzumab PK Analysis

| Study/Cohort              | Cancer Type                                                 | Treatment                             | Analyte     |   Number of subjects providing PKb |
|---------------------------|-------------------------------------------------------------|---------------------------------------|-------------|------------------------------------|
| KEYNOTE-811 Global Cohort | (HER2) positive with advanced gastric or GEJ adenocarcinoma | Pembrolizumab (200 mg Q3 W) plus SOCa | Trastuzumab |                                350 |
| KEYNOTE-811 Global Cohort |                                                             | SOC*                                  | Trastuzumab |                                346 |

SOC = Standard ofcare treatment: Trastuzumab plus either cisplatin plus 5-FU (FP) or oxaliplatin plus capecitabine (CAPOX)

At Cycle 1, Trastuzumab 8 mg/kg loading dose was administered and then 6 mg/kg maintenance thereafter (Q3 W). b Unique subjects providing an evaluable pk sample;

HER2=Humanepidermalgrowthfactorreceptor2;Q3W=Every3weeks

Source:[082S3M: adpctra]

PK sampling schedule in KEYNOTE-811 for trastuzumab: pre infusion trastuzumab serum concentrations (Ctrough) were obtained within 24 hours prior to dosing at Cycle 1, 2, 4 and 8 and every 4 cycles thereafter. Postdose samples (Cmax) were drawn at Cycle 1 and 8, approximately 30 minutes after the end of trastuzumab infusion.

Phoenix™ WinNonlin® (Version 8.1.1.279) software was used for pharmacokinetic analysis.

Mean predose serum trastuzumab concentration-time profiles stratified by treatment groups are shown in Figure 6.

Figure 6 Arithmetic Mean (SE) TrastuzumabPredose Concentration-Time Profiles Following Administration of Multiple I.V. doses of 6 mg/kg Q3W TrastuzumabinKEYNOTE-811,GlobalCohort,StratifiedbyTreatment Groups (Linear scale)

Note: Error bars are associated +/- SE (Standard Error).

<!-- image -->

Source: [082S3M: adpctra]

Summary descriptive statistics of the predose and postdose concentration by Cycle and stratified by treatment groups after multiple I.V. doses of 6 mg/kg Q3W for pembrolizumab plus SOC and SOC groups are presented in Table 6.

<div style=\"page-break-after: always\"></div>

Table 6 Summary Statistics of Trastuzumab ConcentrationValues Following Administration of Multiple I.V. doses of 6mg/kgQ3WTrastuzumabinKEYNOTE-811,Global Cohort,StratifiedbyTreatment

<!-- image -->

|               |          |               | Pembrolizumab plus SOC   | Pembrolizumab plus SOC   | Pembrolizumab plus SOC   | Pembrolizumab plus SOC   | Pembrolizumab plus SOC   | SOC   | SOC               | SOC            | SOC            | SOC            |
|---------------|----------|---------------|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------|-------|-------------------|----------------|----------------|----------------|
| Relative Time | Cyele    | NOMTAFD (Day) | N                        | GM (%CV) (μg/mL)         | AM(SD) (μg/mL)           | (μg/mL) Median           | (g/mL) Ranges            | N     | (μg/mL) (% CV) GM | AM (SD) (g/mL) | (μg/mL) Median | (μg/mL) Ranges |
| Predose       | Cycle1   | 0             | 338                      |                          | 0.00 (0)                 | 0.00                     | 0.00~0.00                | 336   |                   | 0.00 (0)       | 0.00           | 0.00~0.00      |
|               | Cycle2   | 21.0          | 327                      |                          | 14.0 (8.1)               | 13.8                     | 0.00 ~44.2               | 323   |                   | 14.1 (8.3)     | 13.9           | 0.00~41.2      |
|               | Cycle4   | 63.0          | 289                      |                          | 18.2 (10.5)              | 17.3                     | 0.00~66.1                | 281   | 14.7 (120)        | 19.1 (12.1)    | 16.9           | 0.0409~93.2    |
|               | Cycle8   | 147           | 209                      | 18.6 (78)                | 22.2 (12)                | 20.3                     | 0.642~83.9               | 177   | 18.8 (85)         | 22.9 (12.6)    | 22.0           | 0.519~67.5     |
|               | Cycle 12 | 231           | 167                      |                          | 23.0 (11.4)              | 21.6                     | 0.00~67.4                | 140   | 18.7 (97)         | 23.5 (14.4)    | 20.2           | 0.238~91.6     |
|               | Cycle 16 | 315           | 126                      |                          | 24.3 (15.4)              | 23.0                     | 0.00~111                 | 96    | 20.9 (90)         | 26.2 (16.1)    | 24.1           | 1.20 ~101      |
|               | Cycle 20 | 399           | 87                       | 20.2 (96)                | 25.1 (13)                | 25.7                     | 0.928~63.7               | 72    | 20.2 (112)        | 25.7 (14.6)    | 23.4           | 0.127~ 76.6    |
|               | Cycle 24 | 483           | 60                       | 22.1 (89)                | 26.4 (12.2)              | 24.7                     | 0.864~50.4               | 54    | 24.6 (68)         | 28.5 (13.9)    | 26.2           | 2.16~ 71.6     |
|               | Cycle 28 | 567           | 50                       | 26.9 (41)                | 28.9 (11.2)              | 26.5                     | 9.39~59.8                | 43    | 24.9 (67)         | 28.2 (11.8)    | 24.3           | 1.26~57.9      |
|               | Cycle 32 | 651           | 39                       | 22.9 (51)                | 25.2 (10.2)              | 23.8                     | 4.86 ~45.8               | 33    | 27.4 (56)         | 30.6 (13.6)    | 29.5           | 4.55~65.4      |
| Postdose      | Cycle1   | 0.0210        | 313                      | 134 (35)                 | 141 (42.0)               | 138                      | 23.7~323                 | 300   | 140 (32)          | 146 (41.3)     | 142            | 33.2~278       |
|               | Cycle8   | 147           | 209                      | 123 (30)                 | 128 (36.2)               | 121                      | 26.5 ~ 237               | 179   | 120 (30)          | 125 (37.9)     | 119            | 48.2 ~308      |

Source:[082W2B:adpctra]

Comparison boxplots using observed trastuzumab concentration data from both pembrolizumab plus SOC and SOC treatment groups in KEYNOTE-811 Global Cohort were provided in Figure 7.

Figure 7 Boxplots with Serum ConcentrationValues of TrastuzumabFollowing Administration of MultipleI.V.dosesof 6mg/kgQ3WTrastuzumab in KEYNOTE-811, Global Cohort, Stratified by Treatment Groups

<!-- image -->

<div style=\"page-break-after: always\"></div>

## 2.3.3. Pharmacodynamics

## Mechanism of action

KEYTRUDA  is  an  antibody  that  binds  to  the  programmed  death-1  (PD-1)  receptor  and  blocks  its interaction with ligands PD-L1 and PD-L2. The PD-1 receptor is a negative regulator of T-cell activity that has been shown to be involved in the control of T-cell immune responses. KEYTRUDA potentiates T-cell responses, including anti-tumour responses, through blockade of PD-1 binding to PD-L1 and PD-L2, which are expressed in antigen presenting cells and may be expressed by tumours or other cells in the tumour microenvironment.

## IMMUNOGENICITY

The existing immunogenicity assessment for pembrolizumab for the monotherapy setting is based on a sufficiently large dataset of patients across several indications, with very low observed rates of total treatment emergent ADA (1.4 - 3.8%) as well as of neutralizing antibodies (0.4 - 1.6%).

In total 337 subjects from study KEYNOTE-811 were included in the immunogenicity assessment for pembrolizumab  and  672  subjects  were  included  in  the  immunogenicity  assessment  for  the  SOC component trastuzumab.

Overviewof SubjectsIncludedintheImmunogenicityAnalysisafter Pembrolizumabplus SOC or SOC Treatments in SubjectswithHER2 Positive Advanced Gastric or GEJ Adenocarcinoma (KEYNOTE-811)

|             |                                |             | Subjects                       | Subjects                    | Subjects                                                       |
|-------------|--------------------------------|-------------|--------------------------------|-----------------------------|----------------------------------------------------------------|
| Study       | Treatment                      | Analyte     | Subjects Providing ADA Samples | Subjects Dosed with MK-3475 | AssessableSubjects Dosed with MK-3475 andPostTreatment Samples |
| Keynote-811 | MK-3475 (200 mg Q3W) plus SOCa | MK-3475     | 350                            | 350                         | 337                                                            |
| Keynote-811 | MK-3475 (200 mg Q3W) plus SOCa | Trastuzumab | 350                            | 350                         | 338                                                            |
| Keynote-811 | SOCa                           | Trastuzumab | 346                            | 346                         | 334                                                            |

SOC = Standard of care treatment: Trastuzumab plus either cisplatin plus 5-FU (FP) or oxaliplatin plus capecitabine (CAPOX).

a: At Cycle 1, Trastuzumab 8 mg/kg loading dose was administered and then 6 mg/kg maintenance thereafter (Q3 W).

Data source: [085ZRS: analysis-adadapem, analysis-adadatra]

The overall immunogenicity incidence was defined as the proportion of treatment emergent positive subjects to the total number of evaluable subjects (treatment emergent positive, nontreatment emergent positive and negative immunogenicity status).

## Pembrolizumab

For pembrolizumab (200 mg MK-3475 Q3W) plus SOC treatment ADA samples were available from 350 subjects (ADA cut-off date of 20 April 2022).

A subset of the subjects was not assessable for drug-induced immunogenicity analysis, because only a pre-treatment ADA sample was available (N=13). The remaining 337 subjects were assessable for druginduced immunogenicity analysis.

Out of the 337 subjects included in the immunogenicity assessment, 11 subjects were inconclusive, resulting in 326 evaluable subjects. The observed incidence of treatment emergent ADA in evaluable subjects with HER2 positive advanced gastric or GEJ adenocarcinoma is 2.1% (7 out of 326), based on

<div style=\"page-break-after: always\"></div>

7 subjects with treatment emergent positive status, and 319 with negative immunogenicity status. Out of the 7 treatment emergent positive subjects, one subject had antibodies with neutralizing capacity, resulting in a treatment emergent neutralizing positive incidence rate of 0.3% (1 out of 326).

An overview of the immunogenicity status of all assessable subjects is presented in the table below.

SummaryofSubjectImmunogenicityResultsforPembrolizumabafter Pembrolizumab plus SOC Treatment in Subjects with HER2 Positive Advanced Gastric or GEJ Adenocarcinoma (KEYNOTE-811)

| PembrolizumabImmunogenicity      | PembrolizumabImmunogenicity   |
|----------------------------------|-------------------------------|
| Immunogenicitystatus             |                               |
| Assessable subjectsa             | 337                           |
| Inconclusive subjectsb           | 11                            |
| Evaluable subjectsc              | 326                           |
| Negatived                        | 319 (97.9%)                   |
| Non-Treatment emergent positived | 0                             |
| Neutralizing negative            | 0                             |
| Neutralizing positive            | 0                             |
| Treatment emergent positived     | 7 (2.1%)                      |
| Neutralizing missing             | 1 (0.3%)                      |
| Neutralizing negative            | 5 (1.5%)                      |
| Neutralizing positive            | 1 (0.3%)                      |

a: Included are subjects with at least one ADA sample available after treatment with pembrolizumab

b: Inconclusive subjects are the number of subjects with no positive ADA samples present and the drug concentration in the last sample above the drug tolerance level.

c: Evaluable subjects are the total number of negative and positive subjects (non-treatment emergent and treatment emergent.

d: Denominator was total number of evaluable subjects.

Data source:[085ZRS: analysis-adadapem]

The  immunogenicity  incidence  of  treatment  emergent  positive  subjects  for  pembrolizumab  after treatment  with  pembrolizumab  plus  SOC  in  subjects  with  HER2  positive  advanced  gastric  or  GEJ adenocarcinoma is 2.1% (7 out of 326) with 0.3% of neutralizing antibodies (1 out of 326).

## Trastuzumab

For SOC component trastuzumab, ADA samples for trastuzumab were available from 696 subjects, of which 350 were treated with pembrolizumab plus SOC and 346 were treated with SOC. (ADA cut-off date of 22 March 2022)

A subset of the subjects was not assessable for drug-induced immunogenicity analysis, because only a pre-treatment ADA sample was available (N=24). The remaining 672 subjects were assessable for drug-induced immunogenicity analysis, 338 were in the pembrolizumab plus SOC group and 334 were in the SOC group.

Out of the 672 subjects included in the immunogenicity assessment, 16 subjects were inconclusive, resulting in 656 evaluable subjects.

The incidence of trastuzumab treatment emergent ADA in evaluable subjects after pembrolizumab plus SOC therapy is 3.1% (10 out of 327), based on 10 subjects with treatment emergent positive status, 6 subjects with non-treatment emergent positive status and 311 with negative immunogenicity status.

The incidence of trastuzumab treatment emergent ADA in evaluable subjects after SOC therapy is 2.4% (8 out of 329), based on 8 subjects with treatment emergent positive status, 13 subjects with nontreatment emergent positive status and 308 with negative immunogenicity status.

No Nab analysis was performed for trastuzumab ADA positive samples.

An overview of the immunogenicity status of all assessable subjects is presented in the following table:

<div style=\"page-break-after: always\"></div>

SummaryofSubjectImmunogenicityResultsforTrastuzumabafter PembrolizumabplusSOC andSOC TreatmentsinSubjectswithHER2 PositiveAdvanced Gastricor GEJAdenocarcinoma(KEYNOTE-811)

| TrastuzumabImmunogenicity        | TrastuzumabImmunogenicity   | TrastuzumabImmunogenicity   | TrastuzumabImmunogenicity   |
|----------------------------------|-----------------------------|-----------------------------|-----------------------------|
| Immunogenicitystatus             | Total                       | Pembrolizumab plus SOC      | SOC                         |
| Assessable subjectsa             | 672                         | 338                         | 334                         |
| Inconclusive subjectsb           | 16                          | 11                          | 5                           |
| Evaluable subjectsc              | 656                         | 327                         | 329                         |
| Negatived                        | 619 (94.4%)                 | 311 (95.1%)                 | 308 (93.6%)                 |
| Non-Treatment emergent positived | 19 (2.9%)                   | 6 (1.8%)                    | 13 (4.0%)                   |
| Treatment emergent positived     | 18 (2.7%)                   | 10 (3.1%)                   | 8 (2.4%)                    |

a: Included are subjects with at least one ADA sample available after treatment with trastuzumab

b: Inconclusive subjects are the number of participants with no positive ADA samples present and the drug concentration in the last sample above the drug tolerance level.

c: Evaluable subjects are the total number of negative and positive subjects (non-treatment emergent and treatment emergent.

d: Denominator was total number of evaluable subjects.

Data sourcc:[085ZRS: analysis-adadatra]

## IMPACT OF ANTI-DRUG ANTIBODIES ON EXPOSURE

## Pembrolizumab

The effect of ADA on pembrolizumab levels, for the subjects with ADA positive samples, is compared with the subjects treated with the same regimen that only have ADA negative samples.

For  the  ADA  positive  subjects,  the  pembrolizumab  exposure  was  comparable  with  the  exposures observed for the negative subjects treated with the same regimen (see figure below).

<div style=\"page-break-after: always\"></div>

EffectofADAonPembrolizumabExposure afterPembrolizumabplus SOC Therapy in Subjects with HER2 Positive Advanced Gastric or GEJ Adenocarcinoma (KEYNOTE-811),Linear Scale (top) and Log Scale (bottom)

<!-- image -->

<!-- image -->

Footmote:FigureincludesADAsamples with correspondingPKconcentrations.Samples taken&gt;42days after last dose (&gt;2 times thescheduled time)are excluded.Pembrolizumab concentrations for samples with Cycle 1 predose PK concentrations&gt;Owere set to missing as their results are unreliable.

Individualpembrolizumab concentrations for the ADAnegative subjects(grey circles),mean value of the

If a subject is determined tobe ADA positive(non-TE orTE,based on one or more positive samples),all datapoints belonging to that subject are shown in the color ofthe corresponding ADA status group.

TE nAB missing: treatment emergentpositive neutralizing antibody missing subject.

TE nAB Pos: treatment emergent positive neutralizing antibody positive subject.

TE nABNeg: treatment emergent positive neutralizing antibody negative subject.

Data source: [085ZRS: analysis-adadapem]

## Trastuzumab

The effect of ADA on trastuzumab levels, for the subjects with ADA positive samples, is compared with the subjects treated with the same regimen that only have ADA negative samples. No Nab analysis was performed for trastuzumab ADA positive samples.

For the ADA positive subjects, the trastuzumab exposure was comparable with the exposures observed for the negative subjects treated with the same regimen figures below:

<div style=\"page-break-after: always\"></div>

Effect of ADAonTrastuzumabExposure afterPembrolizumabplusSOC Therapy inSubjectswithHER2Positive Advanced Gastric or GEJ Adenocarcinoma (KEYNOTE-811),Linear Scale (top) and Log Scale (bottom)

<!-- image -->

Footmote:Figure includesADAsampleswith correspondingPKconcentrations.Samples taken&gt;42days after last dose (&gt;2 times the scheduled time)are excluded.Trastuzumab concentrations for samples with Cycle 1 predose PK concentrations &gt;0 were set to missing as their results are unreliable.

Individual trastuzumabconcentrationsfor theADAnegative subjects(grey circles),meanvalue of thenegative subjects (grey line), non-treatment emergent neutralizing missing subjects (green/blue dot), treatment emergent neutralizing missing subjects (pink dot).

If a subject is determinedtobe ADA positive (non-TE orTE,based on one ormore positive samples),all datapoints belonging to that subject are shown in the color of the corresponding ADA status group.

Non-TE nAB missing: non-treatment emergent positive neutralizing antibody missing subject. TE nABmissing: treatment emergentpositive neutralizing antibody missing subject.

Data source: [085ZRS: analysis-adadatra]

<div style=\"page-break-after: always\"></div>

Effect of ADAonTrastuzumabExposure afterSOC TherapyinSubjects withHER2PositiveAdvancedGastricorGEJAdenocarcinoma (KEYNOTE-811),LinearScale (top) and LogScale (bottom)

<!-- image -->

<!-- image -->

Footnote:Figure includesADAsamples with correspondingPK concentrations.Samples taken&gt;42days after last dose(&gt;2 times the scheduled time)are excluded.Trastuzumab concentrations for samples with Cycle 1 predose PK concentrations&gt;0were set tomissing as their results are unreliable.

Individual trastuzumab concentrationsfor the ADAnegative subjects(greycircles),mean value of the negative neutralizingmissing subjects(pink dot).

If a subjectis determined tobe ADApositive(non-TE orTE,based on one ormore positive samples),all datapoints belonging to that subject are shown in the color ofthe corresponding ADA status group.

Non-TE nAB missing: non-treatment emergent positive neutralizing antibody missing subject.

Data source:[085ZRS: analysis-adadatra]

## 2.3.4. PK/PD modelling

No new information regarding PK/PD modelling for pembrolizumab is available within this extension of indication.

## 2.3.5. Discussion on clinical pharmacology

In this application, the focus is on PK and immunogenicity data related to the combination of pembrolizumab with trastuzumab plus chemotherapy (hereafter referred to as pembrolizumab plus SOC) from KEYNOTE-811 IA2. The study includes a Global Cohort, in which the chemotherapy is composed by FP or CAPOX, and a Japan-specific SOX Cohort, in which the chemotherapy is composed by S-1 plus oxaliplatin. Clinical pharmacology results from the global cohort are presented herein.

PK data from KEYNOTE-811 show that the observed pembrolizumab serum concentration values in subjects with advanced gastric or GEJ adenocarcinoma are contained within the 90% CI of the

<div style=\"page-break-after: always\"></div>

reference PK model, which indicate consistency with the historical data, in both cycle 1 postdose and cycle 8 predose (at steady state).

In addition, tabular summaries of descriptive statistics and boxplots from early drug treatment at Cycle 1 end of infusion (post-dose) and at pre-dose Cycle 2 and Cycle 8 show that observed pembrolizumab concentrations of 200 mg (Q3W) in combination with SOC (including Trastuzumab) from participants with advanced gastric or GEJ adenocarcinoma in KEYNOTE-811 are similar to the observed pembrolizumab concentration when administered as monotherapy in other trials.

In conclusion, pembrolizumab PK disposition is not affected by the coadministration with SOC including trastuzumab and chemotherapy and in the same way, the PK disposition of the SOC component trastuzumab is not affected by the coadministration of pembrolizumab. Similar exposures for trastuzumab are reported in the SOC arm as well as in the Pembrolizuma SOC arm.

The immunogenicity incidence of treatment emergent ADA positive subjects for pembrolizumab after treatment with pembrolizumab plus SOC in subjects with HER2 positive advanced gastric or GEJ adenocarcinoma is 2.1% (7 out of 326) with 0.3% of neutralizing antibodies (1 out of 326). This incidence rate is comparable to the historical incidence rate reported after pembrolizumab monotherapy, (1.8%) with 0.4% of neutralizing antibodies.

The incidence of trastuzumab treatment emergent ADA in evaluable subjects is similar between pembrolizumab plus SOC arm (3.1%) and SOC arm (2.4%).

No Nab analysis was performed for trastuzumab ADA positive samples. This is considered acceptable since this lack of Nab characterisation for trastuzumab does not impact on pembrolizumab's SmPC.

## 2.3.6. Conclusions on clinical pharmacology

Pembrolizumab PK disposition is not affected by the coadministration with SOC including trastuzumab and chemotherapy and, in the same way, the PK disposition of the SOC component trastuzumab is not affected by the coadministration of pembrolizumab. Similar exposures for trastuzumab are reported in the SOC arm as well as in the Pembrolizumab + SOC arm.

The immunogenicity incidence of treatment emergent ADA positive subjects for pembrolizumab after treatment with pembrolizumab plus SOC in subjects with HER2 positive advanced gastric or GEJ adenocarcinoma is similar to the historical incidence rate reported after pembrolizumab monotherapy.

The incidence of trastuzumab treatment emergent ADA in evaluable subjects is similar between pembrolizumab plus SOC arm and SOC arm.

## 2.4. Clinical efficacy

The current submission is based on a single pivotal study (KEYNOTE-811).

KEYNOTE-811 is an ongoing, Phase 3, randomized, double-blind, placebo-controlled, multicentre study to evaluate the efficacy and safety of pembrolizumab in combination with trastuzumab + chemotherapy (cisplatin and 5-FU or oxaliplatin and capecitabine) versus trastuzumab + chemotherapy alone as 1L treatment in participants with unresectable or metastatic HER-2-positive gastric/gastroesophageal junction (GEJ) adenocarcinoma.

Results are submitted from the IA2 of KEYNOTE-811 (DCO date: 25-MAY-2022) that was triggered approximately 9 months after the last participant was randomized, when 484 PFS events had occurred (80% information fraction).

<div style=\"page-break-after: always\"></div>

## 2.4.1. Dose response study(ies)

No dose-response studies were submitted as part of this application.

## 2.4.2. Main study

## Title of Study

A Phase III, Randomized, Double-blind Trial Comparing Trastuzumab Plus Chemotherapy and Pembrolizumab With Trastuzumab Plus Chemotherapy and Placebo as First-line Treatment in Participants With HER2 Positive Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (KEYNOTE-811)

## Methods

The overall study design of study KEYNOTE-811 is illustrated below. The study included a Global Cohort (planned 692 individuals) and an additional Japan-specific SOX Cohort (40 participants) randomised 1:1 to pembrolizumab or placebo, each in combination with chemotherapy plus trastuzumab. Only efficacy data from the Global Cohort are presented herein. The efficacy data from the Japan-specific SOX Cohort are not presented in the current application.

Figure 9-1 Study Design (Global Cohort)

<!-- image -->

CAPOX = capecitabine/oxaliplatin; FP = cisplatin plus 5 fluorouracil; HER2 = human epidermal growth factor receptor 2; PD-L1 = programmed cell death ligand 1; R = randomization.

<div style=\"page-break-after: always\"></div>

## Study participants

## Inclusion criteria

Participants were eligible to be included in the study only if all of the following criteria applied:

1. Be male/female who were at least 18 years of age on the day of signing the informed consent with histologically or cytologically confirmed diagnosis of previously untreated, locally advanced unresectable or metastatic HER2-positive gastric or GEJ adenocarcinoma.

2. Be HER2-positive defined as either IHC 3+ or IHC 2+ in combination with ISH+ (or FISH), as assessed by central review on primary or metastatic tumor.

3. Had measurable disease as defined by RECIST 1.1 by scans with IV contrast, as determined by the site investigator.

4. If male, agreed to use an adequate method of contraception, as outlined in Appendix 3 of the study protocol [16.1.1], for the course of the study through 7 months after the last dose of all study treatments.

5. If female, not pregnant (see Appendix 3 of the study protocol [16.1.1]), not breastfeeding, and had at least one of the following conditions apply:

a.) Not a WOCBP as defined in Appendix 3 of the study protocol [16.1.1]

OR

- b.) Not a WOCBP who agreed to follow the contraceptive guidance in Appendix 3 of the study protocol [16.1.1] during the treatment period and for at least 7 months after the last dose of study treatment.
6. Provided written informed consent for the study.
7. Had a performance status of 0 or 1 on the ECOG Performance Scale within 3 days prior to the first dose of study treatment.
8. Had a life expectancy of greater than 6 months.
9. Had a 12-lead ECG and ECHO or MUGA scan performed by the investigator or other qualified person to evaluate cardiac function prior to enrollment in the study.
10. Provided tumor tissue sample deemed adequate for PD-L1 and MSI biomarker analysis.
11. Had adequate organ function as defined in Table 2 of the study protocol [16.1.1].

## Exclusion Criteria

Participants were excluded from the study if any of the following criteria applied:

1. Had previous therapy for locally advanced unresectable or metastatic gastric/GEJ cancer.
2. Had major surgery, open biopsy or significant traumatic injury within 28 days prior to randomization, or anticipation of the need for major surgery during the course of study treatment.
3. Had radiotherapy within 14 days of randomization.
4. Had a known additional malignancy that was progressing or had required active treatment within the past 5 years.
5. Had known active CNS metastases and/or carcinomatous meningitis.

<div style=\"page-break-after: always\"></div>

6. Had an active autoimmune disease that had required systemic treatment in past 2 years (ie, with use of disease modifying agents, corticosteroids or immunosuppressive drugs).

7. Had a diagnosis of immunodeficiency or was receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior the first dose of trial drug.

8. Had a history of (noninfectious) pneumonitis that required steroids or had pneumonitis.

9. Had a known history of active TB.

10. Had an active infection requiring systemic therapy.

11. Had poorly controlled diarrhea (eg, watery stool, uncontrollable bowel movement with drugs, Grade ≥ 2 and number of defecations, ≥ 5/day).

12. Had accumulation of pleural, ascitic, or pericardial fluid requiring drainage or diuretic drugs within 2 weeks prior to enrollment.

13. Had a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfered with the participant's participation for the full duration of the study, or was not in the best interest of the participant to participate, in the opinion of the treating investigator.

14. Had peripheral neuropathy &gt; Grade 1.

15. Had a known psychiatric or substance abuse disorder that would interfere with cooperation with the requirements of the study.

16. Was a WOCBP who had a positive urine pregnancy test within 24 hours prior to randomization or treatment allocation (see Appendix 3 of the study protocol [16.1.1]).

17. Removed.

18. Had active or clinically significant cardiac disease.
19. Had a known history of HIV.
20. Had a known history of hepatitis B or known active hepatitis C virus infection.

21. Had severe hypersensitivity ( ≥ Grade 3) to pembrolizumab, trastuzumab, study chemotherapy agents and/or to any excipients, murine proteins, or platinum-containing products.

22. Had an allogeneic tissue/solid organ transplant.

23. Had received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD L2 agent or with an agent directed to another stimulatory or coinhibitory T-cell receptor (eg, CTLA-4, OX 40, CD137).

24. Had received a live vaccine within 30 days prior to the first dose of study treatment.

25. Was participating in or had participated in a study of an investigational agent or had used an investigational device within 4 weeks prior to the first dose of study treatment.

<div style=\"page-break-after: always\"></div>

## Treatments

Table 9-1Study Treatments

| StudyTreatment Name      | Formulation Dose                                   | Strength(s)b Unit Dose                                      | Dosage Level(s)                                                                                                                                                             | Administration Route of       | Use                                      | IMP/NIMIP             | Sourcing                                                                                |
|--------------------------|----------------------------------------------------|-------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------|------------------------------------------|-----------------------|-----------------------------------------------------------------------------------------|
| Pembrolizumab/Placebo    | Pembrolizumab/Placebo                              | Pembrolizumab/Placebo                                       | Pembrolizumab/Placebo                                                                                                                                                       | Pembrolizumab/Placebo         | Pembrolizumab/Placebo                    | Pembrolizumab/Placebo | Pembrolizumab/Placebo                                                                   |
| Pembrolizumab (MK-3475)a | Vial                                               | 25 mg/mL vial                                               | 200 mg on Day 1 of each cycle (Q3W)                                                                                                                                         | IV infusion via infusion pump | Experimental                             | IMP                   | Provided centrally by the Sponsor                                                       |
| Placebo                  | Solution for infusion, refer to the Phamacy Manual | N/A                                                         | On Day 1 of each cycle (Q3W)                                                                                                                                                | IV infusion via infusion pump | Placebo                                  | IMP                   | Provided locally by the study site, subsidiary, of designee                             |
| FP                       | FP                                                 | FP                                                          | FP                                                                                                                                                                          | FP                            | FP                                       | FP                    | FP                                                                                      |
| Cisplatinc               | Vial                                               | 1 mg/mL vial 20 mg vial                                     | 80 mg/m² on Day 1 of each cycle (Q3W)                                                                                                                                       | IV infusion                   | Comparator regimen and combination agent | NIMP                  | Providedcentrally by the Sponsor or locallyby the study site, subsidiary, or designee   |
| 5-FU                     | Vial                                               | 25 mg/mL vial 50 mg/mL vial                                 | 800 mg/m²/day continuous onDays 1-5 of each cycle (Q3W) (120 hours, or per local standard)                                                                                  | IV infusion                   | Comparator regimen and combination agent | NIMP                  | Provided centrally by the Sponsor or locallybythe study site, subsidiary, or designee   |
| CAPOX                    | CAPOX                                              | CAPOX                                                       | CAPOX                                                                                                                                                                       | CAPOX                         | CAPOX                                    | CAPOX                 | CAPOX                                                                                   |
| Oxaliplatind             | Vial                                               | 5 mg/mL vial 50 mg vial                                     | 130 mg/m²on Day1 of each cycle (Q3W) over 2 hours                                                                                                                           | IV infusion                   | Comparator regimen and combination agent | NIMP                  | Provided centrally by the Sponsor or locally by the study site, subsidiary, of designee |
| Capecitabine             | Tablet                                             | 150 mg tablet 500mg tablet                                  | 1000 mg/m²bid on Days 1-14 of each cycle (Q3W)                                                                                                                              | Oral                          | Comparator regimen and combination agent | NIMP                  | Provided centrally by the Sponsor or locally by the study site, subsidiary, of designee |
| SOX (Japan only)         | SOX (Japan only)                                   | SOX (Japan only)                                            | SOX (Japan only)                                                                                                                                                            | SOX (Japan only)              | SOX (Japan only)                         | SOX (Japan only)      | SOX (Japan only)                                                                        |
| S-1                      | Capsule                                            | 20 mg capsule  25 mg capsule                                | <1.25 m² BSA 40 mg bid on Days 1-14 of each cycle (Q3W). 1.25to<1.5m²BSA 50 mg bid on Days 1-14 of each cycle (Q3W). ≥1.5 m²BSA 60 mg bid on Days 1-14 of each cycle (Q3W). | Oral                          | Comparator regimen and combination agent | NIMP                  | Provided locally by the study site, subsidiary, or designee                             |
| Oxaliplatin              | Vial                                               | 5 mg/mL vial 50 mg vial                                     | 130 mg/m²onDay1 of each cycle (Q3W) over 2 hours                                                                                                                            | IV infusion                   | Comparator regimen and combination agent | NIMP                  | Provided locally by the study site, subsidiary, or designee                             |
| Trastuzumaba             | Trastuzumaba                                       | Trastuzumaba                                                | Trastuzumaba                                                                                                                                                                | Trastuzumaba                  | Trastuzumaba                             | Trastuzumaba          | Trastuzumaba                                                                            |
| Trastuzumab              | Vial                                               | 60 mg vial (Japan only) 150 mg vial 440 mg vial 600 mg vial | 8 mg/kg loadingdose,and then 6 mg/kg maintenance thereafter (Q3W)                                                                                                           | IV infusion                   | Comparator regimen and combination agent | NIMP                  | Provided centrally by the Sponsor or locally bythe study site, subsidiary, or designee  |

5-FU=5-fluorouracil; bid=2 times a day; BSA=body surface area; CAPOX=capecitabine/oxaliplatin; CDHP=5-chloro-2,4-dihydroxypyridine; FP= 5-fluorouracil plus cisplatin; IMP=Investigational MedicinalProduct;IV=intravenous;N/A=not applicable;NIMP=Non-Investigational MedicinalProduct;Oxo=potassium oxonate;Q3W=every 3weeks; S-1=combination product containing tegafur, a prodrug of 5-FU, and 2 types of enzyme inhibitors, CDHP and Oxo; SOX=S-1 plus oxaliplatin.

Pembrolizumab/trastuzumab will be administered until disease progression or other withdrawal criteria are met.

b The strength of treatment may vary depending on the source. The table captures the current available strengths, but could vary depending on availability.

C Duration of cisplatin treatment may be capped at 6 cycles as per local country guidelines; however, treatment with 5-FU may continue per protocol.

Durationof oxaliplatinmaybecapped at 6or8cycles asperlocal countryguidelines;however,treatment withcapecitabinemaycontinue perprotocol.

Definition of IMP and NIMP are based on guidance issued by the European Commission. Regional and/or Country differences of the definition of IMP/NIMP may exist. In thesecircumstances,locallegislationisfollowed.

<div style=\"page-break-after: always\"></div>

## Objectives/Outcomes/Endpoints

| Objective/Hypothesis                                                                                                                                                                                                                                                            | Endpoint                                                                                                                        |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------|
| Primary                                                                                                                                                                                                                                                                         |                                                                                                                                 |
| Objective: To compare PFS between treatment groups. Hypothesis (H1): Pembrolizumab in combination with trastuzumab plus chemotherapy is superior to trastuzumab plus chemotherapy alone in teims ofPFS per RECIST 1.1 as assessed by blinded independent central review (BICR). | PFS: The time from randomization to the first documented disease progression or death due to any cause, whichever occurs first. |

<div style=\"page-break-after: always\"></div>

| Objective: To compare OS between treatment groups. Hypothesis (H2): Pembrolizumab in combination with trastuzumab plus chemotherapy is superior to trastuzumab plus chemotherapy alone                                                                                                 | OS: The time from randomization to death due to any cause.                                                                      |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------|
| Secondary                                                                                                                                                                                                                                                                              |                                                                                                                                 |
| Objective: To compare ORR between treatment groups. Hypothesis (H3): Pembrolizumab in combination with trastuzumab plus chemotherapy is superior to trastuzumab plus chemotherapy alone per RECIST 1.1 as assessed by BICR in terms of ORR                                             | Objective Response (OR): Complete response (CR) or partial response (PR)                                                        |
| Objective: To estimate DOR, per RECIST 1.1 as assessed by BICR for each treatment group.                                                                                                                                                                                               | DOR: The time from first response (CR or PR) to subsequent disease progression or death from any cause, whichever occurs first. |
| Objective: To assess the safety and tolerability of pembrolizumab in combination with trastuzumab plus chemotherapy by proportion of adverse events (AEs).                                                                                                                             | Adverse events Discontinuation of study treatment due to AEs                                                                    |
| Tertiary/Exploratory                                                                                                                                                                                                                                                                   |                                                                                                                                 |
| Objective: To compare the change from baseline in health-related quality of life using the EORTC QLQ-C30 and the EORTC QLQ-STO22 among participants when treated with pembrolizumab in combination with trastuzumab plus chemotherapy compared to trastuzumab plus chemotherapy alone. | EORTC QLQ-C30 and EORTC QLQ-STO22 score.                                                                                        |

<div style=\"page-break-after: always\"></div>

| Objective/Hypothesis                                                                                                                                                                                                         | Endpoint                                                                                                                                                                                        |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Objective: To characterize utilities using EuroQoL EQ-5D among participants when treated with pembrolizumab in combination with trastuzumab plus chemotherapy compared to trastuzumab plus chemotherapy alone.               | Health utility scores assessed from the EQ-5D-5L                                                                                                                                                |
| Objective: To evaluate the genetic and genomic correlates of treatment in pre- and post-treatment blood samples where available.                                                                                             | Expression of PD-1, PD-L1 and PD-L2 by IHC or ribonucleic acid (RNA) sequencing. Genetic alterations in PD-1, PD-L1 and PD-L2 on chromosome 9p24.1 by fluorescent in situ hybridization (FISH). |
| Objective: To identify molecular (genomic, metabolic and/or proteomic) biomarkers that may be indicative of clinical response/resistance, safety, pharmacodynamic activity, and/or the mechanism of action of pembrolizumab  | Germline genetic variation, genetic (DNA) mutations from tumor, tumor and blood RNA variation, proteomics and IHC, and other biomarkers                                                         |
| To compare PFS and ORR using modified RECIST 1.1 for immune- based therapeutics (iRECIST), as assessed by the investigator, following administration of pembrolizumab versus placebo when each is combined with chemotherapy | PFS using iRECIST OR using iRECIST                                                                                                                                                              |

## Sample size

The study was planned to randomize approximately 692 participants in the Global Cohort in a 1:1 ratio to receive either pembrolizumab or placebo in combination with trastuzumab plus chemotherapy (FP or CAPOX). An additional 40 participants were planned to be randomized in the study as a Japan-specific SOX Cohort in a 1:1 ratio between the 2 arms. Data from this cohort has been analyzed separately from the Japanese Global Cohort participants, who were randomized as part of the Global Cohort and follow the FP or CAPOX treatment regimens to which they are assigned.

## Sample Size and Power Calculations for PFS and OS

The study includes dual-primary efficacy endpoints: 1) PFS per RECIST 1.1 as assessed by BICR and 2) OS.

The sample size (number of participants) calculations were based on the following assumptions: (1) the enrollment period was 28 months and the ramp-up period of enrolment was 6 months; (2) the duration of PFS and OS is assumed to follow an exponential distribution; (3) median PFS was assumed

<div style=\"page-break-after: always\"></div>

to be 6.7 months in the control group with a true HR of 0.7; (4) median OS was assumed to be 13.8 months in the control group with a true HR ratio of 0.75.

## Progression-free Survival

It was expected that with approximately 606 PFS events at final analysis (FA), the study has approximately 95% power for detecting a HR of 0.7 at an initially assigned 0.003 (1-sided) significance level.

## Overall Survival

It was expected that with approximately 551 deaths at FA, the study has approximately 90% power for detecting an HR of 0.75 at an initially assigned 0.020 (1-sided) significance level.

Software used for sample size calculation

Power and interim analyses calculations were performed using the gsDesign R package.

## Randomisation

Treatment allocation/randomization occurred centrally using an interactive response technology (IRT) system. There are 2 study treatment arms. Participants were assigned randomly in a 1:1 ratio to pembrolizumab and saline placebo, respectively.

Treatment randomization was stratified based on the following criteria:

1. For Global cohort only:
- Geographic region (Europe/Israel/North America/Australia versus Asia versus Rest of the World including South America)
- PD-L1 status (positive (CPS ≥ 1) versus negative (CPS&lt;1))
- Chemotherapy regimen (FP or CAPOX), which was chosen prior to randomization in the study.
2. Japan-specific SOX cohort:
- Disease status (ECOG 0 versus ECOG 1)

## Blinding (masking)

This study has been conducted as a double-blind study under in-house blinding procedures. The participant and the investigator who were involved in the study treatment administration or clinical evaluation of the participants were unaware of the group assignments. Pembrolizumab and placebo were prepared and/or dispensed in a blinded fashion by an unblinded pharmacist or other qualified site personnel dispensed in a blinded fashion by an unblinded pharmacist or unblinded qualified study site.

The official, final database has not been unblinded until medical/scientific review has been performed, protocol deviations have been identified, and data have been declared final and complete. Related to the planned interim analyses, an external Data Monitoring Committee (DMC) served as the primary reviewer of the results of the interim analyses of the study and had the role to make (if needed) recommendations for discontinuation or protocol modifications to an executive committee of the Sponsor who might have been unblinded to results at treatment level in order to act on these recommendations.

<div style=\"page-break-after: always\"></div>

## Statistical methods

Protocol Amendments involving statistical methods

The protocol was subject to eight amendments, of which Amendment 5 (20-May-2020), Amendment 6 (07-Jul-2020) and Amendment 8 (07-Apr-2022) modified the SAP language as follows.

Amendment 5 (20-May-2020): PFS endpoint was added to the first interim analysis (IA1) as an administrative look and futility analysis for ORR was removed from the IA1. The protocol was also updated to clarify how to handle with participants with positive response to study treatment resulting in the opportunity to have curative surgical resection. Among these patients, only patients who had CR or PR prior to the curative surgical resection were used for ORR endpoint. In addition, the associated primary censoring rules of PFS were updated and a sensitivity analysis of PFS in which participants were censored at the time of curative surgical resection were added.

Amendment 6 (07-Jul-2020): Based on Regulatory Authority input, the data might have been immature for PFS at time of IA1 since the enrolment was not completed. For this reason the PFS endpoint was removed from IA1.

Amendment 8 (07-APR-2022): To accommodate the situation in case of significantly slower than anticipated accrual of PFS and/or OS events, greater flexibility of the timing of second interim analysis (IA2), third interim analysis (IA3) and FA has been introduced, allowing the Sponsor to conduct the analyses with up to 3 additional months of follow-up than the minimal follow-up as described above, or when the specified number of events are observed, whichever comes first. In addition, a clarification regarding the alpha spending at FA for PFS and OS hypothesis testing has been added; only the remaining Type I error that has not been spent at earlier analyses can be used during the FA.

The table below shows the history of changes.

<div style=\"page-break-after: always\"></div>

<!-- image -->

| Document          | Date of Issue   | Overall Rationale                                                                                                                                                                                                                                                      |
|-------------------|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Amendment 8       | 07-APR- 2022    | To update SAP language for the flexibility of the timing of the interim and final efficacy analyses in case of significantly slower than anticipated accrual of PFS and/or OS events                                                                                   |
| Amendment 7       | 24-JUN- 2021    | To update the pembrolizumab dose-modification and toxicity-management guidelines for irAEs and update protocol language to allow option for standard of care treatment beyond 35 cycles.                                                                               |
| Amendment 6       | 07-JUL- 2020    | Update SAP language to remove PFS analysis for IA1 in response to Regulatory Authority Input.                                                                                                                                                                          |
| Amendment 5       | 20-MAY- 2020    | Update protocol and SAP language regarding the definition of the curative surgical resection and modification of PFS primary censoring rule associated with the curative surgical resection, remove the ORR futility analysis for IA1, and add a PFS analysis for IA1. |
| Amendment 4       | 27-FEB- 2019    | Update Biomarker Collection Information.                                                                                                                                                                                                                               |
| Amendment 3       | 24-JAN- 2019    | Response to Regulatory Authority Input.                                                                                                                                                                                                                                |
| Amendment 2       | 16-AUG- 2018    | Response to Regulatory Authority Input.                                                                                                                                                                                                                                |
| Amendment 1       | 31-MAY- 2018    | Response to Regulatory Authority Input.                                                                                                                                                                                                                                |
| Original Protocol | 11-APR- 2018    | N/A                                                                                                                                                                                                                                                                    |

## Interim Analyses

There are three planned interim analyses (IA) in addition to the final analysis (FA) for this study. The efficacy analyses in this submission are based on IA2. The timing and the purpose of each analysis are summarized in the table below.

| Analysis   | Timing                                                                                                                                      | Estimated time after first Participant Randomized   | Primary Purpose of Analysis        |
|------------|---------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------|------------------------------------|
| IA1        | The first 260 participants with approximately 8.5 months follow-up.                                                                         | ~ 22.5 months                                       | • Efficacy analysis of OR          |
| IA2 a      | Approximately 542 PFS events have occurred and ~ 9 months after the last participant has been randomized.                                   | ~ 37 months                                         | • Efficacy analysis for PFS and OS |
| IA3 a      | Approximately 18 months after the last participant has been randomized AND ~ 606 PFS events have been observed. This is final PFS analysis. | ~ 46 months                                         | • Efficacy analysis for PFS and OS |

<div style=\"page-break-after: always\"></div>

| Final Analysis a                                                                     | Final OS analysis to be performed until approximately 28 months after the last participant has been randomized AND ~ 551 deaths have occurred.   | ~ 56 months                                                                          | • Efficacy analysis for OS                                                           |
|--------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------|
| ORR = Objective Response Rate; OS= Overall Survival; PFS = Progression-free Survival | ORR = Objective Response Rate; OS= Overall Survival; PFS = Progression-free Survival                                                             | ORR = Objective Response Rate; OS= Overall Survival; PFS = Progression-free Survival | ORR = Objective Response Rate; OS= Overall Survival; PFS = Progression-free Survival |

At the time of data cutoff (25-MAY-2022) for IA2, approximately 484 PFS events (234 in the pembrolizumab plus SOC group and 250 in the SOC group) and 415 OS events (202 in the pembrolizumab plus SOC group and 213 in the SOC group) occurred. Median duration of follow-up in the ITT population (N=698) was 16.1 months (range: 0.6 to 41.6 months) and 14.8 months (range: 0.3, 41.2 months) in the pembrolizumab plus SOC group and SOC group, respectively. For CPS ≥1, the median duration of follow-up of participants was 17.0 months (range: 0.6 to 41.6 months) and 13.9 months (range: 0.3 to 41.2 months) in the pembrolizumab plus SOC group and SOC group, respectively, which was consistent with the ITT population.

## Error probabilities, adjustment for multiplicity

The trial used an extension of the graphical method of Maurer and Bretz to provide strong multiplicity control for multiple hypotheses while making the interim and final analysis timing be more flexible. According to the Maurer and Bretz approach, study hypotheses may be tested in a group sequential fashion, and when a particular null hypothesis is rejected, the alpha allocated to that hypothesis can be reallocated to other hypothesis tests. The overall Type-I error rate among the multiple hypotheses was strongly controlled at 2.5% (one-sided). Figure below shows the Type I Error Reallocation Strategy according to Protocol Amendment 8.

<!-- image -->

The initial 1-sided alpha allocation for each hypothesis in the ellipse representing the hypothesis. The weights for reallocation from each hypothesis to the others are represented in the boxes on the lines connecting hypotheses. The extended graphical method spends alpha as a function of the minimum of the actual event information fraction and the expected event information fraction. This ensures that

<div style=\"page-break-after: always\"></div>

the actual spending will be no more aggressive than the planned, while at the same time ensuring that not all alpha is spent prior to final planned event counts.

## ORR

The study initially allocated alpha=0.002, 1-sided, to test ORR, and ORR was tested only at the IA1. However, if the test did not reach statistical significance at IA1, the p-value from IA1 could has been compared to an updated alpha-level if the null hypotheses for both PFS and OS were rejected at a later time. Power at the possible alpha-levels as well as the approximate treatment difference required to reach the bound (ORR difference) at Interim Analysis 1 are shown in the table below.

|   Alpha | ORRdifference   |   Power |
|---------|-----------------|---------|
|   0.002 | ~0.17           |    0.9  |
|   0.025 | ~ 0.11          |    0.99 |

## PFS

The initial alpha-level for testing PFS was 0.003. If the null hypothesis for ORR was rejected, half of its alpha was reallocated to PFS hypothesis testing. If the null hypothesis for OS was rejected, then alpha=0.02 was essentially fully reallocated to PFS hypothesis testing. Thus, the PFS null hypothesis might be tested at alpha=0.003, alpha=0.004 (if the ORR null hypothesis was rejected but not the OS null hypothesis), alpha=0.023 (if the OS null hypothesis was rejected but not the ORR null hypothesis), or alpha=0.025 (if both the ORR and OS null hypotheses were rejected). Table below shows the boundary properties for each of these alpha-levels for the interim analyses, which were derived using a Lan-DeMets O'Brien-Fleming spending function based on predicted number of events at the planned time of interim analysis. The final row indicates the total power to reject the null hypothesis for PFS at each alpha-level.

| Analysis          | Value               |   α=0.003 |   α=0.004 |   α=0.023 |   α=0.025 |
|-------------------|---------------------|-----------|-----------|-----------|-----------|
| IA 2: 90%a N: 692 | Z                   |    2.927  |    2.826  |    2.137  |    2.1    |
| Events: 542       | p (l-sided)b        |    0.0017 |    0.0024 |    0.0163 |    0.0179 |
| Month: 37         | HR at bounde        |    0.7777 |    0.7849 |    0.8326 |    0.8353 |
| Month: 37         | P(Cross) ifHR=1d    |    0.0017 |    0.0024 |    0.0163 |    0.0179 |
| Month: 37         | P(Cross) if HR=0.7e |    0.8915 |    0.9091 |    0.9785 |    0.9804 |
| IA 3:100%a N: 692 | Z                   |    2.807  |    2.714  |    2.086  |    2.052  |
| Events: 606       | p(l-sided)b         |    0.0025 |    0.0033 |    0.0185 |    0.0201 |
| Month: 46         | HR at bounde        |    0.796  |    0.8024 |    0.8444 |    0.8467 |
| Month: 46         | P(Cross) ifHR=Id    |    0.003  |    0.004  |    0.023  |    0.025  |
| Month: 46         | P(Cross) if HR=0.7e |    0.9475 |    0.9569 |    0.9909 |    0.9917 |

<!-- image -->

The event counts for all analyses was used to compute correlations. Also note that if the OS or ORR null hypothesis was rejected at an interim or final analysis, each PFS interim and final analysis test might be compared to its updated bounds considering the alpha reallocation from the OS or ORR hypothesis.

<div style=\"page-break-after: always\"></div>

## OS

The OS hypothesis may be tested at alpha=0.02 (initially allocated alpha), alpha=0.023 (if the PFS but not the ORR null hypothesis was rejected), alpha=0.021(if the ORR but not the PFS null hypothesis was rejected), or alpha=0.025 (if both the ORR and PFS null hypotheses weree rejected). Table below shows the bounds and boundary properties for OS hypothesis testing derived using a Lan-DeMets O'Brien-Fleming spending function based on the predicted number of events at the planned time of interim analysis.

<!-- image -->

| Analysis                                                                                                                                                                                                                                                                                                                                                                                                                 | Value                                                                                                                                                                                                                                                                                                                                                                                                                    | α=0.02                                                                                                                                                                                                                                                                                                                                                                                                                   | α=0.021                                                                                                                                                                                                                                                                                                                                                                                                                  | α=0.023                                                                                                                                                                                                                                                                                                                                                                                                                  | α=0.025                                                                                                                                                                                                                                                                                                                                                                                                                  |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA 2: 73%a N: 692 Events: 401 Month: 37                                                                                                                                                                                                                                                                                                                                                                                  | Z                                                                                                                                                                                                                                                                                                                                                                                                                        | 2.493                                                                                                                                                                                                                                                                                                                                                                                                                    | 2.47                                                                                                                                                                                                                                                                                                                                                                                                                     | 2.426                                                                                                                                                                                                                                                                                                                                                                                                                    | 2.385                                                                                                                                                                                                                                                                                                                                                                                                                    |
| IA 2: 73%a N: 692 Events: 401 Month: 37                                                                                                                                                                                                                                                                                                                                                                                  | p(l-sided)b                                                                                                                                                                                                                                                                                                                                                                                                              | 0.0063                                                                                                                                                                                                                                                                                                                                                                                                                   | 0.0068                                                                                                                                                                                                                                                                                                                                                                                                                   | 0.0076                                                                                                                                                                                                                                                                                                                                                                                                                   | 0.0085                                                                                                                                                                                                                                                                                                                                                                                                                   |
| IA 2: 73%a N: 692 Events: 401 Month: 37                                                                                                                                                                                                                                                                                                                                                                                  | HR at bounde                                                                                                                                                                                                                                                                                                                                                                                                             | 0.7794                                                                                                                                                                                                                                                                                                                                                                                                                   | 0.7815                                                                                                                                                                                                                                                                                                                                                                                                                   | 0.7849                                                                                                                                                                                                                                                                                                                                                                                                                   | 0.7881                                                                                                                                                                                                                                                                                                                                                                                                                   |
| IA 2: 73%a N: 692 Events: 401 Month: 37                                                                                                                                                                                                                                                                                                                                                                                  | P(Cross) ifHR=1d                                                                                                                                                                                                                                                                                                                                                                                                         | 0.0063                                                                                                                                                                                                                                                                                                                                                                                                                   | 0.0068                                                                                                                                                                                                                                                                                                                                                                                                                   | 0.0076                                                                                                                                                                                                                                                                                                                                                                                                                   | 0.0085                                                                                                                                                                                                                                                                                                                                                                                                                   |
| IA 2: 73%a N: 692 Events: 401 Month: 37                                                                                                                                                                                                                                                                                                                                                                                  | P(Cross) if HR=0.75e                                                                                                                                                                                                                                                                                                                                                                                                     | 0.6513                                                                                                                                                                                                                                                                                                                                                                                                                   | 0.6598                                                                                                                                                                                                                                                                                                                                                                                                                   | 0.6757                                                                                                                                                                                                                                                                                                                                                                                                                   | 0.6902                                                                                                                                                                                                                                                                                                                                                                                                                   |
| IA 3: 89%a N: 692 Events: 488 Month: 46                                                                                                                                                                                                                                                                                                                                                                                  | Z                                                                                                                                                                                                                                                                                                                                                                                                                        | 2.272                                                                                                                                                                                                                                                                                                                                                                                                                    | 2.252                                                                                                                                                                                                                                                                                                                                                                                                                    | 2.213                                                                                                                                                                                                                                                                                                                                                                                                                    | 2.178                                                                                                                                                                                                                                                                                                                                                                                                                    |
| IA 3: 89%a N: 692 Events: 488 Month: 46                                                                                                                                                                                                                                                                                                                                                                                  | p(l-sided)b                                                                                                                                                                                                                                                                                                                                                                                                              | 0.0115                                                                                                                                                                                                                                                                                                                                                                                                                   | 0.0122                                                                                                                                                                                                                                                                                                                                                                                                                   | 0.0134                                                                                                                                                                                                                                                                                                                                                                                                                   | 0.0147                                                                                                                                                                                                                                                                                                                                                                                                                   |
| IA 3: 89%a N: 692 Events: 488 Month: 46                                                                                                                                                                                                                                                                                                                                                                                  | HR at bounde                                                                                                                                                                                                                                                                                                                                                                                                             | 0.814                                                                                                                                                                                                                                                                                                                                                                                                                    | 0.8158                                                                                                                                                                                                                                                                                                                                                                                                                   | 0.8186                                                                                                                                                                                                                                                                                                                                                                                                                   | 0.8212                                                                                                                                                                                                                                                                                                                                                                                                                   |
| IA 3: 89%a N: 692 Events: 488 Month: 46                                                                                                                                                                                                                                                                                                                                                                                  | P(Cross) ifHR=1d                                                                                                                                                                                                                                                                                                                                                                                                         | 0.0134                                                                                                                                                                                                                                                                                                                                                                                                                   | 0.0142                                                                                                                                                                                                                                                                                                                                                                                                                   | 0.0157                                                                                                                                                                                                                                                                                                                                                                                                                   | 0.0172                                                                                                                                                                                                                                                                                                                                                                                                                   |
| IA 3: 89%a N: 692 Events: 488 Month: 46                                                                                                                                                                                                                                                                                                                                                                                  | P(Cross) if HR=0.75e                                                                                                                                                                                                                                                                                                                                                                                                     | 0.8263                                                                                                                                                                                                                                                                                                                                                                                                                   | 0.8316                                                                                                                                                                                                                                                                                                                                                                                                                   | 0.8413                                                                                                                                                                                                                                                                                                                                                                                                                   | 0.85                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Final N: 692 Events: 551 Month: 56                                                                                                                                                                                                                                                                                                                                                                                       | Z                                                                                                                                                                                                                                                                                                                                                                                                                        | 2.152                                                                                                                                                                                                                                                                                                                                                                                                                    | 2.133                                                                                                                                                                                                                                                                                                                                                                                                                    | 2.097                                                                                                                                                                                                                                                                                                                                                                                                                    | 2.064                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Final N: 692 Events: 551 Month: 56                                                                                                                                                                                                                                                                                                                                                                                       | p(l-sided)b                                                                                                                                                                                                                                                                                                                                                                                                              | 0.0157                                                                                                                                                                                                                                                                                                                                                                                                                   | 0.0165                                                                                                                                                                                                                                                                                                                                                                                                                   | 0.018                                                                                                                                                                                                                                                                                                                                                                                                                    | 0.0195                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Final N: 692 Events: 551 Month: 56                                                                                                                                                                                                                                                                                                                                                                                       | HR at bounde                                                                                                                                                                                                                                                                                                                                                                                                             | 0.8325                                                                                                                                                                                                                                                                                                                                                                                                                   | 0.834                                                                                                                                                                                                                                                                                                                                                                                                                    | 0.8366                                                                                                                                                                                                                                                                                                                                                                                                                   | 0.8389                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Final N: 692 Events: 551 Month: 56                                                                                                                                                                                                                                                                                                                                                                                       | P(Cross) ifHR=1d                                                                                                                                                                                                                                                                                                                                                                                                         | 0.02                                                                                                                                                                                                                                                                                                                                                                                                                     | 0.021                                                                                                                                                                                                                                                                                                                                                                                                                    | 0.023                                                                                                                                                                                                                                                                                                                                                                                                                    | 0.025                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Final N: 692 Events: 551 Month: 56                                                                                                                                                                                                                                                                                                                                                                                       | P(Cross) if HR=0.75e                                                                                                                                                                                                                                                                                                                                                                                                     | 0.9001                                                                                                                                                                                                                                                                                                                                                                                                                   | 0.9035                                                                                                                                                                                                                                                                                                                                                                                                                   | 0.9097                                                                                                                                                                                                                                                                                                                                                                                                                   | 0.9151                                                                                                                                                                                                                                                                                                                                                                                                                   |
| HR=Hazard Ratio;IA=interim analysis Percentage of expected number of events at final analysis p (l-sided) is the nominal α for testing. c HR at bound is the approximate HR required to reach an efficacy bound. dP(Cross if HR=1) is the cumulative probability of crossing a bound under the null hypothesis.  P(Cross if HR=0.75) is the cumulative probability of crossing a bound under the alternative hypothesis. | HR=Hazard Ratio;IA=interim analysis Percentage of expected number of events at final analysis p (l-sided) is the nominal α for testing. c HR at bound is the approximate HR required to reach an efficacy bound. dP(Cross if HR=1) is the cumulative probability of crossing a bound under the null hypothesis.  P(Cross if HR=0.75) is the cumulative probability of crossing a bound under the alternative hypothesis. | HR=Hazard Ratio;IA=interim analysis Percentage of expected number of events at final analysis p (l-sided) is the nominal α for testing. c HR at bound is the approximate HR required to reach an efficacy bound. dP(Cross if HR=1) is the cumulative probability of crossing a bound under the null hypothesis.  P(Cross if HR=0.75) is the cumulative probability of crossing a bound under the alternative hypothesis. | HR=Hazard Ratio;IA=interim analysis Percentage of expected number of events at final analysis p (l-sided) is the nominal α for testing. c HR at bound is the approximate HR required to reach an efficacy bound. dP(Cross if HR=1) is the cumulative probability of crossing a bound under the null hypothesis.  P(Cross if HR=0.75) is the cumulative probability of crossing a bound under the alternative hypothesis. | HR=Hazard Ratio;IA=interim analysis Percentage of expected number of events at final analysis p (l-sided) is the nominal α for testing. c HR at bound is the approximate HR required to reach an efficacy bound. dP(Cross if HR=1) is the cumulative probability of crossing a bound under the null hypothesis.  P(Cross if HR=0.75) is the cumulative probability of crossing a bound under the alternative hypothesis. | HR=Hazard Ratio;IA=interim analysis Percentage of expected number of events at final analysis p (l-sided) is the nominal α for testing. c HR at bound is the approximate HR required to reach an efficacy bound. dP(Cross if HR=1) is the cumulative probability of crossing a bound under the null hypothesis.  P(Cross if HR=0.75) is the cumulative probability of crossing a bound under the alternative hypothesis. |

The event counts for all analyses were used to compute correlations. Also note that if the PFS or ORR null hypothesis were rejected at an interim or final analysis, each OS interim and final analysis test might be compared to its updated bounds considering the alpha reallocation from the PFS or ORR hypothesis.

## Efficacy analyses

The Intention-to-Treat (ITT) population, which consisted of all 698 randomized participants, served as the population for primary efficacy analyses. Any participant who receives a randomization number was considered to have been randomized. Participants were included in the treatment group to which they are randomized, regardless of whether they received study treatment. The ITT population excluding MSI-H participants served as the sensitivity analysis for the endpoints of PFS per RECIST 1.1 by BICR, OS, and ORR per RECIST 1.1 per BICR.

A summary of the analysis strategy for key efficacy endpoints as well as censoring rules for primary and sensitivity analyses of PFS are presented in the following tables:

<div style=\"page-break-after: always\"></div>

<!-- image -->

| Endpoint                                                                                                                                                                                                                                                                                                                                                                                                                                                  | Statistical Method t                                                                                                                                                                                                                                                                                                                                                                                                                                      | Analysis Population                                                                                                                                                                                                                                                                                                                                                                                                                                       | Missing Data Approach                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Primary Endpoints                                                                                                                                                                                                                                                                                                                                                                                                                                         | Primary Endpoints                                                                                                                                                                                                                                                                                                                                                                                                                                         | Primary Endpoints                                                                                                                                                                                                                                                                                                                                                                                                                                         | Primary Endpoints                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| PFS per RECIST 1.1 by BICR                                                                                                                                                                                                                                                                                                                                                                                                                                | Test: Stratified Log-rank test Estimation: Stratified Cox model with Efron's tie handling method                                                                                                                                                                                                                                                                                                                                                          | ITT                                                                                                                                                                                                                                                                                                                                                                                                                                                       | ·Primary censoring rule Sensitivity analysis 1 Sensitivity analysis 2 (More details are provided in [Table 1] Censoring Rules for Primary and Sensitivity Analyses of PFS)                                                                                                                                                                                                                                                                                |
| OS                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Test: Stratified Log-rank test Estimation:StratifiedCox model with Efron's tie handling method                                                                                                                                                                                                                                                                                                                                                            | ITT                                                                                                                                                                                                                                                                                                                                                                                                                                                       | Censored at the last known alive date                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Key SecondaryEndpoint                                                                                                                                                                                                                                                                                                                                                                                                                                     | Key SecondaryEndpoint                                                                                                                                                                                                                                                                                                                                                                                                                                     | Key SecondaryEndpoint                                                                                                                                                                                                                                                                                                                                                                                                                                     | Key SecondaryEndpoint                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| ORR per RECIST 1.1 by BICR                                                                                                                                                                                                                                                                                                                                                                                                                                | Test and Estimation: Stratified M&N method with sample size weights                                                                                                                                                                                                                                                                                                                                                                                       | ITT                                                                                                                                                                                                                                                                                                                                                                                                                                                       | Participants without assessments are considered non-responders and conservatively included in the denominator                                                                                                                                                                                                                                                                                                                                             |
| PFS = Progression-free survival; OS = Overall survival; ORR = Objective response rate; ITT = Intention to treat. Statistical models are described in further detail in the text.For stratified analyses, the stratification factors used for randomization (Protocol Section 6.3.1.1) will be applied to the analysis. Small strata will be combined in a way specified by a blinded statistician prior to the analysis. It Miettinen and Nurminen method | PFS = Progression-free survival; OS = Overall survival; ORR = Objective response rate; ITT = Intention to treat. Statistical models are described in further detail in the text.For stratified analyses, the stratification factors used for randomization (Protocol Section 6.3.1.1) will be applied to the analysis. Small strata will be combined in a way specified by a blinded statistician prior to the analysis. It Miettinen and Nurminen method | PFS = Progression-free survival; OS = Overall survival; ORR = Objective response rate; ITT = Intention to treat. Statistical models are described in further detail in the text.For stratified analyses, the stratification factors used for randomization (Protocol Section 6.3.1.1) will be applied to the analysis. Small strata will be combined in a way specified by a blinded statistician prior to the analysis. It Miettinen and Nurminen method | PFS = Progression-free survival; OS = Overall survival; ORR = Objective response rate; ITT = Intention to treat. Statistical models are described in further detail in the text.For stratified analyses, the stratification factors used for randomization (Protocol Section 6.3.1.1) will be applied to the analysis. Small strata will be combined in a way specified by a blinded statistician prior to the analysis. It Miettinen and Nurminen method |

Table 1 Censoring Rules for Primary and Sensitivity Analyses of PFS

| Situation                                                                                                                  | PrimaryAnalysis                                                                                                                            | Sensitivity Analysis 1                                                                                                | Sensitivity Analysis 2                                                                                                                                                                   |
|----------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PDor death documented after≤1misscd diseasc assessment, and before new anti-cancer therapy\", if any                        | Progressed at date of documentedPDor death                                                                                                 | Progressed at date of documented PD or death                                                                          | Progresscd at date of documented PDor death                                                                                                                                              |
| PDor death documented immcdiatcly after≥ 2 consccutive missed disease asscssments or aftcr new anti-canccr therapy, if any | Censored at last disease assessment prior to thccarlicr dateof≥2 consecutive misscd discasc asscssment and new anti-cancer therapy, if any | Progressed at date of documcntcd PD or death                                                                          | Progressed at dateof documented PD or dcath                                                                                                                                              |
| NoPDandnodeath;and new anticanccr trcatment is not initiated                                                               | Ccnsored at last discasc asscssmcnt                                                                                                        | Censored at last discasc asscssmcnt                                                                                   | Progrcsscdattreatmcnt discontinuationduc to reasons other than complete responsc; otherwise censorcd at last discase asscssmcnt if still onstudy treatment or completed study treatment. |
| No PD and no death; new anticancer trcatment is initiated                                                                  | Censored at last discasc assessment beforc new anticancertreatmcnt                                                                         | Censored at last discase assessmcnt                                                                                   | Progrcssed at date of initiation ofnew anticancertreatmentor discontinuation of trcatmentduetoreasons other than complctc responsc, whichever occurs later                               |
| #New anti-cancer therapy: excluding curative surgical resections (the detailed definition in Protocol Section 6.5.3).      | #New anti-cancer therapy: excluding curative surgical resections (the detailed definition in Protocol Section 6.5.3).                      | #New anti-cancer therapy: excluding curative surgical resections (the detailed definition in Protocol Section 6.5.3). | #New anti-cancer therapy: excluding curative surgical resections (the detailed definition in Protocol Section 6.5.3).                                                                    |

<div style=\"page-break-after: always\"></div>

Table 2 Censoring Rules for DOR

| Situation                                                                                                                                                                                                                                             | Date of Progression or Censoring                                                                                                                                                                                                                      | Outcome                                                                                                                                                                                                                                               |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| No progrcssion nor dcath, no new anti-canccr thcrapy initiated                                                                                                                                                                                        |                                                                                                                                                                                                                                                       | Censor (non-cvcnt)                                                                                                                                                                                                                                    |
| No progrcssion nor death, new anti-canccr therapy#initiated                                                                                                                                                                                           | Last adequate discasc asscssmcnt before new anti-cancer therapy initiated                                                                                                                                                                             | Censor (non-cvcnt)                                                                                                                                                                                                                                    |
| Dcath or progrcssion immcdiatcly after ≥ 2 consecutive missed discasc assessments or aftcr ncw anti-cancer therapy\", if any                                                                                                                           | Earlicr datc of last adcquatc discasc assessment prior to ≥ 2 misscdadcquatcdiscasc asscssments and ncw anti-canccr therapy,if any                                                                                                                    | Censor (mon-cvcnt)                                                                                                                                                                                                                                    |
| Dcath or progrcssion aftcr ≤ 1 misscd discasc asscssmcnts and beforc new anti-canccr thcrapy\", if any                                                                                                                                                 | PD or dcath                                                                                                                                                                                                                                           | End of responsc (Evcnt)                                                                                                                                                                                                                               |
| A missed disease assessment includes any assessment that is not obtained or is considered inadequate for evaluation of response. #new anti-cancer therapy: excluding curative surgicalresections (the detailed definition in Protocol Section 6.5.3). | A missed disease assessment includes any assessment that is not obtained or is considered inadequate for evaluation of response. #new anti-cancer therapy: excluding curative surgicalresections (the detailed definition in Protocol Section 6.5.3). | A missed disease assessment includes any assessment that is not obtained or is considered inadequate for evaluation of response. #new anti-cancer therapy: excluding curative surgicalresections (the detailed definition in Protocol Section 6.5.3). |

The non-parametric Kaplan-Meier method was used to estimate the PFS and OS curve in each treatment group. The treatment difference in PFS and OS was assessed by the stratified log-rank test. For PFS and OS a stratified Cox proportional hazard model with Efron's method of tie handling was used to assess the magnitude of the treatment difference between the treatment arms. The hazard ratio (HR) and its 95% confidence interval (CI) from the stratified Cox model with Efron's method of tie handling and with a single treatment covariate was reported. The same stratification factors used for randomization were applied to both the stratified log-rank test and the stratified Cox model.

For OS analysis, participants without documented death at the time of analysis will be censored at the date of last contact.

In order to evaluate the robustness of the PFS endpoint, one primary and two sensitivity analyses with a different set of censoring rules were performed. The censoring rules for primary and sensitivity analyses are summarized in Table 1.

Sensitivity analyses to adjust for the effect of treatment switching to other PD-1 or other new anticancer therapies on OS may be performed as model assumptions permit. Three recognized methods may be included: 1) the Rank Preserving Structural Failure Time (RPSFT) model proposed by Robins and Tsiatis (1989); 2) the two-stage model proposed by Latimer; and 3) the InverseProbability-of-Censoring Weighting (IPCW) model in which an examination of the appropriateness of the data to the assumptions is required by the methods. Other sensitivity analyses described for the PFS endpoint were applied to OS endpoint as appropriate.

The stratified Miettinen and Nurminen method was used for the comparison of the ORR between the two treatment groups. The difference in ORR and its 95% confidence interval from the stratified Miettinen and Nurminen method with strata weighting by sample size was reported. The stratification factors used for randomization were applied to the analysis. The same strategy of combination of small strata defined for the PFS analysis was used for the ORR analysis. The descriptive analysis of ORR based on all participants was performed after IA1. No formal hypothesis testing was conducted.

DOR was summarised descriptively using Kaplan-Meier medians and quartiles. Only the subset of patients who show a complete response (CR) or partial response (PR) were included in this analysis. For each DOR analysis, a corresponding summary of the censoring reasons for responding participant were also provided. Responding subjects who were alive, had not progressed, had not initiated new anti-cancer treatment, had not been determined to be lost to follow-up, and had a disease assessment

<div style=\"page-break-after: always\"></div>

within ~5 months of the data cutoff date were considered ongoing responders at the time of analysis. If a subject met multiple criteria for censoring, the censoring criterion that occurs earliest was applied. Censoring rules for DOR are summarized in Table 2.

## Subgroup analyses

Subgroup Analyses and Effect of Baseline Factors are planned. To determine whether the treatment effect is consistent across various subgroups, the between-group treatment effect for PFS and OS (with a nominal 95% CI) was estimated and plotted by treatment group within each category of the following classification variables: Age category: (&lt;65 versus ≥65 years); Sex: (female, male); Race: (Asian versus non-Asian); Region: Europe/Israel/North America/Australia versus Asia versus Rest of World (including South America); PD-L1: Positive versus Negative: MSI status; Primary location: Stomach versus GEJ; Histological subtype: Diffuse versus intestinal versus indeterminate; Tumor Burden: ≥ median versus &lt;median; Number of Metastases: ≤2 versus ≥3; Prior Gastrectomy/Esophagectomy: yes versus no; Baseline ECOG : 0 versus 1; Region: US versus ex-US; Chemotherapy regimen: FP or CAPOX.

The consistency of the treatment effect was assessed descriptively via summary statistics by category for the classification variables listed above. If any level of a subgroup variable had fewer than 20 participants, above analysis could not be performed for that level of the subgroup variable. The subgroup analyses for PFS and OS were conducted using an unstratified Cox model, and the subgroup analyses for ORR were conducted using the unstratified Miettinen and Nurminen method.

## Safety analyses

Safety analyses were based on the APaT population, which included all 696 randomized participants who received at least 1 dose of study intervention. The analysis of safety results followed a tiered approach as shown in the table below. There were no Tier 1 endpoints in this study, and Tier 2 parameters were assessed via point estimates with 95% CIs provided for provided for between group comparisons; only point estimates by intervention arm were provided for Tier 3 safety parameters. Because many 95% CIs were provided without adjustment for multiplicity, the analysis represents a helpful descriptive measure to be used in review, not a formal method for assessing the statistical significance of the between-group differences. These analyses were performed using the Miettinen and Nurminen method, an unconditional, asymptotic method.

Table 4 Analysis Strategy for Safety Parameters

| Safety Tier                   | Safety Endpoint                                                  | 95% CI for Treatment Comparison   | Descriptive Statistics        |
|-------------------------------|------------------------------------------------------------------|-----------------------------------|-------------------------------|
| Tier 2                        | AEs (≥10%of participants in onc of the trcatment groups)         | X                                 | X                             |
| Tier 2                        | Grade 3-5AEs ≥5% of participants in onc of thc trcatment groups) | X                                 | X                             |
| Tier 2                        | SAEs (5% of participants in onc of the trcatmcnt groups)         | X                                 | X                             |
|                               | AEs(<10% of participants in onc of thc trcatment groups)         |                                   | X                             |
| Ticr 3                        | Discontinuation duc to AE                                        |                                   | X                             |
|                               | Changc fromBasclineRcsults (laboratory tcst toxicity grade)      |                                   | X                             |
| X = results will be provided. | X = results will be provided.                                    | X = results will be provided.     | X = results will be provided. |

## PRO analyses

The patient-reported outcomes were exploratory objectives in KEYNOTE 811, and thus no formal hypotheses were formulated. PRO analyses for the EORTC QLQ-C30, EORTC QLQ-STO22, and EQ-5D-

<div style=\"page-break-after: always\"></div>

5L questionnaires were based on the PRO FAS population, which included all participants in the ITT population who had at least 1 PRO assessment and received at least 1 dose of study intervention.

## Results

## Participant flow

<!-- image -->

## Recruitment

A total of 1367 participants were screened in the study and 698 were randomized across 92 study sites in 19 countries.

All nonrandomized participants were screen failures.

<div style=\"page-break-after: always\"></div>

Participants Ongoing

Table 10-2 Disposition of Participants (Global Cohort) (ITT Population)

|                                                  | Pembrolizumab+SOC   | Pembrolizumab+SOC   | SOC   | SOC    |
|--------------------------------------------------|---------------------|---------------------|-------|--------|
|                                                  |                     | (%)                 |       | (%)    |
| Participants in population                       | 350                 |                     | 348   |        |
| StatusforStudyMedicationofTreatmentPhase         |                     |                     |       |        |
| Started                                          | 350                 |                     | 346   |        |
| Completed                                        | 24                  | (6.9)               | 17    | (4.9)  |
| Discontinued                                     | 257                 | (73.4)              | 286   | (82.7) |
| Adverse Event                                    | 35                  | (10.0)              | 28    | (8.1)  |
| Associated with COVID-19                         | 2                   | (0.6)               | 3     | (0.9)  |
| Clinical Progression                             | 22                  | (6.3)               | 21    | (6.1)  |
| Complete Response                                | 1                   | (0.3)               | 0     | (0.0)  |
| Non-Study Anti-Cancer Therapy                    | 5                   | (1.4)               | 5     | (1.4)  |
| Physician Decision                               | 4                   | (1.1)               | 4     | (1.2)  |
| Progressive Disease                              | 177                 | (50.6)              | 217   | (62.7) |
| Withdrawal By Subject                            | 13                  | (3.7)               | 11    | (3.2)  |
| Participants Ongoing                             | 69                  | (19.7)              | 43    | (12.4) |
| Status for Trial                                 |                     |                     |       |        |
| Discontinued                                     | 202                 | (57.7)              | 214   | (61.5) |
| Death                                            | 201                 | (57.4)              | 211   | (60.6) |
| Associated with COVID-19                         | 2                   | (0.6)               | 3     | (6:0)  |
| Withdrawal By Subject                            | 1                   | (0.3)               | 3     | (6:0)  |
| Not Associatedwith COVID-19,NoFurtherInformation | 0                   | (0.0)               | 1     | (0.3)  |
| Not Associated with COVID-19, Subsequently Died  |                     | (0.3)               | 2     | (0.6)  |

148

(42.3)

134

(38.5)

Ifthe overall count ofparticipants is calculated and displayed within a sectionin the firstrow, then itis used as the denominator for the percentage calculation. Otherwise, participants in population is used as the denominator for the percentage calculation.

For the status for study medication of treatment phase, participants treated with study medication is used as the denominator for percentage calculation.

Database Cutoff Date:25MAY2022

For the status for trial, participants in population is used as the denominator for percentage calculation.

Source: [P811V02MK3475: adam-adsl]

Table 10-3

Summary of Follow-up Duration

(Global Cohort)

(ITT Population)

| Follow-up duration (months)a                                                                                                                                                                                                   | Pembrolizumab+SOC (N=350)                                                                                                                                                                                                      | SOC (N=348)                                                                                                                                                                                                                    | (N=698)                                                                                                                                                                                                                        |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Median (Range)                                                                                                                                                                                                                 | 16.1 (0.6, 41.6)                                                                                                                                                                                                               | 14.8 (0.3, 41.2)                                                                                                                                                                                                               | 15.4 (0.3, 41.6)                                                                                                                                                                                                               |
| Mean (SD)                                                                                                                                                                                                                      | 17.7 (10.0)                                                                                                                                                                                                                    | 16.4 (10.0)                                                                                                                                                                                                                    | 17.1 (10.0)                                                                                                                                                                                                                    |
| aFollow-up duration is defined as the time from randomization to the date of death or the database cutoff date if the participant is still alive. Nis the number of participants in population. Database CutoffDate: 25MAY2022 | aFollow-up duration is defined as the time from randomization to the date of death or the database cutoff date if the participant is still alive. Nis the number of participants in population. Database CutoffDate: 25MAY2022 | aFollow-up duration is defined as the time from randomization to the date of death or the database cutoff date if the participant is still alive. Nis the number of participants in population. Database CutoffDate: 25MAY2022 | aFollow-up duration is defined as the time from randomization to the date of death or the database cutoff date if the participant is still alive. Nis the number of participants in population. Database CutoffDate: 25MAY2022 |

Source:[P811V02MK3475: adam-adsl]

## Conduct of the study

Important protocol deviations were reported for 35 and 27 participants in the pembrolizumab plus SOC and SOC groups, respectively. Of these, 4 participants in the pembrolizumab plus SOC group and 1 participant in the SOC group had important protocol deviations that were considered to be clinically important. The 4 participants in the pembrolizumab plus SOC group had clinically important protocol deviations related to study intervention as described in the table below.

<div style=\"page-break-after: always\"></div>

Table 10-4 Summary of Important Protocol Deviations Considered to be Clinically Important (Global Cohort) (ITT Population)

|                                                                                                                                                             | Pembrolizumab+SOC   | Pembrolizumab+SOC   | SOC   | SOC    |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------|---------------------|-------|--------|
|                                                                                                                                                             | n                   | (%)                 |       | (%)    |
| Participants in population                                                                                                                                  | 350                 |                     | 348   |        |
| with one or more clinicallyimportant protocol deviations                                                                                                    | 4                   | (1.1)               | 1     | (0.3)  |
| with no clinically important protocol deviations                                                                                                            | 346                 | (98.9)              | 347   | (99.7) |
| StudyIntervention                                                                                                                                           | 4                   | (1.1)               | 0     | (0.0)  |
| Participant was administered improperly stored study intervention that was deemed unacceptable for use.                                                     | 2                   | (0.6)               | 0     | (0.0)  |
| Participant was dispensed study intervention other than what was assigned in the allocation schedule,i.e.incorrect medication or potential cross-treatment. | 2                   | (0.6)               | 0     | (0.0)  |
| TrialProcedures                                                                                                                                             | 0                   | (0.0)               |       | (0.3)  |
| Failure toconduct key safety orefficacy assessments                                                                                                         | 0                   | (0.0)               |       | (0.3)  |
| Every participant is counted a single time for each applicable row and column. DatabaseCutoffDate:25MAY2022.                                                |                     |                     |       |        |

Source: [P811V02MK3475: adam-adsl] [P811V02MK3475: sdtm-dv; suppdv]

<div style=\"page-break-after: always\"></div>

## Baseline data

Table 10-5 Participant Characteristics (Global Cohort) (ITT Population)

|                                | Pembrolizumab + SOC   | Pembrolizumab + SOC   | SOC      | SOC    | Total    | Total   |
|--------------------------------|-----------------------|-----------------------|----------|--------|----------|---------|
|                                | 11                    | (%)                   | 11       | (%)    | 11       | (%)     |
| Participants in population     | 350                   |                       | 348      |        | 698      |         |
| Sex                            |                       |                       |          |        |          |         |
| Male                           | 284                   | (81.1)                | 280      | (80.5) | 564      | (80.8)  |
| Female                         | 66                    | (18.9)                | 68       | (19.5) | 134      | (19.2)  |
| Age (Years)                    |                       |                       |          |        |          |         |
| <65                            | 205                   | (58.6)                | 192      | (55.2) | 397      | (56.9)  |
| >=65                           | 145                   | (41.4)                | 156      | (44.8) | 301      | (43.1)  |
| Mean                           | 60.4                  |                       | 61.7     |        | 61.0     |         |
| SD                             | 11.8                  |                       | 10.8     |        | 11.3     |         |
| Median                         | 62.0                  |                       | 63.0     |        | 63.0     |         |
| Range                          | 19 to 85              |                       | 32 to 85 |        | 19 to 85 |         |
| Race                           |                       |                       |          |        |          |         |
| AmericanIndian Or AlaskaNative | 5                     | (1.4)                 | 6        | (1.7)  | 11       | (1.6)   |
| Asian                          | 119                   | (34.0)                | 121      | (34.8) | 240      | (34.4)  |
| Black Or African American      | 2                     | (0.6)                 | 2        | (0.6)  | 4        | (0.6)   |
| Multiple                       | 6                     | (1.7)                 | 5        | (1.4)  | 11       | (1.6)   |
| White                          | 217                   | (62.0)                | 209      | (60.1) | 426      | (61.0)  |
| Missing                        | 1                     | (0.3)                 | 5        | (1.4)  | 6        | (0.9)   |
| Ethnicity                      |                       |                       |          |        |          |         |
| Hispanic Or Latino             | 38                    | (10.9)                | 45       | (12.9) | 83       | (11.9)  |
| Not Hispanic Or Latino         | 309                   | (88.3)                | 292      | (83.9) | 601      | (86.1)  |
| Not Reported                   | 1                     | (0.3)                 | 10       | (2.9)  | 11       | (1.6)   |
| Unknown                        | 2                     | (0.6)                 | 1        | (0.3)  | 3        | (0.4)   |
| Age Group (Years)              |                       |                       |          |        |          |         |
| 18-39                          | 19                    | (5.4)                 | 14       | (4.0)  | 33       | (4.7)   |
| 40-49                          | 44                    | (12.6)                | 30       | (8.6)  | 74       | (10.6)  |
| 50-59                          | 73                    | (20.9)                | 99       | (28.4) | 172      | (24.6)  |
| 60-69                          | 135                   | (38.6)                | 109      | (31.3) | 244      | (35.0)  |
| 70-79                          | 74                    | (21.1)                | 88       | (25.3) | 162      | (23.2)  |
| >=80                           | 5                     | (1.4)                 | 8        | (2.3)  | 13       | (1.9)   |

<div style=\"page-break-after: always\"></div>

|                                                 | Pembrolizumab+ SOC   | Pembrolizumab+ SOC   | SOC   | SOC    | Total   | Total   |
|-------------------------------------------------|----------------------|----------------------|-------|--------|---------|---------|
|                                                 | 11                   | (%)                  | 11    | (%)    | 11      | (%)     |
| AgeGroup2(Years)                                |                      |                      |       |        |         |         |
| <65                                             | 205                  | (58.6)               | 192   | (55.2) | 397     | (56.9)  |
| 65 - 74                                         | 117                  | (33.4)               | 121   | (34.8) | 238     | (34.1)  |
| 75 -84                                          | 27                   | (7.7)                | 34    | (9.8)  | 61      | (8.7)   |
| 85+                                             | 1                    | (0.3)                | 1     | (0.3)  | 2       | (0.3)   |
| GeographicRegionof EnrollingSite                |                      |                      |       |        |         |         |
| Western Europe/Israel/North America/Australia   | 113                  | (32.3)               | 111   | (31.9) | 224     | (32.1)  |
| Asia                                            | 118                  | (33.7)               | 119   | (34.2) | 237     | (34.0)  |
| Rest ofthe World                                | 119                  | (34.0)               | 118   | (33.9) | 237     | (34.0)  |
| ECOGPerformanceScale                            |                      |                      |       |        |         |         |
| 0                                               | 146                  | (41.7)               | 145   | (41.7) | 291     | (41.7)  |
| 1                                               | 204                  | (58.3)               | 202   | (58.0) | 406     | (58.2)  |
| Missing                                         | 0                    | (0.0)                | 1     | (0.3)  | 1       | (0.1)   |
| Primary Location at Diagnosis                   |                      |                      |       |        |         |         |
| Adenocarcinoma of the gastroesophageal junction | 110                  | (31.4)               | 122   | (35.1) | 232     | (33.2)  |
| Adenocarcinoma ofthe stomach                    | 240                  | (68.6)               | 226   | (64.9) | 466     | (66.8)  |
| Current Disease Overall Stage                   |                      |                      |       |        |         |         |
| IIB                                             | 1                    | (0.3)                | 0     | (0.0)  | 1       | (0.1)   |
| IIIA                                            | 2                    | (0.6)                | 1     | (0.3)  | 3       | (0.4)   |
| IIB                                             | 5                    | (1.4)                | 2     | (0.6)  | 7       | (1.0)   |
| mIC                                             | 2                    | (0.6)                | 3     | (0.9)  | 5       | (0.7)   |
| IV                                              | 340                  | (97.1)               | 342   | (98.3) | 682     | (97.7)  |
| DiseaseStatus                                   |                      |                      |       |        |         |         |
| Locally advanced                                | 10                   | (2.9)                | 7     | (2.0)  | 17      | (2.4)   |
| Metastatic                                      | 340                  | (97.1)               | 341   | (98.0) | 681     | (97.6)  |
| Numberof MetastaticSites                        |                      |                      |       |        |         |         |
| 0-2                                             | 182                  | (52.0)               | 200   | (57.5) | 382     | (54.7)  |
| >=3                                             | 168                  | (48.0)               | 148   | (42.5) | 316     | (45.3)  |

<div style=\"page-break-after: always\"></div>

|                                           | Pembrolizumab + SOC   | Pembrolizumab + SOC   | SOC   | SOC    | Total   | Total   |
|-------------------------------------------|-----------------------|-----------------------|-------|--------|---------|---------|
|                                           | 11                    | (%)                   | 11    | (%)    | 11      | (%)     |
| HistologicalSubtype(Laurenclassification) |                       |                       |       |        |         |         |
| Diffuse                                   | 70                    | (20.0)                | 58    | (16.7) | 128     | (18.3)  |
| Intestinal                                | 197                   | (56.3)                | 185   | (53.2) | 382     | (54.7)  |
| Indeterminate                             | 83                    | (23.7)                | 105   | (30.2) | 188     | (26.9)  |
| Prior Gastrectomy/Esophagectomy           |                       |                       |       |        |         |         |
| Yes                                       | 51                    | (14.6)                | 64    | (18.4) | 115     | (16.5)  |
| No                                        | 299                   | (85.4)                | 284   | (81.6) | 583     | (83.5)  |
| PD-L1 Status (CPS>=1)                     |                       |                       |       |        |         |         |
| Positive                                  | 298                   | (85.1)                | 296   | (85.1) | 594     | (85.1)  |
| Negative                                  | 52                    | (14.9)                | 52    | (14.9) | 104     | (14.9)  |
| TumorBurden                               |                       |                       |       |        |         |         |
| <Median                                   | 161                   | (46.0)                | 166   | (47.7) | 327     | (46.8)  |
| >=Median                                  | 172                   | (49.1)                | 170   | (48.9) | 342     | (49.0)  |
| Missing                                   | 17                    | (4.9)                 | 12    | (3.4)  | 29      | (4.2)   |
| HER2Status                                |                       |                       |       |        |         |         |
| IHC 1+                                    | 1                     | (0.3)                 | 1     | (0.3)  | 2       | (0.3)   |
| IHC 2+ISH Equivocal                       | 0                     | (0.0)                 | 1     | (0.3)  | 1       | (0.1)   |
| IHC 2+ ISH Negalive                       | 1                     | (0.3)                 | 1     | (0.3)  | 2       | (0.3)   |
| IHC 2+ ISH Positive                       | 62                    | (17.7)                | 84    | (24.1) | 146     | (20.9)  |
| IHC 3+                                    | 286                   | (81.7)                | 261   | (75.0) | 547     | (78.4)  |
| MSIStatus                                 |                       |                       |       |        |         |         |
| MSI High                                  | 6                     | (1.7)                 | 2     | (0.6)  | 8       | (1.1)   |
| non-MSI-High                              | 326                   | (93.1)                | 329   | (94.5) | 655     | (93.8)  |
| Unknown                                   | 18                    | (5.1)                 | 17    | (4.9)  | 35      | (5.0)   |
| ChemotherapyRegimen                       |                       |                       |       |        |         |         |
| CAPOX                                     | 297                   | (84.9)                | 299   | (85.9) | 596     | (85.4)  |
| FP                                        | 53                    | (15.1)                | 49    | (14.1) | 102     | (14.6)  |

Western Europe includes Belgium, France, Germany, Spain, Italy, United Kingdom, Ireland, Latvia, Lithuania, which is consistent with the'Europe' region defined in the protocol for stratification. Database Cutoff Date: 25MA Y2022.

Source: [P811V02MK3475: adam-adsl]

## Numbers analysed

The ITT population, which consisted of all 698 randomized participants, whether or not treatment was administered, served as the population for primary efficacy analyses.

## Outcomes and estimation

## Primary Endpoints

Progression Free Survival (PFS)

<div style=\"page-break-after: always\"></div>

Figure 11-1 Kaplan-Meier Estimates of Progression-Free Survival (Primary Analysis) Based on BICR Assessment per RECIST 1.1 (Global Cohort) (ITT Population)

<!-- image -->

Database Cutoff Date: 25MAY2022.

Source: [P811V02MK3475: adam-adsl; adlte]

<div style=\"page-break-after: always\"></div>

## Table 11-1 Analysis of Progression-Free Survival (Primary Analysis) Based on BICR Assessment per RECIST 1.1 (Global Cohort) (ITT Population)

|                                   | Pembrolizumab+ SOC (N=350)   | SOC (N=348)       |
|-----------------------------------|------------------------------|-------------------|
| Number of Events (%)              | 234 (66.9)                   | 250 (71.8)        |
| DEATH                             | 36 (10.3)                    | 33 (9.5)          |
| DOCUMENTED PROGRESSION            | 198 (56.6)                   | 217 (62.4)        |
| Kaplan-Meier Estimates(months)a   |                              |                   |
| Median (95% CI)                   | 10.0 (8.6, 11.7)             | 8.1 (7.0, 8.5)    |
| [Q1, Q3]                          | [5.6, 24.7]                  | [4.3, 15.6]       |
| Person-months                     | 4000.4                       | 3181.8            |
| EventRate/100Person-months        | 5.8                          | 7.9               |
| vs SOC                            |                              |                   |
| Hazard Ratio (95% CI)b p-valuec   | 0.72 (0.60, 0.87) 0.0002     |                   |
| PFS Rate at month 6 (%) (95% CI)  | 72.7 (67.6, 77.2)            | 62.0 (56.4, 67.2) |
| PFS Rate at month 12 (%) (95% CI) | 44.3 (38.8, 49.7)            | 33.8 (28.4, 39.2) |
| PFS Rate at month 18 (%)(95% CI)  | 28.6 (23.4, 34.0)            | 22.0 (17.2,27.1)  |
| PFS Rate at month 24 (%) (95% CI) | 25.1 (20.1, 30.5)            | 14.2 (10.1,19.1)  |

From product-limit (Kaplan-Meier) method for censored data.

bBased on Cox regression model with Efron's method of tie handling with treatment as a covariate stratified by Geographic region (Western Europe/Israel/North Amenica/Australia, Asia and Rest ofthe World),PD-L1 status (positive vs. negative), and Chemotherapy regimen (FP or CAPOX) with small strata collapsed as pre-specified in the sSAP.

c One-sided p-value based on log-rank test stratified by Geographic region (Western Europe/Israel/North America/Australia, Asia and Rest ofthe World), PD-L1 status (positive vs. negative), and Chemotherapy regimen (FP or CAPOX) with small strata collapsed as pre-specified in the sSAP.

Western Europe includes Belgium, France, Germany, Spain, Italy,United Kingdom, Ireland, Latvia, Lithuania, which is consistent with the'Europe' region defined in the protocol for stratification.

BICR =Blinded Independent Central Review.

Database CutoffDate: 25MAY2022

Source: [P811V02MK3475: adam-adsl; adtte]

<div style=\"page-break-after: always\"></div>

## Overall Survival (OS)

Figure 11-3 Kaplan-Meier Estimates of Overall Survival (Global Cohort) (ITT Population)

<!-- image -->

Database Cutoff Date: 25MAY2022.

Source: [P811V02MK3475: adam-adsl; adlte]

<div style=\"page-break-after: always\"></div>

## Secondary Endpoints

## ORR

Table 11-2 Analysis of Overall Survival (Global Cohort) (ITT Population)

|                                  | Pembrolizumab + SOC (N=350)   | SOC (N=348)       |
|----------------------------------|-------------------------------|-------------------|
| Number ofEvents (%)              | 202 (57.7)                    | 213 (61.2)        |
| DEATH                            | 202 (57.7)                    | 213 (61.2)        |
| Kaplan-Meier Estimates (months)a |                               |                   |
| Median (95% CI)                  | 20.0 (17.8, 23.2)             | 16.9 (15.0, 19.8) |
| [Q1, Q3]                         | [10.2,]                       | [8.7,]            |
| Person-months                    | 6182.2                        | 5672.8            |
| Event Rate/100Person-months      | 3.3                           | 3.8               |
| vs SOC                           |                               |                   |
| Hazard Ratio (95% CIb p-valuec   | 0.87 (0.72, 1.06) 0.0842      |                   |
| OS Rate at month 6 (%) (95% CI)  | 88.9 (85.1, 91.7)             | 83.9 (79.6, 87.4) |
| OS Rate at month 12 (%) (95% CI) | 69.2 (64.0, 73.7)             | 63.2 (57.9, 68.1) |
| OS Rate at month 18 (%) (95% CI) | 55.3 (49.8, 60.6)             | 48.1 (42.6, 53.5) |
| OS Rate at month 24 (%)(95%CI)   | 42.9 (37.1, 48.5)             | 39.3 (33.7,44.8)  |

a From product-limit (Kaplan-Meier) method for censored data.

+ Based on Cox regression model with Efron's method of tie handling with treatment as a covariate stratified by Geographic region (Western Europe/Israel/North America/Australia,Asia and Rest ofthe World), PD-L1 status (positive vs. negative), and Chemotherapy regimen (FP or CAPOX) with small strata collapsed as pre-specifiedin the sSAP.
- e One-sided p-value based on log-rank test stratified by Geographic region (Western Europe/Israel/North America/Australia, Asia and Rest ofthe World), PD-L1 status (positive vs. negative), and Chemotherapy regimen (FP or CAPOX) with small strata collapsed as pre-specifiedin the sSAP.

NR = Not reached.

Western Europe includes Belgium, France, Germany, Spain, Italy, United Kingdom, Ireland, Latvia, Lithuania, which is consistent with the 'Europe'region definedin the protocol for stratification.

Database CutoffDate: 25MAY2022

Source: [P811V02MK3475: adam-adsl; adlte]

Table 11-3 Analysis of Objective Response with Confirmation Based on BICR Assessment per RECIST 1.1 (Global Cohort) (ITT Population)

|                   |     | Number of           | Objective Response Rate   | Diference in% Pembrolizumab +SOC vs. SOC   | Diference in% Pembrolizumab +SOC vs. SOC   |
|-------------------|-----|---------------------|---------------------------|--------------------------------------------|--------------------------------------------|
| Treatment         | N   | Objective Responses | (%) (95% CI)              | Estimate(95% CI*                           | p-Valueb                                   |
| Pembrolizumab+SOC | 350 | 254                 | 72.6 (67.6, 77.2)         | 12.8 (5.9, 19.7)                           | 0.00015                                    |
| SOC               | 348 | 208                 | 59.8 (54.4, 65.0)         |                                            |                                            |

Bascd onMiettinen&amp;Numminenmethod stratified byGcographicregion(WesternEurope/Israel/NorthAmerica/Australia,Asia andRest oftheWorld),PD-L1 status (positivevs.negative), and Chemotherapy regimen (FP or CAPOX)with small strata collapsed as pre-specified in the sSAP.WesternEurope includes Belgium,France, Germany,Spain,Italy,UnitedKingdom,Ireland,Latvia,Lithuania,which isconsistentwith theEurope'region definedinthe protocolfor stratification.

b One-sided p-value for testing. HO: difference in % = 0 versus Hl: difference in % &gt; 0.

Responses are based on BICR assessment per RECIST 1.1.

BICR=Blinded Independent Central Review.

Database CutoffDatc: 25MAY2022.

Sourcc:[P811V02MK3475: adam-adsl; adrs]

<div style=\"page-break-after: always\"></div>

## Table 11-4 Summary of Objective Response with Confirmation Based on BICR Assessment per RECIST 1.1 (Global Cohort) (ITT Population)

|                                  | Pembrolizumab + SOC   | Pembrolizumab + SOC   | Pembrolizumab + SOC   | SOC   | SOC   | SOC          |
|----------------------------------|-----------------------|-----------------------|-----------------------|-------|-------|--------------|
|                                  |                       | (%)                   | (95% CI)              |       | (%)   | (95% CI)     |
| Number of Subjects in Population | 350                   |                       |                       | 348   |       |              |
| Complete Response (CR)           | 49                    | 14.0                  | (10.5, 18.1)          | 38    | 10.9  | (7.8, 14.7)  |
| Partial Response (PR)            | 205                   | 58.6                  | (53.2, 63.8)          | 170   | 48.9  | (43.5, 54.2) |
| Overall Response (CR+PR)         | 254                   | 72.6                  | (67.6,77.2)           | 208   | 59.8  | (54.4, 65.0) |
| Stable Disease (SD)              | 67                    | 19.1                  | (15.2, 23.7)          | 96    | 27.6  | (23.0, 32.6) |
| Disease Control (CR+PR+SD)       | 321                   | 91.7                  | (88.3,94.4)           | 304   | 87.4  | (83.4, 90.7) |
| Progressive Disease (PD)         | 19                    | 5.4                   | (3.3, 8.3)            | 23    | 6.6   | (4.2,9.8)    |
| Not Evaluable (NEa)              | 1                     | 0.3                   | (0.0, 1.6)            | 5     | 1.4   | (0.5, 3.3)   |
| No Assessmentb                   | 9                     | 2.6                   | (1.2, 4.8)            | 16    | 4.6   | (2.7, 7.4)   |

Responses are based on BICR assessment per RECIST 1.1.

BICR = Blinded independent central review.

Stable disease includes SD, Non-CR/Non-PD, and NED.

NED: No lesions were identified at baseline assessment and there remained no lesions at post baseline assessment(s).

NE: post-baseline assessment(s) available however not being evaluable.

bNo Assessment: no post-baseline assessment available for response evaluation.

Database Cutoff Date: 25MAY2022.

Source:[P811V02MK3475:adam-adsl;adis]

Table 11-5 Summary of Time to Response and Duration of Response Based on BICR Assessment per RECIST 1.1 in Participants with Confirmed Response (Global Cohort)

|                                                                                                                                                                                                           | Pembrolizumab+SOC (N=350)                  | SOC (N=348)                               |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------|-------------------------------------------|
| Number of participants with responsea                                                                                                                                                                     | 254                                        | 208                                       |
| Time toResponse (months)                                                                                                                                                                                  |                                            |                                           |
| Mean (SD) Median (Range)                                                                                                                                                                                  | 1.9 (1.3) 1.4 (0.9-15.2)                   | 2.0 (1.1) 1.5 (0.7-7.0)                   |
| Response Durationb (months)                                                                                                                                                                               |                                            |                                           |
| Median (Range)                                                                                                                                                                                            | 11.2 (1.1+ -40.1+)                         | 9.0 (1.4+ -38.3+)                         |
| Number(%b) of Participants with ExtendedResponseDuration:                                                                                                                                                 |                                            |                                           |
| ≥3months ≥6 months ≥9 months ≥12months Includes participants with best objective response as confirmed complete response or partial response bFrom product-limit (Kaplan-Meier) method for censored data. | 234 (94.0) 179 (74.7) 136 (59.5) 94 (47.8) | 173 (89.9) 129 (68.9) 90 (50.3) 70 (41.7) |

Source: [P811V02MK3475: adam-adsl; adtte]

<div style=\"page-break-after: always\"></div>

Figure 11-7 Kaplan-Meier Estimates of Duration of Response Based on BICR Assessment per RECIST 1.1 (Global Cohort) (In Participants with Confirmed Response)

<!-- image -->

Database Cutoff Date: 25MAY2022.

Source: [P811V02MK3475: adam-adsl; adlte]

<div style=\"page-break-after: always\"></div>

## Patient Reported Outcomes

## Table 11-11 Analysis of Change from Baseline in EORTC QLQ-C30 Global Health Status/QoL to Week 24 (PRO FAS Population)

|                            | Baseline                   | Baseline      | Week 24   | Week 24       | Change from Baseline to Week 24   | Change from Baseline to Week 24   |
|----------------------------|----------------------------|---------------|-----------|---------------|-----------------------------------|-----------------------------------|
| Treatment                  | N                          | Mean (SD)     | N         | Mean (SD)     | N                                 | LS Mean (95% CI)t                 |
| Pembrolizumab + SOC        | 320                        | 68.91 (19.17) | 231       | 70.67 (17.65) | 344                               | 1.18 (-1.12, 3.49)                |
| SOC                        | 322                        | 67.26 (20.59) | 190       | 72.46 (17.25) | 339                               | 2.34 (-0.14,4.82)                 |
| Pairwise Comparison        |                            |               |           |               | Difference in LS Meanst (95% CI)  | p-Valuet                          |
| Pembrolizumab + SOC vs.SOC | Pembrolizumab + SOC vs.SOC |               |           |               | -1.16 (-4.23, 1.91)               | 0.4595                            |

- t Based on a cLDA model with the PRO scores as the response variable with covaniates for treatment by study visit interaction and stratification factois (Geographic region (Westerm Europe/Israel/North America/Australia, Asia and Rest of the World), PD-L1 status (positive vs. negative), and Chemotherapy regimen (FP or CAPOX)).
- Western Europe includes Belgium, France, Germany, Spain, Italy, United Kingdom, Ireland, Latvia, Lithuania, which is consistent with the Europe'region defined in the protocol for stratification.
- For baseline and Week 24, N is the number of participants in each treatment group with non-missing assessments at the specific time point; for change from baseline, N is the number of participants in the analysis population in each treatment group.
- b Based on Cox re gression model with Efron's method of tie handling with treatment as a covariate stratified by (Geographic region (Western Europe/Israel/North America/Australia, Asia and Rest of the World), PD-L1 status (positive vs. ne gative), and Chemotherapy regimen (FP or CAPOX)).
- d Two-sided p-value based on log-rank test stratified by (Geographic region (Westerm Europe/Israel/North America/Australia, Asia and Rest of the World), PDL1 status (positive vs. negative), and Chemotherapy regimen (FP or CAPOX).

- Two-sidedp-value is based on t test.

Database CutoffDate: 25MAY2022

Source: [P811V02MK3475: adam-adsl; adpro]

Table 14.2-52 Analysis of Time toTrueDeteriorationfor EORTC QLQ-STO22SymptomScalePain (PROFAS Population withBaseline)

| Treatment                   | N   | Number of Events (%)   | Median Time toTrue Deterioration a (months) (95% CI)   | Time to True Deterioration Rate at 12 months in % a (95% CI)   |
|-----------------------------|-----|------------------------|--------------------------------------------------------|----------------------------------------------------------------|
| Pembrolizumab+SOC           | 319 | 36 (11.3)              | NR (NR, NR)                                            | 86.5 (81.6, 90.2)                                              |
| SOC                         | 320 | 34 (10.6)              | NR (NR, NR)                                            | 87.8 (83.2, 91.1)                                              |
| PairwiseComparisons         |     |                        | Hazard Ratiob (95% CI)b                                | p-Value                                                        |
| Pembrolizumab + SOC vs. SOC |     |                        | 0.99 (0.62,1.58)                                       | 0.9681d                                                        |

From product-limit (Kaplan-Meier) method for censored data.

NR = Notreached.

Western Europe includes Belgium, France, Germany, Spain, Italy, United Kingdom, Ireland, Latvia, Lithuania, which is consistent with the Europe' region defined in the protocol for stratification.

- True deterioration is defined as the time to first onset of a 10 points or more deterioration (i.e., increase in score) from baseline with confirmation by the subsequentvisit of a10 points ormore deteriorationfrombaseline underright-censoringrule.

Database Cutoff Date: 25MAY2022.

Source:[P811V02MK3475: adam-adsl; adprotte]

<div style=\"page-break-after: always\"></div>

Table14.2-53 Analysis of Change from Baseline in EQ-5D-5L VAS to Week 24 (PRO FAS Population)

|                                                                                                                                                                                                                                                                                                                                         | Baseline                                                                                                                                                                                                                                                                                                                                | Baseline                                                                                                                                                                                                                                                                                                                                | Weck 24                                                                                                                                                                                                                                                                                                                                 | Weck 24                                                                                                                                                                                                                                                                                                                                 | ChangefromBaselinetoWeek24                                                                                                                                                                                                                                                                                                              | ChangefromBaselinetoWeek24                                                                                                                                                                                                                                                                                                              | ChangefromBaselinetoWeek24                                                                                                                                                                                                                                                                                                              |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Treatment                                                                                                                                                                                                                                                                                                                               | N                                                                                                                                                                                                                                                                                                                                       | Mean (SD)                                                                                                                                                                                                                                                                                                                               | N                                                                                                                                                                                                                                                                                                                                       | Mean (SD)                                                                                                                                                                                                                                                                                                                               | N                                                                                                                                                                                                                                                                                                                                       | LS Mean (95% CI)t                                                                                                                                                                                                                                                                                                                       | LS Mean (95% CI)t                                                                                                                                                                                                                                                                                                                       |
| Pembrolizumab+SOC                                                                                                                                                                                                                                                                                                                       | 324                                                                                                                                                                                                                                                                                                                                     | 76.33 (16.82)                                                                                                                                                                                                                                                                                                                           | 232                                                                                                                                                                                                                                                                                                                                     | 78.66 (14.35)                                                                                                                                                                                                                                                                                                                           | 344                                                                                                                                                                                                                                                                                                                                     | 0.95 (-0.87, 2.76)                                                                                                                                                                                                                                                                                                                      | 0.95 (-0.87, 2.76)                                                                                                                                                                                                                                                                                                                      |
| SOC                                                                                                                                                                                                                                                                                                                                     | 324                                                                                                                                                                                                                                                                                                                                     | 75.93 (18.61)                                                                                                                                                                                                                                                                                                                           | 191                                                                                                                                                                                                                                                                                                                                     | 80.16 (14.40)                                                                                                                                                                                                                                                                                                                           | 339                                                                                                                                                                                                                                                                                                                                     | 1.63 (-0.30,3.56)                                                                                                                                                                                                                                                                                                                       | 1.63 (-0.30,3.56)                                                                                                                                                                                                                                                                                                                       |
| Pairwise Comparison                                                                                                                                                                                                                                                                                                                     | Pairwise Comparison                                                                                                                                                                                                                                                                                                                     | Pairwise Comparison                                                                                                                                                                                                                                                                                                                     | Pairwise Comparison                                                                                                                                                                                                                                                                                                                     | Pairwise Comparison                                                                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                                                                                         | Difference in LS Meanst (95% CI)                                                                                                                                                                                                                                                                                                        | p-Valuet                                                                                                                                                                                                                                                                                                                                |
| Pembrolizumab+SOCvs.SOC                                                                                                                                                                                                                                                                                                                 | Pembrolizumab+SOCvs.SOC                                                                                                                                                                                                                                                                                                                 | Pembrolizumab+SOCvs.SOC                                                                                                                                                                                                                                                                                                                 | Pembrolizumab+SOCvs.SOC                                                                                                                                                                                                                                                                                                                 | Pembrolizumab+SOCvs.SOC                                                                                                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                                                                                                                         | -0.69 (-3.06,1.68)                                                                                                                                                                                                                                                                                                                      | 0.5698                                                                                                                                                                                                                                                                                                                                  |
| t Based on a cLDA model with the PRO scores as the response variable with covariates for treatment by study visit interaction and stratification factors (Geographic region (Western Europe/Israel/North America/Australia, Asia and Rest of the World), PD-L1 status (positive vs. negative), and Chemotherapy regimen (FP or CAPOX)). | t Based on a cLDA model with the PRO scores as the response variable with covariates for treatment by study visit interaction and stratification factors (Geographic region (Western Europe/Israel/North America/Australia, Asia and Rest of the World), PD-L1 status (positive vs. negative), and Chemotherapy regimen (FP or CAPOX)). | t Based on a cLDA model with the PRO scores as the response variable with covariates for treatment by study visit interaction and stratification factors (Geographic region (Western Europe/Israel/North America/Australia, Asia and Rest of the World), PD-L1 status (positive vs. negative), and Chemotherapy regimen (FP or CAPOX)). | t Based on a cLDA model with the PRO scores as the response variable with covariates for treatment by study visit interaction and stratification factors (Geographic region (Western Europe/Israel/North America/Australia, Asia and Rest of the World), PD-L1 status (positive vs. negative), and Chemotherapy regimen (FP or CAPOX)). | t Based on a cLDA model with the PRO scores as the response variable with covariates for treatment by study visit interaction and stratification factors (Geographic region (Western Europe/Israel/North America/Australia, Asia and Rest of the World), PD-L1 status (positive vs. negative), and Chemotherapy regimen (FP or CAPOX)). | t Based on a cLDA model with the PRO scores as the response variable with covariates for treatment by study visit interaction and stratification factors (Geographic region (Western Europe/Israel/North America/Australia, Asia and Rest of the World), PD-L1 status (positive vs. negative), and Chemotherapy regimen (FP or CAPOX)). | t Based on a cLDA model with the PRO scores as the response variable with covariates for treatment by study visit interaction and stratification factors (Geographic region (Western Europe/Israel/North America/Australia, Asia and Rest of the World), PD-L1 status (positive vs. negative), and Chemotherapy regimen (FP or CAPOX)). | t Based on a cLDA model with the PRO scores as the response variable with covariates for treatment by study visit interaction and stratification factors (Geographic region (Western Europe/Israel/North America/Australia, Asia and Rest of the World), PD-L1 status (positive vs. negative), and Chemotherapy regimen (FP or CAPOX)). |

Source:[P811V02MK3475: adam-adsl; adpro]

<div style=\"page-break-after: always\"></div>

## Ancillary analyses

## Subgroup analysis

## PFS

Figure 11-2: Forest plot of progression-free survival hazard ratio by subgroup factors based on BICR assessment per RECIST 1.1 (primary analysis) (global cohort) (ITT population)

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

For overall population, analysis is based on Cox regression model with Efron's method oftie handling with treatment as a covariate stratified by Geographic region (Western Europe/Israel/North America/Australia, Asia and Rest of the World), PD-L1 status (positive vs. negative), and Chemotherapy regimen (FP or CAPOX) with small strata collapsed as prespecifiedin the sSAP.

Westem Europe includes Belgium, France, Gemany, Spain, Italy,United Kingdom, Ireland, Latvia, Lithuania, whichis consistent with the'Europe'region defined in the protocol for stratification.

For subgroups, analysis is based on unstratified Cox regression model with treatment as a covariate.

Ifa subgroup variable has two levels and one level of the subgroup variable has fewer than 20 participants, then this subgroup is not displayed in the plot.

Database Cutoff Date: 25MAY2022.

Source:[P811V02MK3475: adam-adsl; adlte]

<div style=\"page-break-after: always\"></div>

## OS

Figure 11-4: Forest plot of overall survival hazard ratio by subgroup factors (global cohort) (ITT population)

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

Foroverall population,analysisisbasedonCoxregressionmodelwithEfron'smethodoftiehandlingwithtreatment as a covariate stratified by Geographic region (Western Europe/Israel/North America/Australia, Asia and Rest oftheWorld), specifiedinthesSAP.

WestemEuropeincludesBelgium,France,Germany,Spain,Italy,UnitedKingdom,Ireland,Latvia,Lithuania,whichis consistentwiththe'Europe'regiondefinedintheprotocolforstratification.

For subgroups,analysis is based on unstratified Cox regression model with treatment as a covariate.

Ifasubgroupvariablehastwolevels and onelevelofthesubgroupvariablehasfewerthan 20participants,then this subgroupisnot displayed in theplot.

DatabaseCutoffDate:25MAY2022.

## Analysis by PD-L1 status

## CPS≥1

## Patient characteristics

Source:[P811V02MK3475:adam-adsl;adtte]

<div style=\"page-break-after: always\"></div>

Table 14.1-16 Participant Characteristics (CPS&gt;=l Participants) (Global Cohort) (ITT Population)

|                                | Pembrolizumab + SOC   | Pembrolizumab + SOC   | SOC      | SOC    | Total   | Total   |
|--------------------------------|-----------------------|-----------------------|----------|--------|---------|---------|
|                                | n                     | (%)                   |          | (%)    | 1n      | (%)     |
| Participants in population     | 298                   |                       | 296      |        | 594     |         |
| Sex                            |                       |                       |          |        |         |         |
| Male                           | 240                   | (80.5)                | 237      | (80.1) | 477     | (80.3)  |
| Female                         | 58                    | (19.5)                | 59       | (19.9) | 117     | (19.7)  |
| Age (Yeais)                    |                       |                       |          |        |         |         |
| <65                            | 174                   | (58.4)                | 165      | (55.7) | 339     | (57.1)  |
| >=65                           | 124                   | (41.6)                | 131      | (44.3) | 255     | (42.9)  |
| Mean                           | 60.6                  |                       | 61.4     |        | 61.0    |         |
| SD                             | 11.8                  |                       | 10.8     |        | 11.3    |         |
| Median                         | 63.0                  |                       | 63.0     |        | 63.0    |         |
| Range                          | 19 to 85              |                       | 32 to 85 |        | 19to 85 |         |
| Race                           |                       |                       |          |        |         |         |
| AmericanIndian OrAlaska Native | 5                     | (1.7)                 | 6        | (2.0)  | 11      | (1.9)   |
| Asian                          | 97                    | (32.6)                | 97       | (32.8) | 194     | (32.7)  |
| Black Or African American      | 2                     | (0.7)                 | 2        | (0.7)  | 4       | (0.7)   |
| Multiple                       | 5                     | (1.7)                 | 4        | (1.4)  | 9       | (1.5)   |
| White                          | 188                   | (63.1)                | 184      | (62.2) | 372     | (62.6)  |
| Missing                        | 1                     | (0.3)                 | 3        | (1.0)  | 4       | (0.7)   |
| Ethnicity                      |                       |                       |          |        |         |         |
| Hispanic Or Latino             | 36                    | (12.1)                | 41       | (13.9) | 77      | (13.0)  |
| NotHispanic Or Latino          | 259                   | (86.9)                | 249      | (84.1) | 508     | (85.5)  |
| Not Reported                   | 1                     | (0.3)                 | 5        | (1.7)  | 6       | (1.0)   |
| Unknown                        | 2                     | (0.7)                 | 1        | (0.3)  | 3       | (0.5)   |
| Age Group (Years)              |                       |                       |          |        |         |         |
| 18-39                          | 16                    | (5.4)                 | 12       | (4.1)  | 28      | (4.7)   |
| 40-49                          | 34                    | (11.4)                | 27       | (9.1)  | 61      | (10.3)  |
| 50-59                          | 59                    | (19.8)                | 86       | (29.1) | 145     | (24.4)  |
| 60-69                          | 118                   | (39.6)                | 92       | (31.1) | 210     | (35.4)  |
| 70-79                          | 67                    | (22.5)                | 73       | (24.7) | 140     | (23.6)  |
| >=80                           | 4                     | (1.3)                 | 6        | (2.0)  | 10      | (1.7)   |

<div style=\"page-break-after: always\"></div>

|                                                 | Pembrolizumab + SOC   | Pembrolizumab + SOC   | SOC   | SOC    | Total   | Total   |
|-------------------------------------------------|-----------------------|-----------------------|-------|--------|---------|---------|
|                                                 | n                     | (%)                   | n     | (%)    | n       | (%)     |
| Age Group 2 (Years)                             |                       |                       |       |        |         |         |
| $9>                                             | 174                   | (58.4)                | 165   | (55.7) | 339     | (57.1)  |
| 65 -74                                          | 101                   | (33.9)                | 104   | (35.1) | 205     | (34.5)  |
| 75 -84                                          | 22                    | (7.4)                 | 26    | (8.8)  | 48      | (8.1)   |
| 85+                                             | 1                     | (0.3)                 | 1     | (0.3)  | 2       | (0.3)   |
| GeographicRegionof EnrollingSite                |                       |                       |       |        |         |         |
| WestemEurope/Israel/North America/Australia     | 97                    | (32.6)                | 96    | (32.4) | 193     | (32.5)  |
| Asia                                            | 96                    | (32.2)                | 96    | (32.4) | 192     | (32.3)  |
| Rest of the World                               | 105                   | (35.2)                | 104   | (35.1) | 209     | (35.2)  |
| ECOGPerformanceScale                            |                       |                       |       |        |         |         |
| 0                                               | 127                   | (42.6)                | 121   | (40.9) | 248     | (41.8)  |
| 1                                               | 171                   | (57.4)                | 174   | (58.8) | 345     | (58.1)  |
| Missing                                         | 0                     | (0.0)                 | 1     | (0.3)  | 1       | (0.2)   |
| PrimaryLocationatDiagnosis                      |                       |                       |       |        |         |         |
| Adenocarcinoma of the gastroesophageal junction | 97                    | (32.6)                | 99    | (33.4) | 196     | (33.0)  |
| Adenocarcinoma of the stomach                   | 201                   | (67.4)                | 197   | (66.6) | 398     | (67.0)  |
| Current Disease Overall Stage                   |                       |                       |       |        |         |         |
| IIB                                             | 1                     | (0.3)                 | 0     | (0.0)  | 1       | (0.2)   |
| VII                                             | 2                     | (0.7)                 | 1     | (0.3)  | 3       | (0.5)   |
| IIIB                                            | 5                     | (1.7)                 | 1     | (0.3)  | 6       | (1.0)   |
| mIC                                             | 0                     | (0.0)                 | 3     | (1.0)  | 3       | (0.5)   |
| IV                                              | 290                   | (97.3)                | 291   | (98.3) | 581     | (97.8)  |
| Disease Status                                  |                       |                       |       |        |         |         |
| Locally advanced                                | 8                     | (2.7)                 | 6     | (2.0)  | 14      | (2.4)   |
| Metastatic                                      | 290                   | (97.3)                | 290   | (98.0) | 580     | (97.6)  |
| Number of MetastaticSites                       |                       |                       |       |        |         |         |
| 0-2                                             | 149                   | (50.0)                | 172   | (58.1) | 321     | (54.0)  |

<div style=\"page-break-after: always\"></div>

|                                           | Pembrolizumab + SOC   | Pembrolizumab + SOC   | SOC   | SOC        | Total   | Total      |
|-------------------------------------------|-----------------------|-----------------------|-------|------------|---------|------------|
| >=3                                       | n 149                 | (%) (50.0)            | n 124 | (%) (41.9) | n 273   | (%) (46.0) |
| HistologicalSubtype(Laurenclassification) |                       |                       |       |            |         |            |
| Diffuse                                   | 56                    | (18.8)                | 49    | (16.6)     | 105     | (17.7)     |
| Intestinal                                | 169                   | (56.7)                | 158   | (53.4)     | 327     | (55.1)     |
| Indeterminate                             | 73                    | (24.5)                | 89    | (30.1)     | 162     | (27.3)     |
| PriorGastrectomy/Esophagectomy            |                       |                       |       |            |         |            |
| Yes                                       | 36                    | (12.1)                | 48    | (16.2)     | 84      | (14.1)     |
| No                                        | 262                   | (87.9)                | 248   | (83.8)     | 510     | (85.9)     |
| PD-L1 Status (CPS>=1)                     |                       |                       |       |            |         |            |
| Positive                                  | 298                   | (100.0)               | 296   | (100.0)    | 594     | (100.0)    |
| TumorBurden                               |                       |                       |       |            |         |            |
| <Median                                   | 139                   | (46.6)                | 139   | (47.0)     | 278     | (46.8)     |
| >=Median                                  | 147                   | (49.3)                | 146   | (49.3)     | 293     | (49.3)     |
| Missing                                   | 12                    | (4.0)                 | 11    | (3.7)      | 23      | (3.9)      |
| HER2Status                                |                       |                       |       |            |         |            |
| IHC 1+                                    | 1                     | (0.3)                 | 1     | (0.3)      | 2       | (0.3)      |
| IHC 2+ISH Equivocal                       | 0                     | (0.0)                 | 1     | (0.3)      | 1       | (0.2)      |
| IHC 2+ISH Negative                        | 1                     | (0.3)                 | 1     | (0.3)      | 2       | (0.3)      |
| IHC 2+ISH Positive                        | 51                    | (17.1)                | 68    | (23.0)     | 119     | (20.0)     |
| IHC 3+                                    | 245                   | (82.2)                | 225   | (76.0)     | 470     | (79.1)     |
| MSIStatus                                 |                       |                       |       |            |         |            |
| MSI High                                  | 6                     | (2.0)                 | 2     | (0.7)      | 8       | (1.3)      |
| non-MSI-High                              | 282                   | (94.6)                | 280   | (94.6)     | 562     | (94.6)     |
| Unknown                                   | 10                    | (3.4)                 | 14    | (4.7)      | 24      | (4.0)      |
| ChemotherapyRegimen                       |                       |                       |       |            |         |            |
| CAPOX                                     | 251                   | (84.2)                | 253   | (85.5)     | 504     | (84.8)     |

FP

47

(15.8)

43

(14.5)

90

(15.2)

WesternEuropeincludesBelgium,France,Germany,SpainItaly,UnitedKingdom,IrelandLatviaLithuania whichisconsistent with the'Europe'regiondefinedinthe protocol for stratification.

DatabaseCutoffDate:25MAY2022.

Source:[P811V02MK3475:adam-adsl]

<div style=\"page-break-after: always\"></div>

<!-- image -->

Database Cutoff Date: 25MAY2022.

Source: [P811V02MK3475: adam-adsl; adlte]

<div style=\"page-break-after: always\"></div>

## Table 11-6 Analysis of Progression-Free Survival (Primary Analysis) Based on BICR Assessment per RECIST 1.1 (CPS&gt;=1 Participants) (Global Cohort) (ITT Population)

|                                   | Pembrolizumab+ SOC (867=N)   | SOC (N=296)       |
|-----------------------------------|------------------------------|-------------------|
| Number of Events (%)              | 199 (66.8)                   | 215 (72.6)        |
| DEATH                             | 29 (9.7)                     | 30 (10.1)         |
| DOCUMENTED PROGRESSION            | 170 (57.0)                   | 185 (62.5)        |
| Kaplan-Meier Estimates (months)   |                              |                   |
| Median (95% CI)                   | 10.8 (8.5, 12.5)             | 7.2 (6.8, 8.4)    |
| [Q1, Q3]                          | [5.6, 27.6]                  | [4.3, 15.2]       |
| Person-months                     | 3530.2                       | 2644.1            |
| Event Rate/100Person-months       | 5.6                          | 8.1               |
| vs SOC                            |                              |                   |
| Hazard Ratio (95% CI)b p-valuec   | 0.70 (0.58, 0.85) 0.0001     |                   |
| PFS Rate at month 6 (%) (95% CI)  | 72.3 (66.7, 77.1)            | 59.9 (53.7, 65.5) |
| PFS Rate at month 12 (%) (95% CI) | 45.7 (39.7, 51.5)            | 32.9 (27.2,38.8)  |
| PFS Rate at month 18(%)(95% CI)   | 29.8 (24.2, 35.6)            | 20.7 (15.7,26.2)  |
| PFS Rate at month 24(%) (95% CI)  | 27.0(21.5, 32.8)             | 13.3 (9.0, 18.5)  |

a From product-limit (Kaplan-Meier) method for censored data.

b Based on Cox regression model with Efron's method of tie handling with treatment as a covariate.

c One-sided p-value based on log-rank test.

BICR =Blinded Independent Central Review.

Database CutoffDate:25MAY2022

Source: [P811V02MK3475: adam-adsl; adlte]

<div style=\"page-break-after: always\"></div>

Figure 11-9: Kaplan-Meier estimates of overall survival (CPS ≥1 participants) (global cohort) (ITT population)

<!-- image -->

DatabaseCutoff Date:25MAY2022.

Source: [P811V02MK3475: adam-adsl; adlte]

<div style=\"page-break-after: always\"></div>

Table 11-7: Analysis of overall survival (CPS ≥1 participants) (global cohort) (ITT population)

|                                  | Pembrolizumab + SOC (N=298)   | SOC (N=296)       |
|----------------------------------|-------------------------------|-------------------|
| Number ofEvents (%)              | 167 (56.0)                    | 183 (61.8)        |
| DEATH                            | 167 (56.0)                    | 183 (61.8)        |
| Kaplan-Meier Estimates (months)a |                               |                   |
| Median (95% CI)                  | 20.5 (18.2,24.3)              | 15.6 (13.5,18.6)  |
| [Q1, Q3]                         | [10.3,]                       | [8.4,]            |
| Person-months                    | 5383.7                        | 4684.2            |
| EventRate/100Person-months       | 3.1                           | 3.9               |
| vs SOC                           |                               |                   |
| Hazard Ratio (95% CI)b p-valuec  | 0.79 (0.64, 0.98) 0.0143      |                   |
| OS Rate at month 6 (%) (95% CI)  | 88.9 (84.8, 92.0)             | 82.4 (77.6, 86.3) |
| OS Rate at month 12 (%) (95% CI) | 69.2 (63.6, 74.1)             | 60.6 (54.7, 65.9) |
| OS Rate at month 18 (%) (95% CI) | 56.9 (50.9, 62.5)             | 45.6 (39.7, 51.4) |
| OS Rate at month 24 (%) (95% CI) | 45.8 (39.5,51.8)              | 37.8 (31.8, 43.8) |

a From product-limit (Kaplan-Meier) method for censored data.

bBased on Cox regression model with Efron's method of tie handling with treatment as a covariate.

c One-sided p-value based on log-rank test.

NR =Not reached.

Database CutoffDate: 25MAY2022

Source: [P811V02MK3475: adam-adsl; adlte]

Table 11-8 Analysis of Objective Response Wwith Confirmation Based on BICR Assessment per RECIST 1.1 (CPS&gt;=1 Participants) (Global Cohort) (ITT Population)

|                   |     | Number of           | Objective Response Rate   | Differencein%Pembrolizumab+SOC Vs.SOC   | Differencein%Pembrolizumab+SOC Vs.SOC   |
|-------------------|-----|---------------------|---------------------------|-----------------------------------------|-----------------------------------------|
| Treatment         | N   | Objective Responses | (%) (95% CI)              | Estimate(95% CI)*                       | p-Valueb                                |
| Pembrolizumab+SOC | 298 | 218                 | 73.2 (67.7, 78.1)         | 14.7 (7.1, 22.2)                        | 0.00008                                 |
| SOC               | 296 | 173                 | 58.4 (52.6, 64.1)         |                                         |                                         |

BasedonunstratifiedMiettinen&amp;Nurminenmethod.

b One-sided p-value for testing. HO: difference in % = 0 versus H1: difference in % &gt; 0.

Responses are based on BICR assessment per RECIST 1.1.

BICR=Blinded Independent Central Review.

DatabaseCutoffDate:25MAY2022

## ORR

Source: [P811V02MK3475: adam-adsl; adrs]

<div style=\"page-break-after: always\"></div>

## Table 11-9

Summary of ObjectiveResponsewith Confirmation

Based on BICR Assessment per RECIST 1.1

(CPS&gt;=1 Participants) (Global Cohort)

(ITT Population)

|                                  | Pembrolizumab + SOC   | Pembrolizumab + SOC   | Pembrolizumab + SOC   | SOC   | SOC   | SOC          |
|----------------------------------|-----------------------|-----------------------|-----------------------|-------|-------|--------------|
|                                  | n                     | (%)                   | (95% CI)              | n     | (%)   | (95% CI)     |
| Number of Subjects in Population | 298                   |                       |                       | 296   |       |              |
| Complete Response (CR)           | 42                    | 14.1                  | (10.4, 18.6)          | 29    | 9.8   | (6.7, 13.8)  |
| Partial Response (PR)            | 176                   | 59.1                  | (53.2,64.7)           | 144   | 48.6  | (42.8, 54.5) |
| OverallResponse(CR+PR)           | 218                   | 73.2                  | (67.7, 78.1)          | 173   | 58.4  | (52.6, 64.1) |
| Stable Disease (SD)              | 55                    | 18.5                  | (14.2, 23.3)          | 83    | 28.0  | (23.0, 33.5) |
| DiseaseControl(CR+PR+SD)         | 273                   | 91.6                  | (87.9, 94.5)          | 256   | 86.5  | (82.1, 90.2) |
| Progressive Disease (PD)         | 16                    | 5.4                   | (3.1, 8.6)            | 22    | 7.4   | (4.7, 11.0)  |
| Not Evaluable (NEa)              | 1                     | 0.3                   | (0.0, 1.9)            | 5     | 1.7   | (0.6,3.9)    |
| No Assessmentb                   | 8                     | 2.7                   | (1.2, 5.2)            | 13    | 4.4   | (2.4, 7.4)   |

Responses are based on BICR assessment per RECIST 1.1.

BICR=Blinded independent central review.

Stable disease includes SD, Non-CR/Non-PD, and NED.

NED: No lesions were identified at baseline assessment and there remained no lesions at post baseline assessment(s).

aNE: post-baseline assessment(s) available however not being evaluable.

bNo Assessment: no post-baseline assessment available for response evaluation.

Database Cutoff Date: 25MAY2022.

## DoR

Table 11-10 Summary of Time toResponse and Durationof Response Based on BICR Assessment per RECIST 1.1 in Participants with Confirmed Response (CPS&gt;=1 Participants) (Global Cohort)

|                                                                                                                                                                                                             | Pembrolizumab+SOC (N=298)                  | SOC (967=N)                               |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------|-------------------------------------------|
| Number of participants with responsea                                                                                                                                                                       | 218                                        | 173                                       |
| Time to Response(months)                                                                                                                                                                                    |                                            |                                           |
| Mean (SD) Median (Range)                                                                                                                                                                                    | 1.9 (1.4) 1.4 (0.9-15.2)                   | 1.9 (1.1) 1.5 (1.0-7.0)                   |
| ResponseDurationb(months)                                                                                                                                                                                   |                                            |                                           |
| Median (Range)                                                                                                                                                                                              | 11.3 (1.1+ - 40.1+)                        | 9.5 (1.4+ -38.3+)                         |
| Number(%b)ofParticipantswithExtendedResponseDuration:                                                                                                                                                       |                                            |                                           |
| ≥3 months ≥6 months ≥9 months ≥12 months Includes participants with best objective response as confirmed complete response or partial response bFrom product-limit (Kaplan-Meier) method for censored data. | 201 (93.9) 155 (74.5) 122 (60.9) 86 (49.2) | 141 (89.1) 104 (67.3) 74 (50.2) 58 (41.2) |

Source: [P811V02MK3475: adam-adsl; adtte]

Source:[P811V02MK3475:adam-adsl;adrs]

<div style=\"page-break-after: always\"></div>

## Forest plots for PFS in CPS≥1

Figure 14.2-42: Forest plot of progression-free survival hazard ratio by subgroup factors based on BICR assessment per RECIST 1.1 (primary analysis) (CPS ≥1 participants) (global cohort) (ITT population)

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

For overall population and subgroups, analyses are based on unstratified Cox regression model with Efrons method oftie handling with treatment as a covariate.

Ifa subgroupvariable has two levels and one level ofthe subgroup variable has fewer than 20 participants,then this subgroup is not displayed in the plot.

Database Cutoff Date: 25MAY2022.

## CPS&lt;1

## Patient characteristics

<div style=\"page-break-after: always\"></div>

Table 14.1-17 Participant Characteristics (CPS&lt;1 Participants) (Global Cohort) (ITT Population)

|                            | Pembrolizumab + SOC   | Pembrolizumab + SOC   | SOC      | SOC    | Total   | Total   |
|----------------------------|-----------------------|-----------------------|----------|--------|---------|---------|
|                            | n                     | (%)                   | n        | (%)    | n       | (%)     |
| Participants in population | 52                    |                       | 52       |        | 104     |         |
| Sex                        |                       |                       |          |        |         |         |
| Male                       | 44                    | (84.6)                | 43       | (82.7) | 87      | (83.7)  |
| Female                     | 8                     | (15.4)                | 9        | (17.3) | 17      | (16.3)  |
| Age (Years)                |                       |                       |          |        |         |         |
| <65                        | 31                    | (59.6)                | 27       | (51.9) | 58      | (55.8)  |
| >=65                       | 21                    | (40.4)                | 25       | (48.1) | 46      | (44.2)  |
| Mean                       | 59.2                  |                       | 63.0     |        | 61.1    |         |
| SD                         | 12.0                  |                       | 10.9     |        | 11.5    |         |
| Median                     | 59.0                  |                       | 64.0     |        | 62.0    |         |
| Range                      | 34 to 84              |                       | 32 to 80 |        | 32to 84 |         |
| Race                       |                       |                       |          |        |         |         |
| Asian                      | 22                    | (42.3)                | 24       | (46.2) | 46      | (44.2)  |
| Multiple                   | 1                     | (1.9)                 | 1        | (1.9)  | 2       | (1.9)   |
| White                      | 29                    | (55.8)                | 25       | (48.1) | 54      | (51.9)  |
| Missing                    | 0                     | (0.0)                 | 2        | (3.8)  | 2       | (1.9)   |
| Ethnicity                  |                       |                       |          |        |         |         |
| Hispanic Or Latino         | 2                     | (3.8)                 | 4        | (7.7)  | 6       | (5.8)   |
| Not Hispanic Or Latino     | 50                    | (96.2)                | 43       | (82.7) | 93      | (89.4)  |
| Not Reported               | 0                     | (0.0)                 | 5        | (9.6)  | 5       | (4.8)   |
| Age Group (Years)          |                       |                       |          |        |         |         |
| 18-39                      | 3                     | (5.8)                 | 2        | (3.8)  | 5       | (4.8)   |
| 40-49                      | 10                    | (19.2)                | 3        | (5.8)  | 13      | (12.5)  |
| 50-59                      | 14                    | (26.9)                | 13       | (25.0) | 27      | (26.0)  |
| 60-69                      | 17                    | (32.7)                | 17       | (32.7) | 34      | (32.7)  |
| 70-79                      | 7                     | (13.5)                | 15       | (28.8) | 22      | (21.2)  |
| >=80                       | 1                     | (1.9)                 | 2        | (3.8)  | 3       | (2.9)   |
| Age Group 2(Years)         |                       |                       |          |        |         |         |
| <65                        | 31                    | (59.6)                | 27       | (51.9) | 58      | (55.8)  |

<div style=\"page-break-after: always\"></div>

|                                                                                                                                                                                                                         | Pembrolizumab + SOC                                                                                                                                                                                                     | Pembrolizumab + SOC                                                                                                                                                                                                     | SOC                                                                                                                                                                                                                     | SOC                                                                                                                                                                                                                     | Total                                                                                                                                                                                                                   | Total                                                                                                                                                                                                                   |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                                                                                                                                                                         | n                                                                                                                                                                                                                       | (%)                                                                                                                                                                                                                     | n                                                                                                                                                                                                                       | (%)                                                                                                                                                                                                                     | n                                                                                                                                                                                                                       | (%)                                                                                                                                                                                                                     |
| 65 -74                                                                                                                                                                                                                  | 16                                                                                                                                                                                                                      | (30.8)                                                                                                                                                                                                                  | 17                                                                                                                                                                                                                      | (32.7)                                                                                                                                                                                                                  | 33                                                                                                                                                                                                                      | (31.7)                                                                                                                                                                                                                  |
| 75-84                                                                                                                                                                                                                   | 5                                                                                                                                                                                                                       | (9.0)                                                                                                                                                                                                                   | 8                                                                                                                                                                                                                       | (15.4)                                                                                                                                                                                                                  | 13                                                                                                                                                                                                                      | (12.5)                                                                                                                                                                                                                  |
| GeographicRegionofEnrollingSite                                                                                                                                                                                         |                                                                                                                                                                                                                         |                                                                                                                                                                                                                         |                                                                                                                                                                                                                         |                                                                                                                                                                                                                         |                                                                                                                                                                                                                         |                                                                                                                                                                                                                         |
| WestemEurope/Israel/North                                                                                                                                                                                               | 16                                                                                                                                                                                                                      | (30.8)                                                                                                                                                                                                                  | 15                                                                                                                                                                                                                      | (28.8)                                                                                                                                                                                                                  | 31                                                                                                                                                                                                                      | (29.8)                                                                                                                                                                                                                  |
| America/Australia Asia                                                                                                                                                                                                  | 22                                                                                                                                                                                                                      | (42.3)                                                                                                                                                                                                                  | 23                                                                                                                                                                                                                      | (44.2)                                                                                                                                                                                                                  | 45                                                                                                                                                                                                                      | (43.3)                                                                                                                                                                                                                  |
| Rest of theWorld                                                                                                                                                                                                        | 14                                                                                                                                                                                                                      | (26.9)                                                                                                                                                                                                                  | 14                                                                                                                                                                                                                      | (26.9)                                                                                                                                                                                                                  | 28                                                                                                                                                                                                                      | (26.9)                                                                                                                                                                                                                  |
| ECOGPerformanceScale                                                                                                                                                                                                    |                                                                                                                                                                                                                         |                                                                                                                                                                                                                         |                                                                                                                                                                                                                         |                                                                                                                                                                                                                         |                                                                                                                                                                                                                         |                                                                                                                                                                                                                         |
| 0                                                                                                                                                                                                                       | 19                                                                                                                                                                                                                      | (36.5)                                                                                                                                                                                                                  | 24                                                                                                                                                                                                                      | (46.2)                                                                                                                                                                                                                  | 43                                                                                                                                                                                                                      | (41.3)                                                                                                                                                                                                                  |
| 1                                                                                                                                                                                                                       | 33                                                                                                                                                                                                                      | (63.5)                                                                                                                                                                                                                  | 28                                                                                                                                                                                                                      | (53.8)                                                                                                                                                                                                                  | 61                                                                                                                                                                                                                      | (58.7)                                                                                                                                                                                                                  |
| PrimaryLocationatDiagnosis                                                                                                                                                                                              |                                                                                                                                                                                                                         |                                                                                                                                                                                                                         |                                                                                                                                                                                                                         |                                                                                                                                                                                                                         |                                                                                                                                                                                                                         |                                                                                                                                                                                                                         |
| Adenocarcinoma of the gastroesophageal junction                                                                                                                                                                         | 13                                                                                                                                                                                                                      | (25.0)                                                                                                                                                                                                                  | 23                                                                                                                                                                                                                      | (44.2)                                                                                                                                                                                                                  | 36                                                                                                                                                                                                                      | (34.6)                                                                                                                                                                                                                  |
| Adenocarcinomaofthestomach                                                                                                                                                                                              | 39                                                                                                                                                                                                                      | (75.0)                                                                                                                                                                                                                  | 29                                                                                                                                                                                                                      | (55.8)                                                                                                                                                                                                                  | 68                                                                                                                                                                                                                      | (65.4)                                                                                                                                                                                                                  |
| Current Disease Overall Stage                                                                                                                                                                                           |                                                                                                                                                                                                                         |                                                                                                                                                                                                                         |                                                                                                                                                                                                                         |                                                                                                                                                                                                                         |                                                                                                                                                                                                                         |                                                                                                                                                                                                                         |
| IIB                                                                                                                                                                                                                     | 0                                                                                                                                                                                                                       | (0.0)                                                                                                                                                                                                                   | 1                                                                                                                                                                                                                       | (61)                                                                                                                                                                                                                    | 1                                                                                                                                                                                                                       | (1.0)                                                                                                                                                                                                                   |
| mIC                                                                                                                                                                                                                     | 2                                                                                                                                                                                                                       | (3.8)                                                                                                                                                                                                                   | 0                                                                                                                                                                                                                       | (0.0)                                                                                                                                                                                                                   | 2                                                                                                                                                                                                                       | (1.9)                                                                                                                                                                                                                   |
| IV                                                                                                                                                                                                                      | 50                                                                                                                                                                                                                      | (96.2)                                                                                                                                                                                                                  | 51                                                                                                                                                                                                                      | (98.1)                                                                                                                                                                                                                  | 101                                                                                                                                                                                                                     | (97.1)                                                                                                                                                                                                                  |
| Disease Status                                                                                                                                                                                                          |                                                                                                                                                                                                                         |                                                                                                                                                                                                                         |                                                                                                                                                                                                                         |                                                                                                                                                                                                                         |                                                                                                                                                                                                                         |                                                                                                                                                                                                                         |
| Locally advanced                                                                                                                                                                                                        | 2                                                                                                                                                                                                                       | (3.8)                                                                                                                                                                                                                   | 1                                                                                                                                                                                                                       | (1.9)                                                                                                                                                                                                                   | 3                                                                                                                                                                                                                       | (2.9)                                                                                                                                                                                                                   |
| Metastatic                                                                                                                                                                                                              | 50                                                                                                                                                                                                                      | (96.2)                                                                                                                                                                                                                  | 51                                                                                                                                                                                                                      | (98.1)                                                                                                                                                                                                                  | 101                                                                                                                                                                                                                     | (97.1)                                                                                                                                                                                                                  |
| Number of Metastatic Sites                                                                                                                                                                                              |                                                                                                                                                                                                                         |                                                                                                                                                                                                                         |                                                                                                                                                                                                                         |                                                                                                                                                                                                                         |                                                                                                                                                                                                                         |                                                                                                                                                                                                                         |
| 0-2                                                                                                                                                                                                                     | 33                                                                                                                                                                                                                      | (63.5)                                                                                                                                                                                                                  | 28                                                                                                                                                                                                                      | (53.8)                                                                                                                                                                                                                  | 61                                                                                                                                                                                                                      | (58.7)                                                                                                                                                                                                                  |
| >=3                                                                                                                                                                                                                     | 19                                                                                                                                                                                                                      | (36.5)                                                                                                                                                                                                                  | 24                                                                                                                                                                                                                      | (46.2)                                                                                                                                                                                                                  | 43                                                                                                                                                                                                                      | (41.3)                                                                                                                                                                                                                  |
| HistologicalSubtype(Laurenclassification)                                                                                                                                                                               |                                                                                                                                                                                                                         |                                                                                                                                                                                                                         |                                                                                                                                                                                                                         |                                                                                                                                                                                                                         |                                                                                                                                                                                                                         |                                                                                                                                                                                                                         |
| Diffuse                                                                                                                                                                                                                 | 14                                                                                                                                                                                                                      | (26.9)                                                                                                                                                                                                                  | 9                                                                                                                                                                                                                       | (17.3)                                                                                                                                                                                                                  | 23                                                                                                                                                                                                                      | (22.1)                                                                                                                                                                                                                  |
| Intestinal                                                                                                                                                                                                              | 28                                                                                                                                                                                                                      | (53.8)                                                                                                                                                                                                                  | 27                                                                                                                                                                                                                      | (51.9)                                                                                                                                                                                                                  | 55                                                                                                                                                                                                                      | (52.9)                                                                                                                                                                                                                  |
| Indeterminate                                                                                                                                                                                                           | 10                                                                                                                                                                                                                      | (19.2)                                                                                                                                                                                                                  | 16                                                                                                                                                                                                                      | (30.8)                                                                                                                                                                                                                  | 26                                                                                                                                                                                                                      | (25.0)                                                                                                                                                                                                                  |
| PriorGastrectomy/Esophagectomy                                                                                                                                                                                          |                                                                                                                                                                                                                         |                                                                                                                                                                                                                         |                                                                                                                                                                                                                         |                                                                                                                                                                                                                         |                                                                                                                                                                                                                         |                                                                                                                                                                                                                         |
| Yes                                                                                                                                                                                                                     | 15                                                                                                                                                                                                                      | (28.8)                                                                                                                                                                                                                  | 16                                                                                                                                                                                                                      | (30.8)                                                                                                                                                                                                                  | 31                                                                                                                                                                                                                      | (29.8)                                                                                                                                                                                                                  |
| No                                                                                                                                                                                                                      | 37                                                                                                                                                                                                                      | (71.2)                                                                                                                                                                                                                  | 36                                                                                                                                                                                                                      | (69.2)                                                                                                                                                                                                                  | 73                                                                                                                                                                                                                      | (70.2)                                                                                                                                                                                                                  |
| PD-L1 Status (CPS>=1)                                                                                                                                                                                                   |                                                                                                                                                                                                                         |                                                                                                                                                                                                                         |                                                                                                                                                                                                                         |                                                                                                                                                                                                                         |                                                                                                                                                                                                                         |                                                                                                                                                                                                                         |
| Negative                                                                                                                                                                                                                | 52                                                                                                                                                                                                                      | (100.0)                                                                                                                                                                                                                 | 52                                                                                                                                                                                                                      | (100.0)                                                                                                                                                                                                                 | 104                                                                                                                                                                                                                     | (100.0)                                                                                                                                                                                                                 |
| TumorBurden                                                                                                                                                                                                             |                                                                                                                                                                                                                         |                                                                                                                                                                                                                         |                                                                                                                                                                                                                         |                                                                                                                                                                                                                         |                                                                                                                                                                                                                         |                                                                                                                                                                                                                         |
| <Median                                                                                                                                                                                                                 | 21                                                                                                                                                                                                                      | (40.4)                                                                                                                                                                                                                  | 28                                                                                                                                                                                                                      | (53.8)                                                                                                                                                                                                                  | 49                                                                                                                                                                                                                      | (47.1)                                                                                                                                                                                                                  |
| >=Median                                                                                                                                                                                                                | 26                                                                                                                                                                                                                      | (50.0)                                                                                                                                                                                                                  | 23                                                                                                                                                                                                                      | (44.2)                                                                                                                                                                                                                  | 49                                                                                                                                                                                                                      | (47.1)                                                                                                                                                                                                                  |
| Missing                                                                                                                                                                                                                 | 5                                                                                                                                                                                                                       | (9.6)                                                                                                                                                                                                                   | 1                                                                                                                                                                                                                       | (61)                                                                                                                                                                                                                    | 6                                                                                                                                                                                                                       | (5.8)                                                                                                                                                                                                                   |
| HER2 Status                                                                                                                                                                                                             |                                                                                                                                                                                                                         |                                                                                                                                                                                                                         |                                                                                                                                                                                                                         |                                                                                                                                                                                                                         |                                                                                                                                                                                                                         |                                                                                                                                                                                                                         |
| IHC 2+ISH Positive                                                                                                                                                                                                      | 11                                                                                                                                                                                                                      | (21.2)                                                                                                                                                                                                                  | 16                                                                                                                                                                                                                      | (30.8)                                                                                                                                                                                                                  | 27                                                                                                                                                                                                                      | (26.0)                                                                                                                                                                                                                  |
| IHC 3+                                                                                                                                                                                                                  | 41                                                                                                                                                                                                                      | (78.8)                                                                                                                                                                                                                  | 36                                                                                                                                                                                                                      | (69.2)                                                                                                                                                                                                                  | 77                                                                                                                                                                                                                      | (74.0)                                                                                                                                                                                                                  |
| MSIStatus                                                                                                                                                                                                               |                                                                                                                                                                                                                         |                                                                                                                                                                                                                         |                                                                                                                                                                                                                         |                                                                                                                                                                                                                         |                                                                                                                                                                                                                         |                                                                                                                                                                                                                         |
| non-MSI-High                                                                                                                                                                                                            | 44                                                                                                                                                                                                                      | (84.0)                                                                                                                                                                                                                  | 49                                                                                                                                                                                                                      | (94.2)                                                                                                                                                                                                                  | 93                                                                                                                                                                                                                      | (89.4)                                                                                                                                                                                                                  |
| Unknown                                                                                                                                                                                                                 | 8                                                                                                                                                                                                                       | (15.4)                                                                                                                                                                                                                  | 3                                                                                                                                                                                                                       | (5.8)                                                                                                                                                                                                                   | 11                                                                                                                                                                                                                      | (10.6)                                                                                                                                                                                                                  |
| Chemotherapy Regimen                                                                                                                                                                                                    |                                                                                                                                                                                                                         |                                                                                                                                                                                                                         |                                                                                                                                                                                                                         |                                                                                                                                                                                                                         |                                                                                                                                                                                                                         |                                                                                                                                                                                                                         |
| CAPOX                                                                                                                                                                                                                   | 46                                                                                                                                                                                                                      | (88.5)                                                                                                                                                                                                                  | 46                                                                                                                                                                                                                      | (88.5)                                                                                                                                                                                                                  | 92                                                                                                                                                                                                                      | (88.5)                                                                                                                                                                                                                  |
| FP                                                                                                                                                                                                                      | 6                                                                                                                                                                                                                       | (11.5)                                                                                                                                                                                                                  | 6                                                                                                                                                                                                                       | (11.5)                                                                                                                                                                                                                  | 12                                                                                                                                                                                                                      | (11.5)                                                                                                                                                                                                                  |
| Western Europe includes Belgium,France, Germany,Spain, Italy,United Kingdom, Ireland, Latvia,Lithuania, whichisconsistentwith the'Europe'regiondefinedinthe protocol for stratification. Database CutoffDate:25MAY2022. | Western Europe includes Belgium,France, Germany,Spain, Italy,United Kingdom, Ireland, Latvia,Lithuania, whichisconsistentwith the'Europe'regiondefinedinthe protocol for stratification. Database CutoffDate:25MAY2022. | Western Europe includes Belgium,France, Germany,Spain, Italy,United Kingdom, Ireland, Latvia,Lithuania, whichisconsistentwith the'Europe'regiondefinedinthe protocol for stratification. Database CutoffDate:25MAY2022. | Western Europe includes Belgium,France, Germany,Spain, Italy,United Kingdom, Ireland, Latvia,Lithuania, whichisconsistentwith the'Europe'regiondefinedinthe protocol for stratification. Database CutoffDate:25MAY2022. | Western Europe includes Belgium,France, Germany,Spain, Italy,United Kingdom, Ireland, Latvia,Lithuania, whichisconsistentwith the'Europe'regiondefinedinthe protocol for stratification. Database CutoffDate:25MAY2022. | Western Europe includes Belgium,France, Germany,Spain, Italy,United Kingdom, Ireland, Latvia,Lithuania, whichisconsistentwith the'Europe'regiondefinedinthe protocol for stratification. Database CutoffDate:25MAY2022. | Western Europe includes Belgium,France, Germany,Spain, Italy,United Kingdom, Ireland, Latvia,Lithuania, whichisconsistentwith the'Europe'regiondefinedinthe protocol for stratification. Database CutoffDate:25MAY2022. |

Source:[P811V02MK3475:adam-adsl]

<div style=\"page-break-after: always\"></div>

## PFS

Figure 14.2-20: Kaplan-Meier estimates of progression-free survival based on BICR assessment per RECIST 1.1 (primary analysis) (CPS &lt;1 participants) (global cohort) (ITT population)

<!-- image -->

Database CutoffDate: 25MAY2022.

<div style=\"page-break-after: always\"></div>

Table 14.2-24: Analysis of progression-free survival based on BICR assessment per RECIST 1.1 (primary analysis) (CPS &lt;1 participants) (global cohort) (ITT population)

|                                   | Pembrolizumab + SOC (N=52)   | SOC (N=52)        |
|-----------------------------------|------------------------------|-------------------|
| Number of Events (%)              | 35 (67.3)                    | 35 (67.3)         |
| DEATH                             | 7 (13.5)                     | 3 (5.8)           |
| DOCUMENTEDPROGRESSION             | 28 (53.8)                    | 32 (61.5)         |
| Kaplan-Meier Estimates (months)a  |                              |                   |
| Median (95% CI)                   | 9.5 (8.3, 11.3)              | 9.6 (7.9, 13.0)   |
| [Q1, Q3]                          | [6.9, 14.5]                  | [5.7, 21.9]       |
| Person-months                     | 470.2                        | 537.7             |
| EventRate/100Person-months        | 7.4                          | 6.5               |
| vs SOC                            |                              |                   |
| Hazard Ratio (95% C1)b p-valuec   | 1.17 (0.73, 1.89) 0.7432     |                   |
| PFS Rate at month 6 (%) (95% CI)  | 75.3 (60.6, 85.2)            | 74.6 (59.6, 84.7) |
| PFS Rate at month 12 (%) (95% CI) | 35.3 (21.4, 49.4)            | 38.6 (24.2, 52.8) |
| PFS Rate at month 18 (%) (95% CI) | 19.8 (8.2, 35.1)             | 29.7 (16.4, 44.2) |
| PFS Rate at month 24 (%) (95% CI) | 9.9 (2.0,25.4)               | 19.8 (8.7,34.2)   |

a From product-limit (Kaplan-Meier) method for censored data.

b Based on Cox regression model with Efron's method of tie handling with treatment as a covariate.

c One-sided p-value based on log-rank test.

BICR=Blinded Independent Central Review.

DatabaseCutoff Date:25MAY2022

Source:[P811V02MK3475:adam-adsl; adtte]

<div style=\"page-break-after: always\"></div>

Figure 14.2-22: Kaplan-Meier estimates of overall survival (CPS &lt;1 participants) (global cohort) (ITT population)

<!-- image -->

DatabaseCutoffDate:25MAY2022.

Table 14.2-26: Analysis of overall survival (CPS &lt;1 participants) (global cohort) (ITT population)

|                                 | Pembrolizumab + SOC (N=52)   | SOC (N=52)                |
|---------------------------------|------------------------------|---------------------------|
| Number of Events (%) DEATH      | 35 (67.3) 35 (67.3)          | 30 (57.7) 30 (57.7)       |
| Kaplan-MeierEstimates(months)a  |                              |                           |
| Median (95% CI) [Q1, Q3]        | 16.1 (13.9, 20.8) [9.3,23.3] | 22.3 (16.6, 30.1) [15.1,] |
| Person-months                   | 798.5                        | 988.5                     |
| EventRate/100Person-months      | 4.4                          | 3.0                       |
| Vs SOC                          |                              |                           |
| Hazard Ratio (95% C1)b p-valuec | 1.61 (0.98, 2.64) 0.9722     |                           |
| OS Rate at month 6 (%) (95%CI)  | 88.5 (76.1, 94.6)            | 92.3 (80.8, 97.0)         |
| OS Rate at month 12 (%)(95%CI)  | 69.1 (54.5, 79.8)            | 78.6 (64.7, 87.5)         |
| OS Rate at month 18 (%)(95%CI)  | 45.7 (31.0, 59.3)            | 62.8 (47.4, 74.8)         |
| OS Rate at month 24 (%)(95% C1) | 24.5 (12.0, 39.4)            | 48.4 (33.2, 62.0)         |

a From product-limit (Kaplan-Meier) method for censored data.

b Based on Cox regression model with Efron's method of tie handling with treatment as a covariate.

c One-sided p-value based on log-rank test.

NR = Not reached.

DatabaseCutoffDate:25MAY2022

Source:[P811V02MK3475: adam-adsl; adtte]

<div style=\"page-break-after: always\"></div>

## DoR

Table 14.2-33 Summary of Time to Response and Duration of Response Based on BICR Assessment per RECIST 1.1 in Participants with Confirmed Response (CPS&lt;1 Participants) (Global Cohort)

|                                                       | Pembrolizmab+SOC (N=52)   | SOC (N=52)       |
|-------------------------------------------------------|---------------------------|------------------|
| Number of participants with responsea                 | 36                        | 35               |
| Time to Response (months)                             |                           |                  |
| Mean (SD)                                             | 2.0 (1.1)                 | 2.2 (1.2)        |
| Median (Range)                                        | 1.5 (1.2-7.1)             | 1.6 (0.7-5.8)    |
| Response Durationb (months)                           |                           |                  |
| Median (Range)                                        | 8.9 (2.6+ -26.0+)         | 9.0 (1.4+ -31.8) |
| Number(%b)ofParticipantswithExtendedResponseDuration: |                           |                  |
| ≥3months                                              | 33 (94.3)                 | 32 (94.1)        |
| ≥6 months                                             | 24 (76.0)                 | 25 (76.3)        |
| ≥9 months                                             | 14 (49.2)                 | 16 (50.9)        |
| ≥12months                                             | 8 (36.9)                  | 12 (44.1)        |

Includes participants with best objective response as confirmed complete response or partial response

bFrom product-limit (Kaplan-Meier)methodfor censored data.

BICR = Blinded independent central review.

\"+\" indicates there is no progressive disease by the time of last disease assessment.

DatabaseCutoffDate:25MAY2022

Table 14.2-32 Summary of Objective Response with Confirmation Based on BICR Assessment per RECIST 1.1 (CPS&lt;l Participants) (Global Cohort) (ITT Population)

|                                | Pembrolizumab+ SOC   | Pembrolizumab+ SOC   | Pembrolizumab+ SOC   | SOC   | SOC   | SOC          |
|--------------------------------|----------------------|----------------------|----------------------|-------|-------|--------------|
|                                |                      | (%)                  | (95% CI)             | n     | (%)   | (95% CI)     |
| Number of SubjectsinPopulation | 52                   |                      |                      | 52    |       |              |
| Complete Response (CR)         | 7                    | 13.5                 | (5.6, 25.8)          | 9     | 17.3  | (8.2,30.3)   |
| Partial Response (PR)          | 29                   | 55.8                 | (41.3, 69.5)         | 26    | 50.0  | (35.8, 64.2) |
| OverallResponse (CR+PR)        | 36                   | 69.2                 | (54.9, 81.3)         | 35    | 67.3  | (52.9, 79.7) |
| Stable Disease (SD)            | 12                   | 23.1                 | (12.5, 36.8)         | 13    | 25.0  | (14.0, 38.9) |
| Disease Control (CR+PR+SD)     | 48                   | 92.3                 | (81.5, 97.9)         | 48    | 92.3  | (81.5, 97.9) |
| Progressive Disease (PD)       | 3                    | 5.8                  | (1.2, 15.9)          | 1     | 1.9   | (0.0,10.3)   |
| Not Evaluable (NE*)            | 0                    | 0.0                  | (0.0, 6.8)           | 0     | 0.0   | (0.0,6.8)    |
| No Assessmentb                 | 1                    | 1.9                  | (0.0, 10.3)          | 3     | 5.8   | (1.2, 15.9)  |

Responses are based on BICR asscssment per RECIST 1.1.

BICR = Blinded independent central review.

Stable disease includesSD,Non-CR/Non-PD,andNED.

NED: Nolesions were identified at baseline asscssment and there remained no Iesions at post baseline assessment(s).

NE:post-baseline assessment(s)availablehowevernotbeingevaluable.

bNoAssessment: no post-baseline assessment available for response evaluation.

DatabaseCutoffDate:25MAY2022.

Source:[P811V02MK3475: adam-adsl; adrs]

Source:[P811V02MK3475:adam-adsl; adtte]

## Summary of main study(ies)

The following tables summarise the efficacy results from the main studies supporting the present application. These summaries should be read in conjunction with the discussion on clinical efficacy as well as the benefit risk assessment (see later sections).

<div style=\"page-break-after: always\"></div>

Table 1. Summary of Efficacy for trial KEYNOTE-811

| Title: A Phase III, Randomized, Double-blind Trial Comparing Trastuzumab Plus Chemotherapy and Pembrolizumab With Trastuzumab Plus Chemotherapy and Placebo as First-line Treatment in Participants With HER2 Positive Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (KEYNOTE-811)   | Title: A Phase III, Randomized, Double-blind Trial Comparing Trastuzumab Plus Chemotherapy and Pembrolizumab With Trastuzumab Plus Chemotherapy and Placebo as First-line Treatment in Participants With HER2 Positive Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (KEYNOTE-811)   | Title: A Phase III, Randomized, Double-blind Trial Comparing Trastuzumab Plus Chemotherapy and Pembrolizumab With Trastuzumab Plus Chemotherapy and Placebo as First-line Treatment in Participants With HER2 Positive Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (KEYNOTE-811)   | Title: A Phase III, Randomized, Double-blind Trial Comparing Trastuzumab Plus Chemotherapy and Pembrolizumab With Trastuzumab Plus Chemotherapy and Placebo as First-line Treatment in Participants With HER2 Positive Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (KEYNOTE-811)   | Title: A Phase III, Randomized, Double-blind Trial Comparing Trastuzumab Plus Chemotherapy and Pembrolizumab With Trastuzumab Plus Chemotherapy and Placebo as First-line Treatment in Participants With HER2 Positive Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (KEYNOTE-811)   | Title: A Phase III, Randomized, Double-blind Trial Comparing Trastuzumab Plus Chemotherapy and Pembrolizumab With Trastuzumab Plus Chemotherapy and Placebo as First-line Treatment in Participants With HER2 Positive Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (KEYNOTE-811)   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                                                                                                                                                    | IND: 123,482; EudraCT: 2018-000224-34                                                                                                                                                                                                                                                               | IND: 123,482; EudraCT: 2018-000224-34                                                                                                                                                                                                                                                               | IND: 123,482; EudraCT: 2018-000224-34                                                                                                                                                                                                                                                               | IND: 123,482; EudraCT: 2018-000224-34                                                                                                                                                                                                                                                               | IND: 123,482; EudraCT: 2018-000224-34                                                                                                                                                                                                                                                               |
| Design                                                                                                                                                                                                                                                                                              | Phase 3, randomized, double-blind, placebo-controlled                                                                                                                                                                                                                                               | Phase 3, randomized, double-blind, placebo-controlled                                                                                                                                                                                                                                               | Phase 3, randomized, double-blind, placebo-controlled                                                                                                                                                                                                                                               | Phase 3, randomized, double-blind, placebo-controlled                                                                                                                                                                                                                                               | Phase 3, randomized, double-blind, placebo-controlled                                                                                                                                                                                                                                               |
| Hypothesis Treatments groups                                                                                                                                                                                                                                                                        | Superiority                                                                                                                                                                                                                                                                                         | Superiority                                                                                                                                                                                                                                                                                         | Superiority                                                                                                                                                                                                                                                                                         | Superiority                                                                                                                                                                                                                                                                                         | Superiority                                                                                                                                                                                                                                                                                         |
|                                                                                                                                                                                                                                                                                                     | Pembrolizumab + SOC                                                                                                                                                                                                                                                                                 | Pembrolizumab + SOC                                                                                                                                                                                                                                                                                 | Pembrolizumab + SOC                                                                                                                                                                                                                                                                                 | Pembrolizumab 200 mg Q3W + CAPOX (Oxaliplating 130 mg/m2 and Capecitabine 1000 mg/m2 BID Q3W) or FP (Cisplatin 80 mg/m2 Q3W and 5-FU 800 mg/m2 Q3W) + Trastuzumab 8 mg/kg loading dose, 6 mg/kg maintenance Q3W                                                                                     | Pembrolizumab 200 mg Q3W + CAPOX (Oxaliplating 130 mg/m2 and Capecitabine 1000 mg/m2 BID Q3W) or FP (Cisplatin 80 mg/m2 Q3W and 5-FU 800 mg/m2 Q3W) + Trastuzumab 8 mg/kg loading dose, 6 mg/kg maintenance Q3W                                                                                     |
|                                                                                                                                                                                                                                                                                                     | SOC                                                                                                                                                                                                                                                                                                 | SOC                                                                                                                                                                                                                                                                                                 | SOC                                                                                                                                                                                                                                                                                                 | N=350 participants CAPOX (Oxaliplating 130 mg/m2 and Capecitabine 1000 mg/m2 BID Q3W) or FP (Cisplatin 80 mg/m2 Q3W and 5-FU 800 mg/m2 Q3W) + Trastuzumab 8                                                                                                                                         | N=350 participants CAPOX (Oxaliplating 130 mg/m2 and Capecitabine 1000 mg/m2 BID Q3W) or FP (Cisplatin 80 mg/m2 Q3W and 5-FU 800 mg/m2 Q3W) + Trastuzumab 8                                                                                                                                         |
|                                                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                                                     | mg/kg loading dose, 6 mg/kg maintenance Q3W                                                                                                                                                                                                                                                         | mg/kg loading dose, 6 mg/kg maintenance Q3W                                                                                                                                                                                                                                                         |
| Endpoints and definitions                                                                                                                                                                                                                                                                           | Dual primary endpoints                                                                                                                                                                                                                                                                              | PFS                                                                                                                                                                                                                                                                                                 | PFS                                                                                                                                                                                                                                                                                                 | N=348 participants Time from randomization to PD, based upon RECIST 1.1 by BICR, or death, whichever occurred earlier                                                                                                                                                                               | N=348 participants Time from randomization to PD, based upon RECIST 1.1 by BICR, or death, whichever occurred earlier                                                                                                                                                                               |
| Endpoints and definitions                                                                                                                                                                                                                                                                           | Dual primary endpoints                                                                                                                                                                                                                                                                              | OS Time                                                                                                                                                                                                                                                                                             | OS Time                                                                                                                                                                                                                                                                                             | from randomization to death due to any cause proportion of subjects who have a CR or a PR by                                                                                                                                                                                                        | from randomization to death due to any cause proportion of subjects who have a CR or a PR by                                                                                                                                                                                                        |
| Endpoints and definitions                                                                                                                                                                                                                                                                           | Secondary endpoint                                                                                                                                                                                                                                                                                  | ORR                                                                                                                                                                                                                                                                                                 | ORR                                                                                                                                                                                                                                                                                                 | BICR                                                                                                                                                                                                                                                                                                | BICR                                                                                                                                                                                                                                                                                                |
| Endpoints and definitions                                                                                                                                                                                                                                                                           | Secondary endpoint                                                                                                                                                                                                                                                                                  | DoR                                                                                                                                                                                                                                                                                                 | DoR                                                                                                                                                                                                                                                                                                 | time from first documented evidence of CR or PR until disease progression or death                                                                                                                                                                                                                  | time from first documented evidence of CR or PR until disease progression or death                                                                                                                                                                                                                  |
| Database lock                                                                                                                                                                                                                                                                                       | 25-MAY-2022                                                                                                                                                                                                                                                                                         | 25-MAY-2022                                                                                                                                                                                                                                                                                         | 25-MAY-2022                                                                                                                                                                                                                                                                                         | 25-MAY-2022                                                                                                                                                                                                                                                                                         | 25-MAY-2022                                                                                                                                                                                                                                                                                         |
| Results and Analysis                                                                                                                                                                                                                                                                                | Results and Analysis                                                                                                                                                                                                                                                                                | Results and Analysis                                                                                                                                                                                                                                                                                | Results and Analysis                                                                                                                                                                                                                                                                                | Results and Analysis                                                                                                                                                                                                                                                                                | Results and Analysis                                                                                                                                                                                                                                                                                |
| Analysis description Analysis population                                                                                                                                                                                                                                                            | Primary Analysis                                                                                                                                                                                                                                                                                    | Primary Analysis                                                                                                                                                                                                                                                                                    | Primary Analysis                                                                                                                                                                                                                                                                                    | Primary Analysis                                                                                                                                                                                                                                                                                    | Primary Analysis                                                                                                                                                                                                                                                                                    |
| and time point description Descriptive statistics and estimate variability                                                                                                                                                                                                                          | Intent to treat                                                                                                                                                                                                                                                                                     | Intent to treat                                                                                                                                                                                                                                                                                     | Pembrolizumab +SOC                                                                                                                                                                                                                                                                                  | Pembrolizumab +SOC                                                                                                                                                                                                                                                                                  | SOC <group descriptor>                                                                                                                                                                                                                                                                              |
| and time point description Descriptive statistics and estimate variability                                                                                                                                                                                                                          | Number of subject                                                                                                                                                                                                                                                                                   | Number of subject                                                                                                                                                                                                                                                                                   | 350                                                                                                                                                                                                                                                                                                 | 350                                                                                                                                                                                                                                                                                                 | 348                                                                                                                                                                                                                                                                                                 |
| and time point description Descriptive statistics and estimate variability                                                                                                                                                                                                                          | PFS (median months)                                                                                                                                                                                                                                                                                 | PFS (median months)                                                                                                                                                                                                                                                                                 | 10                                                                                                                                                                                                                                                                                                  | 10                                                                                                                                                                                                                                                                                                  | 8.1                                                                                                                                                                                                                                                                                                 |
| and time point description Descriptive statistics and estimate variability                                                                                                                                                                                                                          | 95% CI                                                                                                                                                                                                                                                                                              | 95% CI                                                                                                                                                                                                                                                                                              | 8.6, 11.7                                                                                                                                                                                                                                                                                           | 8.6, 11.7                                                                                                                                                                                                                                                                                           | 7, 8.5                                                                                                                                                                                                                                                                                              |
| and time point description Descriptive statistics and estimate variability                                                                                                                                                                                                                          | OS                                                                                                                                                                                                                                                                                                  | OS                                                                                                                                                                                                                                                                                                  | 20                                                                                                                                                                                                                                                                                                  | 20                                                                                                                                                                                                                                                                                                  | 16.9                                                                                                                                                                                                                                                                                                |
| and time point description Descriptive statistics and estimate variability                                                                                                                                                                                                                          | (median months) 95% CI                                                                                                                                                                                                                                                                              | (median months) 95% CI                                                                                                                                                                                                                                                                              | 17.8, 23.2                                                                                                                                                                                                                                                                                          | 17.8, 23.2                                                                                                                                                                                                                                                                                          | 15, 19.8                                                                                                                                                                                                                                                                                            |
| and time point description Descriptive statistics and estimate variability                                                                                                                                                                                                                          | ORR (CR+PR)                                                                                                                                                                                                                                                                                         | ORR (CR+PR)                                                                                                                                                                                                                                                                                         | 72.6                                                                                                                                                                                                                                                                                                | 72.6                                                                                                                                                                                                                                                                                                | 59.8                                                                                                                                                                                                                                                                                                |
| and time point description Descriptive statistics and estimate variability                                                                                                                                                                                                                          | (%) 95% CI                                                                                                                                                                                                                                                                                          | (%) 95% CI                                                                                                                                                                                                                                                                                          | 67.6, 77.2                                                                                                                                                                                                                                                                                          | 67.6, 77.2                                                                                                                                                                                                                                                                                          | 54.4, 65.0                                                                                                                                                                                                                                                                                          |
| and time point description Descriptive statistics and estimate variability                                                                                                                                                                                                                          | DOR                                                                                                                                                                                                                                                                                                 | DOR                                                                                                                                                                                                                                                                                                 | 11.2 (1.1+ - 40.1+)                                                                                                                                                                                                                                                                                 | 11.2 (1.1+ - 40.1+)                                                                                                                                                                                                                                                                                 | 9.0 (1.4+ - 38.3+)                                                                                                                                                                                                                                                                                  |
| Effect estimate per comparison                                                                                                                                                                                                                                                                      | (median months) Primary endpoint                                                                                                                                                                                                                                                                    | (median months) Primary endpoint                                                                                                                                                                                                                                                                    | Pembrolizumab + SOC vs                                                                                                                                                                                                                                                                              | Pembrolizumab + SOC vs                                                                                                                                                                                                                                                                              | PFS                                                                                                                                                                                                                                                                                                 |
| Effect estimate per comparison                                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                                                     | SOC HR                                                                                                                                                                                                                                                                                              | SOC HR                                                                                                                                                                                                                                                                                              | 0.72                                                                                                                                                                                                                                                                                                |
| Effect estimate per comparison                                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                                                     | 95% CI                                                                                                                                                                                                                                                                                              | 95% CI                                                                                                                                                                                                                                                                                              | 0.60; 0.87                                                                                                                                                                                                                                                                                          |
| Effect estimate per comparison                                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                                                     | P-value                                                                                                                                                                                                                                                                                             | P-value                                                                                                                                                                                                                                                                                             | 0.0002                                                                                                                                                                                                                                                                                              |
| Effect estimate per comparison                                                                                                                                                                                                                                                                      | Primary endpoint                                                                                                                                                                                                                                                                                    | Primary endpoint                                                                                                                                                                                                                                                                                    | Pembrolizumab + SOC vs                                                                                                                                                                                                                                                                              | Pembrolizumab + SOC vs                                                                                                                                                                                                                                                                              | OS                                                                                                                                                                                                                                                                                                  |
| Effect estimate per comparison                                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                                                     | SOC HR                                                                                                                                                                                                                                                                                              | SOC HR                                                                                                                                                                                                                                                                                              | 0.87                                                                                                                                                                                                                                                                                                |

<div style=\"page-break-after: always\"></div>

|                      |                                     | 95% CI P-value                      | 0.72; 1.06 0.0842                  |
|----------------------|-------------------------------------|-------------------------------------|------------------------------------|
| Notes                | <free text>                         | <free text>                         | <free text>                        |
| Analysis description | Analysis by CPS                     | Analysis by CPS                     | Analysis by CPS                    |
|                      | CPS ≥ 1                             | Pembrolizumab +SOC                  | SOC                                |
|                      | Number of subject                   | 298                                 | 296                                |
|                      | PFS (median months)                 | 10.8                                | 7.2                                |
|                      | 95% CI                              | 8.5, 12.5                           | 6.8, 8.4                           |
|                      | OS (median months)                  | 20.5                                | 15.6                               |
|                      | 95% CI                              | 18.2, 24.3                          | 13.5, 18.6                         |
|                      | ORR (CR+PR) (%) 95% CI DOR (months) | 73.2 67.7, 78.1 11.3 (1.1+ - 40.1+) | 58.4 52.6, 64.1 9.5 (1.4+ - 38.3+) |
|                      | Primary endpoint                    | Pembrolizumab + SOC vs SOC          | PFS                                |
|                      |                                     | HR                                  | 0.70                               |
|                      |                                     | 95% CI                              | 0.58; 0.85                         |
|                      |                                     | P-value                             | 0.0001                             |
|                      | Primary endpoint                    | Pembrolizumab + SOC vs SOC          | OS                                 |
|                      |                                     | HR                                  | 0.79                               |
|                      |                                     | 95% CI                              | 0.64; 0.98                         |
|                      |                                     | P-value                             | 0.0143                             |

## Analysis performed across trials (pooled analyses and meta-analysis)

N/A

## Clinical studies in special populations

N/A

## Supportive study(ies)

N/A

## 2.4.3. Discussion on clinical efficacy

## Design and conduct of clinical studies

KEYNOTE-811 was a Phase 3, randomized, double-blind study of pembrolizumab vs placebo on top of chemotherapy and trastuzumab in first line HER2-positive gastric or GEJ adenocarcinoma at an advanced disease status (unresectable or metastatic tumours). In support of the sought indication, data derived from the IA2 (cutoff date of 25-MAY-2022) of the Phase 3 trial KEYNOTE-811 are presented.

The study population included relatively fit patients (ECOG 0-1 and adequate organ function). Among the inclusion/exclusion criteria, attention was given to the cardiac function in consideration of the indication to treatment with the HER2-targeted agent trastuzumab and the associated cardiotoxicity.

<div style=\"page-break-after: always\"></div>

Availability of the tissue sample was an additional requirement for study entry in view of the PD-L1based stratification scheme.

Pembrolizumab was administrated at a dose of 200 mg Q3W on top of a background therapy including two distinct chemotherapeutic regimens, namely a CAPOX (oxaliplatin+capecitabine) or FP (cisplatin+5 fluorouracil) combination, in addition to the HER2-targeted drug trastuzumab. The tested treatments are in line with the current clinical recommendations for the front-line approach to advanced/metastatic disease, the adopted drug combinations are considered equally effective and the dose of pembrolizumab can also be deemed appropriate since it is approved in both monotherapy and chemotherapy combined regimens across different indications. The choice of placebo as add-on to chemotherapy plus HER2-targeted therapy as comparator is adequate given the current therapeutic landscape for the intended indication.

The study included dual-primary efficacy endpoints based on PFS per RECIST 1.1 as assessed by BICR and OS. A sample size of 692 participants was calculated based on the assumptions that (1) the enrolment period was 28 months and the ramp-up period of enrolment was 6 months; (2) the duration of PFS and OS followed an exponential distribution; (3) a median PFS of 6.7 months in the control group with a true HR of 0.7; (4) a median OS of 13.8 months in the control group with a true HR ratio of 0.75. The calculation is comprehensible and reproducible, and the assumptions made for median PFS and median OS in the control arm are in line with the available historical data of chemotherapy in the 1L setting. The eight amendments to the protocol did not affect the sample size and power calculation. Only data from the Global Cohort has been used in the present analysis, data from the Japan-specific SOX Cohort remains outside the aim of the present report.

In the Global Cohort, randomization was stratified according to geographic region, PD-L1 status and chemotherapy regimen. The combination of these categories resulted in 3x2x2=12 strata. In the first version of the protocol dated 11-Apr-2018, patients were stratified according to geographic region, disease status and chemotherapy regimen. After the General Amendment n. 1, dated 31-May-2018 the stratification criterion of disease status (ECOG 0 versus ECOG 1) was removed and replaced with the PD-L1 status (positive versus negative, where positive was defined as CPS ≥ 1 and negative was defined as CPS &lt;1). This change should not have inflated the balance of demographic and disease related characteristics at baseline between the two treatment groups, since the first patient, first visit was performed on 05-Oct-2018. It is understood that results from the Phase 1b study KEYNOTE-012 and Phase 2 KEYNOTE-059 in gastric cancer informed the CPS cutoff level (≥1 and &lt;1) used in the current trial. Of note, the assay used for PD-L1 testing in KEYNOTE-811 was the Agilent PD-L1 IHC 22C3 pharmDx kit, which has been analytically validated to determine PD-L1 expression status in gastric tumors. This kit is CE marked as a companion diagnostic for KEYTRUDA in NSCLC, HNSCC, UC, esophageal cancer, TNBC, and cervical cancer. KEYNOTE-811 data will be utilized to seek approval of the kit as a companion diagnostic for gastric cancer.

The demographic and baseline disease characteristics were compared to evaluate balance between the 2 treatment groups and consistency with those of the all-comer participants (ITT).

As of the data cutoff date for IA2, 9 participants (2 in the pembrolizumab + SOC group and 7 in the placebo + SOC group) were inadvertently unblinded to their treatment assignment at the Sponsor level due to unblinded information being revealed by different modes of communication to blinded team members. Overall, 7 out of the 9 participants were unblinded after discontinuation from treatment. Two participants in the pembrolizumab plus SOC group were still on treatment when premature unblinding occurred. These unblinding incidents were reviewed via the Sponsor's Significant Quality Issues process and concluded not to have impacted the quality of the data.

<div style=\"page-break-after: always\"></div>

The ITT population served as the population for the primary efficacy analyses. All randomly assigned participants were included in this population. The IA2 was the first analysis of PFS and OS. Statistical methods were well reported in the protocol section and in the supplemental Statistical Analysis Plan (sSAP), and considered appropriate: the overall type I error over the primary endpoints (PFS and OS) and the key secondary endpoint (ORR) is strongly controlled at 2.5% (one-sided), with initially 0.2% allocated to ORR, 0.3% to PFS and 2% to OS. PFS was tested using a hierarchical strategy and prespecified analysis plan allows alpha from successful hypotheses to be passed to other hypotheses.

There were eight protocol amendments over the study course, of these only amendments 5, 6 and 8 affected the SAP language. The rationale for these amendments was exhaustively explained. Altogether these amendments did not affect the consistency of study results, however some issues are addressed. Just before the first data cut-off (17-Jun-2020), the protocol was amended to add the PFS endpoint at IA1 as an administrative look (amendment 5 of 20-May-2020). Upon health authority feedback, after the DCO of 17-Jun-2020 (but before the database was locked on 14-July-2020) the protocol was amended again to remove PFS from the IA1 analysis (amendment 6 of 07-Jul-2020). The MAH confirmed that these changes were not based on internal data from the study.

Part of the study was conducted during the coronavirus disease 2019 (COVID-19) pandemic. There were no changes in the planned analyses following study unblinding and/or no post-hoc analyses were performed due to the COVID-19 pandemic or any other reason.

Sensitivity analyses were adequate.

At IA1 the stratified analyses were based only on 6 collapsed strata due to the small number of participants or events in some strata. The collapsed strata were based on blinded data taking into considerations both clinical relevance and counts of subjects/events. The same strata, used in the stratified log-rank test and the stratified Cox model, were used consistently at IA2.

## Efficacy data and additional analyses

At the time of IA2 the number of randomized patients in the ITT population was 698 (350 to pembrolizumab + SOC and 348 to placebo + SOC), slightly higher than the planned number of 692 patients, and 696 were started on treatment. At time of data cut-off, only 484 PFS events over 542 required for IA2 were reached, while 415 OS events occurred, more than the expected 401 OS events, representing the 75.3% of information fraction. The median duration of follow-up was 15.4 months (range: 0.3 to 41.6 months).

Discontinuation from study intervention was registered in 78.0% of participants. The frequency of discontinuation from study intervention was higher in the control arm (73.4% and 82.7% in the pembrolizumab and placebo group, respectively), with the most common reason for discontinuation from study intervention being progressive disease (50.6% and 62.7% in the pembrolizumab and placebo group, respectively). Treatment was ongoing in more participants in the pembrolizumab plus SOC group compared with the SOC group (19.7% vs 12.4%).

The treatment arms were overall comparable in their demographic and disease characteristics. The majority of the study population included male patients (80.8% vs 19.2% of male and female subjects, respectively) aged 63 years in median, with equal representation of the different age categories according with disease epidemiology, with the exception of &gt;75 year group that accounted for only 8% of the total population. An equal contribution to recruitment can be noted for the different geographic areas (Eastern Europe, Asia and rest of the World, around 30% each). Metastatic disease was prevailing over a locally advanced stage (97.6% vs 2.4%), mainly including gastric adenocarcinoma (66.8% vs 33.2% of gastroesophageal junction adenocarcinoma). The PD-L1 status was mostly

<div style=\"page-break-after: always\"></div>

positive (85.1% CPS ≥ 1 vs 14.9% of CPS&lt;1), and the backbone therapy was more frequently a CAPOX combination (85.4% vs 14.6% of FP combination). Overall, the study population can be considered representative of the targeted indication, although very elderly patients were poorly represented and only relatively fit patients without significant cardiac conditions were recruited.

The efficacy analysis in the ITT population, showed advantage of pembrolizumab over placebo in terms of PFS (HR=0.72; 95% CI 0.60; 0.87; p&lt;0.0002) with a 2-month gain in disease progression (10 vs 8.1 months in median in the pembrolizumab and control arm, respectively), but no benefit was demonstrated in OS (HR=0.87; 95% CI 0.72;1.06; p&lt;0.0842). With a 75.3% of information fraction in OS events at the time of IA2, data can be considered overall mature.

Among the pre-specified subgroup analysis, the PD-L1 status emerged as the only effect modifier. Specifically, the PFS was unfavourably impacted by pembrolizumab in patients with CPS&lt;1 (HR=1.17; 95% CI 0.73, 1.89), and actually the number of deaths was higher in the pembrolizumab arm relative to control (67.3% vs 57.7%) within this subgroup, leading to a negative effect of treatment on OS (HR=1.61; 95% CI 0.98,2.64; p=0.9722).  For the counterpart CPS ≥ 1, pembrolizumab showed advantage over placebo in PFS (HR=0.70; 95% CI 0.58, 0.85) and OS (HR=0.79; 95% CI 0.64, 0.98; p=0.0143), with a gain in median PFS of 3 months (10.8 vs 7.2) and median OS of 5 months (20.5 vs 15.6). All the remaining strata were consistent with the ITT population.

As regards the analysis by PD-L1 status, it should be noted that the effect of pembrolizumab was almost similar in the two CPS categories for what concerns PFS (10.8 and 9.5 months in median in the CPS ≥ 1 and CPS&lt;1 group, respectively); superiority in the CPS ≥ 1 subgroup was mainly driven by the lower performance of the backbone therapy compared to the effect observed in CPS&lt;1 (7.2 and 9.6 months in median PFS in the placebo arm for the CPS ≥ 1 and CPS&lt;1 group, respectively). The OS results showed a similar trend, although more deaths were registered with pembrolizumab among patients with CPS&lt;1 than those reported in the CPS ≥ 1 group (67.3% vs 56%); on the contrary, placebo performed slightly better in the CPS&lt;1 than CPS ≥ 1 group (57.7% vs 61%). Overall, the superior effect of pembrolizumab over placebo in the CPS ≥ 1 seems to result from a slightly better performance of pembrolizumab and a lower efficacy of chemotherapy in this group. Acknowledging the limited value of subgroups analyses within subgroups, patients aged ≥ 65 years, and Asians within the CPS ≥ 1 population apparently gained no OS benefit. Upon request, the MAH provided additional data for subgroup analysis. The increased frequency in the use of subsequent oncologic therapies in the Asian population may have contributed to differences in OS compared to non-Asians. Concerning the age categories, the subgroup 65-74 year-old patients shows an unfavourable outcome in OS but this was not confirmed in the oldest age group ( ≥ 75), although this latter is numerically limited for a proper analysis. A reduced magnitude of effect based on OS results was also noted for GEJ cancer compared to gastric cancer; no definitive conclusions can be made at the moment given the limited sample size of this subgroup. In any case, a detrimental effect is not envisaged in the GEJ cancer, with a HR=0.94 in OS, and the HR=0.73 in PFS that is similar to the ITT population value.

Based on these data, the MAH seeks indication limited to the CPS ≥ 1 subgroup. Although being a stratification factor, efficacy by PD-L1 score was not incorporated in the multiplicity strategy of the study design. The non-confirmatory nature of these analyses should be considered implying that an effect on both PFS and OS has not been formally demonstrated in CPS ≥1 patients. However, plausibility of a PD-L1 dependent effect of pembrolizumab, and balanced distribution of baseline characteristics between the two CPS categories by virtue of the stratification scheme, provides a good rationale and reliability to the observed results. According to the EMA guidelines on subgroup analysis (EMA/CHMP/539146/2013), the trial was formally successful since a statistically significant effect in the ITT population on one of the two components of the dual endpoint has emerged; however, the therapeutic efficacy or risk-benefit is borderline and clearly not proven in the CPS&lt;1 population, thus

<div style=\"page-break-after: always\"></div>

configuring Scenario 2 of the guideline.  A restriction of indication based on PD-L1 status can therefore be supported. Considering the single pivotal trial, replication of subgroup findings from other relevant trials should be considered, as stated by the EMA guidelines. In this regard, PD-L1 dependency in response to treatment has emerged in other clinical indications; and KEYNOTE-590 offers a relevant precedent in this specific clinical setting where benefit of treatment in the HER-2 negative gastric disease was demonstrated in the subgroup of patients with CPS ≥ 10. The MAH has provided further analyses demonstrating that unlike precedent trials in other gastrointestinal cancer types, a CPS cutoff of 1 clearly distinguishes between favourable and no effect of treatment in this clinical setting, which makes the CPS ≥ 1 in the clinical indication uncontroversial.

Among the secondary endpoints, ORR analysis showed advantage of pembrolizumab over placebo in the ITT population (72.6% vs 59.8%) with a slightly better response duration in pembrolizumab than control arm (11.2 vs 9 months in median); a higher rate of participants with extended duration was achieved in the pembrolizumab arm compared to the control arm at all time points. The results were consistent in the subgroup with CPS≥1.

The PROs showed similar results between treatment arms.

## Additional expert consultation

None.

## Assessment of paediatric data on clinical efficacy

Not applicable

## 2.4.4. Conclusions on the clinical efficacy

In KEYNOTE-811, a statistically significant advantage of pembrolizumab versus placebo in addition to SOC was demonstrated in PFS but not OS, in the ITT population. However, an unfavourable effect of pembrolizumab relative to placebo emerges in the CPS&lt;1 subgroup. An indication restricted to the CPS≥1 group can be considered, as proposed by the MAH, since data indicate superiority of pembrolizumab versus placebo in both PFS and OS in this category of patients.

## 2.5. Clinical safety

## Introduction

Safety results are presented for 4 datasets (see table below):

- Safety results from IA2 of KEYNOTE-811 (DCO date: 25 MAY-2022). Safety analyses were based on the APaT population, which included all randomized participants who received at least 1 dose of study intervention.

- Pooled safety data from studies of pembrolizumab in combination with chemotherapy, as a point of reference. This group is comprised of non-gastric studies (ie, NSCLC, HNSCC, TNBC, esophageal, and cervical) with participants who received a variety of single agent or combination chemotherapies, thus comparisons of safety data may be limited due to the differences in the chemotherapeutic regimens, indications, time of exposure, underlying disease and severity of disease, and demographics between these datasets.

<div style=\"page-break-after: always\"></div>

- Pooled safety data from pembrolizumab monotherapy studies, comprising the pembrolizumab monotherapy RSD, to enable a comparison of the safety profile of pembrolizumab plus SOC observed in KEYNOTE-811 to the established safety profile for pembrolizumab monotherapy.

Table 2: Safety Datasets and Nomenclature

| Datasets                                           | Population                                                                                                                                                                                                                                                                                                                                                   | Nomenclature in Tables                             | Nomenclature in Text            |
|----------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------|---------------------------------|
| KEYNOTE-811 pembrolizumab plus SOC safety dataset  | ( N=350 ): Safety data from participants with gastric/GEJ adenocarcinoma who received pembrolizumab in combination with trastuzumab plus platinum/fluoropyrimidine doublet chemotherapy (FP or CAPOX) in KEYNOTE-811 (global cohort a )                                                                                                                      | KN-811 Pembro + SOC                                | Pembrolizumab plus SOC          |
| KEYNOTE-811 SOC safety dataset                     | ( N=346 ): Safety data from participants with gastric/GEJ adenocarcinoma who received placebo plus trastuzumab plus chemotherapy (FP or CAPOX) in KEYNOTE-811 (global cohort a )                                                                                                                                                                             | KN-811 SOC                                         | SOC                             |
| Pembrolizumab plus chemo pooled                    | ( N=3123 ): Pooled safety data from participants who received at least 1 dose of pembrolizumab chemotherapy combo therapy in KN021 Cohort A, C and G, KN048, KN189, KN355, KN407, KN522, KN590 and KN826 b                                                                                                                                                   | Pembro + Chemo Pooled Dataset                      | Pembrolizumab plus chemo pooled |
| Pembrolizumab monotherapy reference safety dataset | ( N=7631 ): Pooled safety data from participants treated with pembrolizumab monotherapy, who received at least 1 dose of pembrolizumab in KN001 Part B1, B2, B3, D, C, F1, F2, F3, KN002 (original phase), KN006, KN010, KN012 Cohort B and B2, KN013 Cohort 3, KN024, KN040, KN042, KN045, KN048, KN052, KN054, KN055, KN087, KN177, KN204, KN564 and KN716 | Pembrolizumab Monotherapy Reference Safety Dataset | Pembrolizumab monotherapy RSD   |

CAPOX=capecitabine plus oxaliplatin; FP=cisplatin plus 5-fluorouracil; GEJ=gastroesophageal junction; N=number; NSCLC=non-small cell lung cancer; Pembro = pembrolizumab; RSD=reference safety dataset; SOC=standard of care.

a Global cohort=approximately 692 participants were randomized in the global cohort in a 1:1 ratio to receive pembrolizumab or placebo each in combination with chemotherapy plus trastuzumab. The investigator had 2 chemotherapy regimen choices, FP or CAPOX, which were chosen prior to randomization in the trial.

b Chemotherapy combo therapies = KN021 Cohort A, C, G (NSCLC): pemetrexed plus cisplatin or carboplatin/carboplatin plus paclitaxel or nab-paclitaxel; KN189 (NSCLC): pemetrexed plus cisplatin or carboplatin; KN407 (NSCLC): carboplatin plus paclitaxel or nab-paclitaxel; KN048 (HNSCC): carboplatin or cisplatin plus 5-FU; KN355 (TNBC): nab-paclitaxel or paclitaxel, or gemcitabine plus carboplatin; KN590 (esophageal): cisplatin plus 5-FU; KN826 (cervical): paclitaxel plus cisplatin or carboplatin +/- bevacizumab; KN522 (TNBC): carboplatin plus paclitaxel followed by doxorubicin plus cyclophosphamide.

## Patient exposure

Patients enrolled in KN811 study received study intervention as per table below. Pembrolizumab/trastuzumab were given until PD, completion of 35 cycles, or other discontinuation criteria were met. Duration of cisplatin in FP may be capped at 6 cycles, while oxaliplatin in CAPOX may be capped at 6 or 8 cycles as per local country guidelines; however, treatment with 5-FU or capecitabine may continue per protocol. Participants have the option to receive up to 1 additional year of trastuzumab and capecitabine or 5-FU or S1 beyond 35 administrations of pembrolizumab/placebo at the discretion of the investigator and after Sponsor consultation.

<div style=\"page-break-after: always\"></div>

## Table 3: treatments in KEYNOTE-811

| Arm Name         | Arm Type                  | Intervention Name       | Intervention Type   | Dose Formulation      | Unit Dose Strength(s)e                      | Dosage Level(s)                                                      | Route of Adminis- tration   | Regimen/ Treatment Period/ Vaccination Regimen                                   | Use                   | IMP or NIMP/ AxMP           | Sourcing         |
|------------------|---------------------------|-------------------------|---------------------|-----------------------|---------------------------------------------|----------------------------------------------------------------------|-----------------------------|----------------------------------------------------------------------------------|-----------------------|-----------------------------|------------------|
| Pembrolizumab    | Experimental              | Pembrolizumab (MK-3475) | Biological/ Vaccine | Vial                  | 25 mg/mL                                    | 200 mg                                                               | IV Infusion                 | Day l ofeach cycle (Q3 W)                                                        | Test Product          | IMP                         | Central          |
| Placebo          | Placebo Comparator        | Placebo                 | Drug                | Solution for Infusion | N/A                                         | N/A                                                                  | IV Infusion                 | Day l ofeach cycle (Q3 W)                                                        | Placebo               | IMP                         | Local            |
| FPa              | Experimental              | Cisplatinb              | Drug                | Vial                  | 1 mg/mL                                     | 80 mg/m²                                                             | IV Infusion                 | Day l ofeach cycle (Q3W)                                                         | Background Treatment  | NIMP/AxMP                   | Central or Local |
| FPa              | Experimental              | 5-FU                    | Drug                | Vial                  | 25 mg/mL                                    | 800 mg/m²                                                            | IV Infusion                 | Continuous on Days 1 to 5 of each cycle (Q3W) (120 hours, or per local standard) | Back ground Treatment | NIMP/AxMP                   | Central or Local |
| CAPOX d          | Experimental              | Oxaliplatin b           | Drug                | Vial                  | 5 mg/mL                                     | 130 mg/m²                                                            | IV Infusion                 | Dayl ofeach cycle (Q3W) over 2 hours                                             | Background Treatment  | NIMP/AxMP                   | Central or Local |
| CAPOX d          | Experimental              | Capecitabine b          | Drug                | Tablet                | 150 mg or 500 mg                            | 1000 mg/m² BID                                                       | Oral                        | Days 1 to 14 of each cycle (Q3W)                                                 | Background Treatment  | NIMP/AxMP                   | Central or Local |
| SOX (Japan Only) | Experimental              | S1b                     | Drug                | Capsule               | 20 mg or 25 mg                              | 40 mg (<1.25 m² BSA) 50 mg BID (1.25 to <1.5 m²) 60 mg (≥1.5 m² BSA) | Oral                        | Days 1 to 14 of cach cycle (Q3W) BID Days 1 to 14 of each cycle (Q3W).           | Background Treatment  | NIMP/AxMP                   | Local            |
| SOX (Japan Only) | Experimental| Oxaliplatin |                         | Drug                | Vial                  | 5 mg/mL                                     | 130 mg/m²                                                            | IV Infusion                 | Day l ofeach cycle (Q3 W) over 2 hours                                           | Treatment             | Background |NIMP/AxMP|Local |                  |
| All Cohorts      | Experimental              | Trastuzumabb            | Drug                | Vial                  | 60 mg Japan only) 150mg 420 mg 440 mg 600mg | 8 mg/kg loading dose, 6mg/kg maintenance                             | IV Infusion                 | Dayl ofeach cycle (Q3 W)                                                         | Background Treatment  | NIMP/AxMP                   | Central or Local |

5-FU=5 fluorouracil; AxMP = auxiliary medicinal product,BID=twice daily;BSA=body surface area; CAPOX=capecitabine/oxaliplatin; FP=cisplatin plus 5 fluorouracil; IMP=investigational medicinal product; IV=intravenous; Q3W=every 3 weeks; S1=combination product containing tegafur, a prodrug of 5-FU, and 2 types of enzyme inhibitors, CDHP and Oxo; SOX=S1 plus oxaliplatin.

Definitions ofIMP,NIMP, and AxMPare based on guidance issues by the European Commission.Regional and/or country differences ofthe definition ofIMPand NIMP/AxMP may exist.In these circumstances,locallegislationis followed.

Pembrolizumab/trastuzumab will be administered until disease progression, completion of 35 cycles, or other discontinuation criteria are met.

Participants have the option toreceive up to1 additionalyear of trastuzumab and capecitabine or 5-FUor S1beyond 35 administrations of pembrolizumab/placebo at the discretion of the investigator and after Sponsor consultation. Pembrolizumab/placebo treatment is not allowed beyond 35 administrations in the initial treatment course. Participantswhostoppembrolizumab/placebotreatment after 35administrations,forreasons other than diseaseprogression orintolerability,orparticipants who attaina CR and stop trial treatment, may be eligible for up to 17 additional administrations of pembrolizumab upon experiencing disease progression if they are randomized to the pembrolizumab arm.

a FP: Duration of cisplatin treatment may be capped at 6 cycles as per local country guidelines; however, treatment with 5-FU may continue per protocol.

C The strength oftreatment mayvary depending on the source.The table captures the current available strengths but could vary depending on availability.

b Chemotherapy options and trastuzumab are used in both the experimental and placebo arms.

P CAPOX: duration of oxaliplatin may be capped at 6 or 8 cycles as per local country guidelines; however, treatment with capecitabine may continue per protocol.

<div style=\"page-break-after: always\"></div>

Table 4: Summary of Drug Exposure (APaT Population)

|                                                                                                                                                        | KN811 Pembrolizumab + SOC (N=350)                                                                                                                      | KN811 SOC (N=346)                                                                                                                                      | Pembro + Chemo Pooled Dataset i (N=3123)                                                                                                               | Pembrolizumab Monotherapy Reference Safety Dataset j (N=7631)                                                                                          |
|--------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------|
| Duration On Therapy (month)                                                                                                                            |                                                                                                                                                        |                                                                                                                                                        |                                                                                                                                                        |                                                                                                                                                        |
| Mean                                                                                                                                                   | 11.60                                                                                                                                                  | 10.01                                                                                                                                                  | 9.85                                                                                                                                                   | 7.85                                                                                                                                                   |
| Median                                                                                                                                                 | 9.59                                                                                                                                                   | 7.31                                                                                                                                                   | 7.89                                                                                                                                                   | 5.78                                                                                                                                                   |
| SD                                                                                                                                                     | 8.495                                                                                                                                                  | 7.998                                                                                                                                                  | 7.291                                                                                                                                                  | 6.907                                                                                                                                                  |
| Range                                                                                                                                                  | 0.33 to 36.60                                                                                                                                          | 0.03 to 36.11                                                                                                                                          | 0.03 to 48.00                                                                                                                                          | 0.03 to 38.01                                                                                                                                          |
| Number of Cycles                                                                                                                                       |                                                                                                                                                        |                                                                                                                                                        |                                                                                                                                                        |                                                                                                                                                        |
| Mean                                                                                                                                                   | 15.87                                                                                                                                                  | 13.81                                                                                                                                                  | 13.23                                                                                                                                                  | 12.31                                                                                                                                                  |
| Median                                                                                                                                                 | 13.00                                                                                                                                                  | 10.00                                                                                                                                                  | 11.00                                                                                                                                                  | 9.00                                                                                                                                                   |
| SD                                                                                                                                                     | 11.389                                                                                                                                                 | 10.899                                                                                                                                                 | 9.649                                                                                                                                                  | 10.098                                                                                                                                                 |
| Range                                                                                                                                                  | 1.00 to 51.00                                                                                                                                          | 1.00 to 49.00                                                                                                                                          | 1.00 to 68.00                                                                                                                                          | 1.00 to 59.00                                                                                                                                          |
| Each participant is counted once on each applicable duration category row. Duration of exposure is calculated as last dose date - first dose date + 1. | Each participant is counted once on each applicable duration category row. Duration of exposure is calculated as last dose date - first dose date + 1. | Each participant is counted once on each applicable duration category row. Duration of exposure is calculated as last dose date - first dose date + 1. | Each participant is counted once on each applicable duration category row. Duration of exposure is calculated as last dose date - first dose date + 1. | Each participant is counted once on each applicable duration category row. Duration of exposure is calculated as last dose date - first dose date + 1. |

Table 5: Drug Exposure by Duration (APaT Population)

<!-- image -->

|                                                                                                                                                        | KN811 Pembrolizumab SOC (N=350)                                                                                                                        | KN811 Pembrolizumab SOC (N=350)                                                                                                                        | KN811 Pembrolizumab SOC (N=350)                                                                                                                        | KN811 SOC (N=346)                                                                                                                                      | KN811 SOC (N=346)                                                                                                                                      | KN811 SOC (N=346)                                                                                                                                      | Pembro + Chemo Pooled Dataset i (N=3123)                                                                                                               | Pembro + Chemo Pooled Dataset i (N=3123)                                                                                                               | Pembro + Chemo Pooled Dataset i (N=3123)                                                                                                               | Pembrolizumab Monotherapy Reference Safety Dataset j (N=7631)                                                                                          | Pembrolizumab Monotherapy Reference Safety Dataset j (N=7631)                                                                                          | Pembrolizumab Monotherapy Reference Safety Dataset j (N=7631)                                                                                          |
|--------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                                                                                                        | n                                                                                                                                                      | (%)                                                                                                                                                    | Person- years                                                                                                                                          | n                                                                                                                                                      | (%)                                                                                                                                                    | Person- years                                                                                                                                          | n                                                                                                                                                      | (%)                                                                                                                                                    | Person-years                                                                                                                                           | n                                                                                                                                                      | (%)                                                                                                                                                    | Person-years                                                                                                                                           |
| Duration of exposure                                                                                                                                   |                                                                                                                                                        |                                                                                                                                                        |                                                                                                                                                        |                                                                                                                                                        |                                                                                                                                                        |                                                                                                                                                        |                                                                                                                                                        |                                                                                                                                                        |                                                                                                                                                        |                                                                                                                                                        |                                                                                                                                                        |                                                                                                                                                        |
| >0m                                                                                                                                                    | 350                                                                                                                                                    | (100.0)                                                                                                                                                | (338.4)                                                                                                                                                | 346                                                                                                                                                    | (100.0)                                                                                                                                                | (288.7)                                                                                                                                                | 3,118                                                                                                                                                  | (99.8)                                                                                                                                                 | (2,558.5)                                                                                                                                              | 7,631                                                                                                                                                  | (100.0)                                                                                                                                                | (4,995.0)                                                                                                                                              |
| >=1m                                                                                                                                                   | 334                                                                                                                                                    | (95.4)                                                                                                                                                 | (337.6)                                                                                                                                                | 330                                                                                                                                                    | (95.4)                                                                                                                                                 | (288.2)                                                                                                                                                | 2,889                                                                                                                                                  | (92.5)                                                                                                                                                 | (2,550.9)                                                                                                                                              | 6,637                                                                                                                                                  | (87.0)                                                                                                                                                 | (4,962.4)                                                                                                                                              |
| >=3m                                                                                                                                                   | 299                                                                                                                                                    | (85.4)                                                                                                                                                 | (331.9)                                                                                                                                                | 283                                                                                                                                                    | (81.8)                                                                                                                                                 | (280.4)                                                                                                                                                | 2,535                                                                                                                                                  | (81.2)                                                                                                                                                 | (2,488.4)                                                                                                                                              | 5,023                                                                                                                                                  | (65.8)                                                                                                                                                 | (4,693.1)                                                                                                                                              |
| >=6m                                                                                                                                                   | 241                                                                                                                                                    | (68.9)                                                                                                                                                 | (310.0)                                                                                                                                                | 206                                                                                                                                                    | (59.5)                                                                                                                                                 | (251.2)                                                                                                                                                | 1,847                                                                                                                                                  | (59.1)                                                                                                                                                 | (2,225.8)                                                                                                                                              | 3,781                                                                                                                                                  | (49.5)                                                                                                                                                 | (4,240.0)                                                                                                                                              |
| >=12m                                                                                                                                                  | 141                                                                                                                                                    | (40.3)                                                                                                                                                 | (236.7)                                                                                                                                                | 105                                                                                                                                                    | (30.3)                                                                                                                                                 | (179.3)                                                                                                                                                | 1,192                                                                                                                                                  | (38.2)                                                                                                                                                 | (1,760.0)                                                                                                                                              | 1,673                                                                                                                                                  | (21.9)                                                                                                                                                 | (2,558.8)                                                                                                                                              |
| Each participant is counted once on each applicable duration category row. Duration of Exposure is calculated as last dose date - first dose date + 1. | Each participant is counted once on each applicable duration category row. Duration of Exposure is calculated as last dose date - first dose date + 1. | Each participant is counted once on each applicable duration category row. Duration of Exposure is calculated as last dose date - first dose date + 1. | Each participant is counted once on each applicable duration category row. Duration of Exposure is calculated as last dose date - first dose date + 1. | Each participant is counted once on each applicable duration category row. Duration of Exposure is calculated as last dose date - first dose date + 1. | Each participant is counted once on each applicable duration category row. Duration of Exposure is calculated as last dose date - first dose date + 1. | Each participant is counted once on each applicable duration category row. Duration of Exposure is calculated as last dose date - first dose date + 1. | Each participant is counted once on each applicable duration category row. Duration of Exposure is calculated as last dose date - first dose date + 1. | Each participant is counted once on each applicable duration category row. Duration of Exposure is calculated as last dose date - first dose date + 1. | Each participant is counted once on each applicable duration category row. Duration of Exposure is calculated as last dose date - first dose date + 1. | Each participant is counted once on each applicable duration category row. Duration of Exposure is calculated as last dose date - first dose date + 1. | Each participant is counted once on each applicable duration category row. Duration of Exposure is calculated as last dose date - first dose date + 1. | Each participant is counted once on each applicable duration category row. Duration of Exposure is calculated as last dose date - first dose date + 1. |

Table 6: Participant Characteristics (APaT Population)

|                                  | KN811 Pembrolizumab + SOC   | KN811 Pembrolizumab + SOC   | KN811 SOC   | KN811 SOC   | Pembro + Chemo Pooled Dataset i   | Pembro + Chemo Pooled Dataset i   | Pembrolizumab Monotherapy Reference Safety Dataset j   | Pembrolizumab Monotherapy Reference Safety Dataset j   |
|----------------------------------|-----------------------------|-----------------------------|-------------|-------------|-----------------------------------|-----------------------------------|--------------------------------------------------------|--------------------------------------------------------|
|                                  | n                           | (%)                         | n           | (%)         | n                                 | (%)                               | n                                                      | (%)                                                    |
| Participants in population       | 350                         |                             | 346         |             | 3,123                             |                                   | 7,631                                                  |                                                        |
| Sex                              |                             |                             |             |             |                                   |                                   |                                                        |                                                        |
| Male                             | 284                         | (81.1)                      | 278         | (80.3)      | 1,042                             | (33.4)                            | 4,889                                                  | (64.1)                                                 |
| Female                           | 66                          | (18.9)                      | 68          | (19.7)      | 2,081                             | (66.6)                            | 2,742                                                  | (35.9)                                                 |
| Age (Years)                      |                             |                             |             |             |                                   |                                   |                                                        |                                                        |
| <65                              | 205                         | (58.6)                      | 190         | (54.9)      | 2,176                             | (69.7)                            | 4,524                                                  | (59.3)                                                 |
| >=65                             | 145                         | (41.4)                      | 156         | (45.1)      | 947                               | (30.3)                            | 3,107                                                  | (40.7)                                                 |
| Mean                             | 60.4                        |                             | 61.7        |             | 56.6                              |                                   | 59.9                                                   |                                                        |
| SD                               | 11.8                        |                             | 10.8        |             | 12.5                              |                                   | 13.4                                                   |                                                        |
| Median                           | 62.0                        |                             | 63.0        |             | 58.0                              |                                   | 62.0                                                   |                                                        |
| Range                            | 19 to 85                    |                             | 32 to 85    |             | 20 to 94                          |                                   | 15 to 94                                               |                                                        |
| Race                             |                             |                             |             |             |                                   |                                   |                                                        |                                                        |
| American Indian Or Alaska Native | 5                           | (1.4)                       | 6           | (1.7)       | 55                                | (1.8)                             | 59                                                     | (0.8)                                                  |
| Asian                            | 119                         | (34.0)                      | 121         | (35.0)      | 686                               | (22.0)                            | 826                                                    | (10.8)                                                 |

0.03 to 38.01

1.00 to 59.00

(64.1)

(35.9)

(59.3)

(40.7)

15 to 94

(0.8)

(10.8)

<div style=\"page-break-after: always\"></div>

(1.9)

(1.1)

(0.1)

(76.5)

(8.8)

(79.5)

(10.6)

(1.9)

(0.1)

(52.6)

(45.1)

(2.3)

(37.4)

(62.6)

| Black Or African American                                                                         | 2                                                                                                 | (0.6)                                                                                             | 2                                                                                                 | (0.6)                                                                                             | 108                                                                                               | (3.5)                                                                                             | 146                                                                                               | (1.9)                                                                                             |
|---------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------|
| Multiracial                                                                                       | 6                                                                                                 | (1.7)                                                                                             | 5                                                                                                 | (1.4)                                                                                             | 64                                                                                                | (2.0)                                                                                             | 86                                                                                                | (1.1)                                                                                             |
| Native Hawaiian Or Other Pacific Islander                                                         | 0                                                                                                 | (0.0)                                                                                             | 0                                                                                                 | (0.0)                                                                                             | 2                                                                                                 | (0.1)                                                                                             | 5                                                                                                 | (0.1)                                                                                             |
| White                                                                                             | 217                                                                                               | (62.0)                                                                                            | 207                                                                                               | (59.8)                                                                                            | 2,088                                                                                             | (66.9)                                                                                            | 5,838                                                                                             | (76.5)                                                                                            |
| Missing                                                                                           | 1                                                                                                 | (0.3)                                                                                             | 5                                                                                                 | (1.4)                                                                                             | 120                                                                                               | (3.8)                                                                                             | 671                                                                                               | (8.8)                                                                                             |
| Ethnicity                                                                                         |                                                                                                   |                                                                                                   |                                                                                                   |                                                                                                   |                                                                                                   |                                                                                                   |                                                                                                   |                                                                                                   |
| Hispanic Or Latino                                                                                | 38                                                                                                | (10.9)                                                                                            | 44                                                                                                | (12.7)                                                                                            | 429                                                                                               | (13.7)                                                                                            | 604                                                                                               | (7.9)                                                                                             |
| Not Hispanic Or Latino                                                                            | 309                                                                                               | (88.3)                                                                                            | 291                                                                                               | (84.1)                                                                                            | 2,502                                                                                             | (80.1)                                                                                            | 6,064                                                                                             | (79.5)                                                                                            |
| Not Reported                                                                                      | 1                                                                                                 | (0.3)                                                                                             | 10                                                                                                | (2.9)                                                                                             | 105                                                                                               | (3.4)                                                                                             | 808                                                                                               | (10.6)                                                                                            |
| Unknown                                                                                           | 2                                                                                                 | (0.6)                                                                                             | 1                                                                                                 | (0.3)                                                                                             | 66                                                                                                | (2.1)                                                                                             | 145                                                                                               | (1.9)                                                                                             |
| Missing                                                                                           | 0                                                                                                 | (0.0)                                                                                             | 0                                                                                                 | (0.0)                                                                                             | 21                                                                                                | (0.7)                                                                                             | 10                                                                                                | (0.1)                                                                                             |
| ECOG Performance Scale                                                                            |                                                                                                   |                                                                                                   |                                                                                                   |                                                                                                   |                                                                                                   |                                                                                                   |                                                                                                   |                                                                                                   |
| [0] Normal Activity                                                                               | 146                                                                                               | (41.7)                                                                                            | 144                                                                                               | (41.6)                                                                                            | 1,768                                                                                             | (56.6)                                                                                            | 4,016                                                                                             | (52.6)                                                                                            |
| [1] Symptoms, but ambulatory                                                                      | 204                                                                                               | (58.3)                                                                                            | 201                                                                                               | (58.1)                                                                                            | 1,349                                                                                             | (43.2)                                                                                            | 3,440                                                                                             | (45.1)                                                                                            |
| Other/Missing                                                                                     | 0                                                                                                 | (0.0)                                                                                             | 1                                                                                                 | (0.3)                                                                                             | 6                                                                                                 | (0.2)                                                                                             | 175                                                                                               | (2.3)                                                                                             |
| Geographic Region                                                                                 |                                                                                                   |                                                                                                   |                                                                                                   |                                                                                                   |                                                                                                   |                                                                                                   |                                                                                                   |                                                                                                   |
| Western Europe                                                                                    | 98                                                                                                | (28.0)                                                                                            | 91                                                                                                | (26.3)                                                                                            | 1,118                                                                                             | (35.8)                                                                                            | 2,856                                                                                             | (37.4)                                                                                            |
| Ex-Western Europe                                                                                 | 252                                                                                               | (72.0)                                                                                            | 255                                                                                               | (73.7)                                                                                            | 2,005                                                                                             | (64.2)                                                                                            | 4,775                                                                                             | (62.6)                                                                                            |
| Western Europe includes countries in the European Economic Area, United Kingdom, and Switzerland. | Western Europe includes countries in the European Economic Area, United Kingdom, and Switzerland. | Western Europe includes countries in the European Economic Area, United Kingdom, and Switzerland. | Western Europe includes countries in the European Economic Area, United Kingdom, and Switzerland. | Western Europe includes countries in the European Economic Area, United Kingdom, and Switzerland. | Western Europe includes countries in the European Economic Area, United Kingdom, and Switzerland. | Western Europe includes countries in the European Economic Area, United Kingdom, and Switzerland. | Western Europe includes countries in the European Economic Area, United Kingdom, and Switzerland. | Western Europe includes countries in the European Economic Area, United Kingdom, and Switzerland. |

## Adverse events

AEs were coded using MedDRA version 25.0 and reported according to NCI CTCAE version 4.03.

Table 7: Adverse Event Summary (APaT Population)

|                                                                   | KN811 Pembrolizumab + SOC   | KN811 Pembrolizumab + SOC   | KN811 SOC   | KN811 SOC   | Pembro + Chemo Pooled Dataset i   | Pembro + Chemo Pooled Dataset i   | Pembrolizumab Monotherapy Reference Safety Dataset j   | Pembrolizumab Monotherapy Reference Safety Dataset j   |
|-------------------------------------------------------------------|-----------------------------|-----------------------------|-------------|-------------|-----------------------------------|-----------------------------------|--------------------------------------------------------|--------------------------------------------------------|
|                                                                   | n                           | (%)                         | n           | (%)         | n                                 | (%)                               | n                                                      | (%)                                                    |
| Participants in population                                        | 350                         |                             | 346         |             | 3,123                             |                                   | 7,631                                                  |                                                        |
| with one or more adverse events                                   | 347                         | (99.1)                      | 346         | (100.0)     | 3,097                             | (99.2)                            | 7,375                                                  | (96.6)                                                 |
| with no adverse event                                             | 3                           | (0.9)                       | 0           | (0.0)       | 26                                | (0.8)                             | 256                                                    | (3.4)                                                  |
| with drug-related a adverse events                                | 341                         | (97.4)                      | 334         | (96.5)      | 3,020                             | (96.7)                            | 5,462                                                  | (71.6)                                                 |
| with toxicity grade 3-5 adverse events                            | 248                         | (70.9)                      | 225         | (65.0)      | 2,479                             | (79.4)                            | 3,514                                                  | (46.0)                                                 |
| with toxicity grade 3-5 drug-related adverse events               | 204                         | (58.3)                      | 176         | (50.9)      | 2,099                             | (67.2)                            | 1,208                                                  | (15.8)                                                 |
| with serious adverse events                                       | 157                         | (44.9)                      | 157         | (45.4)      | 1,456                             | (46.6)                            | 2,742                                                  | (35.9)                                                 |
| with serious drug-related adverse events                          | 88                          | (25.1)                      | 79          | (22.8)      | 910                               | (29.1)                            | 840                                                    | (11.0)                                                 |
| who died                                                          | 22                          | (6.3)                       | 20          | (5.8)       | 160                               | (5.1)                             | 346                                                    | (4.5)                                                  |
| who died due to a drug-related adverse event                      | 4                           | (1.1)                       | 3           | (0.9)       | 49                                | (1.6)                             | 42                                                     | (0.6)                                                  |
| discontinued any drug due to an adverse event                     | 142                         | (40.6)                      | 126         | (36.4)      | 900                               | (28.8)                            | 1,066                                                  | (14.0)                                                 |
| discontinued pembrolizumab or placebo                             | 45                          | (12.9)                      | 36          | (10.4)      | 548                               | (17.5)                            | 1,066                                                  | (14.0)                                                 |
| discontinued any chemotherapy                                     | 135                         | (38.6)                      | 124         | (35.8)      | 636                               | (20.4)                            | NA                                                     |                                                        |
| discontinued all drugs                                            | 22                          | (6.3)                       | 23          | (6.6)       | 143                               | (4.6)                             | 1,066                                                  | (14.0)                                                 |
| discontinued any drug due to a drug- related adverse event        | 124                         | (35.4)                      | 108         | (31.2)      | 747                               | (23.9)                            | 639                                                    | (8.4)                                                  |
| discontinued pembrolizumab or placebo                             | 29                          | (8.3)                       | 17          | (4.9)       | 405                               | (13.0)                            | 639                                                    | (8.4)                                                  |
| discontinued any chemotherapy                                     | 115                         | (32.9)                      | 106         | (30.6)      | 528                               | (16.9)                            | NA                                                     |                                                        |
| discontinued all drugs                                            | 11                          | (3.1)                       | 9           | (2.6)       | 86                                | (2.8)                             | 639                                                    | (8.4)                                                  |
| discontinued any drug due to a serious adverse event              | 45                          | (12.9)                      | 42          | (12.1)      | 472                               | (15.1)                            | 714                                                    | (9.4)                                                  |
| discontinued pembrolizumab or placebo                             | 34                          | (9.7)                       | 35          | (10.1)      | 382                               | (12.2)                            | 714                                                    | (9.4)                                                  |
| discontinued any chemotherapy                                     | 39                          | (11.1)                      | 39          | (11.3)      | 307                               | (9.8)                             | NA                                                     |                                                        |
| discontinued all drugs                                            | 20                          | (5.7)                       | 23          | (6.6)       | 127                               | (4.1)                             | 714                                                    | (9.4)                                                  |
| discontinued any drug due to a serious drug-related adverse event | 30                          | (8.6)                       | 21          | (6.1)       | 343                               | (11.0)                            | 347                                                    | (4.5)                                                  |
| discontinued pembrolizumab or placebo                             | 21                          | (6.0)                       | 16          | (4.6)       | 261                               | (8.4)                             | 347                                                    | (4.5)                                                  |

7,375

256

5,462

3,514

1,208

2,742

840

346

42

1,066

1,066

1,066

639

639

639

714

(9.4)

(9.4)

(4.5)

(4.5)

<div style=\"page-break-after: always\"></div>

(4.5)

| discontinued any chemotherapy   | 24 (6.9)   | 18 (5.2)   |   213 | (6.8)   |   NA |       |
|---------------------------------|------------|------------|-------|---------|------|-------|
| discontinued all drugs          | 10 (2.9)   | 9 (2.6)    |    73 | (2.3)   |  347 | (4.5) |

a Determined by the investigator to be related to the drug.

Non-serious adverse events up to 30 days of last dose and serious adverse events up to 90 days of last dose are included.

MedDRA preferred terms \"Neoplasm Progression\", \"Malignant Neoplasm Progression\" and \"Disease Progression\" not related to the drug are excluded.

Table 8: Exposure-Adjusted Adverse Event Summary (Including Multiple Occurrences of Events) (APaT Population)

|                                                                      | Event Count and Rate (Events/100 person-months)   | Event Count and Rate (Events/100 person-months)   | Event Count and Rate (Events/100 person-months)   | Event Count and Rate (Events/100 person-months)   |
|----------------------------------------------------------------------|---------------------------------------------------|---------------------------------------------------|---------------------------------------------------|---------------------------------------------------|
|                                                                      | KN811 Pembrolizumab + SOC                         | KN811 SOC                                         | Pembro+ChemoPooled Dataset'                       | Pembrolizumab Monotherapy ReferenceSafetyDataset  |
| Number of subjects exposed                                           | 350                                               | 346                                               | 3123                                              | 7631                                              |
| Total exposure in person-months                                      | 4354.61                                           | 3773.18                                           | 34084.64                                          | 66840.89                                          |
| Total events (rate)                                                  |                                                   |                                                   |                                                   |                                                   |
| adverse events                                                       | 5904 (135.58)                                     | 5325 (141.13)                                     | 66128 (194.01)                                    | 76878 (115.02)                                    |
| dnug-related adverse events                                          | 3953 (90.78)                                      | 3565 (94.48)                                      | 40032 (117.45)                                    | 24542 (36.72)                                     |
| toxicity grade 3-5 adverse events                                    | 724 (16.63)                                       | 615 (16.30)                                       | 9548 (28.01)                                      | 7463 (11.17)                                      |
| toxicity grade 3-5 drug-related adveise events                       | 439 (10.08)                                       | 363 (9.62)                                        | 6869 (20.15)                                      | 1770 (2.65)                                       |
| serious adverse events                                               | 312 (7.16)                                        | 257 (6.81)                                        | 2903 (8.52)                                       | 4801 (7.18)                                       |
| serious drug-related adverse events                                  | 145 (3.33)                                        | 116 (3.07)                                        | 1477 (4.33)                                       | 1093 (1.64)                                       |
| adverse events leading to death                                      | 22 (0.51)                                         | 20 (0.53)                                         | 166 (0.49)                                        | 353 (0.53)                                        |
| dug-related adverse events leading to death                          | 4 (0.09)                                          | 3 (0.08)                                          | 50 (0.15)                                         | 42 (0.06)                                         |
| adverse events resulting in drug discontinuation                     | 188 (4.32)                                        | 152 (4.03)                                        | 1097 (3.22)                                       | 1165 (1.74)                                       |
| dnug-related adverse events resulting in drug discontinuation        | 160 (3.67)                                        | 125 (3.31)                                        | 907 (2.66)                                        | 703 (1.05)                                        |
| serious adveise eventsresulting in drug discontinuation              | 50 (1.15)                                         | 45 (1.19)                                         | 534 (1.57)                                        | 753 (1.13)                                        |
| serious drug-related adverse eventsresulting in drug discontinuation | 34 (0.78)                                         | 21(0.56)                                          | 386 (1.13)                                        | 363 (0.54)                                        |

Eventrate per 100person-months ofexposure=event count *100/person-months ofexposure.

b Drug exposure is defined as the time from the first dose date to the earlier ofthe last dose date + 30 or the database cut-off date.

° Determined by the investigator to be related to the drug.

Non-serious adverse events up to 30 days of last dose and serious adverse events up to 90 days of last dose are included.

MedDRA preferred terms\"Neoplasm progression\", \"Malignant neoplasm progression\" and\"Disease progression\"not related to the drug are excluded.

For KNo01 and KNo54, a new AE episode was recorded when there was any AE change in grade, relationship, or seriousness.Ifthe episode date ranges were continuous, then these records were counted as one AE episode.

Grades are based on NCICTCAE version 4.03.

## All adverse events

Table 9: Participants With Adverse Events (Incidence ≥ 10% in One or More Treatment Groups) By Decreasing Frequency of Preferred Term (APaT Population)

7,375

(96.6)

(3.4)

1,678

(22.0)

1,534

(20.1)

982

(12.9)

945

(12.4)

1,312

(17.2)

53

95

538

83

2,368

(31.0)

(0.3)

628

146

572

1,179

(15.5)

|                                             | KN811 Pembrolizumab + SOC   | KN811 Pembrolizumab + SOC   | KN811 SOC   | KN811 SOC   | Pembro + Chemo Pooled Dataset i   | Pembro + Chemo Pooled Dataset i   | Pembrolizumab Monotherapy Reference Safety Dataset j   | Pembrolizumab Monotherapy Reference Safety Dataset j   |
|---------------------------------------------|-----------------------------|-----------------------------|-------------|-------------|-----------------------------------|-----------------------------------|--------------------------------------------------------|--------------------------------------------------------|
|                                             | n                           | (%)                         | n           | (%)         | n                                 | (%)                               | n                                                      | (%)                                                    |
| Participants in population                  | 350                         |                             | 346         |             | 3,123                             |                                   | 7,631                                                  |                                                        |
| with one or more adverse events             | 347                         | (99.1)                      | 346         | (100.0)     | 3,097                             | (99.2)                            | 7,375                                                  | (96.6)                                                 |
| with no adverse events                      | 3                           | (0.9)                       | 0           | (0.0)       | 26                                | (0.8)                             | 256                                                    | (3.4)                                                  |
| Diarrhoea                                   | 183                         | (52.3)                      | 160         | (46.2)      | 1,071                             | (34.3)                            | 1,678                                                  | (22.0)                                                 |
| Nausea                                      | 168                         | (48.0)                      | 167         | (48.3)      | 1,695                             | (54.3)                            | 1,534                                                  | (20.1)                                                 |
| Anaemia                                     | 157                         | (44.9)                      | 159         | (46.0)      | 1,704                             | (54.6)                            | 982                                                    | (12.9)                                                 |
| Vomiting                                    | 113                         | (32.3)                      | 99          | (28.6)      | 885                               | (28.3)                            | 945                                                    | (12.4)                                                 |
| Decreased appetite                          | 110                         | (31.4)                      | 111         | (32.1)      | 850                               | (27.2)                            | 1,312                                                  | (17.2)                                                 |
| Neutrophil count decreased                  | 96                          | (27.4)                      | 85          | (24.6)      | 621                               | (19.9)                            | 53                                                     | (0.7)                                                  |
| Platelet count decreased                    | 95                          | (27.1)                      | 98          | (28.3)      | 377                               | (12.1)                            | 95                                                     | (1.2)                                                  |
| Aspartate aminotransferase increased        | 85                          | (24.3)                      | 63          | (18.2)      | 490                               | (15.7)                            | 538                                                    | (7.1)                                                  |
| Peripheral sensory neuropathy               | 85                          | (24.3)                      | 73          | (21.1)      | 393                               | (12.6)                            | 83                                                     | (1.1)                                                  |
| Fatigue                                     | 81                          | (23.1)                      | 77          | (22.3)      | 1,197                             | (38.3)                            | 2,368                                                  | (31.0)                                                 |
| Palmar-plantar erythrodysaesthesia syndrome | 79                          | (22.6)                      | 77          | (22.3)      | 34                                | (1.1)                             | 24                                                     | (0.3)                                                  |
| Weight decreased                            | 73                          | (20.9)                      | 59          | (17.1)      | 365                               | (11.7)                            | 628                                                    | (8.2)                                                  |
| Neuropathy peripheral                       | 65                          | (18.6)                      | 65          | (18.8)      | 465                               | (14.9)                            | 146                                                    | (1.9)                                                  |
| Alanine aminotransferase increased          | 63                          | (18.0)                      | 48          | (13.9)      | 564                               | (18.1)                            | 572                                                    | (7.5)                                                  |
| Constipation                                | 59                          | (16.9)                      | 68          | (19.7)      | 1,107                             | (35.4)                            | 1,179                                                  | (15.5)                                                 |

<div style=\"page-break-after: always\"></div>

82

70

324

934

(12.2)

209

(2.7)

(2.1)

880

(11.5)

117

75

(1.0)

674

201

937

(12.3)

487

(6.4)

1,392

(18.2)

630

1,435

(18.8)

1,175

(15.4)

111

1,436

(18.8)

847

(11.1)

528

564

946

(12.4)

150

1,130

(14.8)

52

575

511

118

| Neutropenia                      |   59 | (16.9)   |   57 | (16.5)   | 1,111   | (35.6)   | 82    | (1.1)   |
|----------------------------------|------|----------|------|----------|---------|----------|-------|---------|
| White blood cell count decreased |   55 | (15.7)   |   42 | (12.1)   | 464     | (14.9)   | 70    | (0.9)   |
| Hypokalaemia                     |   54 | (15.4)   |   41 | (11.8)   | 335     | (10.7)   | 324   | (4.2)   |
| Pyrexia                          |   53 | (15.1)   |   46 | (13.3)   | 630     | (20.2)   | 934   | (12.2)  |
| Hypoalbuminaemia                 |   52 | (14.9)   |   55 | (15.9)   | 154     | (4.9)    | 209   | (2.7)   |
| Blood bilirubin increased        |   50 | (14.3)   |   34 | (9.8)    | 64      | (2.0)    | 163   | (2.1)   |
| Asthenia                         |   47 | (13.4)   |   66 | (19.1)   | 661     | (21.2)   | 880   | (11.5)  |
| Thrombocytopenia                 |   43 | (12.3)   |   47 | (13.6)   | 572     | (18.3)   | 117   | (1.5)   |
| Infusion related reaction        |   41 | (11.7)   |   34 | (9.8)    | 122     | (3.9)    | 75    | (1.0)   |
| Abdominal pain                   |   38 | (10.9)   |   42 | (12.1)   | 323     | (10.3)   | 674   | (8.8)   |
| Stomatitis                       |   38 | (10.9)   |   31 | (9.0)    | 451     | (14.4)   | 201   | (2.6)   |
| Hypothyroidism                   |   37 | (10.6)   |   15 | (4.3)    | 434     | (13.9)   | 937   | (12.3)  |
| Pneumonia                        |   37 | (10.6)   |   15 | (4.3)    | 241     | (7.7)    | 487   | (6.4)   |
| Cough                            |   29 | (8.3)    |   19 | (5.5)    | 659     | (21.1)   | 1,392 | (18.2)  |
| Oedema peripheral                |   28 | (8.0)    |   27 | (7.8)    | 347     | (11.1)   | 630   | (8.3)   |
| Pruritus                         |   28 | (8.0)    |   18 | (5.2)    | 468     | (15.0)   | 1,435 | (18.8)  |
| Rash                             |   28 | (8.0)    |   15 | (4.3)    | 644     | (20.6)   | 1,175 | (15.4)  |
| Mucosal inflammation             |   27 | (7.7)    |   26 | (7.5)    | 363     | (11.6)   | 111   | (1.5)   |
| Arthralgia                       |   23 | (6.6)    |   14 | (4.0)    | 660     | (21.1)   | 1,436 | (18.8)  |
| Back pain                        |   21 | (6.0)    |   22 | (6.4)    | 365     | (11.7)   | 847   | (11.1)  |
| Insomnia                         |   21 | (6.0)    |   16 | (4.6)    | 400     | (12.8)   | 528   | (6.9)   |
| Dizziness                        |   19 | (5.4)    |   12 | (3.5)    | 363     | (11.6)   | 564   | (7.4)   |
| Headache                         |   19 | (5.4)    |   20 | (5.8)    | 572     | (18.3)   | 946   | (12.4)  |
| Dysgeusia                        |   17 | (4.9)    |   16 | (4.6)    | 328     | (10.5)   | 150   | (2.0)   |
| Dyspnoea                         |   15 | (4.3)    |   13 | (3.8)    | 425     | (13.6)   | 1,130 | (14.8)  |
| Leukopenia                       |   12 | (3.4)    |   23 | (6.6)    | 367     | (11.8)   | 52    | (0.7)   |
| Myalgia                          |   12 | (3.4)    |    7 | (2.0)    | 361     | (11.6)   | 575   | (7.5)   |
| Urinary tract infection          |   12 | (3.4)    |   13 | (3.8)    | 343     | (11.0)   | 511   | (6.7)   |
| Alopecia                         |    8 | (2.3)    |    6 | (1.7)    | 1,099   | (35.2)   | 118   | (1.5)   |

Every participant is counted a single time for each applicable row and column.

A specific adverse event appears on this report only if its incidence in one or more of the columns meets the incidence criterion in the report title, after rounding.

Non-serious adverse events up to 30 days of last dose and serious adverse events up to 90 days of last dose are included.

<div style=\"page-break-after: always\"></div>

## Adverse Events Related to Study Intervention

Table 10: Participants in KN811 With Drug-Related Adverse Events by Decreasing Incidence (Incidence ≥ 5% in One or More Treatment Groups) (Global Cohort) (APaT Population)

|                                             |   Pembrolizumab+SOC | Pembrolizumab+SOC   | SOC   | SOC    |
|---------------------------------------------|---------------------|---------------------|-------|--------|
|                                             |                   1 | (%)                 |       | (%)    |
| Participants in population                  |                 350 |                     | 346   |        |
| with one or more adverse events             |                 341 | (97.4)              | 334   | (96.5) |
| with no adverse events                      |                   9 | (2.6)               | 12    | (3.5)  |
| Diarrhoea                                   |                 165 | (47.1)              | 145   | (41.9) |
| Nausea                                      |                 154 | (44.0)              | 152   | (43.9) |
| Anaemia                                     |                 109 | (31.1)              | 113   | (32.7) |
| Neutrophil count decreased                  |                  92 | (26.3)              | 83    | (24.0) |
| Decreased appetite                          |                  16 | (26.0)              | 16    | (26.3) |
| Platelet count decreased                    |                  89 | (25.4)              | 93    | (26.9) |
| Vomiting                                    |                  88 | (25.1)              | 86    | (24.9) |
| Peripheralsensoryneuropathy                 |                  84 | (24.0)              | 73    | (21.1) |
| Palmar-plantar erythrodysaesthesia syndrome |                  78 | (22.3)              | 72    | (20.8) |
| Fatigue                                     |                  69 | (19.7)              | 57    | (16.5) |
| Aspartate aminotransferase increased        |                  66 | (18.9)              | 50    | (14.5) |
| Neuropathy peripheral                       |                  60 | (17.1)              | 63    | (18.2) |
| Neutropenia                                 |                  59 | (16.9)              | 54    | (15.6) |
| Whitebloodcell count decreased              |                  53 | (15.1)              | 41    | (11.8) |
| Alanine aminotransferase increased          |                  51 | (14.6)              | 41    | (11.8) |
| Weight decreased                            |                  42 | (12.0)              | 24    | (6.9)  |
| Infusion related reaction                   |                  41 | (11.7)              | 34    | (9.8)  |
| Thrombocytopenia                            |                  40 | (11.4)              | 44    | (12.7) |
| Asthenia                                    |                  39 | (11.1)              | 50    | (14.5) |
| Bloodbilirubinincreased                     |                  39 | (11.1)              | 27    | (7.8)  |
| Stomatitis                                  |                  36 | (10.3)              | 31    | (9.0)  |
| Hypothyroidism                              |                  29 | (8.3)               | 15    | (4.3)  |
| Malaise                                     |                  25 | (7.1)               | 25    | (7.2)  |
| Paraesthesia                                |                  25 | (7.1)               | 21    | (6.1)  |
| Pruritus                                    |                  25 | (7.1)               | 9     | (2.6)  |
| Constipation                                |                  23 | (6.6)               | 28    | (8.1)  |
| Mucosalinflammation                         |                  22 | (6.3)               | 25    | (7.2)  |
| Bloodcreatinineincreased                    |                  21 | (6.0)               | 6     | (1.7)  |
| Hypokalaemia                                |                  21 | (6.0)               | 15    | (4.3)  |
| Pyrexia                                     |                  20 | (5.7)               | 19    | (5.5)  |
| Rash                                        |                  20 | (5.7)               | 6     | (1.7)  |

(3.1)

Leukopenia

Every participant is counted a single time for each applicable row and column.

A specific adverse event appears on this report only ifits incidence in one or more of the columns meets the incidence criterion in the report title, after rounding.

Non-serious adverse events up to 30 days of last dose and serious adverse events up to 90 days of last dose are included.

Database CutoffDate: 25MAY2022.

## All Grade 3 to 5 Adverse Events

Table 11: Participants With Grade 3-5 Adverse Events (Incidence ≥ 1% in One or More Treatment Groups) By Decreasing Frequency of Preferred Term (APaT Population)

7,631

(46.0)

(54.0)

275

114

(1.5)

10

21

10

(0.1)

(0.9)

|                                 | KN811 Pembrolizumab + SOC   | KN811 Pembrolizumab + SOC   | KN811 SOC   | KN811 SOC   | Pembro + Chemo Pooled Dataset i   | Pembro + Chemo Pooled Dataset i   | Pembrolizumab Monotherapy Reference Safety Dataset j   | Pembrolizumab Monotherapy Reference Safety Dataset j   |
|---------------------------------|-----------------------------|-----------------------------|-------------|-------------|-----------------------------------|-----------------------------------|--------------------------------------------------------|--------------------------------------------------------|
|                                 | n                           | (%)                         | n           | (%)         | n                                 | (%)                               | n                                                      | (%)                                                    |
| Participants in population      | 350                         |                             | 346         |             | 3,123                             |                                   | 7,631                                                  |                                                        |
| with one or more adverse events | 248                         | (70.9)                      | 225         | (65.0)      | 2,479                             | (79.4)                            | 3,514                                                  | (46.0)                                                 |
| with no adverse events          | 102                         | (29.1)                      | 121         | (35.0)      | 644                               | (20.6)                            | 4,117                                                  | (54.0)                                                 |
| Anaemia                         | 44                          | (12.6)                      | 35          | (10.1)      | 620                               | (19.9)                            | 275                                                    | (3.6)                                                  |
| Diarrhoea                       | 34                          | (9.7)                       | 29          | (8.4)       | 102                               | (3.3)                             | 114                                                    | (1.5)                                                  |
| Neutrophil count decreased      | 29                          | (8.3)                       | 30          | (8.7)       | 443                               | (14.2)                            | 10                                                     | (0.1)                                                  |
| Neutropenia                     | 23                          | (6.6)                       | 18          | (5.2)       | 727                               | (23.3)                            | 21                                                     | (0.3)                                                  |
| Platelet count decreased        | 22                          | (6.3)                       | 24          | (6.9)       | 114                               | (3.7)                             | 10                                                     | (0.1)                                                  |
| Hypokalaemia                    | 20                          | (5.7)                       | 20          | (5.8)       | 96                                | (3.1)                             | 70                                                     | (0.9)                                                  |

(6.1)

21

<div style=\"page-break-after: always\"></div>

52

(0.7)

166

(2.2)

58

(0.8)

(1.0)

(0.0)

270

(3.5)

23

(0.3)

(1.3)

(1.2)

70

(0.9)

(0.4)

169

(2.2)

(0.1)

97

(1.3)

(0.4)

(0.5)

(1.0)

(1.9)

(0.0)

(1.3)

(0.9)

(0.0)

(0.9)

(0.0)

(0.0)

(0.1)

(0.1)

(0.7)

(0.1)

(0.1)

(0.4)

(0.1)

(0.4)

(0.1)

(0.1)

(1.1)

(0.7)

(0.8)

(0.0)

11

(0.1)

(0.5)

(0.1)

(0.9)

(1.9)

(0.1)

(0.0)

(0.3)

(0.6)

(0.9)

(0.3)

(1.0)

(0.6)

(1.1)

| Vomiting                                    | 17   | (4.9)       | 11   | (3.2)       | 101   | (3.2)       | 52    | (0.7)       |
|---------------------------------------------|------|-------------|------|-------------|-------|-------------|-------|-------------|
| Fatigue                                     | 16   | (4.6)       | 9    | (2.6)       | 158   | (5.1)       | 166   | (2.2)       |
| Nausea                                      | 14   | (4.0)       | 19   | (5.5)       | 108   | (3.5)       | 58    | (0.8)       |
| Decreased appetite                          | 13   | (3.7)       | 14   | (4.0)       | 61    | (2.0)       | 77    | (1.0)       |
| Peripheral sensory neuropathy               | 13   | (3.7)       | 7    | (2.0)       | 26    | (0.8)       | 2     | (0.0)       |
| Pneumonia                                   | 13   | (3.7)       | 7    | (2.0)       | 148   | (4.7)       | 270   | (3.5)       |
| Thrombocytopenia                            | 13   | (3.7)       | 8    | (2.3)       | 201   | (6.4)       | 23    | (0.3)       |
| Pulmonary embolism                          | 11   | (3.1)       | 10   | (2.9)       | 58    | (1.9)       | 101   | (1.3)       |
| Aspartate aminotransferase increased        | 10   | (2.9)       | 3    | (0.9)       | 81    | (2.6)       | 95    | (1.2)       |
| Asthenia                                    | 10   | (2.9)       | 11   | (3.2)       | 112   | (3.6)       | 70    | (0.9)       |
| Blood bilirubin increased                   | 8    | (2.3)       | 3    | (0.9)       | 6     | (0.2)       | 27    | (0.4)       |
| Hyponatraemia                               | 8    | (2.3)       | 10   | (2.9)       | 114   | (3.7)       | 169   | (2.2)       |
| Neuropathy peripheral                       | 8    | (2.3)       | 10   | (2.9)       | 33    | (1.1)       | 4     | (0.1)       |
| Alanine aminotransferase increased          | 7    | (2.0)       | 3    | (0.9)       | 120   | (3.8)       | 97    | (1.3)       |
| Dysphagia                                   | 7    | (2.0)       | 9    | (2.6)       | 40    | (1.3)       | 31    | (0.4)       |
| Weight decreased                            | 7    | (2.0)       | 4    | (1.2)       | 41    | (1.3)       | 35    | (0.5)       |
| Colitis                                     | 6    | (1.7)       | 4    | (1.2)       | 27    | (0.9)       | 74    | (1.0)       |
| Hypertension                                | 6    | (1.7)       | 5    | (1.4)       | 92    | (2.9)       | 148   | (1.9)       |
| Infusion related reaction                   | 6    | (1.7)       | 2    | (0.6)       | 17    | (0.5)       | 1     | (0.0)       |
| Pneumonitis                                 | 6    | (1.7)       | 0    | (0.0)       | 46    | (1.5)       | 97    | (1.3)       |
| Acute kidney injury                         | 5    | (1.4)       | 2    | (0.6)       | 59    | (1.9)       | 65    | (0.9)       |
| COVID-19                                    | 5    | (1.4)       | 1    | (0.3)       | 2     | (0.1)       | 0     | (0.0)       |
| Dehydration Ejection fraction decreased     | 5    | (1.4)       | 5    | (1.4)       | 45    | (1.4)       | 70    | (0.9)       |
|                                             | 5    | (1.4)       | 3    | (0.9)       | 0     | (0.0)       | 0     | (0.0)       |
| Palmar-plantar erythrodysaesthesia syndrome | 5    | (1.4)       | 5    | (1.4)       | 3     | (0.1)       | 1     | (0.0)       |
| Upper gastrointestinal haemorrhage          | 5    | (1.4)       | 4    | (1.2)       | 6     | (0.2)       | 6     | (0.1)       |
| White blood cell count decreased increased  | 5    | (1.4)       | 6    | (1.7) (1.4) | 218   | (7.0)       | 5 56  | (0.1) (0.7) |
| Gamma-glutamyltransferase                   | 4    | (1.1)       | 5    |             | 34    | (1.1)       |       |             |
| Gastric haemorrhage                         | 4    | (1.1)       | 5    | (1.4)       | 4     | (0.1)       | 5     | (0.1)       |
| Gastrointestinal haemorrhage                | 4    | (1.1)       | 3    | (0.9)       | 4     | (0.1)       | 9     | (0.1)       |
| Hypoalbuminaemia                            | 4    | (1.1)       | 4    | (1.2)       | 12    | (0.4)       | 33    | (0.4)       |
| Hypomagnesaemia                             | 4    | (1.1)       | 2    | (0.6)       | 19    | (0.6)       | 5     | (0.1)       |
| Lymphocyte count decreased                  | 4    | (1.1)       | 4    | (1.2)       | 60    | (1.9)       | 33    | (0.4)       |
| Mucosal inflammation                        | 4    | (1.1)       | 3    | (0.9)       | 55    | (1.8)       | 10    | (0.1)       |
| Stomatitis                                  | 4    | (1.1)       | 6    | (1.7)       | 63    | (2.0)       | 9     | (0.1)       |
| Hyperglycaemia                              | 3    | (0.9)       | 3    | (0.9)       | 35    | (1.1)       | 83    | (1.1)       |
| Hypophosphataemia                           | 3    | (0.9)       | 5    | (1.4)       | 35    | (1.1)       | 52    | (0.7)       |
| Sepsis                                      | 3    | (0.9)       | 2    | (0.6)       | 48    | (1.5)       | 60    | (0.8)       |
| COVID-19 pneumonia                          | 2    | (0.6)       | 5    | (1.4)       | 1     | (0.0)       | 2     | (0.0)       |
| Febrile neutropenia                         | 2    | (0.6)       | 4    | (1.2)       | 259   | (8.3)       | 11    | (0.1)       |
| Hypotension                                 | 2    | (0.6)       | 1    | (0.3)       | 31    | (1.0)       | 35    | (0.5)       |
| Leukopenia                                  | 2    | (0.6)       | 4    | (1.2)       | 145   | (4.6)       | 7     | (0.1)       |
| Back pain                                   | 1    | (0.3)       | 4    | (1.2)       | 22    | (0.7)       | 72    | (0.9)       |
| Dyspnoea                                    | 1    | (0.3)       | 1    | (0.3)       | 50    | (1.6)       | 145   | (1.9)       |
| Malaise                                     | 1    | (0.3)       | 4    | (1.2)       | 8     | (0.3)       | 5     | (0.1)       |
| Neurotoxicity                               | 1    | (0.3)       | 4    | (1.2)       | 0     | (0.0)       | 0     | (0.0)       |
| Rash maculo-papular                         | 1    | (0.3)       | 0    | (0.0)       | 37    | (1.2)       | 23    | (0.3)       |
| Syncope pain                                | 1    | (0.3)       | 0    | (0.0)       | 43    | (1.4)       | 43    | (0.6)       |
| Abdominal                                   | 0    | (0.0)       | 4    | (1.2)       | 20    | (0.6)       | 65    | (0.9)       |
| Lymphopenia                                 | 0    | (0.0)       | 0    | (0.0)       | 32    | (1.0)       | 20    | (0.3)       |
| Pleural effusion Rash                       | 0 0  | (0.0) (0.0) | 0 0  | (0.0) (0.0) | 29 37 | (0.9) (1.2) | 73 44 | (1.0) (0.6) |
| Urinary tract infection                     | 0    | (0.0)       | 2    |             | 60    | (1.9)       | 85    | (1.1)       |
|                                             |      |             |      | (0.6)       |       |             |       |             |

Every participant is counted a single time for each applicable row and column.

A specific adverse event appears on this report only if its incidence in one or more of the columns meets the incidence criterion in the report title, after rounding.

Non-serious adverse events up to 30 days of last dose and serious adverse events up to 90 days of last dose are included.

MedDRA preferred terms \"Neoplasm Progression\", \"Malignant Neoplasm Progression\" and \"Disease Progression\" not related to the drug are excluded.

<div style=\"page-break-after: always\"></div>

## Grade 3 to 5 Adverse Events Related to Study Intervention

## Table 12: Participants With Grade 3-5 Drug-related Adverse Events (Incidence ≥ 1% in One or More Treatment Groups) By Decreasing Frequency of Preferred Term (APaT Population)

7,631

(15.8)

(84.2)

(1.0)

13

(0.0)

33

(0.2)

(0.2)

(0.0)

75

(1.0)

(0.3)

(0.2)

11

(0.1)

(0.0)

(0.3)

(0.6)

(0.9)

(0.0)

(0.0)

(1.2)

(0.1)

(0.0)

(0.3)

(0.1)

(0.2)

(0.7)

(0.1)

(0.4)

(0.1)

(0.2)

(0.0)

(0.2)

(0.0)

(0.1)

(0.0)

(0.0)

(0.3)

(0.5)

|                                             | KN811 Pembrolizumab + SOC   | KN811 Pembrolizumab + SOC   | KN811 SOC   | KN811 SOC   | Pembro + Chemo Pooled Dataset i   | Pembro + Chemo Pooled Dataset i   | Pembrolizumab Monotherapy Reference Safety Dataset j   | Pembrolizumab Monotherapy Reference Safety Dataset j   |
|---------------------------------------------|-----------------------------|-----------------------------|-------------|-------------|-----------------------------------|-----------------------------------|--------------------------------------------------------|--------------------------------------------------------|
|                                             | n                           | (%)                         | n           | (%)         | n (%)                             | n (%)                             | n (%)                                                  | n (%)                                                  |
| Participants in population                  | 350                         |                             | 346         |             | 3,123                             |                                   | 7,631                                                  |                                                        |
| with one or more adverse events             | 204                         | (58.3)                      | 176         | (50.9)      | 2,099                             | (67.2)                            | 1,208                                                  | (15.8)                                                 |
| with no adverse events                      | 146                         | (41.7)                      | 170         | (49.1)      | 1,024                             | (32.8)                            | 6,423                                                  | (84.2)                                                 |
| Diarrhoea                                   | 31                          | (8.9)                       | 27          | (7.8)       | 74                                | (2.4)                             | 75                                                     | (1.0)                                                  |
| Neutrophil count decreased                  | 28                          | (8.0)                       | 30          | (8.7)       | 428                               | (13.7)                            | 6                                                      | (0.1)                                                  |
| Neutropenia                                 | 22                          | (6.3)                       | 16          | (4.6)       | 710                               | (22.7)                            | 13                                                     | (0.2)                                                  |
| Platelet count decreased                    | 22                          | (6.3)                       | 23          | (6.6)       | 110                               | (3.5)                             | 2                                                      | (0.0)                                                  |
| Anaemia                                     | 21                          | (6.0)                       | 20          | (5.8)       | 524                               | (16.8)                            | 33                                                     | (0.4)                                                  |
| Nausea                                      | 14                          | (4.0)                       | 15          | (4.3)       | 96                                | (3.1)                             | 13                                                     | (0.2)                                                  |
| Vomiting                                    | 14                          | (4.0)                       | 10          | (2.9)       | 77                                | (2.5)                             | 12                                                     | (0.2)                                                  |
| Peripheral sensory neuropathy               | 13                          | (3.7)                       | 7           | (2.0)       | 26                                | (0.8)                             | 2                                                      | (0.0)                                                  |
| Fatigue                                     | 12                          | (3.4)                       | 8           | (2.3)       | 133                               | (4.3)                             | 75                                                     | (1.0)                                                  |
| Decreased appetite                          | 11                          | (3.1)                       | 11          | (3.2)       | 49                                | (1.6)                             | 23                                                     | (0.3)                                                  |
| Hypokalaemia                                | 11                          | (3.1)                       | 10          | (2.9)       | 41                                | (1.3)                             | 12                                                     | (0.2)                                                  |
| Thrombocytopenia                            | 11                          | (3.1)                       | 6           | (1.7)       | 185                               | (5.9)                             | 11                                                     | (0.1)                                                  |
| Neuropathy peripheral                       | 8                           | (2.3)                       | 9           | (2.6)       | 33                                | (1.1)                             | 2                                                      | (0.0)                                                  |
| Asthenia                                    | 7                           | (2.0)                       | 9           | (2.6)       | 82                                | (2.6)                             | 26                                                     | (0.3)                                                  |
| Aspartate aminotransferase increased        | 6                           | (1.7)                       | 1           | (0.3)       | 63                                | (2.0)                             | 47                                                     | (0.6)                                                  |
| Colitis                                     | 6                           | (1.7)                       | 4           | (1.2)       | 26                                | (0.8)                             | 67                                                     | (0.9)                                                  |
| Infusion related reaction                   | 6                           | (1.7)                       | 2           | (0.6)       | 15                                | (0.5)                             | 1                                                      | (0.0)                                                  |
| Palmar-plantar erythrodysaesthesia syndrome | 5                           | (1.4)                       | 5           | (1.4)       | 3                                 | (0.1)                             | 1                                                      | (0.0)                                                  |
| Pneumonitis                                 | 5                           | (1.4)                       | 0           | (0.0)       | 42                                | (1.3)                             | 91                                                     | (1.2)                                                  |
| Weight decreased                            | 5                           | (1.4)                       | 2           | (0.6)       | 22                                | (0.7)                             | 8                                                      | (0.1)                                                  |
| Ejection fraction decreased                 | 4                           | (1.1)                       | 3           | (0.9)       | 0                                 | (0.0)                             | 0                                                      | (0.0)                                                  |
| Gamma-glutamyltransferase increased         | 4                           | (1.1)                       | 3           | (0.9)       | 19                                | (0.6)                             | 25                                                     | (0.3)                                                  |
| Stomatitis                                  | 4                           | (1.1)                       | 6           | (1.7)       | 60                                | (1.9)                             | 5                                                      | (0.1)                                                  |
| Acute kidney injury                         | 3                           | (0.9)                       | 0           | (0.0)       | 37                                | (1.2)                             | 16                                                     | (0.2)                                                  |
| Alanine aminotransferase increased          | 3                           | (0.9)                       | 1           | (0.3)       | 96                                | (3.1)                             | 56                                                     | (0.7)                                                  |
| Dehydration                                 | 3                           | (0.9)                       | 4           | (1.2)       | 18                                | (0.6)                             | 9                                                      | (0.1)                                                  |
| Hyponatraemia                               | 3                           | (0.9)                       | 6           | (1.7)       | 53                                | (1.7)                             | 32                                                     | (0.4)                                                  |
| Mucosal inflammation                        | 3                           | (0.9)                       | 2           | (0.6)       | 53                                | (1.7)                             | 6                                                      | (0.1)                                                  |
| Pneumonia                                   | 3                           | (0.9)                       | 1           | (0.3)       | 39                                | (1.2)                             | 17                                                     | (0.2)                                                  |
| White blood cell count decreased            | 3                           | (0.9)                       | 6           | (1.7)       | 211                               | (6.8)                             | 2                                                      | (0.0)                                                  |
| Hypertension                                | 2                           | (0.6)                       | 1           | (0.3)       | 32                                | (1.0)                             | 15                                                     | (0.2)                                                  |
| Leukopenia                                  | 2                           | (0.6)                       | 3           | (0.9)       | 142                               | (4.5)                             | 3                                                      | (0.0)                                                  |
| Lymphocyte count decreased                  | 2                           | (0.6)                       | 4           | (1.2)       | 51                                | (1.6)                             | 9                                                      | (0.1)                                                  |
| Febrile neutropenia                         | 1                           | (0.3)                       | 3           | (0.9)       | 245                               | (7.8)                             | 0                                                      | (0.0)                                                  |
| Neurotoxicity                               | 1                           | (0.3)                       | 4           | (1.2)       | 0                                 | (0.0)                             | 0                                                      | (0.0)                                                  |
| Rash maculo-papular                         | 1                           | (0.3)                       | 0           | (0.0)       | 31                                | (1.0)                             | 21                                                     | (0.3) (0.5)                                            |
| Rash                                        | 0                           | (0.0)                       | 0           | (0.0)       | 31                                | (1.0)                             | 37                                                     |                                                        |

Every participant is counted a single time for each applicable row and column.

A specific adverse event appears on this report only if its incidence in one or more of the columns meets the incidence criterion in the report title, after rounding.

Non-serious adverse events up to 30 days of last dose and serious adverse events up to 90 days of last dose are included.

MedDRA preferred terms \"Neoplasm Progression\", \"Malignant Neoplasm Progression\" and \"Disease Progression\" not related to the drug are excluded.

<div style=\"page-break-after: always\"></div>

## Serious adverse event/deaths/other significant events

## SAE

Table 13: Participants With Serious Adverse Events (Incidence ≥ 1% in One or More Treatment Groups) By Decreasing Frequency of Preferred Term (APaT Population)

7,631

(35.9)

(64.1)

272

(3.6)

(0.9)

(1.0)

(0.1)

(1.8)

(0.4)

(0.9)

(0.1)

(0.0)

(0.2)

(0.3)

(0.2)

(0.9)

(0.9)

(0.1)

(0.4)

(1.0)

(0.0)

(0.7)

(0.3)

(0.6)

(0.0)

(0.1)

(0.1)

(0.1)

(1.2)

(0.0)

(1.2)

(0.9)

|                                    | KN811 Pembrolizumab + SOC   | KN811 Pembrolizumab + SOC   | KN811 SOC   | KN811 SOC   | Pembro + Chemo Pooled Dataset i   | Pembro + Chemo Pooled Dataset i   | Pembrolizumab Monotherapy Reference Safety Dataset j   | Pembrolizumab Monotherapy Reference Safety Dataset j   |
|------------------------------------|-----------------------------|-----------------------------|-------------|-------------|-----------------------------------|-----------------------------------|--------------------------------------------------------|--------------------------------------------------------|
|                                    | n                           | (%)                         | n           | (%)         | n                                 | (%)                               | n                                                      | (%)                                                    |
| Participants in population         | 350                         |                             | 346         |             | 3,123                             |                                   | 7,631                                                  |                                                        |
| with one or more adverse events    | 157                         | (44.9)                      | 157         | (45.4)      | 1,456                             | (46.6)                            | 2,742                                                  | (35.9)                                                 |
| with no adverse events             | 193                         | (55.1)                      | 189         | (54.6)      | 1,667                             | (53.4)                            | 4,889                                                  | (64.1)                                                 |
| Pneumonia                          | 18                          | (5.1)                       | 7           | (2.0)       | 145                               | (4.6)                             | 272                                                    | (3.6)                                                  |
| Diarrhoea                          | 17                          | (4.9)                       | 16          | (4.6)       | 47                                | (1.5)                             | 70                                                     | (0.9)                                                  |
| Pulmonary embolism                 | 10                          | (2.9)                       | 7           | (2.0)       | 43                                | (1.4)                             | 78                                                     | (1.0)                                                  |
| Infusion related reaction          | 7                           | (2.0)                       | 2           | (0.6)       | 11                                | (0.4)                             | 5                                                      | (0.1)                                                  |
| Pneumonitis                        | 7                           | (2.0)                       | 1           | (0.3)       | 54                                | (1.7)                             | 136                                                    | (1.8)                                                  |
| Vomiting                           | 7                           | (2.0)                       | 9           | (2.6)       | 41                                | (1.3)                             | 32                                                     | (0.4)                                                  |
| Acute kidney injury                | 6                           | (1.7)                       | 3           | (0.9)       | 55                                | (1.8)                             | 65                                                     | (0.9)                                                  |
| Upper gastrointestinal haemorrhage | 6                           | (1.7)                       | 5           | (1.4)       | 5                                 | (0.2)                             | 6                                                      | (0.1)                                                  |
| COVID-19                           | 5                           | (1.4)                       | 4           | (1.2)       | 2                                 | (0.1)                             | 0                                                      | (0.0)                                                  |
| Dysphagia                          | 5                           | (1.4)                       | 7           | (2.0)       | 21                                | (0.7)                             | 18                                                     | (0.2)                                                  |
| Fatigue                            | 5                           | (1.4)                       | 3           | (0.9)       | 14                                | (0.4)                             | 22                                                     | (0.3)                                                  |
| Gastrointestinal haemorrhage       | 5                           | (1.4)                       | 2           | (0.6)       | 4                                 | (0.1)                             | 12                                                     | (0.2)                                                  |
| Anaemia                            | 4                           | (1.1)                       | 3           | (0.9)       | 86                                | (2.8)                             | 65                                                     | (0.9)                                                  |
| Colitis                            | 4                           | (1.1)                       | 3           | (0.9)       | 28                                | (0.9)                             | 71                                                     | (0.9)                                                  |
| Gastric haemorrhage                | 4                           | (1.1)                       | 5           | (1.4)       | 4                                 | (0.1)                             | 4                                                      | (0.1)                                                  |
| Nausea                             | 4                           | (1.1)                       | 4           | (1.2)       | 28                                | (0.9)                             | 30                                                     | (0.4)                                                  |
| Pyrexia                            | 4                           | (1.1)                       | 6           | (1.7)       | 73                                | (2.3)                             | 79                                                     | (1.0)                                                  |
| COVID-19 pneumonia                 | 3                           | (0.9)                       | 5           | (1.4)       | 1                                 | (0.0)                             | 2                                                      | (0.0)                                                  |
| Sepsis                             | 3                           | (0.9)                       | 2           | (0.6)       | 43                                | (1.4)                             | 56                                                     | (0.7)                                                  |
| Decreased appetite                 | 2                           | (0.6)                       | 4           | (1.2)       | 16                                | (0.5)                             | 20                                                     | (0.3)                                                  |
| Dehydration                        | 2                           | (0.6)                       | 4           | (1.2)       | 21                                | (0.7)                             | 44                                                     | (0.6)                                                  |
| Platelet count decreased           | 2                           | (0.6)                       | 6           | (1.7)       | 19                                | (0.6)                             | 0                                                      | (0.0)                                                  |
| Febrile neutropenia                | 1                           | (0.3)                       | 2           | (0.6)       | 217                               | (6.9)                             | 8                                                      | (0.1)                                                  |
| Hypokalaemia                       | 1                           | (0.3)                       | 6           | (1.7)       | 20                                | (0.6)                             | 9                                                      | (0.1)                                                  |
| Thrombocytopenia                   | 1                           | (0.3)                       | 6           | (1.7)       | 43                                | (1.4)                             | 10                                                     | (0.1)                                                  |
| Dyspnoea                           | 0                           | (0.0)                       | 1           | (0.3)       | 18                                | (0.6)                             | 91                                                     | (1.2)                                                  |
| Neutropenia                        | 0                           | (0.0)                       | 1           | (0.3)       | 50                                | (1.6)                             | 3                                                      | (0.0)                                                  |
| Pleural effusion                   | 0                           | (0.0)                       | 0           | (0.0)       | 31                                | (1.0)                             | 88                                                     | (1.2)                                                  |
| Urinary tract infection            | 0                           | (0.0)                       | 1           | (0.3)       | 33                                | (1.1)                             | 67                                                     | (0.9)                                                  |

Every participant is counted a single time for each applicable row and column.

A specific adverse event appears on this report only if its incidence in one or more of the columns meets the incidence criterion in the report title, after rounding.

MedDRA preferred terms \"Neoplasm Progression\", \"Malignant Neoplasm Progression\" and \"Disease Progression\" not related to the drug are excluded.

Table 14: Participants With Drug-Related Serious Adverse Events (Incidence ≥ 1% in One or More Treatment Groups) By Decreasing Frequency of Preferred Term (APaT Population)

7,631

840

(11.0)

(89.0)

|                                 | KN811 Pembrolizumab + SOC   | KN811 Pembrolizumab + SOC   | KN811 SOC   | KN811 SOC   | Pembro + Chemo Pooled Dataset i   | Pembro + Chemo Pooled Dataset i   | Pembrolizumab Monotherapy Reference Safety Dataset j   | Pembrolizumab Monotherapy Reference Safety Dataset j   |
|---------------------------------|-----------------------------|-----------------------------|-------------|-------------|-----------------------------------|-----------------------------------|--------------------------------------------------------|--------------------------------------------------------|
|                                 | n                           | (%)                         | n           | (%)         | n                                 | (%)                               | n                                                      | (%)                                                    |
| Participants in population      | 350                         |                             | 346         |             | 3,123                             |                                   | 7,631                                                  |                                                        |
| with one or more adverse events | 88                          | (25.1)                      | 79          | (22.8)      | 910                               | (29.1)                            | 840                                                    | (11.0)                                                 |
| with no adverse events          | 262                         | (74.9)                      | 267         | (77.2)      | 2,213                             | (70.9)                            | 6,791                                                  | (89.0)                                                 |

<div style=\"page-break-after: always\"></div>

(0.6)

(0.1)

(0.2)

(1.7)

(0.1)

(0.2)

(0.8)

(0.1)

(0.1)

(0.1)

(0.0)

(0.3)

(0.1)

(0.0)

(0.0)

(0.1)

(0.0)

| Diarrhoea                 | 16 (4.6)   |   15 | (4.3)   |   34 | (1.1)   |   44 | (0.6)   |
|---------------------------|------------|------|---------|------|---------|------|---------|
| Infusion related reaction | 7 (2.0)    |    2 | (0.6)   |   10 | (0.3)   |    5 | (0.1)   |
| Pneumonia                 | 7 (2.0)    |    1 | (0.3)   |   38 | (1.2)   |   19 | (0.2)   |
| Pneumonitis               | 6 (1.7)    |    1 | (0.3)   |   49 | (1.6)   |  129 | (1.7)   |
| Vomiting                  | 6 (1.7)    |    8 | (2.3)   |   30 | (1.0)   |    9 | (0.1)   |
| Acute kidney injury       | 4 (1.1)    |    1 | (0.3)   |   36 | (1.2)   |   19 | (0.2)   |
| Colitis                   | 4 (1.1)    |    3 | (0.9)   |   27 | (0.9)   |   63 | (0.8)   |
| Fatigue                   | 4 (1.1)    |    3 | (0.9)   |   10 | (0.3)   |    7 | (0.1)   |
| Nausea                    | 4 (1.1)    |    4 | (1.2)   |   26 | (0.8)   |    7 | (0.1)   |
| Dehydration               | 2 (0.6)    |    4 | (1.2)   |    8 | (0.3)   |    5 | (0.1)   |
| Platelet count decreased  | 2 (0.6)    |    6 | (1.7)   |   18 | (0.6)   |    0 | (0.0)   |
| Pyrexia                   | 2 (0.6)    |    2 | (0.6)   |   39 | (1.2)   |   22 | (0.3)   |
| Anaemia                   | 1 (0.3)    |    2 | (0.6)   |   68 | (2.2)   |    6 | (0.1)   |
| Febrile neutropenia       | 1 (0.3)    |    2 | (0.6)   |  208 | (6.7)   |    0 | (0.0)   |
| Hypokalaemia              | 1 (0.3)    |    5 | (1.4)   |   11 | (0.4)   |    3 | (0.0)   |
| Thrombocytopenia          | 1 (0.3)    |    5 | (1.4)   |   41 | (1.3)   |    6 | (0.1)   |
| Neutropenia               | 0 (0.0)    |    1 | (0.3)   |   46 | (1.5)   |    1 | (0.0)   |

Every participant is counted a single time for each applicable row and column.

A specific adverse event appears on this report only if its incidence in one or more of the columns meets the incidence criterion in the report title, after rounding.

MedDRA preferred terms \"Neoplasm Progression\", \"Malignant Neoplasm Progression\" and \"Disease Progression\" not related to the drug are excluded.

## Deaths

Table 15: Participants With Adverse Events Resulting in Death By Decreasing Frequency of Preferred Term (APaT Population) - at least 1 event in one of the KN811 arm

7,631

346

(4.5)

(95.5)

(0.5)

(0.0)

(0.6)

(0.1)

(0.0)

(0.1)

(0.0)

(0.0)

(0.0)

(0.0)

(0.1)

(0.1)

(0.0)

(0.1)

(0.1)

(0.1)

(0.0)

(0.1)

(0.0)

(0.0)

(0.0)

(0.0)

(0.0)

(0.0)

(0.0)

(0.0)

|                                                            | KN811 Pembrolizumab + SOC   | KN811 Pembrolizumab + SOC   | KN811 SOC   | KN811 SOC   | Pembro + Chemo Pooled Dataset i   | Pembro + Chemo Pooled Dataset i   | Pembrolizumab Monotherapy Reference Safety Dataset j   | Pembrolizumab Monotherapy Reference Safety Dataset j   |
|------------------------------------------------------------|-----------------------------|-----------------------------|-------------|-------------|-----------------------------------|-----------------------------------|--------------------------------------------------------|--------------------------------------------------------|
|                                                            | n                           | (%)                         | n           | (%)         | n                                 | (%)                               | n                                                      | (%)                                                    |
| Participants in population with one or more adverse events | 350                         |                             | 346         |             | 3,123                             |                                   | 7,631                                                  |                                                        |
|                                                            | 22                          | (6.3)                       | 20          | (5.8)       | 160                               | (5.1)                             | 346                                                    | (4.5)                                                  |
| with no adverse events                                     | 328                         | (93.7)                      | 326         | (94.2)      | 2,963                             | (94.9)                            | 7,285                                                  | (95.5)                                                 |
| Pneumonia                                                  | 3                           | (0.9)                       | 1           | (0.3)       | 16                                | (0.5)                             | 40                                                     | (0.5)                                                  |
| COVID-19                                                   | 2                           | (0.6)                       | 1           | (0.3)       | 1                                 | (0.0)                             | 0                                                      | (0.0)                                                  |
| Death                                                      | 2                           | (0.6)                       | 1           | (0.3)       | 18                                | (0.6)                             | 49                                                     | (0.6)                                                  |
| Pneumonitis                                                | 2                           | (0.6)                       | 0           | (0.0)       | 5                                 | (0.2)                             | 8                                                      | (0.1)                                                  |
| Abdominal infection                                        | 1                           | (0.3)                       | 0           | (0.0)       | 0                                 | (0.0)                             | 0                                                      | (0.0)                                                  |
| Acute respiratory failure                                  | 1                           | (0.3)                       | 0           | (0.0)       | 1                                 | (0.0)                             | 5                                                      | (0.1)                                                  |
| Cardiac failure chronic                                    | 1                           | (0.3)                       | 0           | (0.0)       | 0                                 | (0.0)                             | 0                                                      | (0.0)                                                  |
| Cerebral infarction                                        | 1                           | (0.3)                       | 0           | (0.0)       | 1                                 | (0.0)                             | 0                                                      | (0.0)                                                  |
| Gastric haemorrhage                                        | 1                           | (0.3)                       | 0           | (0.0)       | 0                                 | (0.0)                             | 2                                                      | (0.0)                                                  |
| Hepatitis                                                  | 1                           | (0.3)                       | 0           | (0.0)       | 0                                 | (0.0)                             | 0                                                      | (0.0)                                                  |
| Multiple organ dysfunction syndrome                        | 1                           | (0.3)                       | 1           | (0.3)       | 5                                 | (0.2)                             | 6                                                      | (0.1)                                                  |
| Myocardial infarction                                      | 1                           | (0.3)                       | 0           | (0.0)       | 4                                 | (0.1)                             | 6                                                      | (0.1)                                                  |
| Peritonitis                                                | 1                           | (0.3)                       | 0           | (0.0)       | 1                                 | (0.0)                             | 0                                                      | (0.0)                                                  |
| Pneumonia aspiration                                       | 1                           | (0.3)                       | 0           | (0.0)       | 5                                 | (0.2)                             | 8                                                      | (0.1)                                                  |
| Pulmonary embolism                                         | 1                           | (0.3)                       | 1           | (0.3)       | 4                                 | (0.1)                             | 10                                                     | (0.1)                                                  |
| Sepsis                                                     | 1                           | (0.3)                       | 0           | (0.0)       | 9                                 | (0.3)                             | 11                                                     | (0.1)                                                  |
| Sudden death                                               | 1                           | (0.3)                       | 1           | (0.3)       | 1                                 | (0.0)                             | 2                                                      | (0.0)                                                  |
| Aspiration                                                 | 0                           | (0.0)                       | 2           | (0.6)       | 0                                 | (0.0)                             | 4                                                      | (0.1)                                                  |
| COVID-19 pneumonia Cholangitis                             | 0 0                         | (0.0)                       | 2 1         | (0.6) (0.3) | 0 0                               | (0.0) (0.0)                       | 1 0                                                    | (0.0) (0.0)                                            |
| Completed suicide                                          | 0                           | (0.0) (0.0)                 |             | (0.3)       | 0                                 | (0.0)                             | 3                                                      | (0.0)                                                  |
| Craniocerebral injury                                      | 0                           | (0.0)                       | 1 1         | (0.3)       | 0                                 | (0.0)                             | 0                                                      | (0.0)                                                  |
| Gastric cancer                                             | 0                           | (0.0)                       | 1           | (0.3)       | 0                                 | (0.0)                             | 0                                                      | (0.0)                                                  |
| Intestinal ischaemia                                       | 0                           | (0.0)                       | 1           | (0.3)       | 2                                 | (0.1)                             | 1                                                      | (0.0)                                                  |
| Ischaemic stroke                                           | 0                           | (0.0)                       | 1           | (0.3)       | 2                                 | (0.1)                             | 1                                                      | (0.0)                                                  |
| Myocarditis                                                | 0                           | (0.0)                       | 1           | (0.3)       | 0                                 | (0.0)                             | 1                                                      | (0.0)                                                  |

<div style=\"page-break-after: always\"></div>

(0.0)

(0.0)

(0.0)

| Respiratory tract infection        | 0 (0.0)   | 1 (0.3)   | 0 (0.0)   | 1 (0.0)   |
|------------------------------------|-----------|-----------|-----------|-----------|
| Subdural haematoma                 | 0 (0.0)   | 1 (0.3)   | 0 (0.0)   | 0 (0.0)   |
| Upper gastrointestinal haemorrhage | 0 (0.0)   | 1 (0.3)   | 1 (0.0)   | 1 (0.0)   |

Every participant is counted a single time for each applicable row and column.

A specific adverse event appears on this report only if its incidence in one or more of the columns meets the incidence criterion in the report title, after rounding.

MedDRA preferred terms \"Neoplasm Progression\", \"Malignant Neoplasm Progression\" and \"Disease Progression\" not related to the drug are excluded.

Deaths considered drug-related by investigator were:

- Four AEs resulting in death in the pembrolizumab plus SOC group: pneumonitis, hepatitis, sepsis, and cerebral infarction (of the AEs resulting in death, it is noted in the narrative that an additional case of pneumonitis, which was considered unrelated by the investigator, was instead assessed as drugrelated based on the sponsor's review).

- Three AEs resulting in death in the SOC group: myocarditis, pulmonary embolism, and cholangitis.

## Adverse Events of Special Interest (AEOSI)

AEOSI are immune-mediated events and infusion-related AEs causally associated with pembrolizumab.

Table 16: Adverse Event Summary AEOSI (APaT Population)

|                                                            | KN811 Pembrolizumab + SOC   | KN811 Pembrolizumab + SOC   | KN811 SOC   | KN811 SOC   | Pembro + Chemo Pooled Dataset i   | Pembro + Chemo Pooled Dataset i   | Pembrolizumab Monotherapy Reference Safety Dataset j   | Pembrolizumab Monotherapy Reference Safety Dataset j   |
|------------------------------------------------------------|-----------------------------|-----------------------------|-------------|-------------|-----------------------------------|-----------------------------------|--------------------------------------------------------|--------------------------------------------------------|
|                                                            | n                           | (%)                         | n           | (%)         | n                                 | (%)                               | n                                                      | (%)                                                    |
| Participants in population                                 | 350                         | 350                         | 346         | 346         | 3,123                             | 3,123                             | 7,631                                                  | 7,631                                                  |
| with one or more adverse events                            | 132                         | (37.7)                      | 83          | (24.0)      | 1,052                             | (33.7)                            | 2,042                                                  | (26.8)                                                 |
| with no adverse event                                      | 218                         | (62.3)                      | 263         | (76.0)      | 2,071                             | (66.3)                            | 5,589                                                  | (73.2)                                                 |
| with drug-related a adverse events                         | 122                         | (34.9)                      | 78          | (22.5)      | 943                               | (30.2)                            | 1,790                                                  | (23.5)                                                 |
| with toxicity grade 3-5 adverse events                     | 36                          | (10.3)                      | 12          | (3.5)       | 326                               | (10.4)                            | 523                                                    | (6.9)                                                  |
| with toxicity grade 3-5 drug-related adverse events        | 34                          | (9.7)                       | 12          | (3.5)       | 297                               | (9.5)                             | 462                                                    | (6.1)                                                  |
| with serious adverse events                                | 32                          | (9.1)                       | 15          | (4.3)       | 251                               | (8.0)                             | 502                                                    | (6.6)                                                  |
| with serious drug-related adverse events                   | 29                          | (8.3)                       | 15          | (4.3)       | 230                               | (7.4)                             | 449                                                    | (5.9)                                                  |
| who died                                                   | 3                           | (0.9)                       | 1           | (0.3)       | 9                                 | (0.3)                             | 13                                                     | (0.2)                                                  |
| who died due to a drug-related adverse event               | 2                           | (0.6)                       | 1           | (0.3)       | 9                                 | (0.3)                             | 13                                                     | (0.2)                                                  |
| discontinued any drug due to an adverse event              | 24                          | (6.9)                       | 13          | (3.8)       | 228                               | (7.3)                             | 354                                                    | (4.6)                                                  |
| discontinued pembrolizumab or placebo                      | 14                          | (4.0)                       | 6           | (1.7)       | 176                               | (5.6)                             | 354                                                    | (4.6)                                                  |
| discontinued any chemotherapy                              | 20                          | (5.7)                       | 11          | (3.2)       | 118                               | (3.8)                             | NA                                                     |                                                        |
| discontinued all drugs                                     | 8                           | (2.3)                       | 4           | (1.2)       | 20                                | (0.6)                             | 354                                                    | (4.6)                                                  |
| discontinued any drug due to a drug- related adverse event | 23                          | (6.6)                       | 13          | (3.8)       | 224                               | (7.2)                             | 349                                                    | (4.6)                                                  |
| discontinued pembrolizumab or placebo                      | 13                          | (3.7)                       | 6           | (1.7)       | 172                               | (5.5)                             | 349                                                    | (4.6)                                                  |
| discontinued any chemotherapy                              | 19                          | (5.4)                       | 11          | (3.2)       | 116                               | (3.7)                             | NA                                                     |                                                        |
| discontinued all drugs                                     | 7                           | (2.0)                       | 4           | (1.2)       | 20                                | (0.6)                             | 349                                                    | (4.6)                                                  |
| discontinued any drug due to a serious adverse event       | 16                          | (4.6)                       | 6           | (1.7)       | 144                               | (4.6)                             | 226                                                    | (3.0)                                                  |
| discontinued pembrolizumab or placebo                      | 13                          | (3.7)                       | 6           | (1.7)       | 132                               | (4.2)                             | 226                                                    | (3.0)                                                  |
| discontinued any chemotherapy                              | 13                          | (3.7)                       | 4           | (1.2)       | 65                                | (2.1)                             | NA                                                     |                                                        |
| discontinued all drugs                                     | 8                           | (2.3)                       | 4           | (1.2)       | 17                                | (0.5)                             | 226                                                    | (3.0)                                                  |

2,042

5,589

1,790

523

(6.9)

462

(6.1)

502

(6.6)

449

(5.9)

(0.2)

(0.2)

354

(4.6)

354

(4.6)

NA

354

(4.6)

349

(4.6)

349

(4.6)

NA

349

(4.6)

(3.0)

(3.0)

(3.0)

<div style=\"page-break-after: always\"></div>

(2.9)

(2.9)

(2.9)

| discontinued any drug due to a serious drug-related adverse event   |   15 | (4.3)   | 6 (1.7)   |   141 | (4.5)   | 224   | (2.9)   |
|---------------------------------------------------------------------|------|---------|-----------|-------|---------|-------|---------|
| discontinued pembrolizumab or placebo                               |   12 | (3.4)   | 6 (1.7)   |   129 | (4.1)   | 224   | (2.9)   |
| discontinued any chemotherapy                                       |   12 | (3.4)   | 4 (1.2)   |    63 | (2.0)   | NA    |         |
| discontinued all drugs                                              |    7 | (2.0)   | 4 (1.2)   |    17 | (0.5)   | 224   | (2.9)   |

<div style=\"page-break-after: always\"></div>

Table 17: Participants With Adverse Events of Special Interest (Incidence &gt; 0% in One or More Treatment Groups) By AEOSI Category and Preferred Term (APaT Population)

|                                                                          | KN811 Pembrolizumab + SOC   | KN811 Pembrolizumab + SOC   | KN811 SOC   | KN811 SOC     | Pembro+Chemo Pooled Dataseti   | Pembro+Chemo Pooled Dataseti   | Pembrolizumab Monotherapy Reference Safety Datasee   | Pembrolizumab Monotherapy Reference Safety Datasee   |
|--------------------------------------------------------------------------|-----------------------------|-----------------------------|-------------|---------------|--------------------------------|--------------------------------|------------------------------------------------------|------------------------------------------------------|
|                                                                          |                             | (%)                         | n           | (%)           |                                | (%)                            |                                                      | (%)                                                  |
| Participants in population                                               | 350                         |                             | 346         |               | 3,123                          |                                | 7,631                                                | (26.8)                                               |
| with one or more adverse events with no adverse cvents                   | 132 218                     | (37.7) (62.3)               | 83 263      | (24.0) (76.0) | 1,052 2,071                    | (33.7) (66.3)                  | 2,042 5,589                                          | (73.2)                                               |
| AdrenalInsufficiency                                                     | 4                           | (1.1)                       | 0           | (0.0)         | 40                             | (1.3)                          | 74                                                   | (1.0)                                                |
| Adrenal insufficiency                                                    | 4                           | (1.1)                       | 0           | (0.0)         | 39                             | (1.2)                          | 69                                                   | (0.9)                                                |
| Addison's disease                                                        | 0                           | (0.0)                       | 0           | (0.0)         | 1                              | (0.0)                          | 2                                                    | (0.0) (0.0)                                          |
| Adrenocortical insufficiency acute Secondary adrenocorticalinsufficiency | 0 0                         | (0.0) (0.0)                 | 0 0         | (0.0) (0.0)   | 0 0                            | (0.0) (0.0)                    | 2 2                                                  | (0.0)                                                |
| Cholangitis Sclerosing                                                   | 0                           | (0.0)                       | 0           | (0.0)         | 2                              | (0.1)                          | 0                                                    | (0.0)                                                |
| Cholangitis sclerosing                                                   | 0                           | (0.0)                       | 0           | (0.0)         | 1                              | (0.0)                          | 0                                                    | (0.0)                                                |
| Immune-mediated cholangitis                                              | 0                           | (0.0)                       | 0           | (0.0)         | 1                              | (0.0)                          | 0                                                    | (0.0)                                                |
| Colitis                                                                  | 17                          | (4.9)                       | 10          | (2.9)         | 84                             | (2.7)                          | 159                                                  | (2.1)                                                |
|                                                                          | 13                          | (3.7)                       | 6           | (1.7)         | 64                             | (2.0)                          | 134                                                  | (1.8)                                                |
| Colitis Enterocolitis                                                    | 2                           | (0.6)                       | 2           | (0.6)         | 14                             | (0.4)                          | I1                                                   | (0.1)                                                |
| Immune-mediated enterocolitis                                            | 2                           | (0.6)                       | 2           | (0.6)         | 2                              | (0.1)                          | 6                                                    | (0.1)                                                |
| Autoimmune colitis                                                       | 0                           | (0.0)                       | 0           | (0.0)         | 4                              | (0.1)                          | 6                                                    | (0.1)                                                |
| Colitis microscopic                                                      | 0                           | (0.0)                       | 0           | (0.0)         | 1                              | (0.0)                          | 4                                                    | (0.1)                                                |
| Encephalitis                                                             | 0                           | (0.0)                       | 0           | (0.0)         | 5                              | (0.2)                          | 5                                                    | (0.1)                                                |
|                                                                          | 0                           | (0.0)                       | 0           |               | 2                              | (0.1)                          |                                                      | (0.1)                                                |
| Encephalitis Encephalis autoimmune                                       | 0                           | (0.0)                       | 0           | (0.0) (0.0)   | 3                              | (0.1)                          | 4 1                                                  | (0.0)                                                |
| Guillain-Barre Syndrome                                                  | 0                           | (0.0)                       | 1           | (0.3)         | 2                              | (0.1)                          | 6                                                    | (0.1)                                                |
| Axonal neuropa thy                                                       | 0                           | (0.0)                       | 0           | (0.0)         | 0                              | (0.0)                          | 1                                                    | (0.0)                                                |
| Demyclinating polyncuropa thy                                            | 0                           | (0.0)                       | 1           | (0.3)         | 1                              | (0.0)                          | 1                                                    | (0.0)                                                |
| Guillain-Barre syndrome                                                  | 0                           | (0.0)                       | 0           | (0.0)         | 1                              | (0.0)                          | 4                                                    | (0.1)                                                |
| Hepatitis                                                                | 2 2                         | (0.0) (0.6)                 | 4 3         | (1.2)         | 40                             | (1.3)                          | 80 34                                                | (1.0) (0.4)                                          |
| Hepatitis                                                                |                             |                             |             | (0.9)         | 14                             | (0.4)                          |                                                      | (0.5)                                                |
| Autoimmune hepatitis                                                     | 0                           | (0.0) (0.0)                 | 0           | (0.0)         | 16 0                           | (0.5) (0.0)                    | 35 8                                                 | (0.1)                                                |
| Drug induced liver injury Hepatitis acute                                | 0 0                         | (0.0)                       | 0 0         | (0.0) (0.0)   | 0                              | (0.0)                          | 1                                                    | (0.0)                                                |
| Immune-mediated hepatitis                                                | 0                           | (0.0)                       | 1           | (0.3)         | 11                             | (0.4)                          | 3                                                    | (0.0)                                                |
| Hyperthyroidism                                                          | 14                          | (4.0)                       | 11          | (3.2)         | 173                            | (5.5)                          | 398                                                  | (5.2)                                                |
| Hyperthyroidism                                                          | 14                          | (4.0)                       | 11          | (3.2)         | 171                            | (5.5)                          | 398                                                  | (5.2)                                                |
|                                                                          |                             |                             | 0           |               | 2                              |                                |                                                      | (0.0)                                                |
| Basedow's disease                                                        | 0                           | (0.0)                       |             | (0.0)         |                                | (0.1)                          | 0                                                    |                                                      |
| Hypoparathyroidism Hypoparathyroidism                                    | 0 0                         | (0.0) (0.0)                 | 0 0         | (0.0) (0.0)   | 1 1                            | (0.0) (0.0)                    | 1 1                                                  | (0.0) (0.0)                                          |
| Hypophysitis                                                             | 4                           | (1.1)                       | 0           | (0.0)         | 28 17                          | (0.9)                          | 52 32                                                | (0.7)                                                |
| Hypophysitis                                                             | 4                           | (1.1)                       | 0 0         | (0.0)         | I1                             | (0.5) (0.4)                    | 19                                                   | (0.4)                                                |
| Hypopituitarism Lymphocytic hypophysitis                                 | 0 0                         | (0.0) (0.0)                 | 0           | (0.0) (0.0)   | 0                              | (0.0)                          | 2                                                    | (0.2) (0.0)                                          |
| Hypothyroidism                                                           | 37                          | (10.6)                      | 15          | (4.3)         | 434                            | (13.9)                         | 939                                                  | (12.3)                                               |
| Hypothyroidism                                                           | 37                          | (10.6)                      | 15          | (4.3)         | 434                            | (13.9)                         | 937 1                                                | (12.3)                                               |
| Autoimmune hypothyroidism Immune-mediated hypothyroidism                 | 0                           | (0.0)                       | 0           | (0.0)         | 0                              | (0.0)                          |                                                      | (0.0)                                                |
| Myxocdema                                                                | 0                           | (0.0)                       | 0           | (0.0)         | 1                              | (0.0)                          | 0                                                    | (0.0)                                                |
|                                                                          | 0                           | (0.0)                       | 0           | (0.0)         | 0                              | (0.0)                          | 1                                                    | (0.0)                                                |
| Primary hypothyroidism                                                   | 0                           | (0.0)                       | 0           | (0.0)         | 0                              | (0.0)                          | 1                                                    | (0.0)                                                |
| Infusion Reactions                                                       | 56                          | (16.0)                      | 45          | (13.0)        | 246                            | (7.9)                          | 165                                                  | (2.2)                                                |
| Infusionrelated reaction                                                 | 41                          | (11.7)                      | 34          | (9.8)         | 122                            | (3.9)                          | 75                                                   | (1.0)                                                |
| Hypersensitivity                                                         | 10                          | (2.9)                       | 7 4         | (2.0)         | 76                             | (2.4) (1.3)                    | 49                                                   | (0.6)                                                |
| Drug hypersensitivity Anaphylactic reaction                              | 5 1                         | (1.4) (0.3)                 | 0           | (1.2) (0.0)   | 41 10                          | (0.3)                          | 24 10                                                | (0.3) (0.1)                                          |
| Anaphylactoid reaction                                                   |                             | (0.0)                       |             | (0.0)         | 0 5                            | (0.0)                          | 1 8                                                  |                                                      |
|                                                                          | 0 0                         |                             | 0 0         |               | 1                              | (0.2)                          |                                                      | (0.0) (0.1)                                          |
| Cytokine rclease syndrome Serum sickness                                 | 0                           | (0.0) (0.0)                 | 0           | (0.0) (0.0)   |                                | (0.0)                          | 0                                                    | (0.0)                                                |
| MyasthenicSyndrome                                                       |                             | (0.0)                       |             |               |                                | (0.0)                          | 8                                                    | (0.1)                                                |
| Myasthenia gravis                                                        | 0 0                         |                             | 0 0         | (0.0)         | 1                              |                                | 5                                                    | (0.1)                                                |
| Myasthenic syndrome                                                      |                             | (0.0) (0.0)                 | 0           | (0.0) (0.0)   | 1                              | (0.0) (0.0)                    | 3 3                                                  | (0.0)                                                |
| Myelitis                                                                 | 0 0                         |                             | 0           | (0.0)         | 0 0                            | (0.0)                          | 1                                                    | (0.0)                                                |
| Myelitis                                                                 |                             | (0.0) (0.0)                 |             | (0.0)         | 0                              | (0.0) (0.0)                    |                                                      |                                                      |
| Myelitis transverse                                                      | 0 0                         | (0.0)                       | 0           | (0.0)         | 0                              |                                | 2                                                    | (0.0) (0.0)                                          |
| Myocarditis                                                              | 0                           | (0.0)                       | 0 1         | (0.3)         |                                | (0.3)                          | 9                                                    | (0.1) (0.0)                                          |
| Autoimmune myocarditis Myocarditis                                       |                             | (0.0)                       | 1           | (0.0)         | 8 1                            | (0.0)                          |                                                      |                                                      |
| Myositis                                                                 | 0                           |                             | 0           | (0.3)         |                                | (0.2)                          | 0 9                                                  | (0.1)                                                |
|                                                                          | 0 1                         | (0.0) (0.3)                 | 0           |               | 7                              |                                |                                                      | (0.4)                                                |
| Rhabdomyolysis                                                           |                             |                             |             | (0.0)         | 13                             | (0.4) (0.0)                    | 34 3                                                 | (0.0)                                                |
| Autoimmune myositis                                                      |                             | (0.3)                       | 0 0         | (0.0) (0.0)   | 0                              | (0.0)                          |                                                      | (0.0)                                                |
|                                                                          | 0 0                         | (0.0)                       | 0           | (0.0)         |                                |                                | 0                                                    |                                                      |
| Dermatomyositis                                                          |                             | (0.0)                       |             |               |                                | (0.0)                          | 0                                                    | (0.0)                                                |

<div style=\"page-break-after: always\"></div>

| Myositis                                                                                                                                                                                                   | 1   | (0.3)       | 0   | (0.0)             | 13    | (0.4)       | 34    | (0.4)       | (0.4)       |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-------------|-----|-------------------|-------|-------------|-------|-------------|-------------|
| Myopathy                                                                                                                                                                                                   | 0   | (0.0)       | 0   | (0.0)             | 5     | (0.2)       | 8     | (0.1)       | (0.1)       |
| Myositis                                                                                                                                                                                                   | 0   | (0.0)       | 0   | (0.0)             | 6     | (0.2)       | 22    | (0.3)       | (0.3)       |
| Necrotising myositis                                                                                                                                                                                       | 0   | (0.0)       | 0   | (0.0)             | 0     | (0.0)       | 1     | (0.0)       | (0.0)       |
| Nephritis                                                                                                                                                                                                  | 4   | (1.1)       | 0   | (0.0)             | 25    | (0.8)       | 37    | (0.5)       | (0.5)       |
| Nephritis                                                                                                                                                                                                  | 3   | (0.9)       | 0   | (0.0)             | 14    | (0.4)       | 10    | (0.1)       | (0.1)       |
| Tubulointerstitial nephritis                                                                                                                                                                               | 1   | (0.3)       | 0   | (0.0)             | 10    | (0.3)       | 14    | (0.2)       | (0.2)       |
| Acute kidney injury                                                                                                                                                                                        | 0   | (0.0)       | 0   | (0.0)             | 0     | (0.0)       | 2     | (0.0)       | (0.0)       |
| Autoimmune nephritis                                                                                                                                                                                       | 0   | (0.0)       | 0   | (0.0)             | 2 0   | (0.1) (0.0) | 5 1   | (0.1)       | (0.1)       |
| Glomerulonephritis Glomerulonephritis acute                                                                                                                                                                | 0 0 | (0.0)       | 0   | (0.0) (0.0)       | 0     | (0.0)       | 1     | (0.0) (0.0) | (0.0) (0.0) |
| Glomerulonephritis membranous                                                                                                                                                                              | 0   | (0.0) (0.0) | 0 0 | (0.0)             | 0     | (0.0)       | 1     | (0.0)       | (0.0)       |
| Nephrotic syndrome                                                                                                                                                                                         | 0   | (0.0)       | 0   | (0.0)             | 0     | (0.0)       | 1     | (0.0)       | (0.0)       |
| Renal failure                                                                                                                                                                                              | 0   | (0.0)       | 0   | (0.0)             | 0     | (0.0)       | 2     | (0.0)       | (0.0)       |
| Pancreatitis                                                                                                                                                                                               | 0   | (0.0)       | 1   | (0.3)             | 15    | (0.5)       | 28    | (0.4)       | (0.4)       |
| Autoimmune pancreatitis Pancreatitis                                                                                                                                                                       | 0 0 | (0.0) (0.0) | 0 1 | (0.0) (0.3)       | 0 I1  | (0.0) (0.4) | 1 24  | (0.0) (0.3) | (0.0) (0.3) |
| Pancreatitis acute                                                                                                                                                                                         | 0   | (0.0)       | 0   | (0.0)             | 5     | (0.2)       | 4     | (0.1)       | (0.1)       |
| Pneumonitis                                                                                                                                                                                                | 21  | (6.0)       | 5   | (1.4)             | 124   | (4.0)       | 324   | (4.2)       | (4.2)       |
|                                                                                                                                                                                                            | 19  |             |     |                   |       | (3.6)       | 291   | (3.8)       | (3.8)       |
| Pncumonitis                                                                                                                                                                                                |     | (5.4)       | 5   | (1.4)             | 112   |             |       |             |             |
| Interstitial lung disease                                                                                                                                                                                  | 2   | (0.6)       | 0   | (0.0)             | 10    | (0.3)       | 29    | (0.4)       | (0.4)       |
| Autoimmune lung disease Immune-mediated lung disease                                                                                                                                                       | 1   | (0.3)       | 0   | (0.0)             | 0     | (0.0)       | 0     | (0.0) (0.1) | (0.0) (0.1) |
| Organising pneumonia                                                                                                                                                                                       | 0 0 | (0.0) (0.0) | 0 0 | (0.0) (0.0)       | 1     | (0.0) (0.0) | 4 3   | (0.0)       | (0.0)       |
| Sarcoidosis                                                                                                                                                                                                | 0   | (0.0)       | 0   | (0.0)             | 1     | (0.0)       | 20    | (0.3)       | (0.3)       |
|                                                                                                                                                                                                            |     |             |     |                   |       |             |       | (0.0)       | (0.0)       |
| Cutancous sarcoidosis Pulmonary sarcoidosis                                                                                                                                                                | 0 0 | (0.0) (0.0) | 0 0 | (0.0) (0.0)       | 0 0   | (0.0) (0.0) | 1 2   | (0.0)       | (0.0)       |
| Sarcoidosis                                                                                                                                                                                                | 0   | (0.0)       | 0   | (0.0)             | 1     | (0.0)       | 18    | (0.2)       | (0.2)       |
| SevereSkinReactions                                                                                                                                                                                        | 3   | (0.9)       | 0   | (0.0)             | 96    | (3.1)       | 130   | (1.7)       | (1.7)       |
| Dermatitis exfoliative generalised                                                                                                                                                                         | 1   | (0.3)       | 0   | (0.0)             | 4     | (0.1)       | 2     | (0.0)       | (0.0)       |
| Pruritus                                                                                                                                                                                                   | 1   | (0.3)       | 0   | (0.0)             | 6     | (0.2)       | 16    | (0.2)       | (0.2)       |
| Rash maculo-papular                                                                                                                                                                                        | 1   | (0.3)       | 0   | (0.0)             | 37    | (1.2)       | 23    | (0.3)       | (0.3)       |
| Dermatitis bullous                                                                                                                                                                                         | 0   | (0.0)       | 0   | (0.0)             | 8     | (0.3)       | 9     | (0.1)       | (0.1)       |
| Dermatitis exfoliative                                                                                                                                                                                     | 0   | (0.0)       | 0   | (0.0)             | 0     | (0.0)       | 5     | (0.1)       | (0.1)       |
| Erythema multifome                                                                                                                                                                                         | 0   | (0.0)       |     |                   | 6     |             |       | (0.1)       | (0.1)       |
|                                                                                                                                                                                                            |     |             | 0   | (0.0)             | 96    | (0.2) (3.1) | 8 130 | (1.7)       | (1.7)       |
| SevereSkinReactions Exfoliativc rash                                                                                                                                                                       | 3 0 | (0.9) (0.0) | 0 0 | (0.0) (0.0)       | 0 0   | (0.0) (0.0) | 2 6   | (0.0) (0.1) | (0.0) (0.1) |
| Lichen planus Oral lichen planus                                                                                                                                                                           | 0 0 | (0.0) (0.0) | 0 0 | (0.0) (0.0)       | 0     | (0.0)       | 1     | (0.0)       | (0.0)       |
| Pemphigoid                                                                                                                                                                                                 |     |             | 0   | (0.0)             | 1     | (0.0)       | 3     | (0.0)       | (0.0)       |
| Pemphigus                                                                                                                                                                                                  | 0   | (0.0)       |     | (0.0)             | 0     | (0.0)       | 2     | (0.0)       | (0.0)       |
| Pruritus genital                                                                                                                                                                                           | 0 0 | (0.0) (0.0) | 0 0 | (0.0)             | 0     | (0.0)       | 2     | (0.0)       | (0.0)       |
| Rash                                                                                                                                                                                                       | 0   | (0.0)       | 0   | (0.0)             | 37    | (1.2)       | 44    | (0.6) (0.0) | (0.6) (0.0) |
| Rash crythematous Rash pruritic                                                                                                                                                                            | 0   | (0.0)       | 0   | (0.0) (0.0)       | 1     | (0.0) (0.0) | 1 4   | (0.1)       | (0.1)       |
| Rash pustular                                                                                                                                                                                              | 0 0 | (0.0)       | 0   | (0.0)             | 1     | (0.0)       | 2     | (0.0)       | (0.0)       |
|                                                                                                                                                                                                            | 0   | (0.0)       | 0   | (0.0)             | 0     | (0.0)       | 2     | (0.0)       | (0.0)       |
| Skin necrosis                                                                                                                                                                                              | 0   | (0.0)       | 0 0 | (0.0)             |       | (0.0)       | 4     | (0.1)       | (0.1)       |
| Stevens Johnson syndrome                                                                                                                                                                                   | 0   | (0.0) (0.0) |     |                   | 2     | (0.1)       | 4     | (0.1)       | (0.1)       |
| Toxic skin eruption                                                                                                                                                                                        | 4   | (1.1)       | 0   | (0.0)             | 41    | (1.3)       | 74    | (1.0)       | (1.0)       |
| Thyroiditis Thyroid disorder                                                                                                                                                                               | 2   | (0.6)       | 0 0 | (0.0) (0.0) (0.0) | 0     | (0.0)       | 3 22  | (0.0)       | (0.0)       |
| Autoimmune thyroiditis Thyroiditis                                                                                                                                                                         |     | (0.3)       | 0   |                   | 12 28 | (0.4) (0.9) | 50    | (0.3) (0.7) | (0.3) (0.7) |
| Immune-mediated thyroiditis                                                                                                                                                                                |     | (0.3)       | 0   | (0.0) (0.0)       | 0     |             | 1     |             |             |
|                                                                                                                                                                                                            | 0   | (0.0)       | 0 0 | (0.0)             |       | (0.0) (0.0) | 0     | (0.0) (0.0) | (0.0) (0.0) |
| Thyroiditis acute                                                                                                                                                                                          | 0   | (0.0)       |     |                   | 1     |             |       |             |             |
| Type1 DiabetesMellitus                                                                                                                                                                                     | 1   | (0.3)       | 0   | (0.0)             | 11    | (0.4)       | 34    | (0.4)       | (0.4)       |
| Type I diabetes mellitus                                                                                                                                                                                   | 1   | (0.3)       | 0 0 | (0.0) (0.0)       | 9 3   | (0.3)       | 25    |             |             |
| Diabetic ketoacidosis                                                                                                                                                                                      | 0 1 | (0.0)       |     | (0.3)             | 3     | (0.1) (0.1) | 15    | (0.3) (0.2) | (0.3) (0.2) |
| Uveitis                                                                                                                                                                                                    |     |             | 1   |                   |       | (0.1)       | 25    |             |             |
| Uveitis                                                                                                                                                                                                    | 1   | (0.3) (0.3) | 1   | (0.3) (0.0)       |       |             | 16    | (0.3) (0.2) | (0.3) (0.2) |
| Chonioretinitis Inidocyclitis                                                                                                                                                                              | 0   |             | 0 0 | (0.0)             | 2 0 1 | (0.0) (0.0) | 1 5   |             |             |
| Iritis                                                                                                                                                                                                     | 0 0 | (0.0) (0.0) | 0   | (0.0)             |       | (0.0)       | 4     | (0.0) (0.1) | (0.0) (0.1) |
|                                                                                                                                                                                                            | 4   | (0.0)       |     |                   | 0     |             |       | (0.1)       | (0.1)       |
| Vasculitis                                                                                                                                                                                                 |     | (1.1)       | 1   | (0.3)             |       | (0.7)       | 5     | (0.1)       | (0.1)       |
| Vasculitis                                                                                                                                                                                                 |     | (1.1)       | 1   | (0.3)             | 23 22 | (0.7)       |       |             |             |
|                                                                                                                                                                                                            | 4   |             | 0   |                   | 1     |             | 4     |             |             |
| Central nervous system vasculitis                                                                                                                                                                          | 0   | (0.0)       |     | (0.0)             |       | (0.0)       | 0     | (0.1) (0.0) | (0.1) (0.0) |
| Giant cell arteritis                                                                                                                                                                                       |     |             |     |                   |       |             |       |             |             |
|                                                                                                                                                                                                            |     |             | 0   |                   | 0     |             | 1     |             |             |
|                                                                                                                                                                                                            | 0   |             |     |                   |       | (0.0)       |       |             |             |
|                                                                                                                                                                                                            |     | (0.0)       |     |                   |       |             |       |             |             |
|                                                                                                                                                                                                            |     |             |     | (0.0)             |       |             |       |             |             |
|                                                                                                                                                                                                            |     |             |     |                   |       |             |       | (0.0)       | (0.0)       |
| Every participant is counted a single time for each applicable row and column. A bolded tenm or specific adverse event appears on this report only ifits incidence in one or more of the columns meets the |     |             |     |                   |       |             |       |             |             |

<div style=\"page-break-after: always\"></div>

## Participants With Adverse Events of Special Interest (AEOSI) by Maximum Toxicity Grade (Incidence &gt; O% in One or More Treatment Groups) (APaT Population)

|                            | KN811 Pembrolizumab+ SOC   | KN811 Pembrolizumab+ SOC   | KN811 S0C   | KN811 S0C   | Pembro+Chemo PooledDataseti   | Pembro+Chemo PooledDataseti   | Pembrolizumab Monotherapy Reference Safety Dataseti   | Pembrolizumab Monotherapy Reference Safety Dataseti   |
|----------------------------|----------------------------|----------------------------|-------------|-------------|-------------------------------|-------------------------------|-------------------------------------------------------|-------------------------------------------------------|
|                            | n1                         | (%)                        | n           | (%)         |                               | (%)                           | n1                                                    | (%)                                                   |
| Participantsinpopulation   | 350                        |                            | 346         |             | 3,123                         |                               | 7,631                                                 |                                                       |
| withoneormoreadverseevents | 132                        | (37.7)                     | 83          | (24.0)      | 1,052                         | (33.7)                        | 2,042                                                 | (26.8)                                                |
| Grade 1                    | 35                         | (10.0)                     | 28          | (8.1)       | 252                           | (8.1)                         | 485                                                   | (6.4)                                                 |
| Grade 2                    | 61                         | (17.4)                     | 43          | (12.4)      | 474                           | (15.2)                        | 1,034                                                 | (13.5)                                                |
| Grade 3                    | 30                         | (8.6)                      | 11          | (3.2)       | 274                           | (8.8)                         | 447                                                   | (5.9)                                                 |
| Grade 4                    | 3                          | (0.9)                      | 0           | (0.0)       | 43                            | (1.4)                         | 63                                                    | (0.8)                                                 |
| Grade 5                    | 3                          | (0.9)                      | 1           | (0.3)       | 9                             | (0.3)                         | 13                                                    | (0.2)                                                 |
| withnoadverseevents        | 218                        | (62.3)                     | 263         | (76.0)      | 2,071                         | (66.3)                        | 5,589                                                 | (73.2)                                                |

<div style=\"page-break-after: always\"></div>

## Summary of Concomitant Corticosteroid Use for AEOSI (APaT Population)

|                                      | KN811 Pembrolizumab+ SOC   | KN811 Pembrolizumab+ SOC   | KN811 S0C   | KN811 S0C   | Pembro+Chemo Pooled Dataseti   | Pembro+Chemo Pooled Dataseti   | Pembrolizumab Monotherapy Reference Safety Dataset'   | Pembrolizumab Monotherapy Reference Safety Dataset'   |
|--------------------------------------|----------------------------|----------------------------|-------------|-------------|--------------------------------|--------------------------------|-------------------------------------------------------|-------------------------------------------------------|
|                                      |                            | (%)                        |             | (%)         | n                              | (%)                            |                                                       | (%)                                                   |
| Participants in population           | 350                        |                            | 346         |             | 3123                           |                                | 7631                                                  |                                                       |
| Participantswithoneormoreevents      | 132                        |                            | 83          |             | 1052                           |                                | 2042                                                  |                                                       |
| Treatedwithsystemiccorticosteroid    | 68                         | (51.5)                     | 32          | (38.6)      | 460                            | (43.7)                         | 713                                                   | (34.9)                                                |
| Nottreatedwithsystemiccorticosteroid | 64                         | (48.5)                     | 51          | (61.4)      | 592                            | (56.3)                         | 1329                                                  | (65.1)                                                |

## Summary of Outcome for Participants With AEOSI (Incidence &gt; O% in One or More Treatment Groups) (APaT Population)

|                            |              | KN811 Pembrolizumab + SOC   | KN811 Pembrolizumab + SOC   | KN811 S0C   | KN811 S0C   |   Pembro + Chemo Pooled Dataseti | Pembro + Chemo Pooled Dataseti   | Pembrolizumab Monotherapy Reference Safety Dataseti   | Pembrolizumab Monotherapy Reference Safety Dataseti   |
|----------------------------|--------------|-----------------------------|-----------------------------|-------------|-------------|----------------------------------|----------------------------------|-------------------------------------------------------|-------------------------------------------------------|
|                            | Outcome      |                             | (%)                         | 1n          | (%)         |                                1 | (%)                              | n                                                     | (%)                                                   |
| Participants in population |              | 350                         |                             | 346         |             |                             3123 |                                  | 7631                                                  |                                                       |
| With one or more AEOSI     | Overall      | 132                         | (37.7)                      | 83          | (24.0)      |                             1052 | (33.7)                           | 2042                                                  | (26.8)                                                |
|                            | Fatal        | 3                           | (2.3)                       | 1           | (1.2)       |                                9 | (0.9)                            | 13                                                    | (0.6)                                                 |
|                            | Not Resolved | 36                          | (27.3)                      | 10          | (12.0)      |                              354 | (33.7)                           | 884                                                   | (43.3)                                                |
|                            | Resolving    | 14                          | (10.6)                      | 8           | (9.6)       |                              131 | (12.5)                           | 178                                                   | (8.7)                                                 |
|                            | Unknown      | 0                           | (0.0)                       | 0           | (0.0)       |                                2 | (0.2)                            | 30                                                    | (1.5)                                                 |
|                            | Sequelae     | 2                           | (1.5)                       | 1           | (1.2)       |                               37 | (3.5)                            | 64                                                    | (3.1)                                                 |
|                            | Resolved     | 77                          | (58.3)                      | 63          | (75.9)      |                              519 | (49.3)                           | 873                                                   | (42.8)                                                |

Time to Onset and Duration of AEOSI (APaT Population)

|                                                   | KN811 Pembrolizumab + SOC   | KN811 SOC    | Pembro+Chemo Pooled Dataset   | Pembrolizumab Monotherapy Reference Safety Dataset   |
|---------------------------------------------------|-----------------------------|--------------|-------------------------------|------------------------------------------------------|
| Participants in population                        | 350                         | 346          | 3123                          | 7631                                                 |
| Participants with AEOSI, n (%)                    | 132 (37.7)                  | 83 (24.0)    | 1052 (33.7)                   | 2042 (26.8)                                          |
| Time toOnset ofFirst AEOSI (day)                  |                             |              |                               |                                                      |
| Mean (SD)                                         | 104.6 (117.0)               | 78.0 (127.6) | 120.9 (127.6)                 | 118.1 (121.4)                                        |
| Median                                            | 67.0                        | 21.0         | 83.0                          | 77.0                                                 |
| Range                                             | 1 to 584                    | 1 to 703     | 1 to 825                      | 1 to 796                                             |
| Total number of episodes of AEOSI                 | 205                         | 110          | 1648                          | 2883                                                 |
| Averagenumberof episodes of AEOSI per participant | 1.6                         | 1.3          | 1.6                           | 1.4                                                  |
| Episode Durationb (day)                           |                             |              |                               |                                                      |
| Median                                            | 41.0                        | 2.0          | 58.0                          | 105.0                                                |
| Range                                             | 1 to 1066t                  | 1 to 994+    | 1 to 1748+                    | 1 to 19151                                           |

<div style=\"page-break-after: always\"></div>

## Other or Indication-specific Adverse Events

Trastuzumab can cause cardiomyopathy, and there is a 4- to 6-fold increase in the incidence of symptomatic myocardial dysfunction among participants receiving treatment as a single agent or in combination therapy. As a result, a review of Grade 3 to 5 AEs of cardiac disorders and LVEF &lt;50% and ≥10% decrease from baseline was performed for each treatment group.

The proportion of participants with baseline and postbaseline measurements who experienced decreases from baseline in LVEF was similar between the pembrolizumab plus SOC and SOC treatment groups.

<!-- formula-not-decoded -->

<!-- image -->

|                                                                                                                                                                                                                      | Pembrolizumab + SOC                                                                                                                                                                                                  | Pembrolizumab + SOC                                                                                                                                                                                                  | SOC                                                                                                                                                                                                                  | SOC                                                                                                                                                                                                                  |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                                                                                                                                                                      | n                                                                                                                                                                                                                    | (%)                                                                                                                                                                                                                  | n                                                                                                                                                                                                                    | (%)                                                                                                                                                                                                                  |
| Participants in population                                                                                                                                                                                           | 350                                                                                                                                                                                                                  |                                                                                                                                                                                                                      | 346                                                                                                                                                                                                                  |                                                                                                                                                                                                                      |
| ParticipantswithBaseline andPost-baselineMeasurements                                                                                                                                                                | 324                                                                                                                                                                                                                  |                                                                                                                                                                                                                      | 314                                                                                                                                                                                                                  |                                                                                                                                                                                                                      |
| LVEF<50%andAbsoluteDecreasefromBaseline                                                                                                                                                                              |                                                                                                                                                                                                                      |                                                                                                                                                                                                                      |                                                                                                                                                                                                                      |                                                                                                                                                                                                                      |
| LVEF<50%                                                                                                                                                                                                             | 12                                                                                                                                                                                                                   | (3.7)                                                                                                                                                                                                                | 16                                                                                                                                                                                                                   | (5.1)                                                                                                                                                                                                                |
| LVEF<50%and>=10%DecreasefromBaseline                                                                                                                                                                                 | 9                                                                                                                                                                                                                    | (2.8)                                                                                                                                                                                                                | 12                                                                                                                                                                                                                   | (3.8)                                                                                                                                                                                                                |
| LVEF<50%and>=16%DecreasefromBaseline                                                                                                                                                                                 | 5                                                                                                                                                                                                                    | (1.5)                                                                                                                                                                                                                | 6                                                                                                                                                                                                                    | (1.9)                                                                                                                                                                                                                |
| AbsoluteLVEFDecreasefromBaseline                                                                                                                                                                                     |                                                                                                                                                                                                                      |                                                                                                                                                                                                                      |                                                                                                                                                                                                                      |                                                                                                                                                                                                                      |
| <20%and>=10%                                                                                                                                                                                                         | 46                                                                                                                                                                                                                   | (14.2)                                                                                                                                                                                                               | 53                                                                                                                                                                                                                   | (16.9)                                                                                                                                                                                                               |
| >=20%                                                                                                                                                                                                                | 5                                                                                                                                                                                                                    | (1.5)                                                                                                                                                                                                                | 5                                                                                                                                                                                                                    | (1.6)                                                                                                                                                                                                                |
| Number of participants with at least onebaseline and post-baseline laboratory measurement is used as the denominator in percentage calculation. LVEF: Left Ventricular EjectionFraction DatabaseCutoffDate:25MAY2022 | Number of participants with at least onebaseline and post-baseline laboratory measurement is used as the denominator in percentage calculation. LVEF: Left Ventricular EjectionFraction DatabaseCutoffDate:25MAY2022 | Number of participants with at least onebaseline and post-baseline laboratory measurement is used as the denominator in percentage calculation. LVEF: Left Ventricular EjectionFraction DatabaseCutoffDate:25MAY2022 | Number of participants with at least onebaseline and post-baseline laboratory measurement is used as the denominator in percentage calculation. LVEF: Left Ventricular EjectionFraction DatabaseCutoffDate:25MAY2022 | Number of participants with at least onebaseline and post-baseline laboratory measurement is used as the denominator in percentage calculation. LVEF: Left Ventricular EjectionFraction DatabaseCutoffDate:25MAY2022 |

Three participants in the pembrolizumab plus SOC group experienced Grade 3 SAEs of cardiac disorders and LVEF &lt;50% and ≥ 10% decrease from baseline: 1 congestive cardiac failure (unrelated), 1 cardiac failure (related), and 1 acute myocardial infarction (related). For both SAEs considered related to study intervention by the investigator, study treatment was discontinued. In the SOC group, 1 participant experienced a Grade 3 SAE of acute myocardial infarction, considered unrelated to study intervention.

The incidence of AEs by SOC 'cardiac disorder' is reported below:

<!-- image -->

The incidence of drug-related AEs by SOC 'cardiac disorder' is reported below:

<!-- image -->

| KN811 Pembrolizumab+ SOC   | KN811S0C   | Pembro+Chemo PooledDataset   | Pembrolizumab Monotherapy ReferenceSafety Dataset   |
|----------------------------|------------|------------------------------|-----------------------------------------------------|
| (%)                        | n (%)      | n (%)                        | n (%)                                               |

<div style=\"page-break-after: always\"></div>

| Cardiacdisorders                                 | 18   | (5.1)       | 21   | (6.1)       | 117   | (3.7)       | 74   | (1.0)       |
|--------------------------------------------------|------|-------------|------|-------------|-------|-------------|------|-------------|
| Acute coronary syndrome                          | 0    | (0.0)       | 0    | (0.0)       | 1     | (0.0)       | 0    | (0.0)       |
| Acute myocardialinfarction                       | 1    | (0.3)       | 0    | (0.0)       | 0     | (0.0)       | 1    | (0.0)       |
| Angina pectoris                                  | 0    | (0.0)       | 1    | (0.3)       | 2     | (0.1)       | 1    | (0.0)       |
| Angina unstable                                  | 0    | (0.0)       | 0    | (0.0)       | 0     | (0.0)       | 1    | (0.0)       |
| Aorticvalve calcification                        | 0    | (0.0)       | 1    | (0.3)       | 0     | (0.0)       | 0    | (0.0)       |
| Aortic valve disease                             | 0    | (0.0)       | 1    | (0.3)       | 0     | (0.0)       | 1    | (0.0)       |
| Aorticvalveincompetence                          | 1    | (0.3)       | 2    | (0.6)       | 2     | (0.1)       | 0    | (0.0)       |
| Arrhythmia                                       | 2    | (0.6)       | 0    | (0.0)       | 3     | (0.1)       | 1    | (0.0)       |
| Arteriospasm coronary                            | 0    | (0.0)       | 0    | (0.0)       |       | (0.0)       | 0    | (0.0)       |
| Atrial fibrillation                              | 2    | (0.6)       | 2    | (0.6)       | 4     | (0.1)       | 7    | (0.1)       |
| Atrial flutter                                   | 0    | (0.0)       | 0    | (0.0)       | 1     | (0.0)       | 0    | (0.0)       |
| Atrioventricularblock                            |      | (0.3)       | 0    | (0.0)       |       | (0.0)       | 0    | (0.0)       |
| Atrioventricular block complete                  | 0    | (0.0)       | 0    | (0.0)       | 0     | (0.0)       | 1    | (0.0)       |
| Atrioventricularblockfirstdegree                 | 0    | (0.0)       | 0    | (0.0)       | 2     | (0.1)       | 1    | (0.0)       |
| Autoimmune myocarditis                           | 0    | (0.0)       | 0    | (0.0)       | 1     | (0.0)       | 0    | (0.0)       |
| Autoimmune pericarditis                          | 0    | (0.0)       | 0    | (0.0)       | 0     | (0.0)       | 1    | (0.0)       |
| Bradycardia                                      | 1    | (0.3)       | 1    | (0.3)       | 1     | (0.0)       | 0    | (0.0)       |
| Bundle branch block left                         | 0    | (0.0)       | 0    | (0.0)       | 0     | (0.0)       | 1    | (0.0)       |
| Cardiac arrest                                   | 0    | (0.0)       | 0    | (0.0)       |       | (0.0)       | 0    | (0.0)       |
| Cardiac failure                                  | 1    | (0.3)       | 1    | (0.3)       | 6     | (0.2)       | 3    | (0.0)       |
| Cardiac failure acute                            | 0    | (0.0)       | 0    | (0.0)       | 0     | (0.0)       | 2    | (0.0)       |
| Cardiacfailure chronic                           | 0    | (0.0)       | 0    | (0.0)       | 1     | (0.0)       | 0    | (0.0)       |
| Cardiacfailure congestive                        | 0    | (0.0)       | 0    | (0.0)       | 1     | (0.0)       | 1    | (0.0)       |
| Cardiac tamponade                                | 0    | (0.0)       | 0    | (0.0)       | 0     | (0.0)       | 1    | (0.0)       |
| Cardio-respiratory arrest                        | 0    |             | 0    | (0.0)       | 0     |             |      | (0.0)       |
| Cardiomyopathy                                   | 0    | (0.0) (0.0) | 0    | (0.0)       | 1     | (0.0) (0.0) | 1 0  | (0.0)       |
| Cardiotoxicity                                   | 0    | (0.0)       | 1    | (0.3)       | 0     | (0.0)       | 0    | (0.0)       |
| Cardiovascular disorder                          | 0    | (0.0)       | 0    | (0.0)       | 1     | (0.0)       | 0    | (0.0)       |
| Cardiovascularinsufficiency                      | 0    | (0.0)       | 0    | (0.0)       | 2     | (0.1)       | 0    | (0.0)       |
| Diastolic dysfunction                            | 1    | (0.3)       | 0    | (0.0)       | 0     | (0.0)       | 0    | (0.0)       |
| Extrasystoles                                    | 0    | (0.0)       | 0    | (0.0)       |       | (0.0)       | 0    | (0.0)       |
| Left atrial enlargement                          | 1    | (0.3)       | 2    | (0.6)       | 0     | (0.0)       | 0    | (0.0)       |
|                                                  |      |             |      |             |       |             | 0    | (0.0)       |
| Left ventricular dilatation                      | 0    | (0.0)       | 0    | (0.0)       | 1     | (0.0)       |      |             |
| Left ventricular dysfunction                     | 2    | (0.6)       | 3    | (0.9)       | 3     | (0.1)       | 0    | (0.0)       |
| Left ventricular hypertrophy                     | 0    | (0.0)       | 0    | (0.0)       | 1     | (0.0)       | 0    | (0.0)       |
| Mitral valve disease                             | 0    | (0.0)       | 0    | (0.0)       | 0     | (0.0)       | 1    | (0.0)       |
| Mitral valve incompetence                        | 5    | (1.4)       | 1    | (0.3)       | 3     | (0.1)       | 0 3  | (0.0)       |
| Myocardialinfarction                             | 0    | (0.0)       | 0    | (0.0)       | 4     | (0.1)       |      | (0.0)       |
| Myocardialischaemia                              | 0    | (0.0)       | 0    | (0.0)       | 1 7   | (0.0)       | 0 9  | (0.0)       |
| Myocarditis                                      | 0 0  | (0.0)       | 1 0  | (0.3) (0.0) | 1     | (0.2) (0.0) |      | (0.1) (0.0) |
| Myopericarditis                                  |      | (0.0)       |      |             |       |             | 0    |             |
| Palpitations                                     | 0    | (0.0)       | 2    | (0.6)       | 25    | (0.8)       | 15   | (0.2)       |
| Paroxysmal arrhythmia                            | 0    | (0.0)       | 0    | (0.0)       | 0     | (0.0)       | 1    | (0.0)       |
| Pericardialeffusion                              | 0    | (0.0)       | 1    | (0.3)       | 4     | (0.1)       | 17   | (0.2)       |
| Pericarditis                                     | 2    | (0.6)       | 0    | (0.0)       | 1     | (0.0)       | 5    | (0.1)       |
| Pleuropericarditis                               | 0    | (0.0)       | 0    | (0.0)       | 0     | (0.0)       | 1    | (0.0)       |
| Pulmonaryvalveincompetence                       | 1    | (0.3)       | 1    | (0.3)       | 1     | (0.0)       | 0    | (0.0)       |
| Right ventricular failure                        | 0    | (0.0)       | 0    | (0.0)       |       | (0.0)       | 0    | (0.0)       |
| Right ventricular hypertrophy                    | 0    | (0.0)       | 0    | (0.0)       | 1     | (0.0)       | 0    | (0.0)       |
| Sinus arrhythmia                                 | 0    | (0.0)       | 1    | (0.3)       | 0     | (0.0)       | 0    | (0.0)       |
|                                                  |      | (0.3)       |      | (0.0)       | 1     | (0.0)       | 0    | (0.0)       |
| Sinus bradycardia                                |      |             | 0    |             |       |             |      |             |
| Sinus tachycardia                                | 1 1  | (0.3) (0.3) | 0 1  | (0.0) (0.3) | 20 1  | (0.6) (0.0) | 4 1  | (0.1)       |
| Supraventricular extrasystoles                   | 0    | (0.0)       | 1    | (0.3)       | 3     | (0.1)       | 0    | (0.0) (0.0) |
| Supraventricular tachycardia Tachyarrhythmia     | 0    | (0.0)       | 0    | (0.0)       | 0     | (0.0)       | 1    | (0.0)       |
| Tachycardia                                      | 0    |             | 0    | (0.0)       |       |             |      |             |
| Tachycardia paroxysmal                           | 0    | (0.0)       | 0    | (0.0)       | 21 1  | (0.7) (0.0) | 8 0  | (0.1) (0.0) |
|                                                  | 2    | (0.0) (0.6) | 0    | (0.0)       | 0     | (0.0)       | 0    |             |
| Tricuspidvalve incompetence                      | 1    |             | 0    | (0.0)       | 1     | (0.0)       | 0    | (0.0) (0.0) |
| Ventricular arrhythmia Ventricular extrasystoles | 0    | (0.3) (0.0) | 1    | (0.3)       |       | (0.0)       | 0    | (0.0)       |
| Ventricular hypertrophy                          | 0    |             | 0    | (0.0)       |       | (0.0)       |      | (0.0)       |
|                                                  |      | (0.0)       |      |             | 1     |             | 0    |             |
| Ventricular hypokinesia                          | 0    | (0.0)       | 1    | (0.3)       | 0     | (0.0)       | 0 0  | (0.0) (0.0) |
| Ventricular remodelling                          | 0    | (0.0)       | 0    | (0.0)       | 1     | (0.0)       |      |             |
| Ventriculartachycardia                           | 0    | (0.0)       | 0    | (0.0) (0.0) | 0     | (0.0) (0.0) | 0 1  | (0.0)       |
| Wolff-Parkinson-White syndrome                   | 0    | (0.0)       | 0    |             |       |             |      | (0.0)       |

## The incidence of Grade 3-5 AEs by SOC 'cardiac disorder' is reported below:

<!-- image -->

|                  | KN811 Pembrolizumab+ SOC   | KN811SOC   | Pembro+Chemo PooledDataset   | Pembrolizumab Monotherapy Reference Safety Dataset   |
|------------------|----------------------------|------------|------------------------------|------------------------------------------------------|
| Cardiacdisorders | (2.6)                      | (2.6)      | 105 (3.4)                    | 201 (2.6)                                            |

<div style=\"page-break-after: always\"></div>

The incidence of drug-related Grade 3-5 AEs by SOC 'cardiac disorder' is reported below:

|                  | KN811 Pembrolizumab SOC   | KN811S0C   | Pembro+Chemo PooledDataset   | Pembrolizumab Monotherapy ReferenceSafety Dataset   |
|------------------|---------------------------|------------|------------------------------|-----------------------------------------------------|
| Cardiacdisorders | 3 (0.9)                   | 5 (1.4)    | 32 (1.0)                     | 37 (0.5)                                            |

The incidence of SAE by SOC 'cardiac disorder' is reported below:

|                  | KN811 Pembrolizumab+ SOC   | KN811S0C   | Pembro+Chemo PooledDataset   | Pembrolizumab Monotherapy ReferenceSafety Dataset   |
|------------------|----------------------------|------------|------------------------------|-----------------------------------------------------|
| Cardiacdisorders | (%) 10 (2.9)               | (%) (2.6)  | (%) 99 (3.2)                 | (%) 202 (2.6)                                       |

## Adverse reactions included in the SmPC

The MAH has updated Section 4.8 of the SmPC to include the KEYNOTE-811 population of gastric and gastro-oesophageal junction adenocarcinoma patients, receiving pembrolizumab in combination with trastuzumab plus chemotherapy, into the current 'pembrolizumab in combination with chemotherapy' pooled dataset. This dataset includes all pembrolizumab plus chemotherapy combination indications currently approved in the EU. Supportive table is shown below:

Table 18: Adverse Reactions in Patients Treated with Pembrolizumab in Combination with Chemotherapy

|                                   |                                   | Combination Therapy (N=3473)      | Combination Therapy (N=3473)      |
|-----------------------------------|-----------------------------------|-----------------------------------|-----------------------------------|
|                                   |                                   | All AEs % (m)                     | Gr 3-5 AEs                        |
| Infectionsandinfestations         | Infectionsandinfestations         | Infectionsandinfestations         | Infectionsandinfestations         |
| Common                            | Pneumonia                         | 8.0% (278)                        | 161                               |
| Bloodand lymphaticsystemdisorders | Bloodand lymphaticsystemdisorders | Bloodand lymphaticsystemdisorders | Bloodand lymphaticsystemdisorders |
| Very common                       | Neutropenia                       | 33.7% (1170)                      | 750                               |
| Very common                       | Anaemia                           | 53.6% (1861)                      | 664                               |
| Very common                       | Thrombocytopenia                  | 17.7% (615)                       | 214                               |
| Very common                       | Leukopenia                        | 10.9% (379)                       | 147                               |
| Common                            | Febrile Neutropenia               | 7.8% (271)                        | 261                               |
| Common                            | Lymphopenia                       | 3.0% (105)                        | 32                                |
| Uncommon                          | Eosinophilia                      | 0.6% (20)                         | 2                                 |
| Rare                              | Haemolytic Anaemia                | 0.03% (1)                         | 1                                 |
| Rare                              | ImmuneThrombocytopenia            | 0.03% (1)                         | 0                                 |
| Immunesystemdisorders             | Immunesystemdisorders             | Immunesystemdisorders             | Immunesystemdisorders             |
| Common                            | InfusionReactionsa                | 8.7% (302)                        | 50                                |
| Rare                              | Sarcoidosis                       | 0.03% (1)                         | 0                                 |
| Endocrinedisorders                | Endocrinedisorders                | Endocrinedisorders                | Endocrinedisorders                |
| Very common                       | Hypothyroidismb                   | 13.6% (471)                       | 14                                |
| Common                            | Adrenal Insufficiencye            | 1.3% (44)                         | 19                                |
| Common                            | Thyroiditisd                      | 1.3% (45)                         | 6                                 |
| Common                            | Hyperthyroidisme                  | 5.4% (187)                        | 5                                 |
| Uncommon                          | Hypophysitisf                     | 0.9% (32)                         | 17                                |
| Rare                              | Hypoparathyroidism                | 0.03% (1)                         | 0                                 |
| Metabolismandnutritiondisorders   | Metabolismandnutritiondisorders   | Metabolismandnutritiondisorders   | Metabolismandnutritiondisorders   |
| Very common                       | Hypokalaemia                      | 11.2% (389)                       | 116                               |
| Very common                       | Decreased Appetite                | 27.6% (960)                       | 74                                |
| Common                            | Hyponatraemia                     | 7.1% (245)                        | 122                               |
| Common                            | Hypocalcaemia                     | 4.2% (146)                        | 24                                |
| Uncommon                          | Type 1 Diabetes Mellituss         | 0.3% (12)                         | 11                                |

<div style=\"page-break-after: always\"></div>

| Psychiatricdisorders                        | Psychiatricdisorders                                | Psychiatricdisorders                        | Psychiatricdisorders                        |
|---------------------------------------------|-----------------------------------------------------|---------------------------------------------|---------------------------------------------|
| Very common                                 | Insomnia                                            | 12.1% (421)                                 | 5                                           |
| Nervous system disorders                    | Nervous system disorders                            | Nervous system disorders                    | Nervous system disorders                    |
| Very common                                 | Neuropathy Peripheral                               | 15.3% (530)                                 | 41                                          |
| Very common                                 | Headache                                            | 17.0% (591)                                 | 13                                          |
| Very common                                 | Dizziness                                           | 11.0% (382)                                 |                                             |
| Common                                      | Lethargy                                            | 1.4% (47)                                   | 2                                           |
| Common                                      | Dysgeusia                                           | 9.9% (345)                                  | 1                                           |
| Uncommon                                    | Encephalitish                                       | 0.1% (5)                                    | 5                                           |
| Uncommon                                    | Epilepsy                                            | 0.2% (6)                                    | 3                                           |
| Rare                                        | Guillain-Barre Syndromei                            | 0.06% (2)                                   | 2                                           |
| Rare                                        | Myasthenic Syndrome                                 | 0.03% (1)                                   | 1                                           |
| Eye disorders                               | Eye disorders                                       | Eye disorders                               | Eye disorders                               |
| Common                                      | Dry Eye                                             | 3.8% (132)                                  | 1                                           |
| Uncommon                                    | Uveitis                                             | 0.1% (4)                                    | 0                                           |
| Cardiac disorders                           | Cardiac disorders                                   | Cardiac disorders                           | Cardiac disorders                           |
| Common                                      | Cardiac Arrhythmia (Including Atrial Fibrillation)k | 4.2% (145)                                  | 38                                          |
| Uncommon                                    | Myocarditis!                                        | 0.2% (8)                                    | 6                                           |
| Uncommon                                    | Pericardial Effusion                                | 0.3% (11)                                   | 3                                           |
| Uncommon                                    | Pericarditis                                        | 0.2% (6)                                    | 1                                           |
| Vasculardisorders                           | Vasculardisorders                                   | Vasculardisorders                           | Vasculardisorders                           |
| Common                                      | Hypertension                                        | 6.8% (237)                                  | 98                                          |
| Uncommon                                    | Vasculitism                                         | 0.8% (27)                                   | 3                                           |
| Respiratory,thoracicandmediastinaldisorders | Respiratory,thoracicandmediastinaldisorders         | Respiratory,thoracicandmediastinaldisorders | Respiratory,thoracicandmediastinaldisorders |
| Very common                                 | Dyspnoea                                            | 12.7% (440)                                 | 51                                          |
| Very common                                 | Cough                                               | 19.8% (688)                                 | 5                                           |
| Common                                      | Pneumonitis\"                                        | 4.2% (145)                                  | 56                                          |
| Gastrointestinaldisorders                   | Gastrointestinaldisorders                           | Gastrointestinaldisorders                   | Gastrointestinaldisorders                   |
| Very common                                 | Diarrhoea                                           | 36.1% (1254)                                | 136                                         |
| Very common                                 | Nausea                                              | 53.6% (1863)                                | 122                                         |
| Very common                                 | Vomiting                                            | 28.7% (998)                                 | 118                                         |
| Very common                                 | Abdominal Paino                                     | 17.5% (608)                                 | 33                                          |
| Very common                                 | Constipation                                        | 33.6% (1166)                                |                                             |
| Common                                      | Colitis?                                            | 2.9% (101)                                  | 44                                          |
| Common                                      | Gastritis                                           | 2.3% (79)                                   | 7                                           |
| Common                                      | Dry Mouth                                           | 4.9% (169)                                  | 1                                           |
| Uncommon                                    | Pancreatitis4                                       | 0.4% (15)                                   | II                                          |
| Uncommon                                    | GastrointestinalUlceration'                         | 0.5% (16)                                   | 2                                           |
| Rare                                        | SmallIntestinalPerforation                          | 0.03% (1)                                   | 1                                           |
| Hepatobiliary disorders                     | Hepatobiliary disorders                             | Hepatobiliary disorders                     | Hepatobiliary disorders                     |
| Common                                      | Hepatitiss                                          | 1.2% (42)                                   | 37                                          |
| Rare                                        | Cholangitis Sclerosing                              | 0.06% (2)                                   | 2                                           |
| Skin andsubcutaneoustissuedisorders         | Skin andsubcutaneoustissuedisorders                 | Skin andsubcutaneoustissuedisorders         | Skin andsubcutaneoustissuedisorders         |
| Very common                                 | Alopecia                                            | 31.9% (1107)                                | 6                                           |
| Very common                                 | Rash\"                                               | 23.8% (828)                                 | 4                                           |
| Very common                                 | Pruritusy                                           | 15.3% (530)                                 | 4 87                                        |
| Common Common                               | Severe Skin Reactionsw Erythema                     | 2.9% (99) 4.9% (170)                        | 3                                           |
| Common                                      | Dry Skin                                            | 5.8% (201)                                  | 2                                           |
| Common                                      | Dermatitis Acneiform                                | 2.5% (88)                                   | 2                                           |
| Common                                      | Dermatitis                                          | 1.8% (63)                                   | 2                                           |
| Common                                      | Eczema                                              | 1.5% (51)                                   | 1                                           |
| Uncommon                                    | Psoriasis                                           | 0.5% (18)                                   | 4                                           |
| Uncommon                                    | Lichenoid Keratosisx                                | 0.1% (5)                                    | 1                                           |
| Uncommon                                    | Vitiligoy                                           | 0.6% (21)                                   | 0                                           |
| Uncommon                                    | Papule                                              | 0.2% (8)                                    | 0                                           |
| Rare Rare                                   | Stevens-JohnsonSyndrome Erythema Nodosum            | 0.03% (1) 0.09% (3)                         | 1 0                                         |

<div style=\"page-break-after: always\"></div>

| Rare                                             | Hair Colour Changes                              | 0.03% (1)                                        | 0                                                |
|--------------------------------------------------|--------------------------------------------------|--------------------------------------------------|--------------------------------------------------|
| Musculoskeletalandconnectivetissuedisorders      | Musculoskeletalandconnectivetissuedisorders      | Musculoskeletalandconnectivetissuedisorders      | Musculoskeletalandconnectivetissuedisorders      |
| Very common                                      | Arthralgia                                       | 19.7% (683)                                      | 27                                               |
| Very common                                      | Musculoskeletal Pain²                            | 15.9% (551)                                      | 27                                               |
| Very common                                      | Myositisaa                                       | 11.0% (382)                                      | 15                                               |
| Common                                           | Pain In Extremity                                | 8.5% (296)                                       | 9                                                |
| Common                                           | Arthritisbb                                      | 1.8% (62)                                        | 4                                                |
| Uncommon                                         | Tenosynovitisce                                  | 0.5% (16)                                        | 1                                                |
| Rare                                             | Sjogren's Syndrome                               | 0.03% (1)                                        | 0                                                |
| Renalandurinarydisorders                         | Renalandurinarydisorders                         | Renalandurinarydisorders                         | Renalandurinarydisorders                         |
| Common                                           | Acute Kidney Injury                              | 3.8% (131)                                       | 64                                               |
| Uncommon                                         | Nephritisd                                       | 0.8% (29)                                        | 15                                               |
| Uncommon                                         | Cystitis Noninfective                            | 0.2% (7)                                         | 0                                                |
| Generaldisorders andadministrationsiteconditions | Generaldisorders andadministrationsiteconditions | Generaldisorders andadministrationsiteconditions | Generaldisorders andadministrationsiteconditions |
| Very common                                      | Fatigue                                          | 36.8% (1278)                                     | 174                                              |
| Very common                                      | Asthenia                                         | 20.4% (708)                                      | 122                                              |
| Very common                                      | Pyrexia                                          | 19.7% (683)                                      | 25                                               |
| Common                                           | Oedemac                                          | 5.3% (185)                                       | 7                                                |
| Common                                           | Influenza Like Illness                           | 3.2% (112)                                       | 1                                                |
| Common                                           | Chills                                           | 3.3% (115)                                       | 0                                                |
| Investigations                                   | Investigations                                   | Investigations                                   | Investigations                                   |
| Very common                                      | AlanineAminotransferaseIncreased                 | 18.1% (627)                                      | 127                                              |
| Very common                                      | AspartateAminotransferaseIncreased               | 16.6% (575)                                      | 16                                               |
| Common                                           | Blood CreatinineIncreased                        | 9.5% (330)                                       | 20                                               |
| Common                                           | BloodAlkalinePhosphataseIncreased                | 5.6% (194)                                       | 17                                               |
| Common                                           | BloodBilirubinIncreased                          | 3.3% (114)                                       | 14                                               |
| Common                                           | Hypercalcaemia                                   | 1.8% (64)                                        | 14                                               |

<div style=\"page-break-after: always\"></div>

<!-- image -->

## Laboratory findings

The most frequently reported laboratory abnormalities were generally consistent between the pembrolizumab plus SOC and SOC treatment groups. Most laboratory abnormalities in the pembrolizumab plus SOC group were Grade 1 or 2.

Three participants met the criteria for drug-induced liver injury (2 [0.6%] in the pembrolizumab plus SOC group and 1 [0.3%] in the SOC group): ALT or AST ≥ 3 x ULN and bilirubin ≥ 2 x ULN and ALP &lt;2 x ULN.

<div style=\"page-break-after: always\"></div>

## Safety in special populations

The safety findings in the pembrolizumab plus SOC group based on sex and ECOG performance status were balanced in the pembrolizumab + generally consistent with the established safety profiles of trastuzumab, chemotherapy components, and pembrolizumab monotherapy. The overall summary of AEs in the pembrolizumab plus SOC group was similar between male and female and between patients with ECOG 0 and 1 (data not shown).

Table 19 : Adverse Event Summary by Age Category (&lt; 65, ≥ 65 Years) (APaT Population)

|                                                                   | KN8l1Pembrolizumab+SOC   | KN8l1Pembrolizumab+SOC   | KN8l1Pembrolizumab+SOC   | KN8l1Pembrolizumab+SOC   | KN811 SOC   | KN811 SOC   | KN811 SOC   | KN811 SOC   | Pembro + Chemo Pooled Dataseti   | Pembro + Chemo Pooled Dataseti   | Pembro + Chemo Pooled Dataseti   | Pembro + Chemo Pooled Dataseti   |
|-------------------------------------------------------------------|--------------------------|--------------------------|--------------------------|--------------------------|-------------|-------------|-------------|-------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|
|                                                                   | <65                      | <65                      | >=65                     | >=65                     | <65         | <65         | >=65        | >=65        | <65                              | <65                              | S9=<                             | S9=<                             |
|                                                                   |                          | (%)                      | n                        | (%)                      |             | (%)         |             | (%)         |                                  | (%)                              | n                                | (%)                              |
| Participants in population                                        | 205                      |                          | 145                      |                          | 190         |             | 156         |             | 2,176                            |                                  | 947                              |                                  |
| with one ormore adverse events                                    | 203                      | (99.0)                   | 144                      | (99.3)                   | 190         | (100.0)     | 156         | (100.0)     | 2,158                            | (99.2)                           | 939                              | (99.2)                           |
| with no adverse event                                             | 2                        | (1.0)                    | 1                        | (0.7)                    | 0           | (0.0)       | 0           | (0.0)       | 18                               | (0.8)                            | 8                                | (0.8)                            |
| with drug-related adverse events                                  |                          | (98.0)                   | 140                      | (96.6)                   | 184         | (96.8)      | 150         | (96.2)      | 2,107                            | (96.8)                           | 913                              | (96.4)                           |
| with toxicity grade 3-5 adverse events                            | 151                      | (73.7)                   | 97                       | (66.9)                   | 110         | (57.9)      | 115         | (73.7)      | 1,721                            | (79.1)                           | 758                              | (80.0)                           |
| with toxicity grade 3-5 drug-related adverse events               | 122                      | (59.5)                   | 82                       | (56.6)                   | 85          | (44.7)      | 16          | (58.3)      | 1,464                            | (67.3)                           | 635                              | (67.1)                           |
| with serious adverse events                                       | 96                       | (46.8)                   | 61                       | (42.1)                   | 80          | (42.1)      | 77          | (49.4)      | 935                              | (43.0)                           | 521                              | (55.0)                           |
| with serious drug-related adverse events                          | 52                       | (25.4)                   | 36                       | (24.8)                   | 38          | (20.0)      | 41          | (26.3)      | 592                              | (27.2)                           | 318                              | (33.6)                           |
| who died                                                          | 8                        | (3.9)                    | 14                       | (9.7)                    | 8           | (4.2)       | 12          | (7.7)       | 72                               | (3.3)                            | 88                               | (9.3)                            |
| who died due to a drug-related adverse event                      | 2                        | (1.0)                    | 2                        | (1.4)                    | 0           | (0.0)       | 3           | (1.9)       | 20                               | (0.9)                            | 29                               | (3.1)                            |
| discontinued any drug due to an adverse event                     | 73                       | (35.6)                   | 69                       | (47.6)                   | 49          | (25.8)      | 77          | (49.4)      | 567                              | (26.1)                           | 333                              | (35.2)                           |
| discontinued pembrolizumab/placcbo                                | 16                       | (7.8)                    | 29                       | (20.0)                   | 14          | (7.4)       | 22          | (14.1)      | 332                              | (15.3)                           | 216                              | (22.8)                           |
| discontinued any chemotherapy                                     | 68                       | (33.2)                   | 67                       | (46.2)                   | 48          | (25.3)      | 76          | (48.7)      | 383                              | (17.6)                           | 253                              | (26.7)                           |
| discontinued all drugs                                            | 9                        | (4.4)                    | 13                       | (9.0)                    | 9           | (4.7)       | 14          | (9.0)       | 71                               | (3.3)                            | 72                               | (7.6)                            |
| discontinued any drug due to a drug-related adverse event         | 65                       | (31.7)                   | 59                       | (40.7)                   | 39          | (20.5)      | 69          | (44.2)      | 493                              | (22.7)                           | 254                              | (26.8)                           |
| discontinued pembrolizumab/placebo                                | 12                       | (5.9)                    | 17                       | (11.7)                   | 4           | (2.1)       | 13          | (8.3)       | 261                              | (12.0)                           | 144                              | (15.2)                           |
| discontinued any chemotherapy                                     | 60                       | (29.3)                   | 55                       | (37.9)                   | 38          | (20.0)      | 68          | (43.6)      | 340                              | (15.6)                           | 188                              | (19.9)                           |
| discontinued all drugs                                            | 6                        | (2.9)                    | 5                        | (3.4)                    | 1           | (0.5)       | 8           | (5.1)       | 45                               | (2.1)                            | 41                               | (4.3)                            |
| discontinued any drug due to a serious adverse event              | 17                       | (8.3)                    | 28                       | (19.3)                   | 15          | (7.9)       | 27          | (17.3)      | 270                              | (12.4)                           | 202                              | (21.3)                           |
| discontinued pembrolizumab/placebo                                | I                        | (5.4)                    | 23                       | (15.9)                   | 13          | (6.8)       | 22          | (14.1)      | 210                              | (9.7)                            | 172                              | (18.2)                           |
| discontinued any chemotherapy                                     | 16                       | (7.8)                    | 23                       | (15.9)                   | 14          | (7.4)       | 25          | (16.0)      | 164                              | (7.5)                            | 143                              | (15.1)                           |
| discontinued all drugs                                            | 8                        | (3.9)                    | 12                       | (8.3)                    | 9           | (4.7)       | 14          | (9.0)       | 63                               | (2.9)                            | 64                               | (6.8)                            |
| discontinued any drug due to a serious drug-related adverse event | 12                       | (5.9)                    | 18                       | (12.4)                   | 5           | (2.6)       | 16          | (10.3)      | 211                              | (9.7)                            | 132                              | (13.9)                           |
| discontinued pembrolizumab/placebo                                | 7                        | (3.4)                    | 14                       | (9.7)                    | 3           | (1.6)       | 13          | (8.3)       | 154                              | (7.1)                            | 107                              | (11.3)                           |
| discontinued any chemotherapy                                     |                          | (5.4)                    | 13                       | (9.0)                    | 4           | (2.1)       | 14          | (9.0)       | 126                              | (5.8)                            | 87                               | (9.2)                            |

Table 20: Adverse Event Summary by Age Category (&lt; 65, 65-74, 75-84, &gt;=85 Years) (APaT Population)

|                                                           | KN811 Pembrolizumab + SOC   | KN811 Pembrolizumab + SOC   | KN811 Pembrolizumab + SOC   | KN811 Pembrolizumab + SOC   | KN811 Pembrolizumab + SOC   | KN811 Pembrolizumab + SOC   | KN811 Pembrolizumab + SOC   | KN811 SOC   | KN811 SOC   | KN811 SOC   | KN811 SOC       | KN811 SOC   | KN811 SOC   | KN811 SOC   | KN811 SOC   |
|-----------------------------------------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-------------|-------------|-------------|-----------------|-------------|-------------|-------------|-------------|
|                                                           | <65                         | <65                         | 65-74                       | 65-74                       | 75-84                       | 75-84                       | >=85                        | >=85        | <65         | <65         | 65-74           | 65-74       | 75-84 >=85  | 75-84 >=85  | 75-84 >=85  |
|                                                           | n                           | (%)                         | n                           | (%)                         |                             | (%)                         | n                           | (%)         |             | (%)         |                 | (%)         | (%)         |             | (%)         |
| Participants in population                                | 205                         |                             | 117                         |                             | 27                          |                             | 1                           |             | 190         |             | 121             | 34          | n           | 1           |             |
| with one or more adverse events                           | 203                         | (99.0)                      | 116                         | (99.1)                      | 27                          | (100.0)                     | 1                           | (100.0)     | 190         | (100.0)     | 121 (100.0)     | 34          | (100.0)     | 1           | (100.0)     |
| with no adverse event                                     | 2                           | (1.0)                       | 1                           | (0.9)                       | 0                           | (0.0)                       | 0                           | (0.0)       | 0           | (0.0)       | 0 (0.0)         | 0           | (0.0)       | 0           | (0.0)       |
| with drug-relatedadverse events                           | 201                         | (98.0)                      | 114                         | (97.4)                      | 25                          | (92.6)                      | 1                           | (100.0)     | 184         | (96.8)      | 116 (95.9)      | 33          | (97.1)      | 1           | (100.0)     |
| with toxicity grade 3-5 adverse events                    | 151                         | (73.7)                      | 79                          | (67.5)                      | 17                          | (63.0)                      | 1                           | (100.0)     | 011         | (57.9)      | 90 (74.4)       | 24          | (70.6)      | 1           | (100.0)     |
| with toxicity grade 3-5 drug-rclated adverse events       | 122                         | (59.5)                      | 67                          | (57.3)                      | 14                          | (51.9)                      |                             | (100.0)     | 85          | (44.7)      | 71 (58.7)       | 19          | (55.9)      |             | (100.0)     |
| with serious adverse events                               | 96                          | (46.8)                      | 45                          | (38.5)                      | 15                          | (55.6)                      | 1                           | (100.0)     | 80          | (42.1)      | 60 (49.6)       | 16          | (47.1)      | 1           | (100.0)     |
| with serious drug-related adverse events                  | 52                          | (25.4)                      | 25                          | (21.4)                      | 10                          | (37.0)                      | 1                           | (100.0)     | 38          | (20.0)      | 34 (28.1)       | 7           | (20.6)      | 0           | (0.0)       |
| who died                                                  | 8                           | (3.9)                       | 8                           | (6.8)                       | 5                           | (18.5)                      | 1                           | (100.0)     | 8           | (4.2)       | 6 (5.0)         | 6           | (17.6)      | 0           | (0.0)       |
| who died due to a drug-related adverse event              | 2                           | (1.0)                       | 2                           | (1.7)                       | 0                           | (0.0)                       | 0                           | (0.0)       | 0           | (0.0)       | 2 (1.7)         | 1           | (2.9)       | 0           | (0.0)       |
| discontinued any drug due to an adverse event             | 73                          | (35.6)                      | 53                          | (45.3)                      | 15                          | (55.6)                      |                             | (100.0)     | 49          | (25.8)      | 59 (48.8)       | 17          | (50.0)      |             | (100.0)     |
| discontinuedpembrolizumab/placebo                         | 16                          | (7.8)                       | 20                          | (17.1)                      | 8                           | (29.6)                      | 1                           | (100.0)     | 14          | (7.4)       | 16 (13.2)       | 6           | (17.6)      | 0           | (0.0)       |
| discontinued any chemotherapy                             | 68                          | (33.2)                      | 52                          | (44.4)                      | 14                          | (51.9)                      | 1                           | (100.0)     | 48          | (25.3)      | 58 (47.9)       | 17          | (50.0)      | 1           | (100.0)     |
| discontinued all drugs                                    | 9                           | (4.4)                       | 6                           | (5.1)                       | 6                           | (22.2)                      | 1                           | (100.0)     | 9           | (4.7)       | (9.1)           | 3           | (8.8)       | 0           | (0.0)       |
| discontinued any drug due to a drug-related adverse event | 65                          | (31.7)                      | 48                          | (41.0)                      | II                          | (40.7)                      | 0                           | (0.0)       | 39          | (20.5)      | 54 (44.6)       | 14          | (41.2)      | 1           | (100.0)     |
| discontinued pembrolizumab/placebo                        | 12                          | (5.9)                       | 13                          | (11.1)                      | 4                           | (14.8)                      | 0                           | (0.0)       | 4           | (2.1)       | 12              | 1           | (2.9)       | 0           | (0.0)       |
| discontinued any chemotherapy                             | 60                          | (29.3)                      | 45                          | (38.5)                      | 10                          | (37.0)                      | 0                           | (0.0)       | 38          | (20.0)      | (9.9) 53 (43.8) | 14          | (41.2)      |             | (100.0)     |
| discontinued all drugs                                    | 6                           | (2.9)                       | 3                           | (2.6)                       | 2                           | (7.4)                       | 0                           | (0.0)       | 1           | (0.5)       | 8               | 0           | (0.0)       | 0           | (0.0)       |
| discontinued any drug due to a serious adverse event      | 17                          | (8.3)                       | 18                          | (15.4)                      | 9                           | (33.3)                      | 1                           | (100.0)     | 15          | (7.9) 18    | (6.6) (14.9)    | 9           | (26.5)      | 0           | (0.0)       |
| discontinuedpembrolizumab/placebo                         | 11                          | (5.4)                       | 14                          | (12.0)                      | 8                           | (29.6)                      | 1                           | (100.0)     | 13          | (6.8) 16    | (13.2)          | 6           | (17.6)      | 0           | (0.0)       |
| discontinued any chemotherapy                             | 16                          | (7.8)                       | 14                          |                             |                             |                             | 1                           | (100.0)     |             |             | 16              | 9           | (26.5)      |             | (0.0)       |
|                                                           |                             |                             |                             | (12.0)                      | 8                           | (29.6)                      |                             |             | 14          | (7.4)       | (13.2) (9.1)    |             |             | 0           |             |
| discontinued all drugs                                    | 8                           | (3.9)                       | 5                           | (4.3)                       | 6                           | (22.2)                      |                             | (100.0)     | 9           | (4.7)       | 11              | 3           | (8.8)       | 0           | (0.0)       |

<div style=\"page-break-after: always\"></div>

Table 21: Adverse Event Summary by Age Category (&lt; 65, 65-74, 7584, ≥85 Years) AEOSI

|                                                           | KN811 Pembrolizumab + SOC   | KN811 Pembrolizumab + SOC   | KN811 Pembrolizumab + SOC   | KN811 Pembrolizumab + SOC   | KN811 Pembrolizumab + SOC   | KN811 Pembrolizumab + SOC   | KN811 Pembrolizumab + SOC   | KN811 Pembrolizumab + SOC   | KN811 SOC   | KN811 SOC   | KN811 SOC   | KN811 SOC   | KN811 SOC   | KN811 SOC   | KN811 SOC   | KN811 SOC   |
|-----------------------------------------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|
|                                                           | <65                         | <65                         | 65-74                       | 65-74                       | 75-84                       | 75-84                       | >=85                        | >=85                        | <65         | <65         | 65-74       | 65-74       | 75-84       | 75-84       | >=85        | >=85        |
|                                                           | n                           | (%)                         |                             | (%)                         | n                           | (%)                         | n                           | (%)                         | n           | (%)         | n           | (%)         |             | (%)         | n           | (%)         |
| Participants in population                                | 205                         |                             | 117                         |                             | 27                          |                             |                             |                             | 190         |             | 121         |             | 34          |             | 一           |             |
| with one or more adverse events                           | 80                          | (39.0)                      | 43                          | (36.8)                      | 9                           | (33.3)                      | 0                           | (0.0)                       | 45          | (23.7)      | 32          | (26.4)      | 5           | (14.7)      | 1           | (100.0)     |
| with no adverse cvent                                     | 125                         | (61.0)                      | 74                          | (63.2)                      | 18                          | (66.7)                      | 1                           | (100.0)                     | 145         | (76.3)      | 89          | (73.6)      | 29          | (85.3)      | 0           | (0.0)       |
| with drug-related adverse events                          | 75                          | (36.6)                      | 39                          | (33.3)                      | 8                           | (29.6)                      | 0                           | (0.0)                       | 42          | (22.1)      | 30          | (24.8)      | 5           | (14.7)      | 1           | (100.0)     |
| with toxicity grade 3-5 adverse events                    | 25                          | (12.2)                      | 7                           | (6.0)                       | 4                           | (14.8)                      | 0                           | (0.0)                       | 7           | (3.7)       | 5           | (4.1)       | 0           | (0.0)       | 0           | (0.0)       |
| with toxicity grade 3-5 drug-related adverse events       | 24                          | (11.7)                      | 7                           | (6.0)                       | 3                           | (11.1)                      | 0                           | (0.0)                       | 7           | (3.7)       | 5           | (4.1)       | 0           | (0.0)       | 0           | (0.0)       |
| with serious adverse events                               | 20                          | (9.8)                       | 8                           | (6.8)                       | 4                           | (14.8)                      | 0                           | (0.0)                       | 8           | (4.2)       | 7           | (5.8)       | 0           | (0.0)       | 0           | (0.0)       |
| with serious drug-related adverse events                  | 18                          | (8.8)                       | 8                           | (6.8)                       | 3                           | (11.1)                      | 0                           | (0.0)                       | 8           | (4.2)       | 7           | (5.8)       | 0           | (0.0)       | 0           | (0.0)       |
| who died                                                  | 2                           | (1.0)                       | 0                           | (0.0)                       | 1                           | (3.7)                       | 0                           | (0.0)                       | 0           | (0.0)       | 1           | (0.8)       | 0           | (0.0)       | 0           | (0.0)       |
| who died due to a drug-related adverse event              |                             | (1.0)                       | 0                           | (0.0)                       | 0                           | (0.0)                       | 0                           | (0.0)                       | 0           | (0.0)       | 1           | (0.8)       | 0           | (0.0)       | 0           | (0.0)       |
| discontinued any drug due to an adverse event             | 10                          | (4.9)                       | 10                          | (8.5)                       | 4                           | (14.8)                      | 0                           | (0.0)                       | 5           | (2.6)       | 8           | (6.6)       | 0           | (0.0)       | 0           | (0.0)       |
| discontinued pembrolizumab/placebo                        | 4                           | (2.0)                       | 6                           | (5.1)                       | 4                           | (14.8)                      | 0                           | (0.0)                       | 1           | (0.5)       | 5           | (4.1)       | 0           | (0.0)       | 0           | (0.0)       |
| discontinued any chemotherapy                             | 10                          | (4.9)                       | 8                           | (6.8)                       | 2                           | (7.4)                       | 0                           | (0.0)                       | 4           | (2.1)       | 7           | (5.8)       | 0           | (0.0)       | 0           | (0.0)       |
| discontinued all drugs                                    | 4                           | (2.0)                       | 2                           | (1.7)                       | 2                           | (7.4)                       | 0                           | (0.0)                       | 0           | (0.0)       | 4           | (3.3)       | 0           | (0.0)       | 0           | (0.0)       |
| discontinued any drug due to a drug-related adverse event | 10                          | (4.9)                       | 10                          | (8.5)                       | 3                           | (11.1)                      | 0                           | (0.0)                       | 5           | (2.6)       | 8           | (6.6)       | 0           | (0.0)       | 0           | (0.0)       |
| discontinued pembrolizumab/placebo                        | 4                           | (2.0)                       | 6                           | (5.1)                       | 3                           | (11.1)                      | 0                           | (0.0)                       | 1           | (0.5)       | 5           | (4.1)       | 0           | (0.0)       | 0           | (0.0)       |
| discontinued any chemotherapy                             | 10                          | (4.9)                       | 8                           | (6.8)                       | 1                           | (3.7)                       | 0                           | (0.0)                       | 4           | (2.1)       | 7           | (5.8)       | 0           | (0.0)       | 0           | (0.0)       |
| discontinued all drugs                                    | 4                           | (2.0)                       | 2                           | (1.7)                       | 1                           | (3.7)                       | 0                           | (0.0)                       | 0           | (0.0)       | 4           | (3.3)       | 0           | (0.0)       | 0           | (0.0)       |
| discontinued any drug due to a serious adverse event      | 7                           | (3.4)                       | 5                           | (4.3)                       | 4                           | (14.8)                      | 0                           | (0.0)                       | 1           | (0.5)       | 5           | (4.1)       | 0           | (0.0)       | 0           | (0.0)       |
| discontinued pembrolizumab/placebo                        | 4                           | (2.0)                       | 5                           | (4.3)                       | 4                           | (14.8)                      | 0                           | (0.0)                       | 1           | (0.5)       | 5           | (4.1)       | 0           | (0.0)       | 0           | (0.0)       |
| discontinued any chemotherapy                             | 7                           | (3.4)                       | 4                           | (3.4)                       | 2                           | (7.4)                       | 0                           | (0.0)                       | 0           | (0.0)       | 4           | (3.3)       | 0           | (0.0)       | 0           | (0.0)       |

Table 22: Adverse Event Summary by Region (Western Europe, Ex-Western Europe) (APaT Population)

|                                                                   | KN811 Pembrolizumab +SOC   | KN811 Pembrolizumab +SOC   | KN811 Pembrolizumab +SOC   | KN811 Pembrolizumab +SOC   | KN811 SOC      | KN811 SOC      | KN811 SOC         | KN811 SOC         | Pembro + Chemo Pooled Dataset   | Pembro + Chemo Pooled Dataset   | Pembro + Chemo Pooled Dataset   | Pembro + Chemo Pooled Dataset   |
|-------------------------------------------------------------------|----------------------------|----------------------------|----------------------------|----------------------------|----------------|----------------|-------------------|-------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|
|                                                                   | Western Europe             | Western Europe             | Ex-Westerm Europe          | Ex-Westerm Europe          | Westerm Europe | Westerm Europe | Ex-Westerm Europe | Ex-Westerm Europe | Western Europe                  | Western Europe                  | Ex-Westerm Europe               | Ex-Westerm Europe               |
|                                                                   | (%)                        | (%)                        | n (%)                      | n (%)                      | (%)            | (%)            | (%)               | (%)               | 11 (%)                          | 11 (%)                          | (%)                             | (%)                             |
| Participants in population                                        | 98                         | 98                         | 252                        | 252                        | 16             | 16             | 255               | 255               | 1,118                           | 1,118                           | 2,005                           | 2,005                           |
| with one ormore adverse events                                    | 96                         | (98.0)                     | 251                        | (99.6)                     | 16             | (100.0)        | 255               | (100.0)           | 1,105                           | (98.8)                          | 1,992                           | (99.4)                          |
| with no adverse event                                             | 2                          | (2.0)                      | 1                          | (0.4)                      | 0              | (0.0)          | 0                 | (0.0)             | 13                              | (1.2)                           | 13                              | (0.6)                           |
| with drug-related adverse events                                  | 93                         | (94.9)                     | 248                        | (98.4)                     | 88             | (96.7)         | 246               | (96.5)            | 1,070                           | (95.7)                          | 1,950                           | (97.3)                          |
| with toxicity grade 3-5 adverse events                            | 74                         | (75.5)                     | 174                        | (69.0)                     | 69             | (75.8)         | 156               | (61.2)            | 876                             | (78.4)                          | 1,603                           | (80.0)                          |
| with toxicity grade 3-5 drug-related adverse events               | 65                         | (66.3)                     | 139                        | (55.2)                     | 53             | (58.2)         | 123               | (48.2)            | 727                             | (65.0)                          | 1,372                           | (68.4)                          |
| with serious adverse events                                       | 54                         | (55.1)                     | 103                        | (40.9)                     | 66             | (72.5)         | 16                | (35.7)            | 548                             | (49.0)                          | 908                             | (45.3)                          |
| with serious drug-related adverse events                          | 33                         | (33.7)                     | 55                         | (21.8)                     | 31             | (34.1)         | 48                | (18.8)            | 340                             | (30.4)                          | 570                             | (28.4)                          |
| who died                                                          | 2                          | (2.0)                      | 20                         | (7.9)                      | 8              | (8.8)          | 12                | (4.7)             | 56                              | (5.0)                           | 104                             | (5.2)                           |
| who died due to a drug-related adverse event                      | 0                          | (0.0)                      | 4                          | (1.6)                      | 2              | (2.2)          | 1                 | (0.4)             | 12                              | (1.1)                           | 37                              | (1.8)                           |
| discontinued any drug due to an adverse event                     | 36                         | (36.7)                     | 106                        | (42.1)                     | 37             | (40.7)         | 89                | (34.9)            | 383                             | (34.3)                          | 517                             | (25.8)                          |
| discontinued pembrolizumab/placebo                                | 11                         | (11.2)                     | 34                         | (13.5)                     | 12             | (13.2)         | 24                | (9.4)             | 237                             | (21.2)                          | 311                             | (15.5)                          |
| discontinued any chemotherapy                                     | 34                         | (34.7)                     | 101                        | (40.1)                     | 37             | (40.7)         | 87                | (34.1)            | 266                             | (23.8)                          | 370                             | (18.5)                          |
| discontinued all drugs                                            | 6                          | (6.1)                      | 16                         | (6.3)                      | 7              | (7.7)          | 16                | (6.3)             | 52                              | (4.7)                           | 91                              | (4.5)                           |
| discontinued any drug due to a drug-related adverse event         | 33                         | (33.7)                     | 16                         | (36.1)                     | 33             | (36.3)         | 75                | (29.4)            | 320                             | (28.6)                          | 427                             | (21.3)                          |
| discontinued pembrolizumab/placebo                                | 9                          | (9.2)                      | 20                         | (7.9)                      | 6              | (6.6)          |                   | (4.3)             | 173                             | (15.5)                          | 232                             | (11.6)                          |
| discontinued any chemotherapy                                     | 30                         | (30.6)                     | 85                         | (33.7)                     | 33             | (36.3)         | 73                | (28.6)            | 224                             | (20.0)                          | 304                             | (15.2)                          |
| discontinued all drugs                                            | 4                          | (4.1)                      | 7                          | (2.8)                      | 4              | (4.4)          | 5                 | (2.0)             | 29                              | (2.6)                           | 57                              | (2.8)                           |
| discontinued any drug due to a serious adverse event              | 16                         | (16.3)                     | 29                         | (11.5)                     | 16             | (17.6)         | 26                | (10.2)            | 199                             | (17.8)                          | 273                             | (13.6)                          |
| discontinued pembrolizumab/placebo                                | 10                         | (10.2)                     | 24                         | (9.5)                      | 12             | (13.2)         | 23                | (9.0)             | 165                             | (14.8)                          | 217                             | (10.8)                          |
| discontinued any chemotherapy                                     | 13                         | (13.3)                     | 26                         | (10.3)                     | 16             | (17.6)         | 23                | (9.0)             | 126                             | (11.3)                          | 181                             | (9.0)                           |
| discontinued all drugs                                            | 6                          | (6.1)                      | 14                         | (5.6)                      | 7              | (7.7)          | 16                | (6.3)             | 49                              | (4.4)                           | 78                              | (3.9)                           |
| discontinued any drug due to a serious drug-related adverse event | 13                         | (13.3)                     | 17                         | (6.7)                      | 9              | (9.9)          | 12                | (4.7)             | 142                             | (12.7)                          | 201                             | (10.0)                          |
| discontinued pembrolizumab/placebo                                | 8                          | (8.2)                      | 13                         | (5.2)                      | 6              | (6.6)          | 10                | (3.9)             | 108                             | (9.7)                           | 153                             | (7.6)                           |
| discontinued anychemotherapy                                      | 10                         | (10.2)                     | 14                         | (5.6)                      | 9              | (9.9)          | 9                 | (3.5)             | 88                              | (7.9)                           | 125                             | (6.2)                           |

## Safety related to drug-drug interactions and other interactions

As pembrolizumab is an IgG antibody that is administered parenterally and cleared by catabolism, food and DDI are not anticipated to influence exposure.

Studies evaluating pharmacodynamic drug interactions with pembrolizumab have not been conducted. However, as systemic corticosteroids may be used in combination with pembrolizumab to ameliorate potential side effects, the potential for a PK DDI with pembrolizumab as a victim was assessed as part of the PPK analysis. No relationship was observed between prolonged use of systemic corticosteroids

<div style=\"page-break-after: always\"></div>

and pembrolizumab exposure. Nevertheless, the use of systemic corticosteroids or other immunosuppressants before the start of pembrolizumab treatment should be avoided because of their potential interference with the pharmacodynamic activity and efficacy of pembrolizumab. However, systemic corticosteroids or other immunosuppressants can be used after starting pembrolizumab treatment to treat immune-mediated adverse reactions. Corticosteroids can also be used as premedication, when pembrolizumab is used in combination with chemotherapy, as antiemetic prophylaxis and/or to alleviate chemotherapy-related adverse reactions.

## Discontinuation due to adverse events

Table 23: Participants With Drug-Related Adverse Events Resulting in Treatment Discontinuation of Any Drug by Decreasing Incidence (at least 1 event in the pembrolizumab+SOC group of KN-811) (Global Cohort) (APaT Population)

|                                                        | Pembrolizumab+SOC   | Pembrolizumab+SOC   | SOC     | SOC    |
|--------------------------------------------------------|---------------------|---------------------|---------|--------|
|                                                        |                     | (%)                 | n       | (%)    |
| Participants in population                             | 350                 | (35.4)              | 346     | (31.2) |
| with one or more adverse events with no adverse events | 124 226             | (64.6)              | 108 238 | (68.8) |
| Peripheral sensory neuropathy                          | 18                  | (5.1)               | 15      | (4.3)  |
| Neuropathy peripheral                                  | 17                  | (4.9)               | 19      | (5.5)  |
| Platelet count decreased                               | I1                  | (3.1)               | 13      | (3.8)  |
| Palmar-plantar erythrodysaesthesia syndrome            | 10                  | (2.9)               | 5       | (1.4)  |
| Neutrophil count decreased                             | 7                   | (2.0)               | 5       | (1.4)  |
| Nausea                                                 | 5                   | (1.4)               | +       | (1.2)  |
| Pneumonitis                                            | 5                   | (1.4)               | 1       | (0.3)  |
| Vomiting                                               | 5                   | (1.4)               | 3       | (0.9)  |
| Blood creatinine increased                             | 4                   | (1.1)               | 0       | (0.0)  |
| Decreased appetite                                     | 4                   | (1.1)               | 3       | (0.9)  |
| Infusion related reaction                              | 4                   | (1.1)               | 5       | (1.4)  |
| Neutropenia                                            | 4                   | (1.1)               | 4       | (1.2)  |
| Colitis                                                | 3                   | (0.9)               | 0       | (0.0)  |
| Diarrhoea                                              | 3                   | (0.9)               | 5       | (1.4)  |
| Ejection fraction decreased                            | 3                   | (0.9)               | 1       | (0.3)  |
| Hypersensitivity                                       | 3                   | (0.9)               | 1       | (0.3)  |
| Thrombocytopenia                                       | 3                   | (0.9)               | 3       | (0.9)  |
| Alanine aminotransferase increased                     | 2                   | (0.6)               | 0       | (0.0)  |
| Aspartate aminotransferase increased                   | 2                   | (0.6)               | 0       | (0.0)  |
| Enterocolitis                                          | 2                   | (0.6)               | 0       | (0.0)  |
| Fatigue                                                | 2                   | (0.6)               | 2       | (0.6)  |
| Hepatic function abnormal                              | 2                   | (0.6)               | 0       | (0.0)  |
| Pneumonia                                              | 2                   | (0.6)               | 0       | (0.0)  |
| Acute kidney injury Acute myocardial infarction        | 1                   | (0.3)               | 1       | (0.3)  |
|                                                        | 1                   | (0.3)               | 0       | (0.0)  |
| Anaemia                                                | 1                   | (0.3)               | 0       | (0.0)  |
| Anaphylactic reaction                                  |                     | (0.3)               | 0       | (0.0)  |
| Anxiety                                                |                     | (0.3)               | 0       | (0.0)  |
| Asthenia                                               |                     | (0.3)               | 0       | (0.0)  |
| Autoimmunehaemolyticanaemia                            | 1                   | (0.3)               | 0       | (0.0)  |
| Autoimmune lung disease                                | 1                   | (0.3)               | 0       | (0.0)  |
| Blood alkaline phosphatase increased                   | 1                   | (0.3)               | 0       | (0.0)  |
| Blood bilirubin increased                              |                     | (0.3)               | 0       | (0.0)  |
| Cardiac failure                                        | 1                   | (0.3)               | 0       | (0.0)  |
| Cerebral infarction                                    | 1                   | (0.3)               | 0       | (0.0)  |
| Delirium                                               | 1                   | (0.3)               | 0       | (0.0)  |
| Disseminated intravascular coagulation                 | 1                   | (0.3)               | 0       | (0.0)  |
| Drug hypersensitivity                                  | 1                   | (0.3)               | 1       | (0.3)  |
| Dysaesthesia                                           | 1                   | (0.3)               | 1       | (0.3)  |
| Epistaxis                                              | 1                   | (0.3)               | 0       | (0.0)  |
| Gamma-glutamyltransferaseincreased                     | 1                   | (0.3)               | 0       | (0.0)  |
| Granulocytopenia                                       |                     | (0.3)               | 0       | (0.0)  |
| Hepatitis                                              | 1                   | (0.3)               | 1       | (0.3)  |
| Herpes zoster                                          | 1                   | (0.3)               | 0       | (0.0)  |
| Hyperbilirubinaemia                                    | 1                   | (0.3)               | 0       | (0.0)  |
| Hypoacusis                                             |                     | (0.3)               | 0       | (0.0)  |
| Hypoaesthesia                                          | 1                   | (0.3)               | 0       | (0.0)  |
| Neurotoxicity                                          |                     | (0.3)               | 4       | (1.2)  |
| Paraesthesia                                           | 1                   | (0.3)               |         | (0.3)  |
| Polyneuropathy                                         | 1                   | (0.3)               | 1       | (0.3)  |
| Pyrexia                                                | 1                   | (0.3)               | 1       | (0.3)  |
| Rash                                                   | 1                   | (0.3)               | 0       | (0.0)  |
| Renal failure                                          | 1                   | (0.3)               | 0       | (0.0)  |
| Respiratory failure                                    | 1                   |                     | 0       | (0.0)  |
| Rhabdomyoly sis                                        |                     | (0.3)               | 0       | (0.0)  |
| Sepsis                                                 | 1                   | (0.3) (0.3)         | 0       | (0.0)  |
| Stomatitis                                             |                     | (0.3)               | 1       | (0.3)  |
| Tubulointerstitial nephritis                           |                     | (0.3)               | 0       | (0.0)  |

<div style=\"page-break-after: always\"></div>

## Post marketing experience

The safety profile of pembrolizumab was summarized in the Periodic Safety Update Report covering the period 04-SEP-2021 through 03-SEP-2022. No revocation or withdrawal of pembrolizumab registration for safety reasons has occurred in any country.

## 2.5.1. Discussion on clinical safety

The MAH provided safety data from KN811 study (n=350 experimental treatment, n=346 control), and included for comparisons the pooled chemo combo dataset (n=3123) and the pembrolizumab monotherapy reference safety dataset (RSD) (n=7631).

It should be noted that data from 3,473 patients is the sum of the previous pooled combo dataset (3,123) plus the newly added pembro+chemo arm in KEYNOTE-811 (350).

Regarding exposure, in KEYNOTE-811 the median duration of therapy in the pembrolizumab plus SOC was longer th an all other datasets. The percentage of participants with ≥6 and ≥12 months duration of exposure was longer in the pembrolizumab plus SOC as compared to the control group, while similar to the pembro combo dataset.

While the demographic and baseline characteristics in KEYNOTE-811 were generally well balanced between the two treatment groups, more participants in KEYNOTE-811 were male and Asian, and fewer participants were enrolled from EU sites as compared to pembrolizumab combo and pembrolizumab monotherapy datasets, as expected based on the epidemiology of gastric/GEJ cancer.

The AE rates in the pembrolizumab + SOC group were generally consistent with the control arm, although few more G3-5 AEs (all-causality and drug-related) were observed. There were little more discontinuations due to AEs, drug-related AEs and drug-related SAE. When adjusted for exposure, however, the differences between the two treatment arms of KN-811 do not seem relevant. As compared to the pembro combo dataset, increased rate of discontinuation is observed, which is however mostly due to discontinuation of chemotherapy. As expected, the pembrolizumab+SOC group of KN811 presented safety profile reflective of AEs for the combination of trastuzumab, chemotherapy and pembrolizumab in comparison with pembrolizumab monotherapy.

In the pembrolizumab plus SOC group, the most frequently reported AEs regardless of causality (≥20% incidence) were diarrhoea, nausea, anaemia, vomiting, decreased appetite, neutrophil count decreased, platelet count decreased, AST increased, peripheral sensory neuropathy, fatigue, palmarplantar erythrodysaesthesia syndrome, and weight decreased, which were reported with similar incidences in SOC group.

The most frequently reported drug-related AEs ( ≥ 20% incidence) in the pembrolizumab plus SOC group were diarrhea, nausea, anemia, neutrophil count decreased, decreased appetite, platelet count decreased, vomiting, peripheral sensory neuropathy, and palmar-plantar erythrodysaesthesia syndrome, with similar incidences reported in the SOC group.

The most common Grade 3 to 5 AEs regardless of causality (&gt;5% incidence) in the pembrolizumab plus SOC group were anaemia, diarrhoea, neutrophil count decreased, neutropenia, platelet count decreased, and hypokalaemia, which were reported with similar incidences in SOC group.

The most frequently reported drug-related Grade 3 to 5 events (≥5% incidence) in the pembrolizumab plus SOC group were diarrhoea, neutrophil count decreased, neutropenia, platelet count decreased, and anaemia, with similar incidences in the SOC group.

<div style=\"page-break-after: always\"></div>

The most frequently reported SAEs ( ≥ 2% incidence) in the pembrolizumab plus SOC group were pneumonia, diarrhea, pulmonary embolism, infusion-related reaction, pneumonitis, and vomiting.

The most frequently reported drug-related SAE ( ≥ 3% incidence) in both the pembrolizumab plus SOC and SOC groups was diarrhea (4.6% and 4.3% of participants, respectively).

The most c ommon AEs (≥1% incidence) leading to discontinuation of pembrolizumab in the pembrolizumab plus SOC group were pneumonitis (1.7%) and pneumonia (1.1%), and the most common drug-related AE leading to discontinuation of any drug were peripheral sensory neuropathy/neuropathy peripheral in both arms (about 10%), while the leading AE for discontinuation of pembrolizumab was pneumonitis (1.4%). The most common AEs ( ≥ 10% incidence) leading to treatment interruption of any drug in the pembrolizumab plus SOC group were neutrophil count decreased, diarrhoea, platelet count decreased, and neutropenia, with similar incidences in the SOC group.

With regard to laboratory value, the MAH reported two participants in the pembrolizumab plus SOC arm meeting the laboratory criteria for drug-induced liver injury (vs 1 in the control arm). Furthermore, a higher incidence of ALT, AST and bilirubin increase as AEs was noted in the experimental vs the control arm, and in some cases also as compared to the pembrolizumab combo pooled dataset. Upon request, the MAH reviewed the hepatic toxicity in KEYNOTE-811. Based on the data provided, it is agreed that the hepatic-related AEs require neither a change in the characterization of this risk for pembrolizumab nor an update of the SmPC.

A total of 22 vs 20 patients died due to AEs in the investigational vs control arm of KN811 study. Of those, 5 AEs were treatment-related according to investigator or sponsor, i.e. pneumonitis (2 cases), hepatitis, sepsis and cerebral infarction. Pneumonitis is a known ADR for pembrolizumab. Cerebral infarction was considered by the investigator related to pembrolizumab, but not to chemotherapy nor trastuzumab. Cerebral infarction it is not a known AE of pembrolizumab. At request of the CHMP, a review of cerebral infarction events was performed in the Company Global Safety Database. Based on the data provided, it is agreed that causality assessment was confounded by pre-existing or concurrent conditions that represent known risk factors for cerebral infarction, i.e. hypertension, hyperlipidemia, diabetes, atherosclerosis, coagulation abnormality associated with underlying malignancy. Based on the data provided, no changes in the SmPC are considered warranted at this stage. This event should be monitored in the future.

As expected, the overall incidence of AEOSI was higher in the pembrolizumab plus SOC group compared with the SOC group, but overall similar to pembrolizumab + chemotherapy dataset. The median time to onset of the first AEOSI in the pembrolizumab plus SOC group was 67 days, similar to both pembrolizumab combo and pembrolizumab mono datasets. Median duration of AEOSI episodes (41 days) is similar to the pembrolizumab combo dataset but shorter than pembrolizumab monotherapy. Overall, most AEOSI were Grade 1 or 2 in severity and nonserious. Grade 5 AEOSI occurred in 3 (0.9%) participants in the pembrolizumab plus SOC group (2 patients with pneumonitis and 1 with hepatitis). Most of the AEOSI in the pembrolizumab plus SOC arm resolved (58.3%). The most common (&gt;5% incidence) AEOSI categories reported in the pembrolizumab plus SOC group were infusion reactions, hypothyroidism, and pneumonitis (16.0%, 10.6%, and 6.0%, respectively). The frequency and severity of AEOSI categories in the pembrolizumab plus SOC group were generally consistent with the pembrolizumab plus chemo pooled group and monotherapy RSD, with the exceptions of pneumonitis (6% vs 1.4% vs 4% vs 4.2%) and infusion-related reactions (16% vs 13% vs 7.9% vs 2.2%). A higher frequency of pneumonitis and infusion-related reactions was expected with the addition of trastuzumab and oxaliplatin to pembrolizumab since these are known risks of the SOC combination, as well as due to longer exposure, based on exposure-adjusted data (not shown). A higher incidence of colitis as AEOSI category is noted as compared to the other datasets (4.9% vs

<div style=\"page-break-after: always\"></div>

2.9% vs 2.7% vs 2.1%), but no meaningful difference is observed after adjusting for exposure. Overall, no additional warnings regarding these toxicities are considered needed in the SmPC.

Taking into account the known cardiotoxicity of trastuzumab, the MAH provided data specific for such toxicity as well as an evaluation of LVEF decrease. The MAH noted that the prescribing information for trastuzumab shows 2% of patients experiencing congestive heart failure events and a range from 4% (for monotherapy) to 28% (in combination with chemotherapy) of patients experiencing cardiac dysfunction following treatment with trastuzumab. Based on the data provided, it is agreed that the frequency of cardiac events observed in KEYNOTE-811 is consistent with these results, and no increase in cardiac events for the combination of pembrolizumab with trastuzumab is envisaged.

The adverse event summary showed similar incidence in the pembrolizumab plus SOC arm between patients &lt;65 years and ≥ 65 years, with the exception of death due to AEs and discontinuation due to AEs. A similar pattern is however observed also in the SOC arm, as well as in the pembrolizumab combo pooled dataset. The same observation is made according to age categories &lt;65, 65-74 and 7584. Only 28 patients however were over 75 in the experimental arm.

The MAH was requested by the CHMP to review the AEs occurring in the CPS&lt;1 subset, as the pattern of crossing OS curves raised concern from a safety perspective, acknowledging that this PD-L1 negative patients are nevertheless excluded from the indication. Based on the data provided, the events of death due to AEs (in terms of frequency and causes), do not raise additional safety concern that may impact on the indication for the combination.

## 2.5.2. Conclusions on clinical safety

The safety profile of pembrolizumab in combination with chemotherapy (FP/CAPOX) and trastuzumab in previously untreated participants with locally advanced unresectable or metastatic HER2-positive gastric or GEJ adenocarcinoma in KEYNOTE-811 overall reflects the established safety profiles of the chemotherapy regimen administered and pembrolizumab monotherapy. The addition of pembrolizumab does not appear to increase cardiac toxicity associated with the established safety profile of trastuzumab and the SOC regimens. No new safety concerns were identified.

## 2.5.3. PSUR cycle

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

## 2.6. Risk management plan

The MAH submitted/was requested to submit an updated RMP version with this application.

The CHMP received the following PRAC Advice on the submitted Risk Management Plan:

The PRAC considered that the risk management plan version 38 is acceptable.

The main proposed RMP changes were the following:

- -Addition of a new indication for pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of locally advanced  unresectable  or  metastatic  HER2-positive  gastric  or  gastro-oesophageal  junction adenocarcinoma in adults whose tumours express PDL1 with a CPS ≥ 1.

<div style=\"page-break-after: always\"></div>

- -Addition of study KEYNOTE-811 in Modules SIII, SVII and SVIII.
- -Renaming  the  Important  Identified  Risk  of  'Immune-related  adverse  reactions  (including immune-related pneumonitis, colitis, hepatitis, nephritis, and endocrinopathies' to 'Immunemediated adverse reactions' as per European Medicines Agency (EMA) request.
- -Update to Part V Risk Minimisation Measures (including Evaluation of the Effectiveness of Risk Minimisation Activities) and Annex 6 Details of Proposed Additional Risk Minimisation Activities to  include  additional  symptoms of diabetic ketoacidosis (DKA) in line with the update to the Package leaflet as part of PSUSA/00010403/202109, to retire the Patient Brochure as part of PSUSA/00010403/202209 and to update the Patient Alert Card, to be used as a single document..

## Safety concerns

Table SVIII.1: Summary of Safety Concerns

| Summary of safety concerns   | Summary of safety concerns                                                                                                                                                                                                                                                                                        |
|------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Important identified risks   | Immune-mediated adverse reactions                                                                                                                                                                                                                                                                                 |
| Important potential risks    | For hematologic malignancies: increased risk of severe complications of allogeneic stem cell transplantation (SCT) in patients who have previously received pembrolizumab Graft versus host disease (GVHD) after pembrolizumab administration in patients with a history of allogeneic stem cell transplant (SCT) |
| Missing information          | None                                                                                                                                                                                                                                                                                                              |

## Pharmacovigilance plan

There are no ongoing or planned additional pharmacovigilance studies that are required for pembrolizumab.

## Risk minimisation measures

Table V.3.1: Summary Table of Pharmacovigilance Activities and Risk Minimisation Activities by Safety Concern

| Safety Concern                                                | Risk minimisation Measures                                                                                                                                                                                                                                  | Pharmacovigilance Activities                                                                                                                                                                                           |
|---------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Important Identified Risks: Immune-Mediated Adverse Reactions | Important Identified Risks: Immune-Mediated Adverse Reactions                                                                                                                                                                                               | Important Identified Risks: Immune-Mediated Adverse Reactions                                                                                                                                                          |
| Immune-mediated adverse reactions                             | Routine risk minimisation measures: • The risk of the immune-mediated adverse reactions associated with the use of pembrolizumab is described in the SmPC, Section 4.2, 4.4, 4.8 and appropriate advice is provided to the prescriber to minimize the risk. | Routine pharmacovigilance activities Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection : Targeted questionnaire for spontaneous postmarketing reports of all adverse events |

<div style=\"page-break-after: always\"></div>

## Summary Table of Pharmacovigilance Activities and Risk

Table V.3.1: Minimisation Activities by Safety Concern

| Safety Concern                                                                                                                                | Risk minimisation Measures                                                                                                                                                                                                                                                                                                                                       | Pharmacovigilance Activities                                                                                                                                                           |
|-----------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                                                                                               | Additional risk minimisation measures: • Patient card                                                                                                                                                                                                                                                                                                            | Additional pharmacovigilance including: • Safety monitoring in all ongoing MAH-sponsored clinical trials for pembrolizumab in various tumor types                                      |
| Important Potential Risks                                                                                                                     | Important Potential Risks                                                                                                                                                                                                                                                                                                                                        | Important Potential Risks                                                                                                                                                              |
| For hematologic malignancies: increased risk of severe complications of allogeneic SCT in patients who have previously received pembrolizumab | Routine risk minimisation measures: • For Hematologic malignancies: the increased risk of severe complications of allogeneic SCT in patients who have previously received pembrolizumab is described in the SmPC, Section 4.4, 4.8 and appropriate advice is provided to the prescriber to minimize the risk. No additional risk minimisation measures warranted | Routine pharmacovigilance activities Additional pharmacovigilance including: •                                                                                                         |
| GVHD after pembrolizumab administration in patients with a history of allogeneic SCT                                                          | Routine risk minimisation measures: • GVHD after pembrolizumab administration in patients with a history of allogeneic SCT is described in the SmPC, Section 4.4 and appropriate advice is provided to the prescriber to minimize the risk. No additional risk minimisation measures warranted                                                                   | Routine pharmacovigilance activities Additional pharmacovigilance including: • Safety monitoring in all ongoing MAH-sponsored clinical trials for pembrolizumab in various tumor types |

## 2.7. Update of the Product information

As a result of this variation, section(s) 4.1, 4.8 and 5.1 of the SmPC are being updated. The Package Leaflet (PL) is updated accordingly.

## 2.7.1. User consultation

A justification for not performing a full user consultation with target patient groups on the package leaflet has been submitted by the MAH and has been found acceptable for the following reasons:

There are two changes in the package leaflet for this submission: section 1 (addition of new indication) and in section 4 (minor changes to align to update in 4.8 section of the SmPC). The key messages for the safe use of the medicinal product are however not impacted. Furthermore, the design, layout and format of the package leaflet will not be affected by the proposed revisions. Therefore, the proposed revision does not constitute significant changes that would require the need to conduct a new user consultation.

<div style=\"page-break-after: always\"></div>

## 3. Benefit-Risk Balance

## 3.1. Therapeutic Context

HER-2-positive gastric or GEJ adenocarcinoma at an advanced stage of disease.

## 3.1.1. Disease or condition

Gastric or gastro-oesophageal junction (GEJ) adenocarcinoma

KEYTRUDA, in combination with trastuzumab, fluoropyrimidine and platinum-containing chemotherapy, is indicated for the first-line treatment of locally advanced unresectable or metastatic HER2-positive gastric or gastro-oesophageal junction adenocarcinoma in adults whose tumours express PD-L1 with a CPS ≥ 1.

## 3.1.2. Available therapies and unmet medical need

Chemotherapy plus trastuzumab represents the current SOC for the front-line approach to locally advanced and metastatic HER-2-positive gastric or GEJ adenocarcinoma (ESMO guidelines 2022). However, prognosis remains poor with survival generally below 1 year, which makes development of new therapies a high unmet medical need.

## 3.1.3. Main clinical studies

The current variation is supported by data from KEYNOTE-811, a Phase 3, randomised, double-blind, placebo-controlled trial Comparing Trastuzumab Plus Chemotherapy and Pembrolizumab With Trastuzumab Plus Chemotherapy and Placebo as First-line Treatment in Participants With HER2 Positive Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.

## 3.2. Favourable effects

-The efficacy analysis in the ITT population, showed advantage of pembrolizumab over placebo in the primary endpoint PFS (HR=0.72; 95% CI 0.60;0.87; p&lt;0.0002) with a 2-month gain in disease progression (10 vs 8.1 months in median in the pembrolizumab and control arm, respectively)

-In the CPS ≥1 subgroup, pembrolizumab showed superiority over placebo in PFS (HR=0.70; 95% CI 0.58, 0.85) and OS (HR=0.79; 95% CI 0.64,0.98; p=0.0143), with a gain in median PFS and OS of 3 months (10.8 vs 7.2) and 5 months (20.5 vs 15.6), respectively.

-The ORR analysis showed advantage of pembrolizumab over placebo in the ITT population (72.6% vs 59.8%) with a slightly better response duration (11.2 vs 9 months in median)

## 3.3. Uncertainties and limitations about favourable effects

None.

<div style=\"page-break-after: always\"></div>

## 3.4. Unfavourable effects

- In the pembrolizumab plus SOC group, the most frequently reported AEs regardless of causality  ( ≥ 20% incidence) were diarrhoea, nausea, anaemia, vomiting, decreased appetite, neutrophil count decreased, platelet count decreased, AST increased, peripheral sensory neuropathy, fatigue, palmarplantar erythrodysaesthesia syndrome, and weight decreased, with similar incidences reported in the SOC group, suggesting that the overall safety profile of the proposed combination is mostly influenced by the common chemotherapy backbone. The overall pattern of drug-related AEs was consistent with the overall safety analysis.
- The pattern of Grade 3-5 AEs (all causality and drug related) was similar in the two treatment arms. The most common all-causality Grade 3 to 5 AEs (&gt;5% incidence) in the pembrolizumab plus SOC group were anaemia, diarrhoea, neutrophil count decreased, neutropenia, platelet count decreased, and hypokalaemia.
- SAEs were observed in similar percentage between treatment arms, with diarrhoea being the most common treatment-related SAE in both arms.
- There were few more discontinuation of study drugs due to adverse events in the pembrolizumab+SOC arm as compared to the control arm (40.6% vs 36.4%), although mostly leading to discontinuation of chemotherapy.
- Pembrolizumab is characterized by the occurrence of immune-mediated adverse events. The rate of AEOSI was, as expected, higher in the pembrolizumab containing arm as compared to the control arm (37.7% vs 24%), but not very different to the pembro+chemo pooled dataset (33.7%). Most common (&gt;5%) AEOSI were infusion related reactions (11.7%), hypothyroidism (10.6%) and pneumonitis (5.4%). Infusion-related reaction AEOSI were reported in a similar proportion in both treatment arms, but were more common than in the reference safety datasets of both pembro combo and pembro mono. This may be likely related to the contribution of trastuzumab and oxaliplatin, having known risks of infusion-related reactions. Pneumonitis and hypothyroidism AEOSI were both higher in the pembrolizumab plus SOC group compared with the SOC group. However, pneumonitis was also more commonly reported than in the pembrolizumab reference datasets, possibly due to trastuzumab which has known risk of pneumonitis, while incidence of hypothyroidism was similar to the reference datasets.
- Deaths due to AEs occurred in 6.3% vs 5.8% of patients in the pembrolizumab+SOC vs placebo+SOC arm of KEYNOTE-811. Treatment-related deaths were due to pneumonitis, hepatitis, sepsis, and cerebral infarction in the pembrolizumab + SOC arm. Both pneumonitis and hepatitis are known ADR for pembrolizumab.

## 3.5. Uncertainties and limitations about unfavourable effects

- Similar incidence of AEs are observed in the pembrolizumab plus SOC arm according to age categories, with the exception of death due to AEs and discontinuation due to AEs. A similar pattern is however observed also in the SOC arm, as well as in the pembro combo pooled dataset. Only 28 patients however were over 75 in the experimental arm, limiting conclusion in this subset.

## 3.6. Effects Table

Table 24. Effects Table for [Keytruda in combination with trastuzumab, fluoropyrimidine- and platinumcontaining chemotherapy, for the first-line treatment of locally advanced unresectable or metastatic HER2-positive gastric or gastro-oesophageal junction adenocarcinoma with CPS ≥ 1]  (data cut-off: 25-

<div style=\"page-break-after: always\"></div>

MAY-2022)

| Effect               | Short description                                                                                   | Unit                 | Treatment            | Control              | Uncertainties / Strength of evidence   | References           |
|----------------------|-----------------------------------------------------------------------------------------------------|----------------------|----------------------|----------------------|----------------------------------------|----------------------|
| Favourable Effects   | Favourable Effects                                                                                  | Favourable Effects   | Favourable Effects   | Favourable Effects   | Favourable Effects                     | Favourable Effects   |
| OS                   | duration of survival from randomization to death regardless of cause                                | months (95% CI)      | 20.5 (18.2, 24.3)    | 15.6 (13.5,18.6)     |                                        | CSR                  |
| PFS                  | duration of survival without progression from randomization to PD or death whichever occurred first | months (95% CI)      | 10.8 (8.5, 12.5)     | 7.2 (6.8, 8.4)       |                                        |                      |
| ORR                  | Confirmed CR + PR                                                                                   | %                    | 73.2                 | 58.4                 |                                        |                      |
| DoR                  | Duration of CR/PR until documented PD                                                               | months (95% CI)      | 11.3 (1.1+ -40.1+)   | 9.5 (1.4+ -38.3+)    |                                        |                      |
| Unfavourable Effects | Unfavourable Effects                                                                                | Unfavourable Effects | Unfavourable Effects | Unfavourable Effects | Unfavourable Effects                   | Unfavourable Effects |
| summ ary             | G3-5 AEs                                                                                            | %                    | 70.9                 | 65                   | No new safety concerns identified      | KN-811               |
|                      | SAE                                                                                                 | %                    | 44.9                 | 45.4                 |                                        |                      |
|                      | Death                                                                                               | %                    | 6.3                  | 5.8                  |                                        |                      |
|                      | Discontinuation due to AEs                                                                          | %                    | 40.6                 | 36.4                 |                                        |                      |
|                      | AEOSI                                                                                               | %                    | 37.7                 | 24                   |                                        |                      |
|                      | - IRR                                                                                               | %                    | 11.7                 | 9.8                  |                                        |                      |
|                      | - hypothyroidism                                                                                    | %                    | 10.6                 | 4.3                  |                                        |                      |
|                      | - pneumonitis                                                                                       | %                    | 5.4                  | 1.4                  |                                        |                      |

Abbreviations: AE= adverse event; SAE=serious adverse event; AEOSI= adverse event of special interest; IRR=infusion related reaction; CSR=clinical study report

Notes: DCO 25-MAY-2022

## 3.7. Benefit-risk assessment and discussion

## 3.7.1. Importance of favourable and unfavourable effects

In the ITT population, pembrolizumab as add-on to chemotherapy and trastutzumab demonstrated a statistically significant improvement in median PFS but not in median OS compared to the control arm. In the subgroup of patients with CPS&lt;1 no benefit from the addition of pembrolizumab was observed. The MAH's proposal for a restriction of the indication to the CPS ≥ 1 population is in line with the EMA guidelines on the investigation of subgroups in confirmatory clinical trials. Indeed, the study was formally successful since a statistically significant effect in the ITT population on one of the two components of the dual endpoint was demonstrated; however, the therapeutic efficacy or risk-benefit is borderline and clearly not proven in the CPS&lt;1 group, thus reflecting Scenario 2 of the guideline. In patients with CPS ≥ 1, the addition of pembrolizumab to trastuzumab plus chemotherapy improved the median PFS (HR=0.70; 95% CI 0.58, 0.85, with a 3-month gain compared to placebo) and the median OS (HR=0.79; 95% CI 0.64, 0.98; p=0.0143, with a 5-month gain compared to placebo).

Overall, the safety profile of pembrolizumab in combination with chemotherapy (FP/CAPOX) and trastuzumab in the first line treatment of patients with locally advanced unresectable or metastatic HER2-positive gastric or GEJ adenocarcinoma in KEYNOTE-811 reflects the established safety profiles of the chemotherapy regimen administered and pembrolizumab monotherapy. No new safety concerns have been identified.

<div style=\"page-break-after: always\"></div>

## 3.7.2. Balance of benefits and risks

Considering the poor prognosis of patients in the intended indication, the improved median PFS and OS demonstrated by pembrolizumab as addon to SOC in the CPS≥1 subgroup can be considered of clinical relevance. From a safety perspective, the increased toxicity associated to treatment compared to placebo appears manageable.

## 3.7.3. Additional considerations on the benefit-risk balance

N/A

## 3.7.4. Conclusions

The overall B/R of Keytruda in combination with trastuzumab, fluoropyrimidine and platinumcontaining chemotherapy, for the first-line treatment of locally advanced unresectable or metastatic HER2-positive gastric or gastro-oesophageal junction adenocarcinoma in adults whose tumours express PD-L1 with a CPS ≥ 1 is positive.

## 4. Recommendations

## Outcome

Based on the review of the submitted data, the CHMP considers the following variation acceptable and therefore recommends the variation to the terms of the Marketing Authorisation, concerning the following change:

| Variation accepted   | Variation accepted                                                                                                             | Type    | Annexes affected   |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a              | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I, II and IIIB     |

Extension of indication to include in combination with trastuzumab, fluoropyrimidine and platinumcontaining chemotherapy for treatment of locally advanced unresectable or metastatic HER2- positive gastric or gastro-oesophageal junction adenocarcinoma for Keytruda in adults whose tumours express PD-L1 with a CPS ≥ 1, based on interim results from study KEYNOTE-811, an ongoing Phase 3, doubleblind trial comparing trastuzumab plus chemotherapy and pembrolizumab with trastuzumab plus chemotherapy and placebo as first-line treatment in participants with HER2-positive advanced gastric or gastro-oesophageal junction adenocarcinoma;  As a consequence, sections 4.1, 4.8, and 5.1 of the SmPC are updated. The Annex II, Package Leaflet and Labelling are updated in accordance. Version 38 of the RMP has also been submitted.

## Amendments to the marketing authorisation

In view of the data submitted with the variation, amendments to Annex(es) I, II and IIIB and to the Risk Management Plan are recommended.

<div style=\"page-break-after: always\"></div>

## 5. EPAR changes

The EPAR will be updated following Commission Decision for this variation. In particular the EPAR module \" steps after the authorisation \" will be updated as follows:

## Scope

Please refer to the Recommendations section above.

## Summary

Please refer to Scientific Discussion 'Keytruda-H-C-3820-II-0133'